

# CHEST™ Physician

THE NEWSPAPER OF THE AMERICAN COLLEGE OF CHEST PHYSICIANS



MITCHEL L. ZOLER/FRONTLINE MEDICAL NEWS

Emphysema in the right-middle lobe regressed 0.7% with losartan and progressed 3.3% with placebo, Dr. Allison Lambert reported.

## Losartan may slow emphysema's progress

BY MITCHEL L. ZOLER  
Frontline Medical News

AT CHEST 2015

MONTREAL – Daily treatment with the antihypertensive drug losartan for a year appeared to slow progression of emphysema, compared with placebo, in a controlled pilot study involving 46 patients at one U.S. center, Dr. Allison Lambert reported at the annual meeting of the American College of Chest Physicians.

One year of daily, 100-mg oral treatment with the angiotensin receptor–blocking drug losartan in patients with emphysema produced a statistically significant re-

gression of the disease in their right-middle lung lobes, compared with progression of right-middle lung lobe disease among control patients, as assessed by CT lung scans. In this lung segment, emphysema regressed by 0.7% in patients on losartan (Cozaar), compared with an average 3.3% rate of progression in patients on placebo.

The losartan-treated patients also showed a consistent pattern of either substantially slowed or reversed emphysema throughout multiple lung segments, although the between-group differences did not reach statistical significance in any

See **Losartan** • page 10

## Pediatric pulmonary hypertension guideline is issued

Includes section on pharmacotherapy.

BY MARY ANN MOON  
Frontline Medical News

The first-ever clinical practice guideline for assessing and managing pulmonary hypertension (PH) in the pediatric population was released by the American Heart Association and the American Thoracic Society and has been published online in *Circulation*.

The two organizations developed this guideline because the causes and treatments of PH in neonates, infants, and children are often different from those in adults.

The literature for adult

PH is “robust,” and there are several treatment guidelines available, whereas pediatric PH has not been well studied, “and little is understood about the natural history, fundamental mechanisms, and treatment of childhood PH,” said Dr. Steven H. Abman, cochair of the guideline committee and a pediatric pulmonologist at the University of Colorado and Children’s Hospital, both in Denver.

“It’s important to note that, although these guidelines provide a foundation for taking care of children with pulmonary hyperten-

See **Pediatric PH** • page 6

## MMF as effective as cyclophosphamide for sclerodermal lung disease

BY MITCHEL L. ZOLER  
Frontline Medical News

AT CHEST 2015

MONTREAL – The immunosuppressant mycophenolate mofetil worked as effectively as cyclophosphamide for treating sclero-

derma-related interstitial lung disease while being better tolerated and causing fewer adverse effects in a multicenter, head-to-head comparison with 142 randomized patients.

“The findings support the increasingly common

clinical practice of prescribing MMF [mycophenolate mofetil] for this disease,” Dr. Donald P. Tashkin, FCCP, said at the annual meeting of the American College of Chest Physicians.

Another limitation of

See **MMF** • page 4

### INSIDE

#### News

#### Very-low nicotine cigarettes

Less smoking and little compensatory smoking. • 4

#### Critical Care

#### Acute respiratory failure

Oxygen comparable to noninvasive ventilation. • 28

#### Sleep Medicine

#### Sleep Strategies

How pain disrupts sleep and sleep disturbance enhances pain. • 32

#### Cardiothoracic Surgery

#### Bioprosthetic valves

Stilled leaflets trigger concerns. • 40

#### Practice Economics

#### End-of-life talks

Poll finds 80% support Medicare coverage. • 70

Put the Latest  
Clinical Advances  
Into Immediate  
Practice



CHEST™  
Live Learning  
2016

> Learn More  
[chestnet.org/live-learning](http://chestnet.org/live-learning)

In pulmonary arterial hypertension (PAH)...

Think prostacyclin

SOONER

ENDOTHELIN

NITRIC OXIDE

PROSTACYCLIN

How could we improve utilization of this important pathway for patients with PAH?

In the REVEAL Registry, more than 50% of patients with PAH were not receiving a parenteral prostanoid at time of death<sup>1\*</sup>

\*Data from REVEAL (Registry to Evaluate Early and Long-term PAH Disease Management); US-based, observational registry involving 55 academic and community-based treatment centers. 3515 patients enrolled between March 2006 and December 2009.<sup>2</sup> REVEAL was funded and sponsored by Actelion Pharmaceuticals US, Inc.

**References:** 1. Farber HW, Miller DP, Meltzer LA, McGoon MD. Treatment of patients with pulmonary arterial hypertension at the time of death or deterioration to functional class IV: insights from the REVEAL Registry. *J Heart Lung Transplant.* 2013;32(11):1114-1122. 2. McGoon MD, Miller DP. REVEAL: a contemporary US pulmonary arterial hypertension registry. *Eur Respir Rev.* 2012;21(123):8-18.

# Yoga performs like pulmonary rehab for COPD patients

BY MITCHEL L. ZOLER  
Frontline Medical News

AT CHEST 2015

MONTREAL – A structured regimen of regular yoga exercises was as effective as a standard pulmonary rehabilitation program in patients with chronic obstructive pulmonary disease for improving lung function, exercise tolerance, dyspnea severity, and quality of life in a single-center, randomized comparison of the two strategies with 60 patients.

Also, chronic obstructive pulmonary disease (COPD) patients had a higher level of acceptance of yoga and were more comfortable doing it, compared with standard pulmonary rehabilitation, and yoga is cost effective given the minimal equipment required, Dr. Randeep Guleria said at

the annual meeting of the American College of Chest Physicians.

“Patients with difficulty walking, osteoarthritis, knee problems, or unable to do exercises like cycling or treadmill found yoga to be much more acceptable,” Dr. Guleria said in an interview. Acceptance of yoga was also higher than standard rehabilitation among patients with more severe COPD, said Dr. Guleria, professor and head of the department of pulmonary medicine and sleep disorders at the All India Institute of Medical Sciences in New Delhi.

“I think that yoga could be a very valuable adjunct” to pulmonary rehabilitation in COPD patients, commented Dr. Roger S. Goldstein, FCCP, director of the divisional program in respiratory rehabilitation at the University of Toronto. Dr. Gold-

stein speculated that even better than comparing yoga against conventional pulmonary rehabilitation would be a study that compared a combined yoga plus rehabilitation program against standard rehabilitation alone.

The 12-week study enrolled 60 patients who averaged 56 years old and who had been diagnosed with COPD for an average of 8 years. Just under a third of the patients had moderate COPD, 42% had severe COPD, and 28% had very severe COPD.

Thirty patients were randomized into a yoga program that included 4 weeks of biweekly 1-hour sessions that instructed patients in a series of physical postures, breathing technique, and meditation and relaxation. That was followed by 8 weeks during which patients were mostly left to perform their learned exercises on their own, but with a supervised session once every 2 weeks. The other 30 patients participated for 12 weeks in a pulmonary rehabilitation program that included patient education, upper and lower limb exercises, and breathing exercises.

At baseline and 12 weeks, researchers performed two measures of dyspnea severity, 6-minute walk distance, a quality of life assessment, and two serum markers of inflammation, C-reactive protein and interleukin 6.

Both interventions resulted in modest but statistically significant improvements, such as increases in 6-minute walk distance and a reduced modified Borg scale assessment. The

## VIEW ON THE NEWS

**Dr. Eric Gartman, FCCP comments:** As our patients with progressive COPD have increasing amounts of functional decline, we are often left with little to offer. This study using yoga mirrors similar successes using alternative low impact exercise strategies in COPD patients in efforts ranging from smoking cessation to symptom reduction. It is clear that patients are very accepting of these modalities, and they should find their way into formal rehab programs. Furthermore, given the nature of the exercises, they hold promise to create a longlasting effect on functional improvements, and may prove more successful if patients can continue their regimen independently long after formal rehab has been completed.

average Borg scale score fell from 1.5 at baseline to 1.0 after 12 weeks in the yoga patients, and from 3.0 at baseline to 0.5 after 12 weeks in the rehabilitation patients. A score that measured total quality of life improved by an average of 32% in the yoga patients and by 21% in the rehabilitation patients. At 12 weeks, there were no statistically significant between-group differences.

mzoler@frontlinemedcom.com  
On Twitter @mitchelzoler

## IN THIS ISSUE

News From CHEST • 56

**CHEST educational principles**

Keeping ABIM 2020 goals aligned. • 56

**CHEST Physician Is Online**

CHEST Physician is available on the Web at [chestphysician.org](http://chestphysician.org)



**Dr. Vera A. De Palo, MBA, FCCP, is Medical Editor in Chief of CHEST Physician.**

## CHEST Physician

THE NEWSPAPER OF THE AMERICAN COLLEGE OF CHEST PHYSICIANS

### AMERICAN COLLEGE OF CHEST PHYSICIANS (CHEST)

**Editor in Chief** Vera A. De Palo, M.D., MBA, FCCP  
**Deputy Editor in Chief** David A. Schulman, M.D., FCCP  
**President** Curtis N. Sessler, M.D., FCCP

**Executive Vice President and CEO** Paul A. Markowski, CAE

**Senior VP/Publisher, Publications/Digital Content** Stephen J. Welch

**Manager, Editorial Resources** Pamela L. Goorsky

**Senior Publications Specialist** Martha Zaborowski

### Section Editors

Loren J. Harris, M.D., FCCP - **Pulmonary Perspectives**

Lee E. Morrow, M.D., FCCP - **Critical Care Commentary**

Jeremy A. Weingarten, M.D., FCCP - **Sleep Strategies**

### EDITORIAL ADVISORY BOARD

G. Hossein Almassi, M.D., FCCP, Wisconsin  
Jun Chiong, M.D., FCCP, California  
Jennifer Cox, M.D., FCCP, Florida  
Jacques-Pierre Fontaine, M.D., FCCP, Florida  
Eric Gartman, M.D., FCCP, Rhode Island  
Octavian C. Ioachimescu, M.D., PhD, FCCP, Georgia  
Jason Lazar, M.D., FCCP, New York  
James A.L. Mathers Jr. M.D., FCCP, Virginia  
Susan Millard, M.D., FCCP, Michigan  
Michael E. Nelson, M.D., FCCP, Kansas  
Daniel Ouellette, M.D., FCCP, Michigan  
Frank Podbielski, M.D., FCCP, Massachusetts  
Eleanor Summerhill, M.D., FCCP, Rhode Island  
Krishna Sundar, M.D., FCCP, Utah

**E-mail:** [chestphysiciannews@chestnet.org](mailto:chestphysiciannews@chestnet.org)

**CHEST PHYSICIAN**, the newspaper of the American College of Chest Physicians, provides cutting-edge reports from clinical meetings, FDA coverage, clinical trial results, expert commentary, and reporting on the business and politics of chest medicine. Each issue also provides material exclusive to CHEST members. Content for **CHEST PHYSICIAN** is provided by Frontline Medical Communications Inc. Content for News From Chest is provided by the American College of Chest Physicians.

The statements and opinions expressed in **CHEST PHYSICIAN** do not necessarily reflect those of the American College of Chest Physicians, or of its officers, regents, members, and employees, or those of the Publisher. The American College of Chest Physicians, its officers, regents, members, and employees, and Frontline Medical Communications Inc. do not assume responsibility for damages, loss, or claims of any kind arising from or related to the information contained in this publication, including any claims related to products, drugs, or services mentioned herein.

**POSTMASTER:** Send change of address (with old mailing label) to CHEST PHYSICIAN, Subscription Service, 151 Fairchild Ave., Suite 2, Plainview, NY 11803-1709.

**CHEST PHYSICIAN** (ISSN 1558-6200) is published monthly for the American College of Chest Physicians by Frontline Medical Communications Inc., 7 Century Drive, Suite 302, Parsippany, NJ 07054-4609. Subscription price is \$230.00 per year. Phone 973-206-3434, fax 973-206-9378.

**EDITORIAL OFFICES** 5635 Fishers Lane, Suite 6100, Rockville, MD 20852, 240-221-2400, fax 240-221-2548

**ADVERTISING OFFICES** 7 Century Drive, Suite 302, Parsippany, NJ 07054-4609 973-206-3434, fax 973-206-9378

©Copyright 2015, by the American College of Chest Physicians

### FRONTLINE MEDICAL COMMUNICATIONS SOCIETY PARTNERS

**VP/Group Publisher; Director, FMC Society Partners** Mark Branca  
**Editor in Chief** Mary Jo M. Dales  
**Executive Editors** Denise Fulton, Kathy Scarbeck

**Creative Director** Louise A. Koenig  
**Print Production Manager** Rebecca Slobodnik

**Senior Director of Classified Sales** Tim LaPella, 484-921-5001, [tlapella@frontlinemedcom.com](mailto:tlapella@frontlinemedcom.com)

**Display Advertising Managers** Lauren Provenzano, 609-306-5776, [lprovenzano@americanmedicalcomm.com](mailto:lprovenzano@americanmedicalcomm.com), Michael O'Brien, 978-578-4514, [mobrien@americanmedicalcomm.com](mailto:mobrien@americanmedicalcomm.com)  
**Classified Sales Representative** Lauren Morgan 267-980-6087, [lmorgan@americanmedicalcomm.com](mailto:lmorgan@americanmedicalcomm.com)

### FRONTLINE MEDICAL COMMUNICATIONS

**Chairman** Stephen Stoneburn  
**EVP Digital Business Development/CFO** Douglas E. Grose  
**President/CEO** Alan J. Imhoff  
**President, Custom Solutions** JoAnn Wahl  
**Vice President, Finance** Dennis Quirk  
**Executive Director, Operations** Jim Chicca  
**Vice President, Audience Development** Donna Sickles  
**Vice President, Custom Programs** Carol Nathan  
**Vice President, Custom Solutions** Wendy Raupers  
**Vice President, Marketing & Customer Advocacy** Jim McDonough  
**Vice President, Sales** Phil Soufferis  
**Vice President, Society Partners** Mark Branca  
**Corporate Director, Research & Communications** Lori Raskin  
**Director, eBusiness Development** Lee Schweizer  
In affiliation with Global Academy for Medical Education, LLC  
**Vice President, Medical Education & Conferences** Sylvia H. Reitman, MBA  
**Vice President, Events** David J. Small, MBA



Scan this QR Code to visit [chestnet.org/chestphysician](http://chestnet.org/chestphysician)

# Reduced-nicotine cigarettes cut smoking

BY MARY ANN MOON  
Frontline Medical News

**R**educed-nicotine cigarettes decreased tobacco dependence and the number of cigarettes smoked, with very little evidence of withdrawal or compensatory smoking, in a preliminary study reported online Oct. 1 in the *New England Journal of Medicine*.

Moreover, study participants who smoked very-low-nicotine cigarettes for the 6-week study were twice as likely to report that they attempted to quit 1 month later, compared with participants who smoked their usual brand or control cigarettes that had the usual nicotine content.



© SHWARZ/999/THINKSTOCK

Reduced-nicotine cigarettes differ from “light” cigarettes in that the latter don’t actually reduce the nicotine content of the tobacco but instead increase ventilation of the cigarette – a strategy that is often circumvented by smokers who cover the ventilation holes or increase the number of cigarettes they smoke, said Eric C. Donny, Ph.D., of the department of psychology, University of Pittsburgh, and his associates.

The U.S. Food and Drug Administration recently was granted the authority to reduce, but not eliminate, nicotine in cigarettes if such action

were deemed likely to benefit public health. However, no large-scale clinical trials have yet been performed to assess the potential benefit to public health.

Dr. Donny and his associates, supported by the National Institute on Drug Abuse and the FDA Center for Tobacco Products, conducted a double-blind, randomized trial at 10 sites comparing cigarettes with five levels of nicotine content among 839 adult smokers who were not planning to quit in the near future.

The study participants were assigned to smoke their usual brand of cigarettes (118 study subjects); control cigarettes containing the usual 15.8 mg of nicotine/g of tobacco (119 subjects); or experimental reduced-nicotine cigarettes containing 5.2 mg/g of nicotine (122 subjects), 2.4 mg/g (119 subjects), 1.3 mg/g (119 subjects), or 0.4 mg/g (242 subjects).

All the cigarettes were provided free of charge, and the smokers were paid for participating in the study. The dropout rate was only 8% at week 6 and did not differ significantly among the study groups.

The primary outcome – the average number of cigarettes smoked per day during week 6 – was markedly higher with the usual-brand group (22.2) and the control-cigarette group (21.3) than it was with the three lowest-nicotine groups (16.5, 16.3, and 14.9, respectively). That represents a reduction of 23%-30% in the number of cigarettes smoked in the latter three groups.

Tobacco dependence, as measured by the Wisconsin Inventory of Smoking Dependence Motives and the Fagerstrom Test for Nicotine Dependence, also was markedly lower with

## VIEW ON THE NEWS

### Time for a nicotine-reduction policy?

**T**he findings of Dr. Donny and his colleagues justify exploration of a national nicotine-reduction policy and should encourage clinicians in practice to consider reduced-nicotine cigarettes as a potential resource for patients who want to quit smoking.

Given the number of current smokers in the United States, we can expect at least 20 million Americans to die prematurely if they continue to smoke. Reducing the nicotine content of cigarettes so that they are less addictive ap-

pears to be the most-promising regulatory policy option for preventing those 20 million premature deaths.

*Dr. Michael Fiore and Timothy Baker, Ph.D., are at the Center for Tobacco Research and Intervention and the department of medicine at the University of Wisconsin, Madison. They reported having no relevant financial disclosures. Dr. Fiore and Dr. Baker made these remarks in an editorial accompanying Dr. Donny’s report (N Engl J Med. 2015 Oct 1; 373[14]:1289-91).*

reduced-nicotine cigarettes.

Withdrawal symptoms did not increase; and during a brief voluntary abstinence period, smokers in the three lowest-nicotine groups actually reported fewer cravings than did those in the higher-nicotine groups, the investigators said (*N Engl J Med*. 2015 Oct 1;373[14]:1340-9).

At follow-up 30 days after completing the study, 34.7% of the participants who had smoked cigarettes with 0.4 mg/g of nicotine reported attempting to quit smoking, compared with 17% of those who had smoked cigarettes with 15.8 mg/g. In addition, participants who had smoked cigarettes with 1.3 mg/g or 0.4 mg/g of nicotine were still smoking significantly fewer cigarettes per day, even though the study had ended.

“In summary, these data suggest that if nicotine content is adequately

reduced, smokers may benefit by smoking fewer cigarettes and experiencing less nicotine dependence, with few negative consequences,” Dr. Donny and his associates wrote. “If confirmed in longer-term studies, these findings suggest that, when combined with other tobacco-control policies (e.g., taxation and expanded access to treatment), limiting the nicotine content of cigarettes ... could improve public health.”

The study authors added that a longer clinical trial is now underway to further assess reduced-nicotine cigarettes.

NIDA and the FDA Center for Tobacco Products supported the study. Dr. Donny reported having no relevant financial disclosures. Two of his associates reported ties to Pfizer, and two reported serving as expert witnesses regarding addiction litigation against tobacco companies.

## Fewer side effects

MMF from page 1

cyclophosphamide is that it is usually not used for more than 1 year because of concerns that longer use substantially increases a patient’s risk for developing malignancy. That’s another reason why there is a “strong need for longer and safer immunosuppressive treatment with a drug like MMF,” said Dr. Tashkin, a pulmonologist at the University of California, Los Angeles.

When used in this trial on patients with scleroderma, as defined by the American College of Rheumatology and with a baseline forced vital capacity of no more than 80% of predicted, “MMF was effective at re-

ducing the rate of decline in vital capacity, improving symptoms such as dyspnea – the cardinal symptom of interstitial lung disease, and reducing lung fibrosis seen on CT scans, and MMF was better tolerated” than cyclophosphamide, Dr. Tashkin said in an interview. Cyclophosphamide treatment in this new trial “was associated with more toxicity, especially hematologic toxicity, an was not nearly as well tolerated, with more patients withdrawing because of side effects or a perceived lack of benefit.”

“Cyclophosphamide has a lot of side effects. MMF is just now coming

into increased use. I think we’ll see it being used more for first-line treatment because the side effects with cyclophosphamide are so bad,” commented Dr. Thomas Fuhrman, chief of anesthesiology at the Bay Pines (Fla.) VA Healthcare System.

Dr. Tashkin and his associates conceived the Scleroderma Lung Study II (SLSII) as a follow-up to the first SLC run about a decade ago that compared cyclophosphamide against placebo for controlling progression of interstitial lung disease in scleroderma patients. The results from the first SLC trial established cyclophosphamide as a treatment that could preserve forced vital capacity percent predicted in patients with scleroderma-induced interstitial

*Continued on following page*



MITCHEL L. ZOLER/FRONTLINE MEDICAL NEWS

**I think we’ll see MMF being used more for first-line treatment because the side effects with cyclophosphamide are so bad, Dr. Donald P. Tashkin said.**

Continued from previous page

lung disease (N Engl J Med. 2006 Jun 22;354[25]:2655-666).

For the new study they enrolled patients who averaged 52 years old, with an average scleroderma duration of almost 3 years. Their average percent predicted forced vital capacity was 67%, and their baseline dyspnea index was 7.1.

Patients received either a target oral MMF dosage of 1.5 g b.i.d. for 2 years, or a target cyclophosphamide dosage of 2 mg/kg/day for up to 1 year, followed by a year of placebo. Cyclophosphamide treatment was capped at 1 year to protect against causing malignancy. Among the 73 patients randomized to the cyclophosphamide arm, 58 had data available after 12 months with 48 patients continuing on cyclophosphamide, and 53 had data available out to 2 years, with 37 patients remaining on their assigned regimen. Among 69 patients randomized to MMF 58 had data available after 12 months with 53 continuing on MMF, and 53 patients had data available through 24 months with 49 remaining on their MMF regimen.

After 24 months, the average percent predicted forced vital capacity, the study's primary endpoint, had increased by 3.3% among patients on MMF and 3.0% among those in the

cyclophosphamide arm in an intention-to-treat analysis, a nonsignificant difference. After 24 months 72% of patients in the MMF arm and 65% in the cyclophosphamide arm had a positive change, compared with baseline, in their percent predicted forced vital capacity, Dr. Tashkin reported.

MMF also showed a superior

overall safety profile. Patients on cyclophosphamide had a significantly increased rate of withdrawal from the study medication. Drug discontinuations occurred in 36 of the cyclophosphamide patients and in 20 of those on MMF. Serious adverse events attributable to study medication occurred in eight patients

on cyclophosphamide and three patients on MMF. The most frequent protocol-defined adverse event was leukopenia, which occurred in 30 patients on cyclophosphamide and four patients on MMF.

mzoler@frontlinemedcom.com  
On Twitter @mitchelzoler

#### VIEW ON THE NEWS

### More experience needed to confirm results

**Dr. Daniel R. Ouellette, FCCP, comments:** Unlike idiopathic pulmonary fibrosis (UIP pattern) unrelated to collagen vascular disease, interstitial lung diseases related to autoimmune conditions are sometimes amenable to treatment. However, the potent immunosuppressive agents used to treat these conditions are frequently associated with adverse side-effect profiles. Increasingly, safer agents such as mycophenolate have been successfully used. The recent report that treatment of scleroderma-related interstitial lung disease with mycophenolate may be just as effective as cyclophosphamide treatment is therefore welcome news. Some caution must be urged, as more experience must be gained with this treatment to confirm the results.

## 10 years ago, Boehringer Ingelheim made history in COPD treatment,



## but that was only the beginning...

# First-ever guideline issued

Pediatric PAH from page 1

sion, we still have a huge need for more specific data and research to further improve outcomes,” he said in a statement accompanying the guideline.

The guideline was developed by a working group of 27 clinicians and researchers with expertise in pediatric pulmonology, pediatric and adult cardiology, pediatric in-

tensivism, neonatology, and translational science.

The guideline authors reviewed more than 600 articles in the literature, but given the paucity of high-quality data regarding pediatric PH, the guideline relies heavily on expert opinion and primarily describes “generally acceptable

approaches” to diagnosis and management; more specific and detailed recommendations await the findings of future research, said Dr. Abman and his associates (*Circulation*. 2015 Oct 26. doi:10.1161/CIR.0000000000000329).

In the pediatric population, PH is defined as a resting mean pulmo-



## INDICATION

Stiolto Respimat (tiotropium bromide and olodaterol) Inhalation Spray is a combination of tiotropium, an anticholinergic, and olodaterol, a long-acting beta2-adrenergic agonist (LABA), indicated for the long-term, once-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.

## Important Limitations of Use

STIOLTO is NOT indicated to treat acute deterioration of COPD and is not indicated to treat asthma.

## IMPORTANT SAFETY INFORMATION

### WARNING: ASTHMA-RELATED DEATH

**Long-acting beta2-adrenergic agonists (LABA) such as olodaterol, one of the active ingredients in STIOLTO RESPIMAT, increase the risk of asthma-related death. Data from a large, placebo-controlled US study that compared the safety of another long-acting beta2-adrenergic agonist (salmeterol) with placebo added to usual asthma therapy showed an increase in asthma-related deaths in patients receiving salmeterol. This finding with salmeterol is considered a class effect of all LABA, including olodaterol, one of the active ingredients in STIOLTO RESPIMAT. The safety and efficacy of STIOLTO RESPIMAT in patients with asthma have not been established. STIOLTO RESPIMAT is not indicated for the treatment of asthma.**

## CONTRAINDICATION

All LABA are contraindicated in patients with asthma without use of a long-term asthma control medication. STIOLTO is contraindicated in patients with

hypersensitivity to tiotropium, ipratropium (atropine derivatives), olodaterol, or any component of this product.

In clinical trials and postmarketing experience with tiotropium, immediate hypersensitivity reactions, including angioedema (including swelling of the lips, tongue, or throat), itching, or rash have been reported. Hypersensitivity reactions were also reported in clinical trials with STIOLTO.

## WARNINGS AND PRECAUTIONS

STIOLTO should not be initiated in patients with acutely deteriorating COPD, which may be a life-threatening condition, or used as rescue therapy for acute symptoms. Acute symptoms should be treated with an inhaled short-acting beta2-agonist. Patients who have been taking inhaled, short-acting beta2-agonists on a regular basis should discontinue the regular use of these drugs and use them only for acute respiratory symptoms.

STIOLTO should not be used more often or at higher doses than recommended, or in conjunction with other LABA as an overdose may result.

Immediate hypersensitivity reactions, including urticaria, angioedema, rash, bronchospasm, anaphylaxis, or itching may occur after administration of STIOLTO. If such a reaction occurs, discontinue therapy with STIOLTO and consider alternative treatments. Patients with a history of hypersensitivity reactions to atropine or its derivatives should be closely monitored for similar hypersensitivity reactions to STIOLTO.

If paradoxical bronchospasm occurs, STIOLTO should be discontinued immediately.

STIOLTO can produce a clinically significant cardiovascular effect in some patients, as measured by increases in pulse rate, systolic or diastolic blood pressure, and/or symptoms. If such effects occur, STIOLTO may need to be discontinued.

Use caution in patients with convulsive disorders, thyrotoxicosis, diabetes mellitus, ketoacidosis, in patients with known or suspected prolongation of the QT interval, and in patients who are unusually responsive to sympathomimetic amines.

Contains tiotropium, the active ingredient in





**We still have a huge need for more specific data and research to further improve outcomes.**

DR. ABMAN

nary artery pressure greater than 25 mm Hg after the first few months of life and is usually related to cardiac, lung, or systemic diseases.

Idiopathic PH, a pulmonary vasculopathy, is a diagnosis of exclusion after diseases of the left side of the heart, lung parenchyma, heart valves, thromboembolism, and oth-

er miscellaneous causes have been ruled out.

The guideline emphasizes that children thought to have PH should be evaluated and receive treatment at comprehensive, multidisciplinary clinics at specialized pediatric centers.

“When children are diagnosed,

parents often feel helpless. However, it’s important that parents seek doctors and centers that see these children on a regular basis and can offer them access to new molecular diagnostics, new drug therapies, and new devices, as well as surgeries that have recently been

*Continued on following page*

## Introducing STIOLTO™ RESPIMAT®: from the makers of SPIRIVA®

- Significant improvement in lung function\* vs SPIRIVA® RESPIMAT® and olodaterol<sup>1</sup>
- Lung function improvement starting within 5 minutes and lasting 24 hours<sup>1</sup>
  - STIOLTO RESPIMAT is NOT a rescue medication and does NOT replace fast-acting inhalers to treat acute symptoms
- Improved lung function vs SPIRIVA RESPIMAT earlier in the course of COPD<sup>2</sup>
- Reduced rescue medication use at week 52<sup>1</sup>
- Frequency of adverse events in patients taking STIOLTO RESPIMAT was comparable to that for patients taking the individual components<sup>1</sup>

## Help your patients improve lung function from the start of COPD maintenance therapy with STIOLTO RESPIMAT

\*FEV<sub>1</sub>, forced expiratory volume in 1 second.

### IMPORTANT SAFETY INFORMATION (CONT'D)

Use with caution in patients with narrow-angle glaucoma. Instruct patients to contact a physician immediately if signs or symptoms of acute narrow-angle glaucoma develop (e.g., eye pain or discomfort, blurred vision, visual halos or colored images in association with red eyes from conjunctival congestion and corneal edema).

Use with caution in patients with urinary retention, which can be associated with symptoms like difficulty passing urine and painful urination in patients with prostatic hyperplasia or bladder-neck obstruction. Instruct patients to consult a physician immediately should any of these signs or symptoms develop.

Patients with moderate to severe renal impairment (creatinine clearance of  $\leq 60$  mL/min) treated with STIOLTO should be monitored closely for anticholinergic side effects.

Be alert to hypokalemia, which has the potential to produce adverse cardiovascular effects. Be alert to hyperglycemia.

### ADVERSE REACTIONS

The most common adverse reactions with STIOLTO (>3% incidence and higher than any of the comparators tiotropium and/or olodaterol) were: nasopharyngitis, 12.4% (11.7%/12.6%), cough, 3.9% (4.4%/3.0%), and back pain, 3.6% (1.8%/3.4%).

### DRUG INTERACTIONS

- Use caution if administering adrenergic drugs because sympathetic effects of olodaterol may be potentiated.
- Concomitant treatment with xanthine derivatives, steroids, or diuretics may potentiate any hypokalemic effect of olodaterol.
- Beta agonists, such as olodaterol, can acutely worsen the ECG changes and/or hypokalemia that may result from administration of non-potassium sparing diuretics. The action of adrenergic agents on the cardiovascular system may be potentiated by monoamine oxidase inhibitors or tricyclic antidepressants or other drugs known to

prolong the QTc interval. Therefore beta-agonists should be used with extreme caution in patients being treated with these drugs. Drugs that prolong the QTc interval may be associated with an increased risk of ventricular arrhythmias.

- Beta-blockers should be used with caution as they can inhibit the therapeutic effect of beta agonists which may produce severe bronchospasms in patients with COPD. However, under certain circumstances, e.g. as prophylaxis after myocardial infarction, there may be no acceptable alternatives to the use of beta-blockers in patients with COPD. In this setting, cardio selective beta-blockers could be considered, although they should be administered with caution.
- Avoid co-administration of STIOLTO with other anticholinergic-containing drugs as this may lead to an increase in anticholinergic adverse effects.

STIOLTO is for oral inhalation only. The STIOLTO cartridge is only intended for use with the STIOLTO RESPIMAT inhaler.

Inform patients not to spray STIOLTO into the eyes.



References: 1. STIOLTO RESPIMAT Prescribing Information. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc. 2. Data on file. Boehringer Ingelheim Pharmaceuticals, Inc.

**Please see brief summary of Prescribing Information on the following pages.**

**STIOLTO™**  
RESPIMAT®  
(tiotropium bromide & olodaterol)  
INHALATION SPRAY

Continued from previous page

developed,” Dr. Stephen L. Archer, cochair of the guideline committee and head of medicine at Queen’s University, Kingston, Ont., said in the statement.

“These children suffer with health issues throughout their lives or die

## Properly classifying the type of PH is a key first step in determining treatment.

prematurely, particularly if they’re not properly diagnosed and managed. But with the proper diagnosis and treatment at a specialized center for PH, the prognosis for many

of these children is excellent,” he noted.

Properly classifying the type of PH is a key first step in determining treatment.

The guideline addresses numerous methods for diagnosing and monitoring PH, including imaging studies, echocardiograms, cardiac catheterization, brain natriuretic peptide and other laboratory testing, 6-minute walk distance (at appropriate ages), sleep studies, and genetic testing.

### STIOLTO™ RESPIMAT® (tiotropium bromide and olodaterol) inhalation spray, for oral inhalation use

#### BRIEF SUMMARY OF PRESCRIBING INFORMATION

Please see package insert for full Prescribing Information

#### WARNING: ASTHMA-RELATED DEATH

Long-acting beta<sub>2</sub>-adrenergic agonists (LABA) such as olodaterol, one of the active ingredients in STIOLTO RESPIMAT, increase the risk of asthma-related death. Data from a large, placebo-controlled US study that compared the safety of another long-acting beta<sub>2</sub>-adrenergic agonist (salmeterol) with placebo added to usual asthma therapy showed an increase in asthma-related deaths in patients receiving salmeterol. This finding with salmeterol is considered a class effect of all LABA, including olodaterol, one of the active ingredients in STIOLTO RESPIMAT. The safety and efficacy of STIOLTO RESPIMAT in patients with asthma have not been established. STIOLTO RESPIMAT is not indicated for the treatment of asthma [see Contraindications, Warnings and Precautions].

**INDICATIONS AND USAGE: Maintenance Treatment of COPD:** STIOLTO RESPIMAT is a combination of tiotropium and olodaterol indicated for long-term, once-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. **Important Limitations of Use:** STIOLTO RESPIMAT is not indicated to treat acute deteriorations of COPD [see Warnings and Precautions]; STIOLTO RESPIMAT is not indicated to treat asthma. The safety and effectiveness of STIOLTO RESPIMAT in asthma have not been established.

**CONTRAINDICATIONS:** All LABAs are contraindicated in patients with asthma without use of a long-term asthma control medication [see Warnings and Precautions]. STIOLTO RESPIMAT is not indicated for the treatment of asthma. STIOLTO RESPIMAT is contraindicated in patients with a hypersensitivity to tiotropium, ipratropium, olodaterol, or any component of this product [see Warnings and Precautions]. In clinical trials and postmarketing experience with tiotropium, immediate hypersensitivity reactions, including angioedema (including swelling of the lips, tongue, or throat), itching, or rash have been reported. Hypersensitivity reactions were also reported in clinical trials with STIOLTO RESPIMAT.

**WARNINGS AND PRECAUTIONS: Asthma-Related Death [See Boxed Warning]:** Data from a large placebo-controlled study in asthma patients showed that long-acting beta<sub>2</sub>-adrenergic agonists may increase the risk of asthma-related death. Data are not available to determine whether the rate of death in patients with COPD is increased by long-acting beta<sub>2</sub>-adrenergic agonists. A 28-week, placebo-controlled US study comparing the safety of another long-acting beta<sub>2</sub>-adrenergic agonist (salmeterol) with placebo, each added to usual asthma therapy, showed an increase in asthma-related deaths in patients receiving salmeterol (13/13,176 in patients treated with salmeterol vs. 3/13,179 in patients treated with placebo; RR 4.37, 95% CI 1.25, 15.34). The increased risk of asthma-related death is considered a class effect of long-acting beta<sub>2</sub>-adrenergic agonists, including olodaterol, one of the active ingredients in STIOLTO RESPIMAT. No study adequate to determine whether the rate of asthma-related death is increased in patients treated with STIOLTO RESPIMAT has been conducted. The safety and efficacy of STIOLTO RESPIMAT in patients with asthma have not been established. STIOLTO RESPIMAT is not indicated for the treatment of asthma. [See Contraindications]. **Deterioration of Disease and Acute Episodes:** STIOLTO RESPIMAT should not be initiated in patients with acutely deteriorating COPD, which may be a life-threatening condition. STIOLTO RESPIMAT has not been studied in patients with acutely deteriorating COPD. The use of STIOLTO RESPIMAT in this setting is inappropriate. STIOLTO RESPIMAT should not be used for the relief of acute symptoms, i.e., as rescue therapy for the treatment of acute episodes of bronchospasm. STIOLTO RESPIMAT has not been studied in the relief

of acute symptoms and extra doses should not be used for that purpose. Acute symptoms should be treated with an inhaled short-acting beta<sub>2</sub>-agonist. When beginning STIOLTO RESPIMAT, patients who have been taking inhaled, short-acting beta<sub>2</sub>-agonists on a regular basis (e.g., four times a day) should be instructed to discontinue the regular use of these drugs and use them only for symptomatic relief of acute respiratory symptoms. When prescribing STIOLTO RESPIMAT, the healthcare provider should also prescribe an inhaled, short-acting beta<sub>2</sub>-agonist and instruct the patient on how it should be used. Increasing inhaled beta<sub>2</sub>-agonist use is a signal of deteriorating disease for which prompt medical attention is indicated. COPD may deteriorate acutely over a period of hours or chronically over several days or longer. If STIOLTO RESPIMAT no longer controls symptoms of bronchoconstriction, or the patient’s inhaled, short-acting beta<sub>2</sub>-agonist becomes less effective or the patient needs more inhalation of short-acting beta<sub>2</sub>-agonist than usual, these may be markers of deterioration of disease. In this setting, a re-evaluation of the patient and the COPD treatment regimen should be undertaken at once. Increasing the daily dosage of STIOLTO RESPIMAT beyond the recommended dose is not appropriate in this situation. **Excessive Use of STIOLTO RESPIMAT and Use With Other Long-Acting Beta<sub>2</sub>-Agonists:** As with other inhaled drugs containing beta<sub>2</sub>-adrenergic agents, STIOLTO RESPIMAT should not be used more often than recommended, at higher doses than recommended, or in conjunction with other medications containing long-acting beta<sub>2</sub>-agonists, as an overdose may result. Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. **Immediate Hypersensitivity Reactions:** Immediate hypersensitivity reactions, including urticaria, angioedema (including swelling of the lips, tongue or throat), rash, bronchospasm, anaphylaxis, or itching may occur after administration of STIOLTO RESPIMAT. If such a reaction occurs, therapy with STIOLTO RESPIMAT should be stopped at once and alternative treatments should be considered. Given the similar structural formula of atropine to tiotropium, patients with a history of hypersensitivity reactions to atropine or its derivatives should be closely monitored for similar hypersensitivity reactions to STIOLTO RESPIMAT. **Paradoxical Bronchospasm:** As with other inhaled medicines, STIOLTO RESPIMAT may cause paradoxical bronchospasm that may be life-threatening. If paradoxical bronchospasm occurs, STIOLTO RESPIMAT should be stopped immediately and alternative therapy instituted. **Cardiovascular Effects:** Olodaterol, like other beta<sub>2</sub>-agonists, can produce a clinically significant cardiovascular effect in some patients as measured by increases in pulse rate, systolic or diastolic blood pressure, and/or symptoms. If such effects occur, STIOLTO RESPIMAT may need to be discontinued. In addition, beta-agonists have been reported to produce ECG changes, such as flattening of the T wave, prolongation of the QTc interval, and ST segment depression. The clinical significance of these findings is unknown. Long acting beta<sub>2</sub>-adrenergic agonists should be administered with caution in patients with cardiovascular disorders, especially coronary insufficiency, cardiac arrhythmias, hypertrophic obstructive cardiomyopathy, and hypertension. **Coexisting Conditions:** Olodaterol, like other sympathomimetic amines, should be used with caution in patients with convulsive disorders or thyrotoxicosis, in patients with known or suspected prolongation of the QT interval, and in patients who are unusually responsive to sympathomimetic amines. Doses of the related beta<sub>2</sub>-agonist albuterol, when administered intravenously, have been reported to aggravate pre-existing diabetes mellitus and ketoacidosis. **Worsening of Narrow-Angle Glaucoma:** STIOLTO RESPIMAT should be used with caution in patients with narrow-angle glaucoma. Prescribers and patients should be alert for signs and symptoms of acute narrow-angle glaucoma (e.g., eye pain or discomfort, blurred vision, visual halos or colored images in association with red eyes from conjunctival congestion and corneal edema). Instruct patients to consult a physician immediately should any of these signs or symptoms develop. **Worsening of Urinary Retention:** STIOLTO RESPIMAT should be used

with caution in patients with urinary retention. Prescribers and patients should be alert for signs and symptoms of prostatic hyperplasia or bladder-neck obstruction (e.g., difficulty passing urine, painful urination), especially in patients with prostatic hyperplasia or bladder neck obstruction. Instruct patients to consult a physician immediately should any of these signs or symptoms develop.

**Renal Impairment:** Because tiotropium is a predominantly renally excreted drug, patients with moderate to severe renal impairment (creatinine clearance of ≤60 mL/min) treated with STIOLTO RESPIMAT should be monitored closely for anticholinergic side effects [see Use in Specific Populations]. **Hypokalemia and Hyperglycemia:** Beta-adrenergic agonists may produce significant hypokalemia in some patients, which has the potential to produce adverse cardiovascular effects. The decrease in serum potassium is usually transient, not requiring supplementation. Inhalation of high doses of beta<sub>2</sub>-adrenergic agonists may produce increases in plasma glucose. In patients with severe COPD, hypokalemia may be potentiated by hypoxia and concomitant treatment [see Drug Interactions], which may increase the susceptibility for cardiac arrhythmias. Clinically notable decreases in serum potassium or changes in blood glucose were infrequent during clinical studies with long-term administration of olodaterol with the rates similar to those for placebo controls. Olodaterol has not been investigated in patients whose diabetes mellitus is not well controlled.

**ADVERSE REACTIONS:** LABA, such as olodaterol, one of the active components in STIOLTO RESPIMAT, increase the risk of asthma-related death. STIOLTO RESPIMAT is not indicated for the treatment of asthma [see Boxed Warning and Warning and Precautions]. The following adverse reactions are described, or described in greater detail, in other sections: Immediate hypersensitivity reactions [see Warnings and Precautions]; Paradoxical bronchospasm [see Warnings and Precautions]; Worsening of narrow-angle glaucoma [see Warnings and Precautions]; Worsening of urinary retention [see Warnings and Precautions]. **Clinical Trials Experience in Chronic Obstructive Pulmonary Disease:** Because clinical trials are conducted under widely varying conditions, the incidence of adverse reactions observed in the clinical trials of a drug cannot be directly compared to the incidences in the clinical trials of another drug and may not reflect the incidences observed in practice. The clinical program for STIOLTO RESPIMAT included 7151 subjects with COPD in two 52-week active-controlled trials, one 12-week placebo-controlled trial, three 6-week placebo-controlled crossover trials, and four additional trials of shorter duration. A total of 1988 subjects received at least 1 dose of STIOLTO RESPIMAT. Adverse reactions observed in the ≤12-week trials were consistent with those observed in the 52-week trials, which formed the primary safety database. The primary safety database consisted of pooled data from the two 52-week double-blind, active-controlled, parallel group confirmatory clinical trials. These trials included 5162 adult COPD patients (72.9% males and 27.1% females) 40 years of age and older. Of these patients, 1029 were treated with STIOLTO RESPIMAT once daily. The STIOLTO RESPIMAT group was composed of mostly Caucasians (71.1%) with a mean age of 63.8 years and a mean percent predicted FEV<sub>1</sub> at baseline of 43.2%. In these two trials, tiotropium 5 mcg and olodaterol 5 mcg were included as active control arms and no placebo was used. In these two clinical trials, 74% of patients exposed to STIOLTO RESPIMAT reported an adverse reaction compared to 76.6% and 73.3% in the olodaterol 5 mcg and tiotropium 5 mcg groups, respectively. The proportion of patients who discontinued due to an adverse reaction was 7.4% for STIOLTO RESPIMAT treated patients compared to 9.9% and 9.0% for olodaterol 5 mcg and tiotropium 5 mcg treated patients. The adverse reaction most commonly leading to discontinuation was worsening COPD. The most common serious adverse reactions were COPD exacerbation and pneumonia. Table 1 shows all adverse drug reactions that occurred with an incidence of >3% in the STIOLTO RESPIMAT treatment group and a higher incidence rate than the active comparator groups listed.

The guideline specifically deals with persistent PH of the newborn and PH arising from congenital diaphragmatic hernia; bronchopulmonary dysplasia or other lung diseases; heart disease such as atrial-septal defect or patent ductus arteriosus; and systemic diseases such as hemolytic hemoglobinopathies

and hepatic, renal, or metabolic illness; as well as idiopathic PH and PH that is related to high-altitude pulmonary edema.

Regarding ongoing outpatient care, the guideline recommends that children with PH receive influenza and pneumococcal vaccinations and prophylaxis for respiratory syncytial

virus (if they are eligible), as well as antibiotic prophylaxis to prevent subacute bacterial endocarditis in those who are cyanotic or have indwelling central lines.

Growth must be monitored rigorously, and infections and respiratory illnesses must be recognized and treated promptly.

Any surgeries require careful preoperative planning and should be performed at hospitals with expertise in PH.

The guideline includes an extensive section on pharmacotherapy for childhood PH.

Topics addressed include the use of digitalis, diuretics, long-term anticoagulation, oxygen therapy, calcium channel blockers, phosphodiesterase type 5 inhibitors, endothelin receptor antagonists, intravenous and subcutaneous prostacyclin therapy, and the transition from parenteral to oral or inhaled treatment.

In addition, the guideline addresses exercise and sports participation, travel restrictions, and contraceptive counseling for adolescent PH patients.

Finally, "given the impact of childhood PH on the entire family, [patients], siblings, and caregivers should be assessed for psychosocial stress and be readily provided support and referral as needed," the guideline recommends.

The pediatric PH guidelines are available at <http://my.americanheart.org/statements>.

**Table 1: Number and frequency of adverse drug reactions greater than 3% (and higher than any of the comparators tiotropium and/or olodaterol) in COPD patients exposed to STIOLTO RESPIMAT: Pooled data from the two 52-week, double-blind, active-controlled clinical trials in COPD patients 40 years of age and older**

Treatment	STIOLTO RESPIMAT (once daily)	Tiotropium (5 mcg once daily)	Olodaterol (5 mcg once daily)
<b>Body system (adverse drug reaction)</b>	<b>n=1029 n (%)</b>	<b>n=1033 n (%)</b>	<b>n=1038 n (%)</b>
Infections and infestations			
Nasopharyngitis	128 (12.4)	121 (11.7)	131 (12.6)
Respiratory, thoracic, and mediastinal disorders			
Cough	40 (3.9)	45 (4.4)	31 (3.0)
Musculoskeletal and connective tissue disorders			
Back Pain	37 (3.6)	19 (1.8)	35 (3.4)

Other adverse drug reactions in patients receiving STIOLTO RESPIMAT that occurred in  $\leq 3\%$  of patients in clinical studies are listed below: *Metabolism and nutrition disorders*: dehydration; *Nervous system disorders*: dizziness, insomnia; *Eye disorders*: glaucoma, intraocular pressure increased, vision blurred; *Cardiac/vascular disorders*: atrial fibrillation, palpitations, supraventricular tachycardia, tachycardia, hypertension; *Respiratory, thoracic, and mediastinal disorders*: epistaxis, pharyngitis, dysphonia, bronchospasm, laryngitis, sinusitis; *Gastrointestinal disorders*: dry mouth, constipation, oropharyngeal candidiasis, dysphagia, gastroesophageal reflux disease, gingivitis, glossitis, stomatitis, intestinal obstruction including ileus paralytic; *Skin and subcutaneous disorders*: rash, pruritus, angioneurotic edema, urticaria, skin infection, and skin ulcer, dry skin, hypersensitivity (including immediate reactions); *Musculoskeletal and connective tissue disorders*: arthralgia, joint swelling; *Renal and urinary disorders*: urinary retention, dysuria, and urinary tract infection.

**DRUG INTERACTIONS: Adrenergic Drugs:** If additional adrenergic drugs are to be administered by any route, they should be used with caution because the sympathetic effects of olodaterol, one component of STIOLTO RESPIMAT may be potentiated [see Warnings and Precautions]. **Sympathomimetics, Xanthine Derivatives, Steroids, or Diuretics:** Tiotropium has been used concomitantly with short-acting and long-acting sympathomimetic (beta-agonists) bronchodilators, methylxanthines, and oral and inhaled steroids, without increases in adverse reactions. Concomitant treatment with xanthine derivatives, steroids, or diuretics may potentiate any hypokalemic effect of olodaterol [see Warnings and Precautions]. **Non-Potassium Sparing Diuretics:** The ECG changes and/or hypokalemia that may result from the administration of non-potassium sparing diuretics (such as loop or thiazide diuretics) can be acutely worsened by beta-agonists, especially when the recommended dose of the beta-agonist is exceeded. Although the clinical significance of these effects is not known, caution is advised in the co-administration of STIOLTO RESPIMAT with non-potassium sparing diuretics. **Monoamine Oxidase Inhibitors, Tricyclic Antidepressants, QTc Prolonging Drugs:** STIOLTO RESPIMAT, as with other drugs containing beta<sub>2</sub>-agonists, should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants or other drugs known to prolong the QTc interval because the action of adrenergic agonists on the cardiovascular system may be potentiated by these agents. Drugs that are known to prolong the QTc interval may be associated with an increased risk of ventricular arrhythmias. **Beta-Blockers:** Beta-adrenergic receptor antagonists (beta-blockers) and the olodaterol

component of STIOLTO RESPIMAT may interfere with the effect of each other when administered concurrently. Beta-blockers not only block the therapeutic effects of beta-agonists, but may produce severe bronchospasm in COPD patients. Therefore, patients with COPD should not normally be treated with beta-blockers. However, under certain circumstances, e.g. as prophylaxis after myocardial infarction, there may be no acceptable alternatives to the use of beta-blockers in patients with COPD. In this setting, cardioselective beta-blockers could be considered, although they should be administered with caution. **Anticholinergics:** There is potential for an additive interaction with concomitantly used anticholinergic medications. Therefore, avoid co-administration of STIOLTO RESPIMAT with other anticholinergic-containing drugs as this may lead to an increase in anticholinergic adverse effects [see Warnings and Precautions and Adverse Reactions]. **Inhibitors of Cytochrome P450 and P-gp Efflux Transporter:** In a drug interaction study using the strong dual CYP and P-gp inhibitor ketoconazole, a 1.7-fold increase of olodaterol maximum plasma concentrations and AUC was observed [see Pharmacokinetics]. Olodaterol was evaluated in clinical trials for up to one year at doses up to twice the recommended therapeutic dose. No dose adjustment of STIOLTO RESPIMAT is necessary.

**USE IN SPECIFIC POPULATIONS: Pregnancy: Teratogenic Effects: Pregnancy Category C:** There are no adequate and well-controlled studies with STIOLTO RESPIMAT or its individual components, tiotropium bromide and olodaterol, in pregnant women. Animal reproduction studies were conducted with the individual components of STIOLTO RESPIMAT, tiotropium bromide and olodaterol. STIOLTO RESPIMAT should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. **Tiotropium:** No evidence of structural alterations was observed in rats and rabbits at approximately 790 and 8 times the recommended human daily inhalation dose (RHDID; on a mcg/m<sup>2</sup> basis at maternal inhalation doses of 1471 and 7 mcg/kg/day in rats and rabbits, respectively). However, in rats, tiotropium caused fetal resorption, litter loss, decreases in the number of live pups at birth and the mean pup weights, and a delay in pup sexual maturation at approximately 40 times the RHDID (on a mcg/m<sup>2</sup> basis at a maternal inhalation dose of 78 mcg/kg/day). In rabbits, tiotropium caused an increase in post-implantation loss at approximately 430 times the RHDID (on a mcg/m<sup>2</sup> basis at a maternal inhalation dose of 400 mcg/kg/day). Such effects were not observed at approximately 5 and 95 times the RHDID (on a mcg/m<sup>2</sup> basis at maternal inhalation doses of 9 and 88 mcg/kg/day in rats and rabbits, respectively). **Olodaterol:** Olodaterol was not teratogenic in rats at approximately 2731 times the RHDID (on an AUC basis at a maternal inhalation dose of 1054 mcg/kg/day). Placental transfer of olodaterol was observed in pregnant rats. Olodaterol has been shown to be teratogenic in New Zealand rabbits at approximately 7130 times the RHDID in adults (on an AUC basis at a maternal inhalation dose of 2489 mcg/kg/day). Olodaterol exhibited the following fetal toxicities: enlarged or small heart atria or ventricles, eye abnormalities, and split or distorted sternum. No significant effects occurred at approximately 1353 times the RHDID in adults (on an AUC basis at a maternal inhalation dose of 974 mcg/kg/day). **Labor and Delivery:** There are no adequate and well-controlled human studies that have investigated the effects of STIOLTO RESPIMAT on preterm labor or labor at term. Because of the potential for beta-agonist interference with uterine contractility, use of STIOLTO RESPIMAT during labor should be restricted to those patients in whom the benefits clearly outweigh the risks. **Nursing Mothers:** Clinical data from nursing women or infants exposed to STIOLTO RESPIMAT or its individual active components are not available. Tiotropium, olodaterol, and metabolites of olodaterol are excreted into the milk of lactating rats. It is not known whether these compounds are excreted in human milk, but because many drugs are excreted in human milk and given these findings in rats, caution should be exercised if STIOLTO RESPIMAT is administered to a nursing woman. **Pediatric Use:** COPD does not normally occur in children. The safety and effec-

tiveness of STIOLTO RESPIMAT in the pediatric population has not been established. **Geriatric Use:** Based on available data, no adjustment of STIOLTO RESPIMAT dosage in geriatric patients is warranted. Of the 1029 patients who received STIOLTO RESPIMAT at the recommended dose once daily in the clinical studies from the pooled 1-year database, 525 (51.0%) were <65 years of age, 407 (39.6%) were 65 to <75, 96 (9.3%) were 75 to <85, and 1 (0.1%) was  $\geq 85$ . No overall differences in effectiveness were observed, and in the 1-year pooled data, the adverse drug reaction profiles were similar in the older population compared to the patient population overall. **Hepatic Impairment:** No dose adjustment is needed in patients with mild and moderate hepatic impairment. A study in subjects with severe hepatic impairment was not performed. **Renal Impairment:** No dose adjustment is required for patients with renal impairment. However, patients with moderate to severe renal impairment (creatinine clearance of  $\leq 60$  mL/min) treated with STIOLTO RESPIMAT should be monitored closely for anticholinergic side effects [see Warnings and Precautions].

**OVERDOSAGE:** STIOLTO RESPIMAT contains both tiotropium bromide and olodaterol; therefore, the risks associated with overdosage for the individual components described below apply to STIOLTO RESPIMAT. **Tiotropium:** High doses of tiotropium may lead to anticholinergic signs and symptoms. However, there were no systemic anticholinergic adverse effects following a single inhaled dose of up to 282 mcg tiotropium in 6 healthy volunteers. In a study of 12 healthy volunteers, bilateral conjunctivitis and dry mouth were seen following repeated once-daily inhalation of 141 mcg of tiotropium. Dry mouth/throat and dry nasal mucosa occurred in a dose-dependent [10-40 mcg daily] manner, were observed following 14-day dosing of up to 40 mcg tiotropium bromide inhalation solution in healthy subjects. **Olodaterol:** The expected signs and symptoms with overdosage of olodaterol are those of excessive beta-adrenergic stimulation and occurrence or exaggeration of any of the signs and symptoms, e.g., myocardial ischemia, angina pectoris, hypertension or hypotension, tachycardia, arrhythmias, palpitations, dizziness, nervousness, insomnia, anxiety, headache, tremor, dry mouth, muscle spasms, nausea, fatigue, malaise, hypokalemia, hyperglycemia, and metabolic acidosis. As with all inhaled sympathomimetic medications, cardiac arrest and even death may be associated with an overdose of olodaterol. Treatment of overdosage consists of discontinuation of STIOLTO RESPIMAT together with institution of appropriate symptomatic and supportive therapy. The judicious use of a cardioselective beta-receptor blocker may be considered, bearing in mind that such medication can produce bronchospasm. There is insufficient evidence to determine if dialysis is beneficial for overdosage of STIOLTO RESPIMAT. Cardiac monitoring is recommended in cases of overdosage.

Copyright © 2015 Boehringer Ingelheim International GmbH  
ALL RIGHTS RESERVED

STO-BS-5/15 IT6053AD302015 305630-01  
PC-STO-0092-PROF



## VIEW ON THE NEWS

# A new roadmap to pediatric PH diagnosis, care

**Dr. Susan L. Millard, FCCP, comments:** The pediatric pulmonary, pediatric cardiology, and neonatal and pediatric intensivists all have greatly anticipated directions for the care of pediatric pulmonary hypertension.



The guidelines have excellent care maps for the diagnosis and evaluation of the various etiologies of pulmonary hypertension.

The new pediatric PH guidelines also should help with insurance authorizations for the expensive medications for pulmonary hypertension.

Dr. Robyn J. Barst, who was a renowned leader in pediatric pulmonary hypertension and passed away in 2013, would have been so proud of this new pediatric PH guideline.

# Decline in extent of emphysema

Losartan from page 1

other segment, said Dr. Lambert, of Johns Hopkins Hospital in Baltimore.

Throughout the entire lung, 12 months of losartan treatment was linked to an average 0.32% reduction in emphysema extent from baseline when measured by CT, compared with a 2.18% rate of emphysema progression in control patients on usual care, which just missed statistical significance ( $P = .064$ ).

Data from other researchers “suggest the right-middle lobe most commonly progresses in emphysema,” which may explain why that lung segment showed the most dramatic effect from treatment, Dr. Lambert said. Also striking was the consistent trend toward slowed emphysema progression in multiple lung segments.

Dr. Lambert called this a “proof of concept” trial. She and her associates have begun a larger, phase III version that will study the effect of 100-mg daily losartan during 1 year of treatment in 220 patients with emphysema, she said. This trial received funding from the Pulmonary Trials Cooperative of the National Heart Lung and Blood Institute.

“These are some of the most in-

teresting and exciting data I’ve seen,” commented Dr. David P.L. Sachs, who practices in Stanford, Calif., and cochaired the session in which Dr. Lambert gave her report.

“Having an agent that could slow progression of emphysema would be unique,” he said in an interview. One aspect that makes this treatment especially attractive is losartan’s extensive safety record as an antihypertensive drug that is also often used to treat patients with heart failure.

To put the 100-mg/day dosage used in the current study in perspective, results from a multicenter randomized trial of more than 3,800 heart failure patients published in 2009 showed that a losartan dosage of 150 mg once daily was safe and effective and produced outcomes superior to those seen with a 50 mg once-daily dosage (Lancet. 2009;374[9704]:1840-8).

Previously reported results from other groups showed favorable effects of losartan on animal models of emphysema. Nonprospective clinical studies also have suggested angiotensin-receptor blockers might benefit lung function and COPD.

The current study enrolled patients with mild to severe COPD who were current or former cigarette smokers with at least a 10 pack-year history and were on stable treatment for their COPD. The researchers excluded patients already taking an angiotensin-receptor blocker or angiotensin-converting enzyme inhibitor.

The study included 106 patients with COPD, including the 46 with emphysema at baseline. Their average age was about 58 years old, the enrolled patients included roughly equal numbers of men and women, and about two-thirds were current smokers. All patients had CT lung scans at baseline and after 6 and 12 months, as well as other lung function assessments. The primary endpoint was the amount of additional emphysema in patients’ lungs beyond that seen at baseline using CT imaging.

The entire group of 106 COPD patients showed no significant differences in emphysema progression at either 6 or 12 months between the 54 patients treated with losartan and the 52 controls on placebo, but a second, prespecified analysis that focused only on the 46 enrolled patients who had visible emphysema at baseline showed a significant slowing of progression at the 1-year follow-up.

The study received partial funding

from Merck, which markets losartan (Cozaar). Dr. Lambert and Dr. Sachs had no disclosures.

mzoler@frontlinemedcom.com

On Twitter @mitchelzoler

## VIEW ON THE NEWS

**Dr. Vera A. De Palo, MBA, FCCP**

**comments:** These provocative results may have significant implication for future treatment of COPD patients. Until now, the mainstay of COPD treatment has been inhaled medications to optimize respiratory functional status. As needed, treatment of inflammation, supplemental oxygen use, antibiotics, and pulmonary rehab have been added. The reported study outlines a slowed progression, and some regression of emphysema changes. The addition, to the armamentarium for COPD treatment, of a medication that could slow progression and potentially lead to regression of disease would truly be life-changing for our COPD patients. Continued studies are needed to understand the potential promise for patients.

Take advantage of thorough, hands-on, and immediately relevant professional training with customized guidance from the top names in the field. Upon completion, apply your improved clinical skills immediately to enhance patient care.

#### Our Certificate of Completion Program provides:

- An assessment-based certificate that fulfills the quality standards set forth by the Institute for Credentialing Excellence.
- Instruction and training to acquire specific knowledge, skills, and/or competencies associated with intended learning outcomes.
- Evaluation of the intended learning outcomes.
- A certificate awarded only to those participants who meet the performance, proficiency, or passing standard for the assessment(s).

#### Program requirements include:

- Participate in CHEST live simulation courses for intensive, hands-on training.
- Complete online learning modules to supplement, strengthen, and refine learning.
- Complete a portfolio to document performance in practice.
- Pass a final comprehensive assessment exam.

> Learn More [chestnet.org/coc](http://chestnet.org/coc)

## Expand Your Ultrasonography Skills

Innovation, Simulation, and Training Center  
Glenview, Illinois



Build your critical care ultrasonography skills with courses designed to help you in diagnosis and management of critically ill patients. Advance your practice, and enhance patient care through hands-on training by experts in the field of ultrasonography.

#### Ultrasonography: Essentials in Critical Care

December 3-5, 2015 • March 11-13, 2016

Discover key elements of critical care ultrasonography in this intensive 3-day course. Practice image acquisition with human models using high quality ultrasound machines.

#### Critical Care Ultrasonography: Integration Into Clinical Practice

May 5-7, 2016

Study whole body ultrasonography for diagnosis and management of the critical ill patient in a hands-on learning environment using human models and state-of-the-art simulators.

#### Advanced Critical Care Echocardiography

June 2-4, 2016

Focus on practical elements of advanced critical care echocardiography through hands-on training. Learn practical measurement skills relevant to the diagnosis and management of patients with cardiopulmonary failure.

#### NEW! Transesophageal Echocardiography

June 5, 2016

Learn critical care transesophageal echocardiography (TEE) image acquisition through the use of high fidelity TEE simulators in small group training sessions.



> Register Now [chestnet.org/live-learning](http://chestnet.org/live-learning)

#### Who Should Attend?

Frontline intensivists, pulmonary/critical care specialists, and fellows; hospitalists; emergency medicine/critical care, anesthesia/critical care, and surgical/critical care fellows; physicians; nurse practitioners; and physician assistants are encouraged to attend.

# Inhaled budesonide cut bronchopulmonary dysplasia

BY MARY ANN MOON  
*Frontline Medical News*

Inhaled budesonide delivered within 24 hours of birth decreases the incidence of bronchopulmonary dysplasia in extremely preterm neonates, but this benefit may be offset by a possible increase in mortality, according to a report published in the *New England Journal of Medicine*.

Systemic glucocorticoids reduce the rate of bronchopulmonary dysplasia, but appear to cause severe short- and long-term adverse effects including intestinal perforation and cerebral palsy. Administering the drugs by inhalation may avert these adverse systemic effects, but until now most studies of this mode of delivery have been small, haven't initiated the treatment immediately after birth, and have produced inconclusive results. So researchers performed a large double-blind placebo-controlled randomized trial in which inhaled budesonide or a matching placebo was administered within 24 hours of birth to 863 extremely preterm neonates.

The infants were treated at 40 medical centers in nine countries during a 3-year period, until they no longer needed supplemental oxygen and positive-pressure support or reached a postmenstrual age of 32 weeks, said Dr. Dirk Bassler of the University Hospital Zurich, and his associates.

The primary outcome measure – a composite of death or bronchopulmonary dysplasia at 36 weeks postmenstrual age – occurred in 40% of the budesonide group and 46% of

the placebo group (relative risk, 0.86), indicating that the active drug produced a benefit of borderline significance, Dr. Bassler and his associates noted (*N Engl J Med*. 2015 Oct 14; doi: 10.1056/NEJMoa1501917).

However, when the two components of the composite outcome were examined separately, inhaled budesonide was significantly better than was placebo at reducing the rate of bronchopulmonary dysplasia but was associated with a nonsignificant excess in mortality. The lung disorder developed in 28% of neonates assigned to active treatment and in 38% of those assigned to placebo (RR, 0.74), while mortality was 17% for budesonide and 14% for placebo (RR, 1.24). Notably, the nonsignificant difference in mortality may have been due to chance, the investigators said.

Budesonide also significantly reduced the incidence of two important secondary outcomes: patent ductus arteriosus requiring surgical ligation (RR, 0.55) and the need for reintubation after completion of the study drug (RR, 0.58). The therapy did not offer any benefit over placebo in the frequency of all other secondary outcomes, including retinopathy of prematurity, brain injury, necrotizing enterocolitis, patent ductus arteriosus requiring medical treatment, infections, oral candidiasis requiring treatment, hypertension requiring treatment, hyperglycemia requiring treatment, length of hospital stay, increase in weight or head circumference, and age at the last use of respiratory pressure support.

The rates of adverse events did not



HERJUA/THINKSTOCK

## VIEW ON THE NEWS

### Budesonide's risks remain uncertain

The risk/benefit profile of inhaled budesonide to prevent bronchopulmonary dysplasia remains uncertain, given that the treatment effects on the composite outcome in this study moved in opposite directions.

Inhaled budesonide's ability to reduce rates of bronchopulmonary dysplasia, severe patent ductus arteriosus, and reintubation are probably real. But according to the available data, it is still uncertain

whether the differential in mortality in favor of placebo represents truth or artifact.

*Dr. Barbara Schmidt is in the division of neonatology at Children's Hospital of Philadelphia. She reported receiving nonfinancial support from Chiesi Farmaceutici outside of this work. Dr. Schmidt made these remarks in an editorial accompanying Dr. Bassler's report (N Engl J Med. 2015 Oct 14. doi: 10.1056/NEJMe1509243).*

differ significantly between the groups.

The overall efficacy of early inhaled budesonide, as well as its associated risks, cannot be ascertained from these short-term outcomes alone. "Follow-up of our study cohort, including assessment of neurodevelopmental outcomes at 18-22 months of corrected age, is currently under way," the researchers wrote.

This study was supported by the European Union and Chiesi Farmaceutici. Chiesi supplied the study drugs and Trudell Medical International supplied spacers for the inhalers. Dr. Bassler and three of his associates reported receiving grant support and personal fees from Chiesi Farmaceutici. The other authors reported no financial disclosures.

# CMS 2016 schedule will pay for advance care planning

BY ALICIA GALLEGOS  
*Frontline Medical News*

Officials at the Centers for Medicare & Medicaid Services have issued the final 2016 fee schedule for physicians, making modifications to the Physician Quality Reporting System (PQRS) and loosening requirements for its controversial two-midnight rule.

The fee schedule – the first since repeal of the Sustainable Growth Rate (SGR) formula and enactment of the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA) – includes changes to payment policies, modifications to misvalued codes, and updates to quality performance metrics under the PQRS, the Medicare Shared Savings Program, and Physician Compare, among others.

As part of the final fee schedule rule, CMS is relaxing its two-midnight rule to allow doctors greater flexibility when determining whether hospital stays are subject to the regulation.

For hospital stays for which physicians expect the patient will need less than two midnights of hospital care, an inpatient admission may still be payable under Medicare Part A on a case-by-case basis based on the admitting physician's judgment. CMS plans to use Beneficiary and Family Centered Care Quality Improvement Organizations to conduct initial medical reviews of claims for short-stay inpatient admissions. The claim reviews will focus on educating physicians and hospitals about the policy for inpatient admissions. Only physicians with questionable practice patterns, such as high rates of claims denial after medical review, will be referred to auditors, according to CMS.

"These changes continue CMS' long-standing emphasis on the importance of a physician's medical judgment in meeting the needs of Medicare beneficiaries," CMS officials stated in a fact sheet.

CMS also finalized two new advance care planning codes that will pay physicians for time spent

discussing patient options for advance directives. The first code will cover an initial 30 minutes of the physicians' time, and the second code will cover additional 30-minute blocks as necessary.

The AMA Current Procedural Terminology (CPT) Editorial Panel and the AMA Relative Value Update Committee (RUC) created the new CPT codes and recommended the associated payments for calendar year 2015, but CMS delayed the codes' enactment until collecting public comment.

The fee schedule also includes modifications to the Medicare Shared Savings Program including a new measure on statin therapy for cardiovascular disease in the "preventive health domain" of the Shared Savings Program quality measure set. The final rule also clarifies how PQRS-eligible professionals participating within an Accountable Care Organization can meet reporting requirements.

## SELECTED IMPORTANT SAFETY INFORMATION

### WARNING: (A) PREMATURE DISCONTINUATION OF ELIQUIS INCREASES THE RISK OF THROMBOTIC EVENTS, (B) SPINAL/EPIDURAL HEMATOMA

**(A) Premature discontinuation of any oral anticoagulant, including ELIQUIS, increases the risk of thrombotic events. If anticoagulation with ELIQUIS is discontinued for a reason other than pathological bleeding or completion of a course of therapy, consider coverage with another anticoagulant.**

**(B) Epidural or spinal hematomas may occur in patients treated with ELIQUIS who are receiving neuraxial anesthesia or undergoing spinal puncture. These hematomas may result in long-term or permanent paralysis. Consider these risks when scheduling patients for spinal procedures. Factors that can increase the risk of developing epidural or spinal hematomas in these patients include:**

- use of indwelling epidural catheters
- concomitant use of other drugs that affect hemostasis, such as nonsteroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, other anticoagulants
- a history of traumatic or repeated epidural or spinal punctures
- a history of spinal deformity or spinal surgery
- optimal timing between the administration of ELIQUIS and neuraxial procedures is not known

**Monitor patients frequently for signs and symptoms of neurological impairment. If neurological compromise is noted, urgent treatment is necessary.**

**Consider the benefits and risks before neuraxial intervention in patients anticoagulated or to be anticoagulated.**

### CONTRAINDICATIONS

- Active pathological bleeding
- Severe hypersensitivity reaction to ELIQUIS (e.g., anaphylactic reactions)

### WARNINGS AND PRECAUTIONS

- **Increased Risk of Thrombotic Events After Premature Discontinuation:** Premature discontinuation of any oral anticoagulant, including ELIQUIS, in the absence of adequate alternative anticoagulation increases the risk of thrombotic events. An increased rate of stroke was observed during the transition from ELIQUIS to warfarin in clinical trials in atrial fibrillation patients. If ELIQUIS is discontinued for a reason other than pathological bleeding or completion of a course of therapy, consider coverage with another anticoagulant.
- **Bleeding Risk:** ELIQUIS increases the risk of bleeding and can cause serious, potentially fatal, bleeding.
  - Concomitant use of drugs affecting hemostasis increases the risk of bleeding, including aspirin and other antiplatelet agents, other anticoagulants, heparin, thrombolytic agents, SSRIs, SNRIs, and NSAIDs.
  - Advise patients of signs and symptoms of blood loss and to report them immediately or go to an emergency room. Discontinue ELIQUIS in patients with active pathological hemorrhage.
  - There is no established way to reverse the anticoagulant effect of apixaban, which can be expected to persist for at least 24 hours after the last dose (i.e., about two half-lives). A specific antidote for ELIQUIS is not available.

- **Spinal/Epidural Anesthesia or Puncture:** Patients treated with ELIQUIS undergoing spinal/epidural anesthesia or puncture may develop an epidural or spinal hematoma which can result in long-term or permanent paralysis.

The risk of these events may be increased by the postoperative use of indwelling epidural catheters or the concomitant use of medicinal products affecting hemostasis. Indwelling epidural or intrathecal catheters should not be removed earlier than 24 hours after the last administration of ELIQUIS. The next dose of ELIQUIS should not be administered earlier than 5 hours after the removal of the catheter. The risk may also be increased by traumatic or repeated epidural or spinal puncture. If traumatic puncture occurs, delay the administration of ELIQUIS for 48 hours.

Monitor patients frequently and if neurological compromise is noted, urgent diagnosis and treatment is necessary. Physicians should consider the potential benefit versus the risk of neuraxial intervention in ELIQUIS patients.

- **Prosthetic Heart Valves:** The safety and efficacy of ELIQUIS have not been studied in patients with prosthetic heart valves and is not recommended in these patients.
- **Acute PE in Hemodynamically Unstable Patients or Patients who Require Thrombolysis or Pulmonary Embolectomy:** Initiation of ELIQUIS is not recommended as an alternative to unfractionated heparin for the initial treatment of patients with PE who present with hemodynamic instability or who may receive thrombolysis or pulmonary embolectomy.

### ADVERSE REACTIONS

- The most common and most serious adverse reactions reported with ELIQUIS were related to bleeding.

### TEMPORARY INTERRUPTION FOR SURGERY AND OTHER INTERVENTIONS


- ELIQUIS should be discontinued at least 48 hours prior to elective surgery or invasive procedures with a moderate or high risk of unacceptable or clinically significant bleeding. ELIQUIS should be discontinued at least 24 hours prior to elective surgery or invasive procedures with a low risk of bleeding or where the bleeding would be noncritical in location and easily controlled. Bridging anticoagulation during the 24 to 48 hours after stopping ELIQUIS and prior to the intervention is not generally required. ELIQUIS should be restarted after the surgical or other procedures as soon as adequate hemostasis has been established.

### DRUG INTERACTIONS

- **Strong Dual Inhibitors of CYP3A4 and P-gp:** Inhibitors of cytochrome P450 3A4 (CYP3A4) and P-glycoprotein (P-gp) increase exposure to apixaban and increase the risk of bleeding. For patients receiving ELIQUIS doses of 5 mg or 10 mg twice daily, reduce the dose of ELIQUIS by 50% when ELIQUIS is coadministered with drugs that are strong dual inhibitors of CYP3A4 and P-gp (e.g., ketoconazole, itraconazole, ritonavir, or clarithromycin). In patients already taking 2.5 mg twice daily, avoid coadministration of ELIQUIS with strong dual inhibitors of CYP3A4 and P-gp.
- **Strong Dual Inducers of CYP3A4 and P-gp:** Avoid concomitant use of ELIQUIS with strong dual inducers of CYP3A4 and P-gp (e.g., rifampin, carbamazepine, phenytoin, St. John's wort) because such drugs will decrease exposure to apixaban and increase the risk of stroke and other thromboembolic events.

Please see Brief Summary of Full Prescribing Information, including Boxed WARNINGS, on the adjacent pages.

Approved for 6 indications



Learn more about ELIQUIS for the treatment of DVT/PE and access reprints of our clinical studies.

[hcp.eliquis.com](http://hcp.eliquis.com)

NVAF=nonvalvular atrial fibrillation; DVT=deep vein thrombosis; PE=pulmonary embolism.

#### SELECTED IMPORTANT SAFETY INFORMATION (CONT'D)

##### DRUG INTERACTIONS (CONT'D)

- **Anticoagulants and Antiplatelet Agents:** Coadministration of antiplatelet agents, fibrinolytics, heparin, aspirin, and chronic NSAID use increases the risk of bleeding. APPRAISE-2, a placebo-controlled clinical trial of apixaban in high-risk post-acute coronary syndrome patients treated with aspirin or the combination of aspirin and clopidogrel, was terminated early due to a higher rate of bleeding with apixaban compared to placebo.

##### PREGNANCY CATEGORY B

- There are no adequate and well-controlled studies of ELIQUIS in pregnant women. Treatment is likely to increase the risk of hemorrhage during pregnancy and delivery. ELIQUIS should be used during pregnancy only if the potential benefit outweighs the potential risk to the mother and fetus.

Please see Brief Summary of Full Prescribing Information, including Boxed WARNINGS, on the adjacent pages.

## ELIQUIS® (apixaban) tablets, for oral use

R<sub>x</sub> ONLY

**Brief Summary of Prescribing Information. For complete prescribing information consult official package insert.**

**WARNING: (A) PREMATURE DISCONTINUATION OF ELIQUIS INCREASES THE RISK OF THROMBOTIC EVENTS  
(B) SPINAL/EPIDURAL HEMATOMA**

**(A) PREMATURE DISCONTINUATION OF ELIQUIS INCREASES THE RISK OF THROMBOTIC EVENTS**

Premature discontinuation of any oral anticoagulant, including ELIQUIS, increases the risk of thrombotic events. If anticoagulation with ELIQUIS is discontinued for a reason other than pathological bleeding or completion of a course of therapy, consider coverage with another anticoagulant [see *Dosage and Administration, Warnings and Precautions, and Clinical Studies (14.1)* in full Prescribing Information].

**(B) SPINAL/EPIDURAL HEMATOMA**

Epidural or spinal hematomas may occur in patients treated with ELIQUIS who are receiving neuraxial anesthesia or undergoing spinal puncture. These hematomas may result in long-term or permanent paralysis. Consider these risks when scheduling patients for spinal procedures. Factors that can increase the risk of developing epidural or spinal hematomas in these patients include:

- use of indwelling epidural catheters
- concomitant use of other drugs that affect hemostasis, such as nonsteroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, other anticoagulants
- a history of traumatic or repeated epidural or spinal punctures
- a history of spinal deformity or spinal surgery
- optimal timing between the administration of ELIQUIS and neuraxial procedures is not known

[see *Warnings and Precautions*]

Monitor patients frequently for signs and symptoms of neurological impairment. If neurological compromise is noted, urgent treatment is necessary [see *Warnings and Precautions*].

Consider the benefits and risks before neuraxial intervention in patients anticoagulated or to be anticoagulated [see *Warnings and Precautions*].

### INDICATIONS AND USAGE

**Reduction of Risk of Stroke and Systemic Embolism in Nonvalvular Atrial Fibrillation—**ELIQUIS® (apixaban) is indicated to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation.

**Prophylaxis of Deep Vein Thrombosis Following Hip or Knee Replacement Surgery—**ELIQUIS is indicated for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in patients who have undergone hip or knee replacement surgery.

**Treatment of Deep Vein Thrombosis—**ELIQUIS is indicated for the treatment of DVT.

**Treatment of Pulmonary Embolism—**ELIQUIS is indicated for the treatment of PE.

**Reduction in the Risk of Recurrence of DVT and PE—**ELIQUIS is indicated to reduce the risk of recurrent DVT and PE following initial therapy.

### DOSAGE AND ADMINISTRATION (Selected information)

#### Temporary Interruption for Surgery and Other Interventions

ELIQUIS should be discontinued at least 48 hours prior to elective surgery or invasive procedures with a moderate or high risk of unacceptable or clinically significant bleeding. ELIQUIS should be discontinued at least 24 hours prior to elective surgery or invasive procedures with a low risk of bleeding or where the bleeding would be non-critical in location and easily controlled. Bridging anticoagulation during the 24 to 48 hours after stopping ELIQUIS and prior to the intervention is not generally required. ELIQUIS should be restarted after the surgical or other procedures as soon as adequate hemostasis has been established. (For complete *Dosage and Administration* section, see full Prescribing Information.)

### CONTRAINDICATIONS

ELIQUIS is contraindicated in patients with the following conditions:

- Active pathological bleeding [see *Warnings and Precautions and Adverse Reactions*]
- Severe hypersensitivity reaction to ELIQUIS (e.g., anaphylactic reactions) [see *Adverse Reactions*]

### WARNINGS AND PRECAUTIONS

#### Increased Risk of Thrombotic Events after Premature Discontinuation

Premature discontinuation of any oral anticoagulant, including ELIQUIS, in the absence of adequate alternative anticoagulation increases the risk of thrombotic events. An increased rate of stroke was observed during the transition from ELIQUIS to warfarin in clinical trials in atrial fibrillation patients. If ELIQUIS is discontinued for a reason other than pathological bleeding or completion of a course of therapy, consider coverage with another anticoagulant [see *Dosage and Administration (2.4)* and *Clinical Studies (14.1)* in full Prescribing Information].

#### Bleeding

ELIQUIS increases the risk of bleeding and can cause serious, potentially fatal, bleeding [see *Dosage and Administration (2.1)* in full Prescribing Information and *Adverse Reactions*].

Concomitant use of drugs affecting hemostasis increases the risk of bleeding. These include aspirin and other antiplatelet agents, other anticoagulants, heparin, thrombolytic agents, selective serotonin reuptake inhibitors, serotonin norepinephrine reuptake inhibitors, and nonsteroidal anti-inflammatory drugs (NSAIDs) [see *Drug Interactions*].

Advise patients of signs and symptoms of blood loss and to report them immediately or go to an emergency room. Discontinue ELIQUIS in patients with active pathological hemorrhage.

There is no established way to reverse the anticoagulant effect of apixaban, which can be expected to persist for at least 24 hours after the last dose, i.e., for about two drug half-lives. A specific antidote for ELIQUIS is not available. Hemodialysis does not appear to have a substantial impact on apixaban exposure [see *Clinical Pharmacology (12.3)* in full Prescribing Information]. Protamine sulfate and vitamin K are not expected to affect the anticoagulant activity of apixaban. There is no experience with antifibrinolytic agents (tranexamic acid, aminocaproic acid) in individuals receiving apixaban. There is neither scientific rationale for reversal nor experience with systemic hemostatics (desmopressin and aprotinin) in individuals receiving apixaban. Use of procoagulant reversal agents such as prothrombin

complex concentrate, activated prothrombin complex concentrate, or recombinant factor VIIa may be considered but has not been evaluated in clinical studies. Activated oral charcoal reduces absorption of apixaban, thereby lowering apixaban plasma concentration [see *Overdosage*].

#### Spinal/Epidural Anesthesia or Puncture

When neuraxial anesthesia (spinal/epidural anesthesia) or spinal/epidural puncture is employed, patients treated with antithrombotic agents for prevention of thromboembolic complications are at risk of developing an epidural or spinal hematoma which can result in long-term or permanent paralysis.

The risk of these events may be increased by the postoperative use of indwelling epidural catheters or the concomitant use of medicinal products affecting hemostasis. Indwelling epidural or intrathecal catheters should not be removed earlier than 24 hours after the last administration of ELIQUIS (apixaban). The next dose of ELIQUIS should not be administered earlier than 5 hours after the removal of the catheter. The risk may also be increased by traumatic or repeated epidural or spinal puncture. If traumatic puncture occurs, delay the administration of ELIQUIS for 48 hours.

Monitor patients frequently for signs and symptoms of neurological impairment (e.g., numbness or weakness of the legs, bowel, or bladder dysfunction). If neurological compromise is noted, urgent diagnosis and treatment is necessary. Prior to neuraxial intervention the physician should consider the potential benefit versus the risk in anticoagulated patients or in patients to be anticoagulated for thromboprophylaxis.

#### Patients with Prosthetic Heart Valves

The safety and efficacy of ELIQUIS have not been studied in patients with prosthetic heart valves. Therefore, use of ELIQUIS is not recommended in these patients.

#### Acute PE in Hemodynamically Unstable Patients or Patients who Require Thrombolysis or Pulmonary Embolectomy

Initiation of ELIQUIS is not recommended as an alternative to unfractionated heparin for the initial treatment of patients with PE who present with hemodynamic instability or who may receive thrombolysis or pulmonary embolectomy.

### ADVERSE REACTIONS

The following serious adverse reactions are discussed in greater detail in other sections of the prescribing information.

- Increased risk of thrombotic events after premature discontinuation [see *Warnings and Precautions*]
- Bleeding [see *Warnings and Precautions*]
- Spinal/epidural anesthesia or puncture [see *Warnings and Precautions*]

### Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

#### Reduction of Risk of Stroke and Systemic Embolism in Patients with Nonvalvular Atrial Fibrillation

The safety of ELIQUIS was evaluated in the ARISTOTLE and AVERROES studies [see *Clinical Studies (14)* in full Prescribing Information], including 11,284 patients exposed to ELIQUIS 5 mg twice daily and 602 patients exposed to ELIQUIS 2.5 mg twice daily. The duration of ELIQUIS exposure was  $\geq 12$  months for 9375 patients and  $\geq 24$  months for 3369 patients in the two studies. In ARISTOTLE, the mean duration of exposure was 89 weeks ( $>15,000$  patient-years). In AVERROES, the mean duration of exposure was approximately 59 weeks ( $>3000$  patient-years).

The most common reason for treatment discontinuation in both studies was for bleeding-related adverse reactions; in ARISTOTLE this occurred in 1.7% and 2.5% of patients treated with ELIQUIS and warfarin, respectively, and in AVERROES, in 1.5% and 1.3% on ELIQUIS and aspirin, respectively.

#### Bleeding in Patients with Nonvalvular Atrial Fibrillation in ARISTOTLE and AVERROES

Tables 1 and 2 show the number of patients experiencing major bleeding during the treatment period and the bleeding rate (percentage of subjects with at least one bleeding event per 100 patient-years) in ARISTOTLE and AVERROES.

**Table 1: Bleeding Events in Patients with Nonvalvular Atrial Fibrillation in ARISTOTLE\***

	ELIQUIS N=9088 n (per 100 pt-year)	Warfarin N=9052 n (per 100 pt-year)	Hazard Ratio (95% CI)	P-value
Major†	327 (2.13)	462 (3.09)	0.69 (0.60, 0.80)	<0.0001
Intracranial (ICH)‡	52 (0.33)	125 (0.82)	0.41 (0.30, 0.57)	-
Hemorrhagic stroke§	38 (0.24)	74 (0.49)	0.51 (0.34, 0.75)	-
Other ICH	15 (0.10)	51 (0.34)	0.29 (0.16, 0.51)	-
Gastrointestinal (GI)¶	128 (0.83)	141 (0.93)	0.89 (0.70, 1.14)	-
Fatal**	10 (0.06)	37 (0.24)	0.27 (0.13, 0.53)	-
Intracranial	4 (0.03)	30 (0.20)	0.13 (0.05, 0.37)	-
Non-intracranial	6 (0.04)	7 (0.05)	0.84 (0.28, 2.15)	-

\* Bleeding events within each subcategory were counted once per subject, but subjects may have contributed events to multiple endpoints. Bleeding events were counted during treatment or within 2 days of stopping study treatment (on-treatment period).

† Defined as clinically overt bleeding accompanied by one or more of the following: a decrease in hemoglobin of  $\geq 2$  g/dL, a transfusion of 2 or more units of packed red blood cells, bleeding at a critical site: intracranial, intraspinal, intraocular, pericardial, intra-articular, intramuscular with compartment syndrome, retroperitoneal or with fatal outcome.

‡ Intracranial bleed includes intracerebral, intraventricular, subdural, and subarachnoid bleeding. Any type of hemorrhagic stroke was adjudicated and counted as an intracranial major bleed.

§ On-treatment analysis based on the safety population, compared to ITT analysis presented in Section 14.

¶ GI bleed includes upper GI, lower GI, and rectal bleeding.

\*\* Fatal bleeding is an adjudicated death with the primary cause of death as intracranial bleeding or non-intracranial bleeding during the on-treatment period.

In ARISTOTLE, the results for major bleeding were generally consistent across most major subgroups including age, weight, CHADS<sub>2</sub> score (a scale from 0 to 6 used to estimate risk of stroke, with higher scores predicting greater risk), prior warfarin use, geographic region, and aspirin use at randomization (Figure 1). Subjects treated with apixaban with diabetes bled more (3.0% per year) than did subjects without diabetes (1.9% per year).

Adverse reactions occurring in ≥1% of patients undergoing hip or knee replacement surgery in the 1 Phase II study and the 3 Phase III studies are listed in Table 4.

**Table 4: Adverse Reactions Occurring in ≥1% of Patients in Either Group Undergoing Hip or Knee Replacement Surgery**

	ELIQUIS (apixaban), n (%) 2.5 mg po bid N=5924	Enoxaparin, n (%) 40 mg sc qd or 30 mg sc q12h N=5904
Nausea	153 (2.6)	159 (2.7)
Anemia (including postoperative and hemorrhagic anemia, and respective laboratory parameters)	153 (2.6)	178 (3.0)
Contusion	83 (1.4)	115 (1.9)
Hemorrhage (including hematoma, and vaginal and urethral hemorrhage)	67 (1.1)	81 (1.4)
Postprocedural hemorrhage (including postprocedural hematoma, wound hemorrhage, vessel puncture site hematoma and catheter site hemorrhage)	54 (0.9)	60 (1.0)
Transaminases increased (including alanine aminotransferase increased and alanine aminotransferase abnormal)	50 (0.8)	71 (1.2)
Aspartate aminotransferase increased	47 (0.8)	69 (1.2)
Gamma-glutamyltransferase increased	38 (0.6)	65 (1.1)

Less common adverse reactions in apixaban-treated patients undergoing hip or knee replacement surgery occurring at a frequency of ≥0.1% to <1%:

*Blood and lymphatic system disorders:* thrombocytopenia (including platelet count decreases)

*Vascular disorders:* hypotension (including procedural hypotension)

*Respiratory, thoracic, and mediastinal disorders:* epistaxis

*Gastrointestinal disorders:* gastrointestinal hemorrhage (including hematemesis and melena), hematochezia

*Hepatobiliary disorders:* liver function test abnormal, blood alkaline phosphatase increased, blood bilirubin increased

*Renal and urinary disorders:* hematuria (including respective laboratory parameters)

*Injury, poisoning, and procedural complications:* wound secretion, incision-site hemorrhage (including incision-site hematoma), operative hemorrhage

Less common adverse reactions in apixaban-treated patients undergoing hip or knee replacement surgery occurring at a frequency of <0.1%:

Gingival bleeding, hemoptysis, hypersensitivity, muscle hemorrhage, ocular hemorrhage (including conjunctival hemorrhage), rectal hemorrhage

*Treatment of DVT and PE and Reduction in the Risk of Recurrence of DVT or PE*

The safety of ELIQUIS has been evaluated in the AMPLIFY and AMPLIFY-EXT studies, including 2676 patients exposed to ELIQUIS 10 mg twice daily, 3359 patients exposed to ELIQUIS 5 mg twice daily, and 840 patients exposed to ELIQUIS 2.5 mg twice daily.

Common adverse reactions (≥1%) were gingival bleeding, epistaxis, contusion, hematuria, rectal hemorrhage, hematoma, menorrhagia, and hemoptysis.

AMPLIFY Study

The mean duration of exposure to ELIQUIS was 154 days and to enoxaparin/warfarin was 152 days in the AMPLIFY study. Adverse reactions related to bleeding occurred in 417 (15.6%) ELIQUIS-treated patients compared to 661 (24.6%) enoxaparin/warfarin-treated patients. The discontinuation rate due to bleeding events was 0.7% in the ELIQUIS-treated patients compared to 1.7% in enoxaparin/warfarin-treated patients in the AMPLIFY study.

In the AMPLIFY study, ELIQUIS was statistically superior to enoxaparin/warfarin in the primary safety endpoint of major bleeding (relative risk 0.31, 95% CI [0.17, 0.55], P-value <0.0001).

Bleeding results from the AMPLIFY study are summarized in Table 5.

**Table 5: Bleeding Results in the AMPLIFY Study**

	ELIQUIS N=2676 n (%)	Enoxaparin/Warfarin N=2689 n (%)	Relative Risk (95% CI)
Major	15 (0.6)	49 (1.8)	0.31 (0.17, 0.55) p<0.0001
CRNM*	103 (3.9)	215 (8.0)	
Major + CRNM	115 (4.3)	261 (9.7)	
Minor	313 (11.7)	505 (18.8)	
All	402 (15.0)	676 (25.1)	

\* CRNM = clinically relevant nonmajor bleeding.

Events associated with each endpoint were counted once per subject, but subjects may have contributed events to multiple endpoints.

Adverse reactions occurring in ≥1% of patients in the AMPLIFY study are listed in Table 6.

**Table 6: Adverse Reactions Occurring in ≥1% of Patients Treated for DVT and PE in the AMPLIFY Study**

	ELIQUIS N=2676 n (%)	Enoxaparin/Warfarin N=2689 n (%)
Epistaxis	77 (2.9)	146 (5.4)
Contusion	49 (1.8)	97 (3.6)
Hematuria	46 (1.7)	102 (3.8)
Menorrhagia	38 (1.4)	30 (1.1)
Hematoma	35 (1.3)	76 (2.8)
Hemoptysis	32 (1.2)	31 (1.2)
Rectal hemorrhage	26 (1.0)	39 (1.5)
Gingival bleeding	26 (1.0)	50 (1.9)

AMPLIFY-EXT Study

The mean duration of exposure to ELIQUIS was approximately 330 days and to placebo was 312 days in the AMPLIFY-EXT study. Adverse reactions related to bleeding occurred in 219 (13.3%) ELIQUIS-treated patients compared to 72 (8.7%) placebo-treated patients. The discontinuation rate due to bleeding events was approximately 1% in the ELIQUIS-treated patients compared to 0.4% in those patients in the placebo group in the AMPLIFY-EXT study.

Bleeding results from the AMPLIFY-EXT study are summarized in Table 7.

**Table 7: Bleeding Results in the AMPLIFY-EXT Study**

	ELIQUIS (apixaban) 2.5 mg bid N=840 n (%)	ELIQUIS 5 mg bid N=811 n (%)	Placebo N=826 n (%)
Major	2 (0.2)	1 (0.1)	4 (0.5)
CRNM*	25 (3.0)	34 (4.2)	19 (2.3)
Major + CRNM	27 (3.2)	35 (4.3)	22 (2.7)
Minor	75 (8.9)	98 (12.1)	58 (7.0)
All	94 (11.2)	121 (14.9)	74 (9.0)

\* CRNM = clinically relevant nonmajor bleeding.

Events associated with each endpoint were counted once per subject, but subjects may have contributed events to multiple endpoints.

Adverse reactions occurring in ≥1% of patients in the AMPLIFY-EXT study are listed in Table 8.

**Table 8: Adverse Reactions Occurring in ≥1% of Patients Undergoing Extended Treatment for DVT and PE in the AMPLIFY-EXT Study**

	ELIQUIS 2.5 mg bid N=840 n (%)	ELIQUIS 5 mg bid N=811 n (%)	Placebo N=826 n (%)
Epistaxis	13 (1.5)	29 (3.6)	9 (1.1)
Hematuria	12 (1.4)	17 (2.1)	9 (1.1)
Hematoma	13 (1.5)	16 (2.0)	10 (1.2)
Contusion	18 (2.1)	18 (2.2)	18 (2.2)
Gingival bleeding	12 (1.4)	9 (1.1)	3 (0.4)

Other Adverse Reactions

Less common adverse reactions in ELIQUIS-treated patients in the AMPLIFY or AMPLIFY-EXT studies occurring at a frequency of ≥0.1% to <1%:

*Blood and lymphatic system disorders:* hemorrhagic anemia

*Gastrointestinal disorders:* hematochezia, hemorrhoidal hemorrhage, gastrointestinal hemorrhage, hematemesis, melena, anal hemorrhage

*Injury, poisoning, and procedural complications:* wound hemorrhage, postprocedural hemorrhage, traumatic hematoma, periorbital hematoma

*Musculoskeletal and connective tissue disorders:* muscle hemorrhage

*Reproductive system and breast disorders:* vaginal hemorrhage, metrorrhagia, menometrorrhagia, genital hemorrhage

*Vascular disorders:* hemorrhage

*Skin and subcutaneous tissue disorders:* ecchymosis, skin hemorrhage, petechiae

*Eye disorders:* conjunctival hemorrhage, retinal hemorrhage, eye hemorrhage

*Investigations:* blood urine present, occult blood positive, occult blood, red blood cells urine positive

*General disorders and administration-site conditions:* injection-site hematoma, vessel puncture-site hematoma

## DRUG INTERACTIONS

Apixaban is a substrate of both CYP3A4 and P-gp. Inhibitors of CYP3A4 and P-gp increase exposure to apixaban and increase the risk of bleeding. Inducers of CYP3A4 and P-gp decrease exposure to apixaban and increase the risk of stroke and other thromboembolic events.

### Strong Dual Inhibitors of CYP3A4 and P-gp

For patients receiving ELIQUIS 5 mg or 10 mg twice daily, the dose of ELIQUIS should be decreased by 50% when it is coadministered with drugs that are strong dual inhibitors of CYP3A4 and P-gp (e.g., ketoconazole, itraconazole, ritonavir, or clarithromycin) [see *Dosage and Administration (2.5) and Clinical Pharmacology (12.3) in full Prescribing Information*].

For patients receiving ELIQUIS at a dose of 2.5 mg twice daily, avoid coadministration with strong dual inhibitors of CYP3A4 and P-gp [see *Dosage and Administration (2.5) and Clinical Pharmacology (12.3) in full Prescribing Information*].

### Strong Dual Inducers of CYP3A4 and P-gp

Avoid concomitant use of ELIQUIS with strong dual inducers of CYP3A4 and P-gp (e.g., rifampin, carbamazepine, phenytoin, St. John's wort) because such drugs will decrease exposure to apixaban [see *Clinical Pharmacology (12.3) in full Prescribing Information*].

### Anticoagulants and Antiplatelet Agents

Coadministration of antiplatelet agents, fibrinolytics, heparin, aspirin, and chronic NSAID use increases the risk of bleeding.

APPRAISE-2, a placebo-controlled clinical trial of apixaban in high-risk, post-acute coronary syndrome patients treated with aspirin or the combination of aspirin and clopidogrel, was terminated early due to a higher rate of bleeding with apixaban compared to placebo. The rate of ISTH major bleeding was 2.8% per year with apixaban versus 0.6% per year with placebo in patients receiving single antiplatelet therapy and was 5.9% per year with apixaban versus 2.5% per year with placebo in those receiving dual antiplatelet therapy.

In ARISTOTLE, concomitant use of aspirin increased the bleeding risk on ELIQUIS from 1.8% per year to 3.4% per year and concomitant use of aspirin and warfarin increased the bleeding risk from 2.7% per year to 4.6% per year. In this clinical trial, there was limited (2.3%) use of dual antiplatelet therapy with ELIQUIS.

## USE IN SPECIFIC POPULATIONS

### Pregnancy

#### *Pregnancy Category B*

There are no adequate and well-controlled studies of ELIQUIS in pregnant women. Treatment is likely to increase the risk of hemorrhage during pregnancy and delivery. ELIQUIS should be used during pregnancy only if the potential benefit outweighs the potential risk to the mother and fetus.

Treatment of pregnant rats, rabbits, and mice after implantation until the end of gestation resulted in fetal exposure to apixaban, but was not associated with increased risk for fetal malformations or toxicity. No maternal or fetal deaths were attributed to bleeding. Increased incidence of maternal bleeding was observed in mice, rats, and rabbits at maternal exposures that were 19, 4, and 1 times, respectively, the human exposure of unbound drug, based on area under plasma-concentration time curve (AUC) comparisons at the maximum recommended human dose (MRHD) of 10 mg (5 mg twice daily).

### Labor and Delivery

Safety and effectiveness of ELIQUIS during labor and delivery have not been studied in clinical trials. Consider the risks of bleeding and of stroke in using ELIQUIS in this setting [see *Warnings and Precautions*].

Treatment of pregnant rats from implantation (gestation Day 7) to weaning (lactation Day 21) with apixaban at a dose of 1000 mg/kg (about 5 times the human exposure based on unbound apixaban) did not result in death of offspring or death of mother rats during labor in association with uterine bleeding. However, increased incidence of maternal bleeding, primarily during gestation, occurred at apixaban doses of ≥25 mg/kg, a dose corresponding to ≥1.3 times the human exposure.

### Nursing Mothers

It is unknown whether apixaban or its metabolites are excreted in human milk. Rats excrete apixaban in milk (12% of the maternal dose).

Women should be instructed either to discontinue breastfeeding or to discontinue ELIQUIS (apixaban) therapy, taking into account the importance of the drug to the mother.

### Pediatric Use

Safety and effectiveness in pediatric patients have not been established.

### Geriatric Use

Of the total subjects in the ARISTOTLE and AVERROES clinical studies, >69% were 65 and older, and >31% were 75 and older. In the ADVANCE-1, ADVANCE-2, and ADVANCE-3 clinical studies, 50% of subjects were 65 and older, while 16% were 75 and older. In the AMPLIFY and AMPLIFY-EXT clinical studies, >32% of subjects were 65 and older and >13% were 75 and older. No clinically significant differences in safety or effectiveness were observed when comparing subjects in different age groups.

### Renal Impairment

No dose adjustment is recommended for patients with renal impairment alone, including those with end-stage renal disease (ESRD) maintained on hemodialysis, except nonvalvular atrial fibrillation patients who meet the criteria for dosage adjustment [see *Dosage and Administration (2.1) in full Prescribing Information*]. Patients with ESRD (CrCl <15 mL/min) receiving or not receiving hemodialysis were not studied in clinical efficacy and safety studies with ELIQUIS; therefore, the dosing recommendations are based on pharmacokinetic and pharmacodynamic (anti-Factor Xa activity) data in subjects with ESRD maintained on dialysis [see *Clinical Pharmacology (12.3) in full Prescribing Information*].

### Hepatic Impairment

No dose adjustment is required in patients with mild hepatic impairment (Child-Pugh class A). Because patients with moderate hepatic impairment (Child-Pugh class B) may have intrinsic coagulation abnormalities and there is limited clinical experience with ELIQUIS in these patients, dosing recommendations cannot be provided [see *Clinical Pharmacology (12.2) in full Prescribing Information*]. ELIQUIS is not recommended in patients with severe hepatic impairment (Child-Pugh class C) [see *Clinical Pharmacology (12.2) in full Prescribing Information*].

## OVERDOSAGE

There is no antidote to ELIQUIS. Overdose of ELIQUIS increases the risk of bleeding [see *Warnings and Precautions*].

In controlled clinical trials, orally administered apixaban in healthy subjects at doses up to 50 mg daily for 3 to 7 days (25 mg twice daily for 7 days or 50 mg once daily for 3 days) had no clinically relevant adverse effects.

In healthy subjects, administration of activated charcoal 2 and 6 hours after ingestion of a 20-mg dose of apixaban reduced mean apixaban AUC by 50% and 27%, respectively. Thus, administration of activated charcoal may be useful in the management of apixaban overdose or accidental ingestion.

## PATIENT COUNSELING INFORMATION

See *FDA-approved patient labeling (Medication Guide)*.

Advise patients of the following:

- They should not discontinue ELIQUIS without talking to their physician first.
- They should be informed that it might take longer than usual for bleeding to stop, and they may bruise or bleed more easily when treated with ELIQUIS. Advise patients about how to recognize bleeding or symptoms of hypovolemia and of the urgent need to report any unusual bleeding to their physician.
- They should tell their physicians and dentists they are taking ELIQUIS, and/or any other product known to affect bleeding (including nonprescription products, such as aspirin or NSAIDs), before any surgery or medical or dental procedure is scheduled and before any new drug is taken.
- If the patient is having neuraxial anesthesia or spinal puncture, inform the patient to watch for signs and symptoms of spinal or epidural hematomas, such as numbness or weakness of the legs, or bowel or bladder dysfunction [see *Warnings and Precautions*]. If any of these symptoms occur, the patient should contact his or her physician immediately.
- They should tell their physicians if they are pregnant or plan to become pregnant or are breastfeeding or intend to breastfeed during treatment with ELIQUIS [see *Use in Specific Populations*].
- If a dose is missed, the dose should be taken as soon as possible on the same day and twice-daily administration should be resumed. The dose should not be doubled to make up for a missed dose.

Marketed by:  
Bristol-Myers Squibb Company  
Princeton, New Jersey 08543 USA  
and  
Pfizer Inc  
New York, New York 10017 USA

1356615A0 / 1356514A0

Rev September 2015

432US1501679-06-01

## COMMENTARY: Flu vaccine safety in patients with egg allergy

BY DOUGLAS S. PAAUW, M.D.  
*Frontline Medical News*

A 35-year-old woman with asthma presents for a follow-up visit in October. You recommend that she receive the influenza vaccine. She tells you that she cannot take the influenza vaccine because she is allergic to eggs.

### What do you recommend?

- A. Give her the influenza vaccine.
- B. Give her an oseltamivir prescription, and have her start it if any flu-like symptoms appear.
- C. Give her the nasal influenza vaccine.
- D. Give her the cell-based influenza vaccine.

The clinic I work in asks all patients if they have allergy to eggs before giving the influenza vaccine.



DR. PAAUW

If the patient replies yes, then the vaccine is not given and the physician is consulted.

For many years, allergy to egg was considered a contraindication to receiving the influenza vaccine. This contraindication was based on the fear that administering a vaccine that was grown in eggs and could contain egg protein might cause anaphylaxis in patients with immunoglobulin E antibodies against egg proteins.

Fortunately, there is a good evidence base that shows that administering influenza vaccine to patients with egg allergy is safe.

This is extremely important information, because it is estimated that there are about 200,000-300,000 hospitalizations annually because of influenza. For the 2012-2013 influenza season, the CDC estimated that the flu vaccine prevented 6.6 million cases of influenza, 3.2 million doctor visits, and 79,000 hospitalizations. There were 170 pediatric deaths from the flu during the 2012-2013 influenza season (MMWR Morb Mortal Wkly Rep. 2013 Dec 13;62[49]:997-1000). The need for widespread vaccination is great, and decreasing the number of people unable to receive the vaccine is an important goal.

There are many studies in children and adults that show that those with egg allergy can be safely vaccinated with influenza vaccine.

Dr. John M. James and colleagues reported a study of mostly children (average age, 3 years) with egg allergy confirmed with skin testing receiving influenza vaccine (*J Pediatr.* 1998 Nov;133[5]:624-8). A

total of 83 patients with egg allergy received the vaccine (including 27 with a history of anaphylaxis or severe reactions after egg ingestion). No patients suffered severe reactions with the vaccine, with only

four patients having mild, self-limited symptoms.

In another study, Dr. Anne Des Roches and colleagues performed a prospective, cohort study recruiting and vaccinating egg-allergic



What could be worse than having NTM?  
Not knowing you have NTM.

References: 1. Mirsaeidi M, et al. *Int J Infect Dis.* 2013;17(11):e1000-e1004. 2. Adjemian J, et al. *Am J Respir Crit Care Med.* 2012;185(8):881-886. 3. Young JD, et al. *J Respir Dis.* 2007;28(1):7-18. 4. Griffith DE, et al; ATS Mycobacterial Diseases Subcommittee. *Am J Respir Crit Care Med.* 2007;175(4):367-416. 5. Winthrop KL, et al. *Am J Respir Crit Care Med.* 2010;182(7):977-982. 6. Mehta M, et al. *Respir Med.* 2011;105(11):1718-1725.

Insmid Copyright 2015 © Insmid and the Insmid logo are trademarks of Insmid. All Rights Reserved. NP-US-00024



RAQUEL CAMACHO GÃ³MEZ/THINKSTOCK

patients with trivalent inactivated influenza vaccine between 2010 and 2012 (J Allergy Clin Immunol. 2012 Nov;130[5]:1213-1216.e1). In the second year of the study, the focus was on recruiting patients with a history of anaphylaxis or severe cardiopulmonary symptoms upon egg ingestion. In addition, a retro-

spective study of all egg-allergic patients who had received an influenza vaccine between 2007 and 2010 was included.

A total of 457 doses of vaccine were administered to 367 patients with egg allergy, of whom 132 had a history of severe allergy. No patients developed anaphylaxis, and 13 patients developed mild allergiclike symptoms in the 24 hours after vaccination.

In an authoritative review on the subject of influenza vaccination in egg-allergic patients, Dr. John Kelso reported on 28 studies with a total of 4,315 patients with egg allergy, including 656 with history of anaphylaxis with egg ingestion (Expert Rev Vaccines. 2014 Aug;13[8]:1049-57). None of these patients developed a serious reaction when they received influenza vaccine.

Dr. De Roches and colleagues reported on a prospective, cohort study in which 68 children with previous egg allergy received intranasal live attenuated influenza vaccine (J Allergy Clin Immunol Pract. 2015 Jan-Feb;3[1]:138-9). No patients had anaphylaxis or a severe allergic reaction. There were more adverse reactions in the patients with egg (7 patients) than in the control group (1 patient), but these were mild and nonspecific (abdominal pain, nasal congestion, headache, and cough).

The 2012 adverse reactions to vaccines practice parameter update recommended that patients with egg allergy should receive influenza vaccinations (trivalent influenza vaccine), because the risks of vaccinating are outweighed by the risks of not vaccinating (J Allergy Clin Immunol. 2012 Jul;130[1]:25-43).

A subsequent recommendation takes this a step further, recommending that all patients with egg allergy of any severity should receive inactivated influenza vaccine annually, using any age-approved brand (Ann Allergy Asthma Immunol. 2013 Oct;111[4]:301-2). In addition, there are no special waiting periods after vaccination of egg allergic patients beyond what is standard practice for any vaccine.

I think that we have plenty of evidence now to immunize all patients who report egg allergy, and to do so in the primary care setting.

*Dr. Paauw is professor of medicine in the division of general internal medicine at the University of Washington, Seattle, and he serves as third-year medical student clerkship director at the University of Washington. Contact Dr. Paauw at [dpaauw@uw.edu](mailto:dpaauw@uw.edu).*



### Up to 50% of all patients with bronchiectasis also have an active pulmonary NTM infection.<sup>1</sup>

- A nontuberculous mycobacterial (NTM) lung infection is a chronic and debilitating pulmonary condition that can get progressively worse. NTM prevalence is increasing steadily, **growing by 8%** every year.<sup>2,5</sup>
- The signs and symptoms are common among other comorbidities, like bronchiectasis and COPD. These similarities can result in NTM being **masked**, with patients suffering for months or years before a diagnosis.<sup>2,3,6</sup>
- Patients with bronchiectasis are particularly susceptible to NTM, and routine screening is recommended.<sup>1</sup>

Think NTM? Test for NTM.

Visit [NTMfacts.com](http://NTMfacts.com) to learn more

**insmed**

INTRODUCING  
CO-SUSPENSION TECHNOLOGY

---


THE NEW SCIENCE OF  
INTELLIGENT DELIVERY  
IN RESPIRATORY MEDICINE

---

Exploring a new formulation for inhaled drug delivery

*A specially engineered,  
phospholipid carrier particle  
with multiple drug crystals!*





Visit [Co-SuspensionParticles.com](http://Co-SuspensionParticles.com)  
to Learn More

# CO-SUSPENSION TECHNOLOGY

All images are for illustrative purposes only.

**Reference:** 1. Vehring R, Lechuga-Ballesteros D, Joshi V, Noga B, Dwivedi SK. Cosuspensions of microcrystals and engineered microparticles for uniform and efficient delivery of respiratory therapeutics from pressurized metered dose inhalers. *Langmuir*. 2012;28(42):15015-15023.

# Rifapentine boosts adherence for workers with LTBI


BY AMY KARON  
Frontline Medical News

SAN DIEGO – Health care workers with latent tuberculosis infection (LTBI) were significantly more likely to continue a shorter course of weekly rifapentine plus isoniazid (INH) than daily INH monotherapy, researchers reported at an annual scientific meeting on infectious diseases.

“Consideration should be given to no longer routinely recommending INH for the treatment of LTBI among health care workers,” said Dr. Esther Arguello Perez of Memorial Sloan Kettering Cancer Center, New York.

Health care workers face a greater risk of TB infection than the general population, regardless of the income level in the country where they live; patients with undiagnosed laryngeal or pulmonary TB usually pose the greatest risk, especially during procedures that cause coughing, such as sputum induction and bronchoscopy (*Int J Tuberc Lung Dis.* 2007;11[6]:593-605).

Although occupational TB testing is routine in U.S. health care organizations, more than half of health care workers who start treatment for LTBI historically have failed to finish (*Chest.* 2010;137[2]:401-9. doi: 10.1378/chest.09-0394). The standard LTBI regimen – 300 mg INH daily for 9 months – has been linked to potentially intolerable adverse effects such as hepatotoxicity, persistent gastrointestinal symptoms, rash, and neuropsychiatric problems (*Drug Healthc Patient Saf.* 2014;6:145-9. doi: 10.2147/DHPS.S68837).



In a 2011 multicenter trial, investigators reported a significantly higher completion rate for weekly rifapentine plus INH (900 mg each; 82% vs. 69% for daily INH;  $P < .001$ ).

Rates of adverse effects were significantly lower with weekly rifapentine plus INH, although grade 3-4 events and risk of death did not differ between the groups (*N Engl J Med.* 2011;365:2155-66. doi: 10.1056/NEJMoa1104875). The results of that trial quickly transformed recommendations for LTBI treatment (*MMWR.* 2011;60[48]:1650-53).

Memorial Sloan Kettering implemented weekly rifapentine plus INH for its LTBI personnel in 2011. By 2014, about three-quarters of personnel with LTBI received rifapentine plus INH, while the rest were evenly split between rifampin and INH monotherapy, Dr. Arguello Perez reported at the

combined annual meetings of the Infectious Diseases Society of America, the Society for Healthcare Epidemiology of America, the HIV Medicine Association, and the Pediatric Infectious Diseases Society.

To understand how health care workers' attitudes and treatment acceptance shifted along with practice, the investigators reviewed records from all health care workers at Memorial Sloan Kettering who were diagnosed with LTBI for 2005-2014. Among 930 patients, only 357 (38%) accepted treatment, although 76% of these individuals finished the regimen they started, she noted.

Rifapentine plus INH had the highest completion rate (88%), significantly exceeding rates for a 4-month course of daily rifampin (84%) and for 9 months of INH monotherapy (70%;  $P < .01$  for both differences).

In contrast, completion rates for rifampin and INH did not differ significantly, Dr. Arguello Perez said.

Notably, LTBI treatment completion rates among health care workers rose by 26% between 2013, when most prescriptions were for rifampin or INH monotherapy, and 2014, when most were for rifapentine plus INH. “Health care workers might be more likely to accept treatment for LTBI if they know about alternatives to INH,” she concluded.

Dr. Arguello Perez and her associates reported no funding sources and had no financial disclosures.

## Simple breath test effectively detected tuberculosis

BY DOUG BRUNK  
Frontline Medical News

SAN DIEGO – Researchers in England used a novel gas analysis technique to detect tuberculosis in the breath, with a sensitivity of 93% and a specificity of 94%.

“Clearly these are promising results,” Dr. Amandip Sahota said at the annual Interscience Conference on Antimicrobial Agents and Chemotherapy. “What interested me the most is that we were able to detect a significant difference in chemicals in both pulmonary and extra-pulmonary TB, which did indicate to us that the disease does not need to be limited to the lungs to be detectable in the breath.”

According to the latest data from the World Health Organization, there were 9 million active TB cases and 1.5 million deaths from the disease in 2013. Of these deaths, 80,000 were in children.

“TB remains a diagnostic challenge well into the 21st Century,” said Dr. Sahota, a consultant physician in infectious diseases at University

Hospitals of Leicester, England. “We are still heavily reliant on the standard culture, which is both slow and resource-intensive throughout the world. Despite the advent of



**What is exciting 'is the advent of newer gas sensor technologies ... being developed in line with a clinical need.'**

DR. SAHOTA

TB-PCR, we are still far away from a diagnostic test which is both available at point of care, at low cost, and is available throughout the world.”

In a study he conducted during his time as a research fellow at the University Hospitals of Coventry, in association with colleagues at the University of Warwick, Dr. Sahota and his associates used a field asymmetric ion mobility spectrometry device to collect samples of exhaled breath from 25 patients with suspected pulmonary or extra-pulmonary

TB over a period of 6 months, before or within 1 week of treatment. For comparison, exhaled breath from 19 healthy controls was also obtained.

While ion mobility spectrometry has been used for years by the military and the security industry to detect explosives, for example, the technology has more recently been used to help diagnose medical conditions ranging from cancers to infections.

“Breath testing for TB is not new, but what is very exciting is the advent of newer gas sensor technologies which are being developed in line with a clinical need,” Dr. Sahota explained. “The point of interest here is volatile organic compounds: chemicals which are gaseous at ambient temperatures often produce odors, and are endogenous products of metabolism in both health and disease states. So testing for breath can be quick, easy, and noninvasive. Clearly there's plenty of sample. It's rapid, and it allows access to chemicals in the blood, which are visible in the breath through ventilator processes.”

Patients in the study, which is

believed to be the first of its kind, breathed into a 3L Tedlar air sample bag and the samples were tested within 2 hours with a portable field asymmetric ion mobility spectrometry device made by Oxford Immunotec, Inc.

After measuring the ionic mobility of volatile organic compounds in the headspace, the researchers determined that the test was highly effective in detecting TB in the breath, with a sensitivity of 93% and a specificity of 94%.

“Clearly this is a small study and we do need to repeat this in a larger cohort to validate it further,” Dr. Sahota said. “We also need to investigate potential confounders such as other comorbidities and medications. Ideally, we'd like to use a smaller, more portable instrument which is ideally hand-held, so we're exploring commercial partnerships.”

The study was funded by the Medical Research Council. The researchers reported having no financial disclosures.


dbrunk@frontlinemedcom.com

# Biofilm pathogens dominate waterborne illnesses

BY SHARON WORCESTER  
Frontline Medical News

ATLANTA – Emerging biofilm-associated pathogens are overtaking those transmitted by the fecal-oral route as the most-common cause of death from waterborne illness in the United States, according to findings from a review of administrative and disease-specific surveillance data.

Between 2003 and 2009, a mean of 2,516 deaths occurred per year as a result of exposure to 1 of more of 14 different waterborne germs or diseases, including campylobacterio-



JAMES HELLMAN, M.D./CC BY-SA 3.0/WIKIMEDIA COMMONS

sis, cryptosporidiosis, *Escherichia coli* infections, free-living amoeba, giardiasis, hemolytic uremic syndrome, hepatitis A, Legionnaires' disease, nontuberculous *Mycobacterium*, otitis externa, *Pseudomonas*, salmonellosis, shigellosis, and vibriosis, Julia Gargano, Ph.D., reported in a poster at the International Conference on Emerging Infectious Diseases.

The most commonly documented causes of death, accounting for 88% of deaths, were *Pseudomonas* pneumonia or *P. septicemia*, nontuberculous *Mycobacterium*, and Legionnaires' disease – all biofilm pathogens. For those illnesses potentially linked to ingestion of contaminated water – as opposed to those associated with inhalation and contact – the most-commonly documented causes of death were hepatitis A, hemolytic uremic syndrome, and vibriosis, noted Dr. Gargano of the Center for Disease Control and Prevention's National Center for Emerging and Zoonotic Infectious Diseases, Atlanta.

The findings were obtained from U.S. death certificates, the Nationwide Inpatient Sample, and disease-specific surveillance.

Although surveillance data consistently show that transmission of waterborne diarrheal diseases

continue, such diseases are rarely fatal in the United States. Further, advances in water treatment and sanitation have reduced the burden of such diseases.

The findings of this study demon-

strate that the burden of mortality has shifted.

“This is the first time the annual number of deaths due to potentially waterborne disease has been calculated, and [the findings] highlight the

emerging trend in biofilm-related illness,” she wrote.

Dr. Gargano reported having no financial disclosures.

sworcester@frontlinemedcom.com

OFEV IS RECOMMENDED\* FOR THE TREATMENT OF IPF BY THE ATS/ERS/JRS/ALAT GUIDELINES<sup>1</sup>

## SLOW THE PATH OF IPF PROGRESSION

OFEV (nintedanib) has demonstrated reproducible reductions in the annual rate of FVC decline in 3 clinical trials<sup>2</sup>

OFEV significantly reduced the risk of first acute IPF exacerbation over 52 weeks compared with placebo in 2 out of 3 clinical trials<sup>2</sup>

Learn more about OFEV inside.

### INDICATION AND USAGE

OFEV is indicated for the treatment of idiopathic pulmonary fibrosis (IPF).

### IMPORTANT SAFETY INFORMATION WARNINGS AND PRECAUTIONS

#### Elevated Liver Enzymes

- OFEV is not recommended in patients with moderate (Child Pugh B) or severe (Child Pugh C) hepatic impairment.
- OFEV was associated with elevations of liver enzymes (ALT, AST, ALKP, and GGT) and bilirubin. Liver enzyme increases were reversible with dose modification or interruption and not associated with clinical signs or symptoms of liver injury. The majority (94%) of patients with ALT and/or AST elevations had elevations <5 times ULN. The majority (95%) of patients with bilirubin elevations had elevations <2 times ULN.
- Conduct liver function tests prior to treatment, monthly for 3 months, and every 3 months thereafter, and as clinically indicated. Monitor for adverse reactions and consider dosage modifications, interruption, or discontinuation as necessary for liver enzyme elevations.

Please see additional Important Safety Information and brief summary for OFEV on the following pages.

\*This conditional recommendation means that clinicians are encouraged to discuss preferences with their patients when making treatment decisions as the majority of patients would want treatment, but many would not.<sup>1</sup>

ALAT, Latin American Thoracic Association; ATS, American Thoracic Society; ERS, European Respiratory Society; FVC, forced vital capacity; JRS, Japanese Respiratory Society.

 **OFEV**<sup>®</sup>  
(nintedanib)  
capsules 150mg

TREAT NOW. SLOW PROGRESSION.

# Coccidioidomycosis threatens Southwestern workers

BY **BIANCA NOGRADY**  
Frontline Medical News

The expansion of the solar energy industry in *Coccidioides*-endemic areas of the Southwestern Unit-

ed States is exposing more workers to the infection, say the authors of a study that found an attack rate of 1.2 cases per 100 workers.

A study among 3,572 workers at two solar power-generating facilities

in California identified 44 individuals with the infection between October 2011 and April 2014, 9 of whom were hospitalized.


The disease is acquired through inhalation of the soil-dwelling *Coc-*

*cidoides* fungus spores and while the majority of the patients said they had received safety training about the risk of coccidioidomycosis, only six of those who regularly performed soil-disruptive work re-

## The totality of the evidence demonstrates that OFEV slows IPF progression<sup>2-6</sup>


### REPRODUCIBLE REDUCTIONS IN THE ANNUAL RATE OF FVC DECLINE ACROSS 3 TRIALS<sup>2\*</sup>

#### INPULSIS<sup>®</sup>-1 (Study 2)<sup>2,7</sup>



- -115 mL/year for OFEV (nintedanib) compared with -240 mL/year for placebo\*

#### INPULSIS<sup>®</sup>-2 (Study 3)<sup>2,7</sup>



- -114 mL/year for OFEV compared with -207 mL/year for placebo\*

**TOMORROW (Study 1):** OFEV demonstrated a 68% relative reduction in the annual rate of FVC decline compared with placebo (-60 mL/year vs -191 mL/year, respectively; P=.01, 95% CI=27, 235)<sup>2,8</sup>

CI, confidence interval; HR, hazard ratio.

\*The annual rate of decline in FVC (mL/year) was analyzed using a random coefficient regression model.<sup>2</sup>

## IMPORTANT SAFETY INFORMATION WARNINGS AND PRECAUTIONS (CONT'D)


### Gastrointestinal Disorders

#### Diarrhea

- Diarrhea was the most frequent gastrointestinal event reported in 62% versus 18% of patients treated with OFEV and placebo, respectively. Events were primarily mild to moderate intensity and occurred within the first 3 months. Diarrhea led to permanent dose reduction in 11% and discontinuation in 5% of OFEV patients versus 0 and <1% in placebo patients, respectively.
- Dosage modifications or treatment interruptions may be necessary in patients with diarrhea. Treat diarrhea at first signs with adequate hydration and antidiarrheal medication (e.g., loperamide), and consider treatment interruption if diarrhea continues. OFEV treatment may be resumed at the full dosage (150 mg twice daily), or at the reduced dosage (100 mg twice daily), which subsequently may be increased to the full dosage. If severe diarrhea persists, discontinue treatment.

#### Nausea and Vomiting

- Nausea was reported in 24% versus 7% and vomiting was reported in 12% versus 3% of patients treated with OFEV and placebo, respectively. Events were primarily of mild to moderate intensity. Nausea and vomiting led to discontinuation of OFEV in 2% and 1% of patients, respectively.
- If nausea or vomiting persists despite appropriate supportive care including anti-emetic therapy, consider dose reduction or treatment interruption. OFEV treatment may be resumed at full dosage or at reduced dosage, which subsequently may be increased to full dosage. If severe nausea or vomiting does not resolve, discontinue treatment.



COURTESY CDC/ LUCILLE GEORG

ported regularly using respiratory protection (Emerg Infect Dis. 2015 Nov;21[11]:1997-2005).

“Large-scale construction, including solar farm construction, might involve substantial soil disturbance for months, and many employees, particularly from non-*Coccidioides*-endemic areas, probably lack immunity

to *Coccidioides*,” wrote Jason A. Wilken, Ph.D., of the Centers for Disease Control and Prevention, and his coauthors.

“Medical providers should consider work-related coccidioidomycosis when evaluating construction workers with prolonged febrile respiratory illness, particularly after work in Cen-

tral or Southern California or in Arizona, and medical providers should follow all statutory requirements for documenting and reporting occupational illness,” Dr. Wilken concluded.

The study was supported by the Centers for Disease Control and Prevention. No conflicts of interest were declared.

## SIGNIFICANT REDUCTION IN THE RISK OF FIRST ACUTE IPF EXACERBATION OVER 52 WEEKS COMPARED WITH PLACEBO IN 2 OUT OF 3 CLINICAL TRIALS<sup>2</sup>

- **INPULSIS<sup>®</sup>-2** (adjudicated): HR=0.20 (95% CI=0.07, 0.56)
- **TOMORROW** (investigator-reported): HR=0.16 (95% CI=0.04, 0.71)
- **INPULSIS<sup>®</sup>-1** (adjudicated): HR=0.55 (95% CI=0.20, 1.54; not statistically significant)

## THE MOST COMMON ADVERSE EVENTS WERE GASTROINTESTINAL IN NATURE AND GENERALLY OF MILD OR MODERATE INTENSITY<sup>2</sup>

- Diarrhea was reported in 62% of patients receiving OFEV vs 18% on placebo
- Diarrhea can be managed by symptomatic treatment, dose reduction, or treatment interruption until diarrhea resolves to levels that allow continuation of therapy. If severe diarrhea persists despite symptomatic treatment, discontinue OFEV



ONE CAPSULE,  
TWICE DAILY WITH FOOD<sup>2</sup>

Not shown at actual size

Visit [hcp.OFEV.com](http://hcp.OFEV.com) for more information.

## IMPORTANT SAFETY INFORMATION WARNINGS AND PRECAUTIONS (CONT'D)

**Embryofetal Toxicity:** OFEV is Pregnancy category D. It can cause fetal harm when administered to a pregnant woman and patients should be advised of the potential hazard to a fetus. Women should be advised to avoid becoming pregnant while receiving OFEV and to use adequate contraception during treatment and at least 3 months after the last dose of OFEV.

**Arterial Thromboembolic Events:** Arterial thromboembolic events were reported in 2.5% of OFEV and 0.8% of placebo patients, respectively. Myocardial infarction was the most common arterial thromboembolic event, occurring in 1.5% of OFEV and 0.4% of placebo patients. Use caution when treating patients at higher cardiovascular risk including known coronary artery disease. Consider treatment interruption in patients who develop signs or symptoms of acute myocardial ischemia.

**Risk of Bleeding:** OFEV may increase the risk of bleeding. Bleeding events were reported in 10% of OFEV versus 7% of placebo patients. Use OFEV in patients with known risk of bleeding only if the anticipated benefit outweighs the potential risk.

**Gastrointestinal Perforation:** OFEV may increase the risk of gastrointestinal perforation. Gastrointestinal perforation was reported in 0.3% of OFEV versus in 0% placebo patients. Use caution when treating patients who have had recent abdominal surgery. Discontinue therapy with OFEV in patients who develop gastrointestinal perforation. Only use OFEV in patients with known risk of gastrointestinal perforation if the anticipated benefit outweighs the potential risk.

Please see additional Important Safety Information and brief summary for OFEV on the following pages.

 **OFEV<sup>®</sup>**  
(nintedanib)  
capsules 150mg

TREAT NOW. SLOW PROGRESSION.

# Big declines seen in aspergillosis mortality

BY BRUCE JANCIN  
Frontline Medical News

SAN DIEGO – In-hospital mortality in patients with aspergillosis plummeted nationally, according to data from

2001-2011, with the biggest improvement seen in immunocompromised patients traditionally considered at high mortality risk. Dr. Masako Mizusawa reported at the annual Inter-science Conference on Antimicrobial

Agents and Chemotherapy.

The decline in in-hospital mortality wasn't linear. Rather, it followed a stepwise pattern, and those steps occurred in association with three major advances during the study

years: Food and Drug Administration approval of voriconazole in 2002, the FDA's 2003 approval of the galactomannan serologic assay allowing for speedier diagnosis of aspergillosis, and the 2008 Infectious Diseases

GRANTED BREAKTHROUGH THERAPY DESIGNATION FOR IPF DURING FDA REVIEW<sup>9</sup>

## Start your appropriate patients with IPF on OFEV



**CONDUCT** liver function tests (ALT, AST, and bilirubin) prior to initiating treatment with OFEV (nintedanib)



**COMPLETE** the OFEV Prescription Form—available at [www.hcp.OFEV.com](http://www.hcp.OFEV.com)—and fax it to one of the participating specialty pharmacies listed on the form



**OFFER** enrollment in OPEN DOORS™, a patient support program for patients receiving OFEV

### IMPORTANT SAFETY INFORMATION ADVERSE REACTIONS

- Adverse reactions reported in ≥5% of OFEV patients included diarrhea, nausea, abdominal pain, liver enzyme elevation, vomiting, decreased appetite, weight decreased, headache, and hypertension.
- The most frequent serious adverse reactions reported in OFEV patients were bronchitis and myocardial infarction. The most common adverse events leading to death in OFEV patients versus placebo were pneumonia (0.7% vs. 0.6%), lung neoplasm malignant (0.3% vs. 0%), and myocardial infarction (0.3% vs. 0.2%). In the predefined category of major adverse cardiovascular events (MACE) including MI, fatal events were reported in 0.6% of OFEV versus 1.8% in placebo patients.

### DRUG INTERACTIONS

- **P-glycoprotein (P-gp) and CYP3A4 Inhibitors and Inducers:** Coadministration with oral doses of a P-gp and CYP3A4 inhibitor, ketoconazole, increased exposure to nintedanib by 60%. Concomitant use of potent P-gp and CYP3A4 inhibitors (e.g., erythromycin) with OFEV may increase exposure to nintedanib. In such cases, patients should be monitored closely for tolerability of OFEV. Management of adverse reactions may require

interruption, dose reduction, or discontinuation of therapy with OFEV. Coadministration with oral doses of a P-gp and CYP3A4 inducer, rifampicin, decreased exposure to nintedanib by 50%. Concomitant use of P-gp and CYP3A4 inducers (e.g., carbamazepine, phenytoin, and St. John's wort) with OFEV should be avoided as these drugs may decrease exposure to nintedanib.

- **Anticoagulants:** Nintedanib may increase the risk of bleeding. Monitor patients on full anticoagulation therapy closely for bleeding and adjust anticoagulation treatment as necessary.

### USE IN SPECIFIC POPULATIONS

- **Nursing Mothers:** Excretion of nintedanib and/or its metabolites into human milk is probable. Because of the potential for serious adverse reactions in nursing infants from OFEV, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.
- **Smokers:** Smoking was associated with decreased exposure to OFEV, which may affect the efficacy of OFEV. Encourage patients to stop smoking prior to and during treatment.

OFHCPISISEP15

Please see brief summary for OFEV on the following pages.

**References:** 1. Raghu G et al; on behalf of the ATS, ERS, JRS, and ALAT. *Am J Respir Crit Care Med.* 2015;192(2):238-248. 2. OFEV® (nintedanib) Prescribing Information. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc; 2014. 3. Zappala CJ et al. *Eur Respir J.* 2010;35(4):830-836. 4. Schmidt SL et al. *Chest.* 2014;145(3):579-585. 5. du Bois RM et al. *Am J Respir Crit Care Med.* 2011;184(12):1382-1389. 6. Song JW et al. *Eur Respir J.* 2011;37(2):356-363. 7. Richeldi L et al; for the INPULSIS Trial Investigators. *N Engl J Med.* 2014;370(22):2071-2082. 8. Richeldi L et al. *N Engl J Med.* 2011;365(12):1079-1087. 9. US Food and Drug Administration. [http://www.fda.gov/downloads/Regulatory Information/Legislation/FederalFoodDrugandCosmeticActFDCA/SignificantAmendmentsstotheFDCA/UCM380724.pdf](http://www.fda.gov/downloads/Regulatory%20Information/Legislation/FederalFoodDrugandCosmeticActFDCA/SignificantAmendmentsstotheFDCA/UCM380724.pdf). Accessed September 1, 2015.



Copyright ©2015, Boehringer Ingelheim Pharmaceuticals, Inc. All rights reserved. (09/15) PC-OF-0267-PROF

**OFEV**<sup>®</sup>  
(nintedanib)  
capsules 150mg

TREAT NOW. SLOW PROGRESSION.

Society of America clinical practice guidelines on the treatment of aspergillosis (Clin Infect Dis. 2008 Feb 1;46[3]:327-60).

“This was an observational study and we can’t actually say that these events are causative. But just looking at the time relationship, it certainly looks plausible,” Dr. Mizusawa said.



**The stepwise mortality decline mirrored FDA approvals of voriconazole and an assay for galactomannan.**

DR. MIZUSAWA

In addition, the median hospital length of stay decreased from 9 to 7 days in patients with this potentially life-threatening infection, noted Dr. Mizusawa of Tufts Medical Center, Boston.

She presented what she believes is the largest U.S. longitudinal study of hospital care for aspergillosis. The

retrospective study used nationally representative data from the Agency for Healthcare Research and Quality’s Healthcare Utilization and Cost Project–Nationwide Inpatient Sample.

Dr. Mizusawa and coinvestigators defined aspergillosis patients as being at high mortality risk if they had

*Continued on following page*

**OFEV® (nintedanib) capsules, for oral use**

**BRIEF SUMMARY OF PRESCRIBING INFORMATION**

**Please see package insert for full Prescribing Information, including Patient Information**

**INDICATIONS AND USAGE:** OFEV is indicated for the treatment of idiopathic pulmonary fibrosis (IPF).

**DOSE AND ADMINISTRATION: Testing Prior to OFEV Administration:**

Conduct liver function tests prior to initiating treatment with OFEV [see *Warnings and Precautions*]. **Recommended Dosage:** The recommended dosage of OFEV is 150 mg twice daily administered approximately 12 hours apart. OFEV capsules should be taken with food and swallowed whole with liquid. OFEV capsules should not be chewed or crushed because of a bitter taste. The effect of chewing or crushing of the capsule on the pharmacokinetics of nintedanib is not known. If a dose of OFEV is missed, the next dose should be taken at the next scheduled time. Advise the patient to not make up for a missed dose. Do not exceed the recommended maximum daily dosage of 300 mg. **Dosage Modification due to Adverse Reactions:** In addition to symptomatic treatment, if applicable, the management of adverse reactions of OFEV may require dose reduction or temporary interruption until the specific adverse reaction resolves to levels that allow continuation of therapy. OFEV treatment may be resumed at the full dosage (150 mg twice daily), or at the reduced dosage (100 mg twice daily), which subsequently may be increased to the full dosage. If a patient does not tolerate 100 mg twice daily, discontinue treatment with OFEV [see *Warnings and Precautions and Adverse Reactions*]. Dose modifications or interruptions may be necessary for liver enzyme elevations. For aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >3 times to <5 times the upper limit of normal (ULN) without signs of severe liver damage, interrupt treatment or reduce OFEV to 100 mg twice daily. Once liver enzymes have returned to baseline values, treatment with OFEV may be reintroduced at a reduced dosage (100 mg twice daily), which subsequently may be increased to the full dosage (150 mg twice daily) [see *Warnings and Precautions and Adverse Reactions*]. Discontinue OFEV for AST or ALT elevations >5 times ULN or >3 times ULN with signs or symptoms of severe liver damage.

**CONTRAINDICATIONS:** None

**WARNINGS AND PRECAUTIONS: Elevated Liver Enzymes:**

The safety and efficacy of OFEV has not been studied in patients with moderate (Child Pugh B) or severe (Child Pugh C) hepatic impairment. Treatment with OFEV is not recommended in patients with moderate or severe hepatic impairment [see *Use in Specific Populations*]. In clinical trials, administration of OFEV was associated with elevations of liver enzymes (ALT, AST, ALKP, GGT). Liver enzyme increases were reversible with dose modification or interruption and not associated with clinical signs or symptoms of liver injury. The majority (94%) of patients with ALT and/or AST elevations had elevations <5 times ULN. Administration of OFEV was also associated with elevations of bilirubin. The majority (95%) of patients with bilirubin elevations had elevations <2 times ULN [see *Use in Specific Populations*]. Conduct liver function tests (ALT, AST, and bilirubin) prior to treatment with OFEV, monthly for 3 months, and every 3 months thereafter, and as clinically indicated. Dosage modifications or interruption may be necessary for liver enzyme elevations. **Gastrointestinal Disorders:** **Diarrhea:** Diarrhea was the most frequent gastrointestinal event reported in 62% versus 18% of patients treated with OFEV and placebo, respectively [see *Adverse Reactions*]. In most patients, the event was of mild to moderate intensity and occurred within the first 3 months of treatment. Diarrhea led to permanent dose reduction in 11% of patients treated with OFEV compared to 0 placebo-treated patients. Diarrhea led to discontinuation of OFEV in 5% of the patients compared to <1% of placebo-treated patients. Dosage modifications or treatment interruptions may be necessary in patients with adverse reactions of diarrhea. Treat diarrhea at first signs with adequate hydration and antidiarrheal medication (e.g., loperamide), and consider treatment interruption if diarrhea continues. OFEV treatment may be resumed at the full dosage (150 mg twice daily), or at the

reduced dosage (100 mg twice daily), which subsequently may be increased to the full dosage. If severe diarrhea persists despite symptomatic treatment, discontinue treatment with OFEV (nintedanib). **Nausea and Vomiting:** Nausea was reported in 24% versus 7% and vomiting was reported in 12% versus 3% of patients treated with OFEV and placebo, respectively [see *Adverse Reactions*]. In most patients, these events were of mild to moderate intensity. Nausea led to discontinuation of OFEV in 2% of patients. Vomiting led to discontinuation of OFEV in 1% of the patients. For nausea or vomiting that persists despite appropriate supportive care including anti-emetic therapy, dose reduction or treatment interruption may be required. OFEV treatment may be resumed at the full dosage (150 mg twice daily), or at the reduced dosage (100 mg twice daily), which subsequently may be increased to the full dosage. If severe nausea or vomiting does not resolve, discontinue treatment with OFEV. **Embryofetal Toxicity:** OFEV can cause fetal harm when administered to a pregnant woman. Nintedanib was teratogenic and embryofetotoxic in rats and rabbits at less than and approximately 5 times the maximum recommended human dose (MRHD) in adults (on an AUC basis at oral doses of 2.5 and 15 mg/kg/day in rats and rabbits, respectively). If OFEV is used during pregnancy, or if the patient becomes pregnant while taking OFEV, the patient should be advised of the potential hazard to a fetus. Women of childbearing potential should be advised to avoid becoming pregnant while receiving treatment with OFEV and to use adequate contraception during treatment and at least 3 months after the last dose of OFEV [see *Use in Specific Populations*].

**Arterial Thromboembolic Events:** Arterial thromboembolic events have been reported in patients taking OFEV. In clinical trials, arterial thromboembolic events were reported in 2.5% of patients treated with OFEV and 0.8% of placebo-treated patients. Myocardial infarction was the most common adverse reaction under arterial thromboembolic events, occurring in 1.5% of OFEV-treated patients compared to 0.4% of placebo-treated patients. Use caution when treating patients at higher cardiovascular risk including known coronary artery disease. Consider treatment interruption in patients who develop signs or symptoms of acute myocardial ischemia. **Risk of Bleeding:** Based on the mechanism of action (VEGFR inhibition), OFEV may increase the risk of bleeding. In clinical trials, bleeding events were reported in 10% of patients treated with OFEV and in 7% of patients treated with placebo. Use OFEV in patients with known risk of bleeding only if the anticipated benefit outweighs the potential risk. **Gastrointestinal Perforation:** Based on the mechanism of action, OFEV may increase the risk of gastrointestinal perforation. In clinical trials, gastrointestinal perforation was reported in 0.3% of patients treated with OFEV, compared to 0 cases in the placebo-treated patients. Use caution when treating patients who have had recent abdominal surgery. Discontinue therapy with OFEV in patients who develop gastrointestinal perforation. Only use OFEV in patients with known risk of gastrointestinal perforation if the anticipated benefit outweighs the potential risk.

**ADVERSE REACTIONS:** The following adverse reactions are discussed in greater detail in other sections of the labeling: Liver Enzyme and Bilirubin Elevations [see *Warnings and Precautions*]; Gastrointestinal Disorders [see *Warnings and Precautions*]; Embryofetal Toxicity [see *Warnings and Precautions*]; Arterial Thromboembolic Events [see *Warnings and Precautions*]; Risk of Bleeding [see *Warnings and Precautions*]; Gastrointestinal Perforation [see *Warnings and Precautions*]. **Clinical Trials Experience:** Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The safety of OFEV was evaluated in over 1000 IPF patients with over 200 patients exposed to OFEV for more than 2 years in clinical trials. OFEV was studied in three randomized, double-blind, placebo-controlled, 52-week trials. In the phase 2 (Study 1) and phase 3 (Studies 2 and 3) trials, 723 patients with IPF received OFEV 150 mg twice daily and 508 patients received placebo. The median duration of exposure was 10 months for patients treated with OFEV and 11 months for patients treated with placebo. Subjects ranged in age from 42 to

89 years (median age of 67 years). Most patients were male (79%) and Caucasian (60%). The most frequent serious adverse reactions reported in patients treated with OFEV (nintedanib), more than placebo, were bronchitis (1.2% vs. 0.8%) and myocardial infarction (1.5% vs. 0.4%). The most common adverse events leading to death in patients treated with OFEV, more than placebo, were pneumonia (0.7% vs. 0.6%), lung neoplasm malignant (0.3% vs. 0%), and myocardial infarction (0.3% vs. 0.2%). In the predefined category of major adverse cardiovascular events (MACE) including MI, fatal events were reported in 0.6% of OFEV-treated patients and 1.8% of placebo-treated patients. Adverse reactions leading to permanent dose reductions were reported in 16% of OFEV-treated patients and 1% of placebo-treated patients. The most frequent adverse reaction that led to permanent dose reduction in the patients treated with OFEV was diarrhea (11%). Adverse reactions leading to discontinuation were reported in 21% of OFEV-treated patients and 15% of placebo-treated patients. The most frequent adverse reactions that led to discontinuation in OFEV-treated patients were diarrhea (5%), nausea (2%), and decreased appetite (2%). The most common adverse reactions with an incidence of ≥5% and more frequent in the OFEV than placebo treatment group are listed in Table 1.

**Table 1 Adverse Reactions Occurring in ≥5% of OFEV-treated Patients and More Commonly Than Placebo in Studies 1, 2, and 3**

Adverse Reaction	OFEV, 150 mg n=723	Placebo n=508
<b>Gastrointestinal disorders</b>		
Diarrhea	62%	18%
Nausea	24%	7%
Abdominal pain <sup>a</sup>	15%	6%
Vomiting	12%	3%
<b>Hepatobiliary disorders</b>		
Liver enzyme elevation <sup>b</sup>	14%	3%
<b>Metabolism and nutrition disorders</b>		
Decreased appetite	11%	5%
<b>Nervous systemic disorders</b>		
Headache	8%	5%
<b>Investigations</b>		
Weight decreased	10%	3%
<b>Vascular disorders</b>		
Hypertension <sup>c</sup>	5%	4%

<sup>a</sup> Includes abdominal pain, abdominal pain upper, abdominal pain lower, gastrointestinal pain and abdominal tenderness.

<sup>b</sup> Includes gamma-glutamyltransferase increased, hepatic enzyme increased, alanine aminotransferase increased, aspartate aminotransferase increased, hepatic function abnormal, liver function test abnormal, transaminase increased, blood alkaline phosphatase-increased, alanine aminotransferase abnormal, aspartate aminotransferase abnormal, and gamma-glutamyltransferase abnormal.

<sup>c</sup> Includes hypertension, blood pressure increased, hypertensive crisis, and hypertensive cardiomyopathy.

In addition, hypothyroidism was reported in patients treated with OFEV, more than placebo (1.1% vs. 0.6%).

**DRUG INTERACTIONS: P-glycoprotein (P-gp) and CYP3A4 Inhibitors and Inducers:**

Nintedanib is a substrate of P-gp and, to a minor extent, CYP3A4. Coadministration with oral doses of a P-gp and CYP3A4 inhibitor, ketoconazole, increased exposure to nintedanib by 60%. Concomitant use of P-gp and CYP3A4 inhibitors (e.g., erythromycin) with OFEV may increase exposure to nintedanib. In such cases, patients should be monitored closely for tolerability of OFEV. Management of adverse reactions may require interruption, dose reduction, or discontinuation of therapy with OFEV. Coadministration with oral doses of a P-gp and CYP3A4 inducer, rifampicin, decreased exposure to nintedanib by 50%. Concomitant use of P-gp and CYP3A4 inducers (e.g., carbamazepine, phenytoin, and St. John’s wort) with OFEV should be avoided as these drugs may decrease exposure to nintedanib. **Anticoagulants:** Nintedanib is a VEGFR inhibitor, and may increase the risk of bleeding. Monitor patients on full anticoagulation therapy closely for bleeding and adjust

Continued from previous page

they had established risk factors indicative of immunocompromise, including hematologic malignancy, neutropenia, recent stem cell or solid organ transplantation, HIV, or rheumatologic disease. Patients at lower mortality risk included

those with asthma, COPD, diabetes, malnutrition, pulmonary tuberculosis, or non-TB mycobacterial infection.

The proportion of patients who were high risk climbed over the years, from 41% among the 892 patients with aspergillosis-related hospitalization in the 2001 sample to 50%

among 1,420 patients in 2011. Yet in-hospital mortality in high-risk patients fell from 26.4% in 2001 to 9.1% in 2011. Meanwhile, the mortality rate in lower-risk patients improved from 14.6% to 6.6%. The overall in-hospital mortality rate went from 18.8% to 7.7%.

Of note, the proportion of as-

pergillosis patients with renal failure jumped from 9.8% in 2001 to 21.5% in 2011, even though the treatments for aspergillosis are relatively non-nephrotoxic, with the exception of amphotericin B. The outlook for these patients has improved greatly: In-hospital mortality for aspergillosis patients in renal failure went from 40.2% in 2001 to 16.1% in 2011.

While in-hospital mortality and length of stay were decreasing during the study years, total hospital charges

anticoagulation treatment as necessary [see Warnings and Precautions].

**USE IN SPECIFIC POPULATIONS: Pregnancy:** *Pregnancy Category D.* [See Warnings and Precautions]: OFEV (nintedanib) can cause fetal harm when administered to a pregnant woman. If OFEV is used during pregnancy, or if the patient becomes pregnant while taking OFEV, the patient should be apprised of the potential hazard to a fetus. Women of childbearing potential should be advised to avoid becoming pregnant while receiving treatment with OFEV. In animal reproduction toxicity studies, nintedanib caused embryofetal deaths and teratogenic effects in rats and rabbits at less than and approximately 5 times the maximum recommended human dose (MRHD) in adults (on a plasma AUC basis at maternal oral doses of 2.5 and 15 mg/kg/day in rats and rabbits, respectively). Malformations included abnormalities in the vasculature, urogenital, and skeletal systems. Vasculature anomalies included missing or additional major blood vessels. Skeletal anomalies included abnormalities in the thoracic, lumbar, and caudal vertebrae (e.g., hemivertebra, missing, or asymmetrically ossified), ribs (bifid or fused), and sternbrae (fused, split, or unilaterally ossified). In some fetuses, organs in the urogenital system were missing. In rabbits, a significant change in sex ratio was observed in fetuses (female:male ratio of approximately 71%:29%) at approximately 15 times the MRHD in adults (on an AUC basis at a maternal oral dose of 60 mg/kg/day). Nintedanib decreased post-natal viability of rat pups during the first 4 post-natal days when dams were exposed to less than the MRHD (on an AUC basis at a maternal oral dose of 10 mg/kg/day). **Nursing Mothers:** Nintedanib and/or its metabolites are excreted into the milk of lactating rats. Milk and plasma of lactating rats have similar concentrations of nintedanib and its metabolites. Excretion of nintedanib and/or its metabolites into human milk is probable. There are no human studies that have investigated the effects of OFEV on breast-fed infants. Because of the potential for serious adverse reactions in nursing infants from OFEV, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother. **Pediatric Use:** Safety and effectiveness in pediatric patients have not been established. **Geriatric Use:** Of the total number of subjects in phase 2 and 3 clinical studies of OFEV, 60.8% were 65 and over, while 16.3% were 75 and over. In phase 3 studies, no overall differences in effectiveness were observed between subjects who were 65 and over and younger subjects; no overall differences in safety were observed

between subjects who were 65 and over or 75 and over and younger subjects, but greater sensitivity of some older individuals cannot be ruled out. **Hepatic Impairment:** Nintedanib is predominantly eliminated via biliary/fecal excretion (>90%). No dedicated pharmacokinetic (PK) study was performed in patients with hepatic impairment. Monitor for adverse reactions and consider dose modification or discontinuation of OFEV (nintedanib) as needed for patients with mild hepatic impairment (Child Pugh A). The safety and efficacy of nintedanib has not been investigated in patients with hepatic impairment classified as Child Pugh B or C. Therefore, treatment of patients with moderate (Child Pugh B) and severe (Child Pugh C) hepatic impairment with OFEV is not recommended [see Warnings and Precautions]. **Renal Impairment:** Based on a single-dose study, less than 1% of the total dose of nintedanib is excreted via the kidney. Adjustment of the starting dose in patients with mild to moderate renal impairment is not required. The safety, efficacy, and pharmacokinetics of nintedanib have not been studied in patients with severe renal impairment (<30 mL/min CrCl) and end-stage renal disease. **Smokers:** Smoking was associated with decreased exposure to OFEV, which may alter the efficacy profile of OFEV. Encourage patients to stop smoking prior to treatment with OFEV and to avoid smoking when using OFEV.

**OVERDOSAGE:** In the trials, one patient was inadvertently exposed to a dose of 600 mg daily for a total of 21 days. A non-serious adverse event (nasopharyngitis) occurred and resolved during the period of incorrect dosing, with no onset of other reported events. Overdose was also reported in two patients in oncology studies who were exposed to a maximum of 600 mg twice daily for up to 8 days. Adverse events reported were consistent with the existing safety profile of OFEV. Both patients recovered. In case of overdose, interrupt treatment and initiate general supportive measures as appropriate.

**PATIENT COUNSELING INFORMATION:** Advise the patient to read the FDA-approved patient labeling (*Patient Information*). **Liver Enzyme and Bilirubin Elevations:** Advise patients that they will need to undergo liver function testing periodically. Advise patients to immediately report any symptoms of a liver problem (e.g., skin or the whites of eyes turn yellow, urine turns dark or brown (tea colored), pain on the right side of stomach, bleed or bruise more easily than normal, lethargy) [see Warnings and Precautions]. **Gastrointestinal Disorders:** Inform patients that gastrointestinal disorders such as diarrhea, nausea,

and vomiting were the most commonly reported gastrointestinal events occurring in patients who received OFEV (nintedanib). Advise patients that their healthcare provider may recommend hydration, antidiarrheal medications (e.g., loperamide), or anti-emetic medications to treat these side effects. Temporary dosage reductions or discontinuations may be required. Instruct patients to contact their healthcare provider at the first signs of diarrhea or for any severe or persistent diarrhea, nausea, or vomiting [see Warnings and Precautions and Adverse Reactions]. **Pregnancy:** Counsel patients on pregnancy planning and prevention. Advise females of childbearing potential of the potential hazard to a fetus and to avoid becoming pregnant while receiving treatment with OFEV. Advise females of childbearing potential to use adequate contraception during treatment, and for at least 3 months after taking the last dose of OFEV. Advise female patients to notify their doctor if they become pregnant during therapy with OFEV [see Warnings and Precautions and Use in Specific Populations]. **Arterial Thromboembolic Events:** Advise patients about the signs and symptoms of acute myocardial ischemia and other arterial thromboembolic events and the urgency to seek immediate medical care for these conditions [see Warnings and Precautions]. **Risk of Bleeding:** Bleeding events have been reported. Advise patients to report unusual bleeding [see Warnings and Precautions]. **Gastrointestinal Perforation:** Serious gastrointestinal perforation events have been reported. Advise patients to report signs and symptoms of gastrointestinal perforation [see Warnings and Precautions]. **Nursing Mothers:** Advise patients to discontinue nursing while taking OFEV or discontinue OFEV while nursing [see Use in Specific Populations]. **Smokers:** Encourage patients to stop smoking prior to treatment with OFEV and to avoid smoking when using with OFEV. **Administration:** Instruct patients to swallow OFEV capsules whole with liquid and not to chew or crush the capsules due to the bitter taste. Advise patients to not make up for a missed dose [see Dosage and Administration].

Copyright © 2014 Boehringer Ingelheim International GmbH

ALL RIGHTS RESERVED

OF-BS-10-14 (10-15) OF629900PROF

Rx only



## VITALS

**Key clinical point:** In-hospital mortality has more than halved for patients with aspergillosis-related hospitalization during a recent 10-year period.

**Major finding:** In-hospital mortality among patients with an aspergillosis-related hospitalization fell nationally from 18.8% in 2001 to 7.7% in 2011, with the biggest drop occurring in those at high risk.

**Data source:** A retrospective study of nationally representative data from the Healthcare Utilization and Cost Project—Nationwide Inpatient Sample for 2001-2011.

**Disclosures:** The presenter reported having no financial conflicts regarding this unfunded study.

for patients with aspergillosis were going up: from a median of \$29,998 in 2001 to \$44,888 in 2011 dollars a decade later. This cost-of-care increase was confined to patients at lower baseline risk or with no risk factors. Somewhat surprisingly, the high-risk group didn't have a significant increase in hospital charges over the 10-year period.

"Maybe we're just doing a better job of treating them, so they may not necessarily have to use a lot of resources," Dr. Mizusawa offered as explanation.

[bjancin@frontlinemedcom.com](mailto:bjancin@frontlinemedcom.com)

It's a  
Brand New Day  
for CHEST Logo  
Products



> Purchase at: [chestcollection.com](http://chestcollection.com)



CHEST  
AMERICAN COLLEGE  
of CHEST PHYSICIANS

# True pertussis incidence 93-fold higher than reported

BY BRUCE JANCIN  
Frontline Medical News

SAN DIEGO – The true incidence of pertussis in recent years in Americans less than 50 years old is estimated to be 58- to 93-fold greater than the laboratory-confirmed reported case count, Philip O. Buck, Ph.D., reported at the annual Interscience Conference on Antimicrobial Agents and Chemotherapy.

It's widely accepted that national surveillance systems vastly underestimate the incidence of pertussis because most cases don't get reported.



BRUCE JANCIN/FRONTLINE MEDICAL NEWS

In order to obtain a more complete picture of the situation, Dr. Buck utilized a regression equation to estimate the proportion of cough illnesses attributable to laboratory-confirmed pertussis.

A closely similar regression model has previously been utilized by other investigators in published studies that provided estimates of the true bur-

nosed pertussis in individuals under age 50 in the IMS PharmMetric Plus claims database for the years 2008-2013. The database includes more than 150 million enrollees. The average reported incidence of pertussis in individuals

less than 50 years old during the study years was 9 cases per 100,000 per year; however, the average regression-estimated incidence was 649 per 100,000, a 72-fold greater figure.

During 2011-2013, the 3 most re-


cent years covered by the study, the regression-estimated incidence of pertussis was 93-fold, 62-fold, and 87-fold greater than the reported rates.

bjancin@frontlinemedcom.com



EKOS®

History's greatest instruments really get the blood moving.



## VITALS

**Key clinical point:** The annual rate of pertussis in Americans less than 50 years old is up to 93-fold greater than the reported incidence.

**Major finding:** The true incidence of pertussis in Americans less than 50 years old is estimated to be 58-93 times greater per year than the reported annual rates during recent years.

**Data source:** This was a retrospective cohort study which utilized a regression model to estimate the true fraction of cough illness attributable to laboratory-confirmed pertussis through analysis of 6 years worth of medical claims data from a large national database.

**Disclosures:** The study was funded by GlaxoSmithKline. The presenter is a company employee.

dens of influenza (Epidemiol Infect. 2002 Aug;129:99-106) and respiratory syncytial virus (Eur J Pediatr. 2010 Aug;169:997-1008), noted Dr. Buck, director of U.S. Health Outcomes at GlaxoSmithKline in Philadelphia.

He applied the regression model to medical claims for ICD-9-CM-diag-



EKOS CORPORATION | 888.400.3567 | EKOSCORP.COM

**FDA CLEARED INDICATIONS:** The EkoSonic® Endovascular System is indicated for the ultrasound-facilitated, controlled, and selective infusion of physician-specified fluids, including thrombolytics, into the vasculature for the treatment of pulmonary embolism; the controlled and selective infusion of physician-specified fluids, including thrombolytics, into the peripheral vasculature; and the infusion of solutions into the pulmonary arteries. Instructions for use, including warnings, precautions, potential complications, and contraindications can be found at [www.ekoscorp.com](http://www.ekoscorp.com). Caution: Federal (USA) law restricts these devices to sale by or on the order of a physician. **THE CE MARK (CE0086) HAS BEEN AFFIXED TO THE EKOSONIC® PRODUCT WITH THE FOLLOWING INDICATIONS:** **Peripheral Vasculature:** The EkoSonic® Endovascular Device, consisting of the Intelligent Drug Delivery Catheter (IDDC) and the MicroSonic™ Device (MSD), is intended for controlled and selective infusion of physician-specified fluids, including thrombolytics, into the peripheral vasculature. All therapeutic agents utilized with the EkoSonic® Endovascular System should be fully prepared and used according to the instruction for use of the specific therapeutic agent. **Pulmonary Embolism:** The EkoSonic® Endovascular System is intended for the treatment of pulmonary embolism patients with ≥ 50% clot burden in one or both main pulmonary arteries or lobar pulmonary arteries, and evidence of right heart dysfunction based on right heart pressures (mean pulmonary artery pressure ≥ 25mmHg) or echocardiographic evaluation.

EKOS and EkoSonic are registered trademarks of EKOS Corporation, a BTG International group company. BTG and the BTG roundel logo are registered trademarks of BTG International Ltd. US-EKO-2015-0936

# Oxygen alone best for immunocompromised patients

BY JENNIFER SHEPPHARD  
Frontline Medical News

Early noninvasive ventilation, compared with oxygen therapy alone, did not reduce 28-day all-cause mortality in critically ill immunocompromised patients with acute respiratory failure, based on a randomized, parallel-group study of 374 patients conducted in 28 ICUs in France and Belgium.

Overall, 46 of 191 patients (24%) in the noninvasive ventilation group died, compared with 50 of 183 (27%) in the oxygen-alone group. A similar number of patients from each group required intubation – 38% in the noninvasive ventilation group and 45% in the oxygen group – with similar time to intubation. Nearly 85% of the patients were receiving treatment for hematologic malignancies or solid tumors, researchers reported.

No significant differences between groups were observed in requirement for intubation, ICU or hospital length of stay, or duration of invasive mechanical ventilation. The study found no evidence that noninvasive ventilation influenced mortality estimates or was beneficial to any subgroup based on hypoxemia severity or underlying condition.

The study was limited, however, by

## VITALS

**Key clinical point:** Noninvasive ventilation, compared with oxygen therapy alone, did not reduce 28-day mortality among immunocompromised patients with acute respiratory failure.

**Major finding:** After 28 days, 46 of 191 patients (24%) in the noninvasive ventilation group had died, compared with 50 of 183 (27%) in the oxygen-alone group.

**Data source:** The randomized, parallel-group study was conducted in 28 ICUs in France and Belgium and included 374 immunocompromised patients with acute respiratory failure.

**Disclosures:** Dr. Lemiale and coauthors reported having no disclosures.

a lower than expected mortality rate with oxygen alone, and as a result was not powered to detect significant between-group differences. Based on earlier studies, the researchers assumed a 35% mortality rate in the oxygen-alone group, but the actual rate was 27% (JAMA. 2015 Oct 7. doi: 10.1001/jama.2015.12402).

“Therefore, there remains uncertainty regarding our null finding, which may nonetheless fail to exclude a clinically important effect,” wrote Dr. Virginie Lemiale of Saint-Louis University Hospital, Paris, and colleagues.

## VIEW ON THE NEWS

### Noninvasive ventilation in flux

In contrast to reports from 10 years ago, the current study by Lemiale et al. failed to demonstrate a mortality benefit for noninvasive ventilation, compared with oxygen alone. However, the results should be interpreted in the context of recent advances in ICU care. Targeted chemotherapy, prophylactic use of antibiotics, and improved supportive care have contributed to overall mortality declines in the immunocompromised critically ill population. Dr. Lemiale and colleagues anticipated a higher baseline mortality rate (35% vs. 27% observed). The lower mortality rate limited the study’s power to detect a mortality difference between groups.

Second, patients in this trial may have had a lower acuity of illness, evidenced by less tachypnea, compared with that seen in earlier studies.

Third, the oxygen-alone group

received more high-flow oxygen via nasal cannula than the noninvasive ventilation group, which may have diluted the benefits of noninvasive ventilation.

As efforts continue to reduce requirements for invasive mechanical ventilation, further examination of strategies for noninvasive ventilation, such as high-flow oxygen, compared with noninvasive ventilation, are warranted.

*Dr. Bhakti Patel is a clinical instructor of medicine in the section of pulmonary and critical care, department of medicine, University of Chicago. Dr. John Kress is professor of medicine and director of the Medical Intensive Care Unit at University of Chicago Medicine. These remarks were part of an editorial accompanying the report (JAMA. 2015 Oct 7. doi: 10.1001/jama.2015.12401). Dr. Patel and Dr. Kress reported having no disclosures.*

Furthermore, high-flow nasal oxygen was used in about 40% of all patients, which may have decreased requirements for intubation as well as mortal-

ity rates. High-flow nasal oxygen was used more often in the oxygen group (44%) than in the noninvasive ventilation group (31%) ( $P = .01$ ).

# Venovenous ECMO effective for trauma lung failure

BY M. ALEXANDER OTTO  
Frontline Medical News

CHICAGO – Venovenous extracorporeal membrane oxygenation will save perhaps a third of patients who – despite maximum ventilator support – go into end-stage respiratory failure after trauma, according to investigators from the University of Maryland, Baltimore.

“Institutions without the available expertise and ICU capabilities should promptly refer patients with end-stage respiratory failure secondary to trauma to a tertiary care center. Venovenous ECMO [extracorporeal membrane oxygenation] life support may be their only chance for survival and should not be overlooked due to fear of complications,” they concluded.

ECMO usually requires heparin anticoagulation to prevent clots; the fear of subsequent bleeding is one of the things that prevents ECMO’s widespread use in trauma. As a result, “a lot of patients who need ECMO lung support don’t get it,” said Dr. Sarwat Ahmad, of the university.

Dr. Ahmad and her colleagues, however, found



that ECMO did not lead to worse outcomes in their lung failure patients.

Their conclusions come from a review of 39 adult blunt and penetrating trauma patients who received ECMO at the university’s Level I trauma center over the past 9 years.

Thirty-two patients had venovenous ECMO mostly for acute respiratory distress; maximal ventilator support, adjunctive medications, and chest therapy did not help. ECMO outflow was from the femoral vein, and blood was returned to the internal jugular vein. Twelve patients (38%) survived, which “is good in this scenario because they otherwise would have died,” Dr. Ahmad said.

The mean pre-ECMO P/F ratio – arterial oxygen partial pressure to fractional inspired oxygen – among the survivors was 98 mm Hg. Values below 100 mm Hg indicate severe lung injury, but some patients had values approaching 200 mm Hg, meaning that ECMO was a good idea even in patients with less severe lung injury.

Seven patients received venoarterial ECMO mostly for cardiac arrest, with outflow from the femoral vein and blood returned via the femoral

## VITALS

**Key clinical point:** Venovenous ECMO can be life saving when trauma patients go into respiratory failure.

**Major finding:** Thirty-two patients had venovenous ECMO, mostly for acute respiratory distress; twelve (38%) survived.

**Data source:** Review of ECMO in 39 trauma patients.

**Disclosures:** The lead investigator has no disclosures, and there was no external funding for the work.

artery. The patients were pulseless on arrival, so bypassing the heart seemed the only option, but none of them survived. Because of that, the investigators concluded that venoarterial ECMO is “not going to help” in trauma patients, Dr. Ahmad said.

One of the 12 survivors and over half of those who died had injury severity scores above 40 points. Also, Glasgow coma scores below 8 points were far more common among patients who died.

All 12 of the survivors and 14 of the 27 who died were anticoagulated with heparin. “There was no increased incidence of complications between those who got heparin and those who did not,” and there wasn’t a higher incidence of complications in ECMO patients than in other trauma patients.

Considering treatment options for your pulmonary arterial hypertension (PAH) patients?

# REVATIO® (sildenafil) — is now available as an oral suspension treatment for PAH



## Important Safety Information

REVATIO is contraindicated in patients with concomitant use of organic nitrates in any form, either regularly or intermittently, because of the greater risk of hypotension.

REVATIO is contraindicated in patients with concomitant use of riociguat, a soluble guanylate cyclase (sGC) stimulator medication. PDE5 inhibitors, including sildenafil, may potentiate the hypotensive effects of riociguat.

REVATIO is contraindicated in patients with a known hypersensitivity to sildenafil or any other ingredient in REVATIO. Hypersensitivity, including anaphylactic reaction, anaphylactic shock, and anaphylactoid reaction has been reported in association with the use of sildenafil.

Use of REVATIO, particularly chronic use, is not recommended in children.

Before starting REVATIO, physicians should carefully consider whether their patients with underlying conditions could be adversely affected by the mild and transient vasodilatory effects of REVATIO on blood pressure. Pulmonary vasodilators may significantly worsen the cardiovascular status of patients with pulmonary veno-occlusive disease (PVOD) and administration of REVATIO to these patients is not recommended. Should signs of pulmonary edema occur when sildenafil is administered, the possibility of associated PVOD should be considered.

Caution is advised when PDE5 inhibitors, such as REVATIO, are administered with  $\alpha$ -blockers as both are vasodilators with blood pressure lowering effects.

In PAH patients, the concomitant use of vitamin K antagonists and REVATIO resulted in a greater incidence of reports of bleeding (primarily epistaxis) versus placebo. The incidence of epistaxis was higher in patients with PAH secondary to CTD (sildenafil 13%, placebo 0%) than in PPH patients (sildenafil 3%, placebo 2%).

Co-administration of REVATIO with potent CYP3A4 inhibitors (eg, ketoconazole, itraconazole, and ritonavir) is not recommended as serum concentrations of sildenafil substantially increase. Co-administration of REVATIO with potent CYP3A4 inducers such as barbiturates, carbamazepine, phenytoin, efavirenz, nevirapine, rifampin, and rifabutin, is expected to cause substantial decreases in plasma levels of sildenafil. Treatment with doses higher than 20 mg three times a day is not recommended.

Non-arteritic anterior ischemic optic neuropathy (NAION) has been reported post-marketing in temporal association with the use of PDE5 inhibitors for the treatment of erectile dysfunction, including sildenafil. Physicians should advise patients to seek immediate medical attention in the event of sudden loss of vision while taking PDE5 inhibitors, including REVATIO. Physicians should also discuss the increased risk of NAION with patients who have already experienced NAION in one eye, including whether such individuals could be adversely affected by use of vasodilators, such as PDE-5 inhibitors.

Sudden decrease or loss of hearing has been reported in temporal association with the intake of PDE5 inhibitors, including REVATIO. It is not possible to determine whether these events are related directly to the use of PDE5 inhibitors or to other factors. Physicians should advise patients to seek prompt medical attention in the event of sudden decrease or loss of hearing while taking PDE5 inhibitors, including REVATIO.

REVATIO should be used with caution in patients with anatomical deformation of the penis or patients who have conditions which may predispose them to priapism.

The effectiveness of REVATIO in pulmonary hypertension (PH) secondary to sickle cell anemia has not been established. In a small, prematurely terminated study of patients with PH secondary to sickle cell disease, vaso-occlusive crises requiring hospitalization were more commonly reported by patients who received REVATIO than by those randomized to placebo.

Patients with retinitis pigmentosa and patients on bosentan did not participate in the preapproval clinical trial. The safety of REVATIO is unknown in patients with bleeding disorders and patients with active peptic ulceration. In these patients, physicians should prescribe REVATIO with caution.

REVATIO contains sildenafil, the same active ingredient found in VIAGRA®. Combinations of REVATIO with VIAGRA or other PDE5 inhibitors have not been studied. Patients taking REVATIO should not take VIAGRA or other PDE5 inhibitors.

The most common side effects of REVATIO (placebo-subtracted) were epistaxis (8%), headache (7%), dyspepsia (6%), flushing (6%), and insomnia (6%). Adverse events were generally transient and mild to moderate. Adverse events of REVATIO injection were similar to those seen with oral tablets.

The most common side effects of REVATIO (placebo-subtracted) as an adjunct to intravenous epoprostenol were headache (23%), edema (14%), dyspepsia (14%), pain in extremity (11%), diarrhea (7%), nausea (7%), and nasal congestion (7%).

At doses higher than the recommended 20 mg TID, there was a greater incidence of some adverse events including flushing, diarrhea, myalgia, and visual disturbances.

No dose adjustment required for renal impaired.

No dose adjustment required for mild to moderate hepatic impaired. Severe impairment has not been studied.

## Indication

REVATIO is a phosphodiesterase-5 (PDE-5) inhibitor indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group I) in adults to improve exercise ability and delay clinical worsening. Studies establishing effectiveness were short-term (12 to 16 weeks), and included predominately patients with NYHA Functional Class II-III symptoms. Etiologies were idiopathic (71%) or associated with connective tissue disease (25%).

**Limitation of Use:** Adding sildenafil to bosentan therapy does not result in any beneficial effect on exercise capacity.

Consider REVATIO oral suspension for your appropriate PAH patients.  
To learn more about REVATIO, please visit [REVATIOHCP.com](http://REVATIOHCP.com).

Please see brief summary of Full Prescribing Information on following pages.

**Revatio**<sup>®</sup>  
sildenafil  
20 mg tablets

### INDICATION AND USAGE

REVATIO is indicated for the treatment of pulmonary arterial hypertension (WHO Group I) in adults to improve exercise ability and delay clinical worsening. The delay in clinical worsening was demonstrated when REVATIO was added to background epoprostenol therapy.

Studies establishing effectiveness were short-term (12 to 16 weeks), and included predominately patients with New York Heart Association (NYHA) Functional Class II-III symptoms and idiopathic etiology (71%) or associated with connective tissue disease (CTD) (25%).

**Limitation of Use:** Adding sildenafil to bosentan therapy does not result in any beneficial effect on exercise capacity.

### DOSAGE AND ADMINISTRATION

**REVATIO Tablets and Oral Suspension** The recommended dose of REVATIO is 5 mg or 20 mg three times a day. Administer REVATIO doses 4–6 hours apart. In the clinical trial no greater efficacy was achieved with the use of higher doses. Treatment with doses higher than 20 mg three times a day is not recommended.

**Reconstitution of the Powder for Oral Suspension** 1. Tap the bottle to release the powder. 2. Remove the cap. 3. Accurately measure out 60 mL of water and pour the water into the bottle. 4. Replace the cap and shake the bottle vigorously for a minimum of 30 seconds. 5. Remove the cap. 6. Accurately measure out another 30 mL of water and add this to the bottle. You should always add a total of 90 mL of water irrespective of the dose prescribed. 7. Replace the cap and shake the bottle vigorously for a minimum of 30 seconds. 8. Remove the cap. 9. Press the bottle adaptor into the neck of the bottle. The adaptor is provided so that you can fill the oral syringe with medicine from the bottle. Replace the cap on the bottle. 10. Write the expiration date of the constituted oral suspension on the bottle label (the expiration date of the constituted oral suspension is 60 days from the date of constitution).

**Incompatibilities** Do not mix with any other medication or additional flavoring agent.

### CONTRAINDICATIONS

REVATIO is contraindicated in patients with concomitant use of organic nitrates in any form, either regularly or intermittently, because of the greater risk of hypotension [see *Warnings and Precautions*]. Concomitant use of riociguat, a guanylate cyclase stimulator. PDE5 inhibitors, including sildenafil, may potentiate the hypotensive effects of riociguat. REVATIO is also contraindicated in patients with known hypersensitivity to sildenafil or any component of the tablet, injection, or oral suspension. Hypersensitivity, including anaphylactic reaction, anaphylactic shock and anaphylactoid reaction, has been reported in association with the use of sildenafil.

### WARNINGS AND PRECAUTIONS

**Mortality with Pediatric Use** In a long-term trial in pediatric patients with PAH, an increase in mortality with increasing REVATIO dose was observed. Deaths were first observed after about 1 year and causes of death were typical of patients with PAH. Use of REVATIO, particularly chronic use, is not recommended in children [see *Use in Specific Populations*].

**Hypotension** REVATIO has vasodilatory properties, resulting in mild and transient decreases in blood pressure. Before prescribing REVATIO, carefully consider whether patients with certain underlying conditions could be adversely affected by such vasodilatory effects (e.g., patients on antihypertensive therapy or with resting hypotension [BP less than 90/50], fluid depletion, severe left ventricular outflow obstruction, or automatic dysfunction). Monitor blood pressure when co-administering blood pressure lowering drugs with REVATIO.

**Worsening Pulmonary Vascular Occlusive Disease** Pulmonary vasodilators may significantly worsen the cardiovascular status of patients with pulmonary veno-occlusive disease (PVOD). Since there are no clinical data on administration of REVATIO to patients with veno-occlusive disease, administration of REVATIO to such patients is not recommended. Should signs of pulmonary edema occur when REVATIO is administered, consider the possibility of associated PVOD.

**Epistaxis** The incidence of epistaxis was 13% in patients taking REVATIO with PAH secondary to CTD. This effect was not seen in idiopathic PAH (REVATIO 3%, placebo 2%) patients. The incidence of epistaxis was also higher in REVATIO-treated patients with a concomitant oral vitamin K antagonist (9% versus 2% in those not treated with concomitant vitamin K antagonist). The safety of REVATIO is unknown in patients with bleeding disorders or active peptic ulceration.

**Visual Loss** When used to treat erectile dysfunction, non-arteritic anterior ischemic optic neuropathy (NAION), a cause of decreased vision including permanent loss of vision, has been reported postmarketing in temporal association with the use of phosphodiesterase type 5 (PDE-5) inhibitors, including sildenafil. Most, but not all, of these patients had underlying anatomic or vascular risk factors for developing NAION, including but not necessarily limited to: low cup to disc ratio (“crowded disc”), age over 50, diabetes, hypertension, coronary artery disease, hyperlipidemia and smoking. Based on published literature, the annual incidence of NAION is 2.5–11.8 cases per 100,000 males aged ≥ 50 per year in the general population. An observational study evaluated whether recent, episodic use of PDE5 inhibitors (as a class), typical of erectile dysfunction treatment, was associated with acute onset of NAION. The results suggest an approximately 2-fold increase in the risk of NAION within 5 half-lives of PDE5 inhibitor use. It is not possible to determine whether these events are related directly to the use of PDE-5 inhibitors, to the patient’s underlying vascular risk factors or anatomical defects, to a combination of these factors, or to other factors. Advise patients to seek immediate medical attention in the event of a sudden loss of vision in one or both eyes while taking PDE-5 inhibitors, including REVATIO. Physicians should also discuss the increased risk of NAION with patients who have already experienced NAION in one eye, including whether such individuals could be adversely affected by use of vasodilators, such as PDE-5 inhibitors.

There are no controlled clinical data on the safety or efficacy of REVATIO in patients with retinitis pigmentosa, a minority whom have genetic disorders of retinal phosphodiesterases. Prescribe REVATIO with caution in these patients.

**Hearing Loss** Cases of sudden decrease or loss of hearing, which may be accompanied by tinnitus and dizziness, have been reported in temporal association with the use of PDE-5 inhibitors, including REVATIO. In some of the cases, medical conditions and other factors were reported that may have played a role. In many cases, medical follow-up information was limited. It is not possible to determine whether these reported events are related directly to the use of REVATIO, to the patient’s underlying risk factors for hearing loss, a combination of these factors, or to other factors. Advise patients to seek prompt medical attention in the event of sudden decrease or loss of hearing while taking PDE-5 inhibitors, including REVATIO.

**Combination with Other PDE-5 Inhibitors** Sildenafil is also marketed as VIAGRA®. The safety and efficacy of combinations of REVATIO with VIAGRA or other PDE-5 inhibitors have not been studied. Inform patients taking REVATIO not to take VIAGRA or other PDE-5 inhibitors.

**Priapism** Use REVATIO with caution in patients with anatomical deformation of the penis (e.g., angulation, cavernosal fibrosis, or Peyronie’s disease) or in patients who have conditions, which may predispose them to priapism (e.g., sickle cell anemia, multiple myeloma, or leukemia). In the event of an erection that persists longer than 4 hours, the patient should seek immediate medical assistance. If priapism (painful erection greater than 6 hours in duration) is not treated immediately, penile tissue damage and permanent loss of potency could result.

**Vaso-occlusive Crisis in Patients with Pulmonary Hypertension Secondary to Sickle Cell Anemia** In a small, prematurely terminated study of patients with pulmonary hypertension (PH) secondary to sickle cell disease, vaso-occlusive crises requiring hospitalization were more commonly reported by patients who received REVATIO than by those randomized to placebo. The effectiveness and safety of REVATIO in the treatment of PAH secondary to sickle cell anemia has not been established.

### ADVERSE REACTIONS

**Clinical Trials Experience** Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Safety data of REVATIO in adults were obtained from the 12-week, placebo-controlled clinical study (Study 1) and an open-label extension study in 277 REVATIO-treated patients with PAH, WHO Group I.

The overall frequency of discontinuation in REVATIO-treated patients on 20 mg three times a day was 3% and was the same for the placebo group. In Study 1, the adverse reactions that were reported by at least 3% of REVATIO-treated patients (20 mg three times a day) and were more frequent in REVATIO-treated patients than in placebo-treated patients are shown in Table 1. Adverse reactions were generally transient and mild to moderate in nature.

**Table 1: Most Common Adverse Reactions in Patients with PAH in Study 1 (More Frequent in REVATIO-Treated Patients than Placebo-Treated Patients and Incidence ≥3% in REVATIO-Treated Patients)**

	Placebo, % (n=70)	REVATIO 20 mg three times a day, % (n=69)	Placebo-Subtracted, %
Epistaxis	1	9	8
Headache	39	46	7
Dyspepsia	7	13	6
Flushing	4	10	6
Insomnia	1	7	6
Erythema	1	6	5
Dyspnea exacerbated	3	7	4
Rhinitis	0	4	4
Diarrhea	6	9	3
Myalgia	4	7	3
Pyrexia	3	6	3
Gastritis	0	3	3
Sinusitis	0	3	3
Paresthesia	0	3	3

At doses higher than the recommended 20 mg three times a day, there was a greater incidence of some adverse reactions including flushing, diarrhea, myalgia and visual disturbances. Visual disturbances were identified as mild and transient, and were predominately color-tinge to vision, but also increased sensitivity to light or blurred vision.

The incidence of retinal hemorrhage with REVATIO 20 mg three times a day was 1.4% versus 0% placebo and for all REVATIO doses studied was 1.9% versus 0% placebo. The incidence of eye hemorrhage at both 20 mg three times a day and at all doses studied was 1.4% for REVATIO versus 1.4% for placebo. The patients experiencing these reactions had risk factors for hemorrhage including concurrent anticoagulant therapy.

**Postmarketing Experience** The following adverse reactions have been identified during post approval use of sildenafil (marketed for both PAH and erectile dysfunction). Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

**Cardiovascular Events** In postmarketing experience with sildenafil at doses indicated for erectile dysfunction, serious cardiovascular, cerebrovascular, and vascular events, including myocardial infarction, sudden cardiac death, ventricular arrhythmia, cerebrovascular hemorrhage, transient ischemic attack, hypertension, pulmonary hemorrhage, and subarachnoid and intracerebral hemorrhages have been reported in temporal association with the use of the drug. Most, but not all, of these patients had preexisting cardiovascular risk factors. Many of these events were reported to occur during or shortly after sexual activity, and a few were reported to occur shortly after the use of sildenafil without sexual activity. Others were reported to have occurred hours to days after use concurrent with sexual activity. It is not possible to determine whether these events are related directly to sildenafil, to sexual activity, to the patient’s underlying cardiovascular disease, or to a combination of these or other factors.

**Nervous system** Seizure, seizure recurrence.

### DRUG INTERACTIONS

**Nitrates** Concomitant use of REVATIO with nitrates in any form is contraindicated [see *Contraindications*].

**Ritonavir and other Potent CYP3A Inhibitors** Concomitant use of REVATIO with ritonavir and other potent CYP3A inhibitors is not recommended.

**Other drugs that reduce blood pressure** *Alpha blockers.* In drug-drug interaction studies, sildenafil (25 mg, 50 mg, or 100 mg) and the alpha-blocker doxazosin (4 mg or 8 mg) were administered simultaneously to patients with benign prostatic hyperplasia (BPH) stabilized on doxazosin therapy. In these study populations, mean additional reductions of supine systolic and diastolic blood pressure of 7/7 mmHg, 9/5 mmHg, and 8/4 mmHg, respectively, were observed. Mean additional reductions of standing blood pressure of 6/6 mmHg, 11/4 mmHg, and 4/5 mmHg, respectively, were also observed. There were infrequent reports of patients who experienced symptomatic postural hypotension. These reports included dizziness and light-headedness, but not syncope.

*Amlodipine.* When sildenafil 100 mg oral was co-administered with amlodipine, 5 mg or 10 mg oral, to hypertensive patients, the mean additional reduction on supine blood pressure was 8 mmHg systolic and 7 mmHg diastolic.

Monitor blood pressure when co-administering blood pressure lowering drugs with REVATIO® (sildenafil).

#### USE IN SPECIFIC POPULATIONS

##### Pregnancy

**Pregnancy Category B** There are no adequate and well-controlled studies of sildenafil in pregnant women. No evidence of teratogenicity, embryotoxicity, or fetotoxicity was observed in pregnant rats or rabbits dosed with sildenafil 200 mg/kg/day during organogenesis, a level that is, on a mg/m<sup>2</sup> basis, 32- and 68-times, respectively, the recommended human dose (RHD) of 20 mg three times a day. In a rat pre- and postnatal development study, the no-observed-adverse-effect dose was 30 mg/kg/day (equivalent to 5-times the RHD on a mg/m<sup>2</sup> basis).

**Labor and Delivery** The safety and efficacy of REVATIO during labor and delivery have not been studied.

**Nursing Mothers** It is not known if sildenafil or its metabolites are excreted in human breast milk. Because many drugs are excreted in human milk, caution should be exercised when REVATIO is administered to a nursing woman.

**Pediatric Use** In a randomized, double-blind, multi-center, placebo-controlled, parallel-group, dose-ranging study, 234 patients with PAH, aged 1 to 17 years, body weight greater than or equal to 8 kg, were randomized, on the basis of body weight, to three dose levels of REVATIO, or placebo, for 16 weeks of treatment. Most patients had mild to moderate symptoms at baseline: WHO Functional Class I (32%), II (51%), III (15%), or IV (0.4%). One-third of patients had primary PAH; two-thirds had secondary PAH (systemic-to-pulmonary shunt in 37%; surgical repair in 30%). Sixty-two percent of patients were female. Drug or placebo was administered three times a day.

The primary objective of the study was to assess the effect of REVATIO on exercise capacity as measured by cardiopulmonary exercise testing in pediatric patients developmentally able to perform the test (n=115). Administration of REVATIO did not result in a statistically significant improvement in exercise capacity in those patients. No patients died during the 16-week controlled study.

After completing the 16-week controlled study, a patient originally randomized to REVATIO remained on his/her dose of REVATIO or, if originally randomized to placebo, was randomized to low-, medium-, or high-dose REVATIO. After all patients completed 16 weeks of follow-up in the controlled study, the blind was broken and doses were adjusted as clinically indicated. Patients treated with sildenafil were followed for a median of 4.6 years (range 2 days to 8.6 years). During the study, there were 42 reported deaths, with 37 of these deaths reported prior to a decision to titrate subjects to a lower dosage because of a finding of increased mortality with increasing REVATIO doses. For the survival analysis which included 37 deaths, the hazard ratio for high dose compared to low dose was 3.9, p=0.007. Causes of death were typical of patients with PAH. Use of REVATIO, particularly chronic use, is not recommended in children.

**Geriatric Use** Clinical studies of REVATIO did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

**Patients with Hepatic Impairment** No dose adjustment for mild to moderate impairment is required. Severe impairment has not been studied.

**Patients with Renal Impairment** No dose adjustment is required (including severe impairment CL<sub>Cr</sub> <30 mL/min).

#### PATIENT COUNSELING INFORMATION

- Inform patients of contraindication of REVATIO with regular and/or intermittent use of organic nitrates.
- Inform patients that sildenafil is also marketed as VIAGRA for erectile dysfunction. Advise patients taking REVATIO not to take VIAGRA or other PDE-5 inhibitors.
- Advise patients to seek immediate medical attention for a sudden loss of vision in one or both eyes while taking REVATIO. Such an event may be a sign of NAION.
- Advise patients to seek prompt medical attention in the event of sudden decrease or loss of hearing while taking REVATIO. These events may be accompanied by tinnitus and dizziness.

#### Rx only

Rev. June 2015

RVU751714-02 ©2015 Pfizer Inc. All rights reserved. June 2015



# Undiagnosed OSA often underlies insomnia

BY DOUG BRUNK  
Frontline Medical News

SAN DIEGO – The prevalence of insomnia in obstructive sleep apnea (OSA) patients “is not that surprising,” and adds to the complexity of managing these patients, Dr. David N. Neubauer said at the annual U.S. Psychiatric and Mental Health Congress.

In a study of 810 primary care outpatients with no sleep disorder history, 11% were found to have potential



**Sleep-onset insomnia is common and is associated with functional somatic syndromes.**

DR. NEUBAUER

complex insomnia: a mix of symptoms meeting criteria for moderate/severe insomnia disorder and specific sleep-disordered breathing (Sleep Med. 2013;14[9]:814-23). Further, at least three sleep studies conducted in older patients with insomnia found a high prevalence of OSA. The largest study, of 394 postmenopausal women aged 55-70 years, found that 67% had an apnea-hypopnea index (AHI) of greater than 5, said Dr. Neubauer, associate director of the Johns Hopkins Sleep Disorders Center, Baltimore.

In another trial, 435 community-dwelling veterans in the Los Angeles area who were at least 60 years old and had seen a Veterans Affairs outpatient provider in the past 2 years were recruited for an insomnia behavioral intervention trial (J Clin Sleep Med. 2013; 9[11]:1173-8). To be eligible for the trial, participants must have had a sleep disturbance with daytime consequences for at least 3 months; those with a history of sleep apnea diagnosis or treatment were excluded.

Researchers found that the prevalence of OSA – defined as an AHI threshold of 15 or greater – was 47%.

In another study from Stanford (Calif.) University, researchers set out to evaluate the impact of a cognitive-behavioral intervention in people with insomnia and major depression (J Psychosom Res. 2009;67[2]:135-41).

The screening consisted of a

phone interview, in-person screening, and an overnight polysomnography test. Again, sleep apnea proved to be part of the underlying problem, as 24% had an AHI between 15 and 25, and 16% had an AHI of greater than 25.

Patients with a combination of OSA and insomnia symptoms “tend to be some of the people with milder sleep apnea, or those who are under the radar, who wouldn’t even get diagnosed with OSA, but they have that same physiologic process of some inspiratory flow limitation,” Dr. Neubauer said. This subset of patients might meet criteria for upper airway resistance syndrome, which was first described in 1993 and is characterized by repetitive increases in resistance to airflow, increased respiratory effort, absence of oxygen desaturation, brief sleep state changes or arousals, and daytime somnolence.

“The diagnosis of upper airway resistance syndrome is somewhat debatable, because some people think that if you don’t have absolute apnea events, they don’t count [as a sleep disorder],” Dr. Neubauer said. “But these ‘under the radar’ events may still have a significant effect on sleep.”

Compared with OSA patients, those with upper airway resistance syndrome tend to be younger, female, and have a lower body mass index (Respiration 2012;83[6]:559-66). In addition, he said, sleep-onset insomnia is common, and the condition is associated with functional somatic syndromes, such as headache, irritable bowel syndrome, gastroesophageal reflux, rhinitis, and orthostatic intolerance.

A recent analysis of 14 second-generation antidepressants based on Food and Drug Administration data and pharmaceutical company records found that the Top 5 most likely to cause insomnia, compared with placebo, are bupropion, desvenlafaxine, sertraline, fluvoxamine, and fluoxetine (J Clin Psychopharmacol. 2015;35[3]:296-303). The Top 5 most likely to cause somnolence, compared with placebo, are fluvoxamine, mirtazapine, reboxetine, paroxetine, and desvenlafaxine.

Dr. Neubauer reported having no financial disclosures.

dbrunk@frontlinemedcom.com

# SLEEP STRATEGIES: Pain and Sleep

BY DR. TIMOTHY ROEHRS

**S**leep and pain interact in complex ways to compromise the biological and behavioral capacity of individuals. Disturbed sleep is frequently reported by people with acute and chronic pain conditions, and it is now becoming clear the sleep-pain relation is bidirectional; that is, pain disrupts sleep and sleep disturbance in turn enhances pain. Serious limitations to the currently available pharmacotherapies for pain exist and as a consequence, inadequate pain control and management remain serious problems for clinicians.

## Sleep Laboratory Studies

Epidemiologic studies show 60% to 80% of people experiencing acute and/or chronic pain report disturbed sleep and sleep laboratory studies using polysomnography (PSG) [the terminology used to describe the continuous 8-h recording of multiple physiologic measures during sleep (ie, EEG, EMG, EOG, and ECG)] have well documented the nature of the sleep disturbance.

Most typically, the PSGs show sleep maintenance is disturbed, often with brief arousals and awakenings (often referred to as sleep fragmentation) of which the individual is unaware. Persons with such pain-related sleep disturbance report in the morning having experienced light and unrefreshing sleep.

We also know that sleep disturbance enhances daytime sleepiness/fatigue and that sleepiness/fatigue is associated with increased pain. For example, when people are asked to rate their nightly sleep, daily pain, and fatigue over several weeks, nights with poorer sleep are associated with greater daytime fatigue and pain and the greater the fatigue, the greater the pain.

Some studies have suggested that the sleep-pain side of the relation accounts for a greater amount of the variance among these variables than the pain-sleep side of the relation. What accounts for the sleepiness/fatigue and pain relation is not well known.

Sleep laboratory studies in pain-free individuals have totally deprived sleep, reduced sleep time by 2 to 4 h, disrupted the continuity of sleep with brief awakenings, and selectively deprived specific sleep stages thought to be critical in pain processing (ie, slow wave NREM or REM sleep). These experimental

studies have found next-day pain thresholds to mechanical pressure and hot or cold stimuli are reduced, pain sensitivity to radiant heat is increased, and normal pain processing is compromised. While total sleep loss and shortened and disrupted sleep clearly enhance pain, it is not as certain that specific sleep stages are critical.

Given the early 1970s clinical description of the alpha-delta sleep anomaly in fibromyalgia, the majority of the specific sleep stages studies have focused on the deprivation or disruption of slow wave sleep. But, the studies have been equivocal regarding the impact of slow wave sleep loss on pain. However, it is difficult to reduce slow wave sleep without also reducing sleep time and, as we noted above, even 2-hour reductions of sleep time can enhance pain sensitivity.

The other important sleep stage is REM sleep, which has been little studied in humans. One study showed a modest correlation of REM sleep time with pain reports and a second study selectively deprived REM sleep while controlling for sleep time and sleep fragmentation. That REM deprivation study found pain sensitivity to a radiant heat stimulus was enhanced.

## Mechanism(s)

Thus, it is fairly well established that the sleep-pain relation is bidirectional and what remains to be determined is the mechanism(s) that underlie this relation. One strong explanatory candidate is proinflammatory activation. First, there are emerging data that show sleep loss, either total sleep deprivation or sleep restriction, produces elevations in proinflammatory cytokines. A number of controlled laboratory studies has shown elevations of IL-1, IL-6, and TNF-alpha associated with sleep loss. In healthy volunteers, 1 week of restricted bedtime to 6 h nightly produced, relative to the 8-h baseline, increased sleepiness/fatigue and elevated 24-h secretion of IL-6. Another recent study in healthy normal subjects restricted bedtime to 4 h nightly for 12 consecutive nights and found elevated levels of IL-6 relative to an 8-h bedtime control group. The IL-6 levels were

correlated with self-rated bodily discomfort and tiredness-fatigue. Finally, in healthy normal subjects, after one night of total sleep deprivation, sleepiness was increased as were IL-6 levels. A midday nap the following day reduced the sleepiness and importantly, the IL-6 levels relative to a no-nap condition.

Second, the proinflammatory cytokines in both the peripheral and central nervous system are known to play a key role in both acute and chronic pain conditions. In the periphery, the cytokines are released by macrophages in response to tissue injury. In human chronic pain conditions, both IL-6 and TNF-alpha levels are elevated locally, and their levels are correlated with experienced pain.

The proinflammatory cytokines that are released peripherally are also recognized as having a signaling function in the central nervous system that then produces de novo central synthesis and release of the cytokines from brain glia cells. Thus, pain transmission is facilitated downward from central to spinal pathways by the central cytokine release.

Proinflammatory activation has been shown to enhance dorsal root ganglion cell excitability, as well as A-delta and C nerve fiber excitability in the periphery. Thus, one likely mechanism by which sleep loss enhances pain is through proinflammatory cytokine activation.

## Treatments

Numerous studies of antidepressants, including sedating tricyclics, selective serotonin reuptake inhibitors, and serotonin-norepinephrine reuptake inhibitors, have been done in patients with fibromyalgia and other chronic pain populations. While some of these studies have shown improved pain outcomes, not all patients seem to benefit. More importantly, this literature is limited as to understanding the role of sleep in chronic pain in that sleep is either inadequately or not assessed.

Pharmacologic treatment studies directed toward sleep in chronic pain conditions have been done in patients with rheumatoid arthritis (RA) and fibromyalgia. The non-benzodiazepine hypnotic zopiclone, 7.5 mg, improved sleep in patients with rheumatoid arthritis and fibromyalgia but did not improve self-rated pain. Similarly, zolpidem, 10 mg, improved sleep but not pain in patients with fibromyalgia. In contrast, triazolam, 0.25 mg, improved sleep, reduced daytime sleepiness, and morning

stiffness; and eszopiclone, 2 mg, improved both sleep and daytime pain and disability in patients with RA. The precursor of GABA in sodium salt form, sodium oxybate, 4.5 and 6 g/night, reduced daytime pain and fatigue and improved sleep in patients with fibromyalgia. Sodium oxybate is known to increase slow wave sleep. The alpha 2-delta ligand, pregabalin, 450 mg/day, which in healthy normal subjects also increases slow wave sleep, improved self-reported pain, sleep, fatigue, and quality of life in a large trial in patients with fibromyalgia.

The few behavioral treatment trials for sleep in chronic pain have produced equivocal results.

Cognitive behavioral treatment directed to sleep (CBT-I) in chronic pain patients relative to wait-list controls improved measures of sleep but not pain.

In older adults with a range of medical or psychiatric illnesses, CBT-I relative to no treatment reduced wake time during sleep, but, again, did not improve daytime outcomes. CBT-I in older adults, 36% with osteoarthritis, reported improved sleep, but pain assessments were not improved. In a follow-up study that included 55% patients with osteoarthritis, CBT-I improved 8 of 10 sleep measures and a global rating of daytime function but not specifically pain. CBT-I involving sleep restriction improved sleep efficiency and wake time relative to the control group, but it did not improve pain measures. In post-hoc analyses, a sleep hygiene sub-group which regularized their sleep schedule showed improved pain scores.

The major problem with the behavioral treatment studies is that although sleep continuity was improved, sleep time was not increased. A major component of CBT-I is sleep restriction and in healthy normal subjects and pain patients, reducing sleep time enhances pain sensitivity. This would suggest consolidating sleep alone is not sufficient to improve pain. Increasing sleep time after having consolidated it is probably also necessary. Those pharmacologic studies that improved pain outcomes increased sleep time by 30 min or more.

## Summary

While a more complete understanding of the role of sleep disturbance in the normal physiology and pathophysiology of acute and chronic

*Continued on following page*



DR. ROEHRS



©TAB1962/THINKSTOCK

Continued from previous page

pain continues to emerge, barriers to managing pain clinically continue. There are serious limitations to the currently available pharmacotherapies. The modulating role of sleep in acute and chronic pain and the extent to which pharmacologic and behavioral treatment of sleep may have an impact on the medical, social, and economic burdens of acute and chronic pain need further exploration.

Dr. Roehrs is with the Sleep Disorders & Research Center, Henry Ford Hospital and Department of Psychiatry and Behavioral Neuroscience, Wayne State University, School of Medicine, Detroit, Michigan.

#### Further Reading

Affleck G, Urrows S, Tennen H, Higgins P, Abeles M. Sequential daily relations of sleep, pain intensity, and attention to pain among women with fibromyalgia. *Pain*. 1996;68:363-368.

Crofford LJ, Rowbotham MC, Mease PJ, Russell IJ, and the Pregabalin 1080-105 Study Group. Pregabalin for the treatment of fibromyalgia syndrome. *Arthritis Rheum*. 2005;52:1264-1273.

Currie SR, Wilson KG, Pontefract AJ, deLaplante L. Cognitive-behavioral treatment of insomnia secondary to chronic pain. *J Consul Clin Psychol*. 2000;68:407-416.

Haack M, Sanchez E, Mullington JM. Elevated inflammatory markers in re-

sponse to prolonged sleep restriction are associated with increased pain experience in healthy volunteers. *Sleep*. 2007;30:1145-1152.

Lentz MJ, Landis CA, Rothermel J, Shaver JLF. Effects of selective slow wave sleep disruption on musculoskeletal pain and fatigue in middle aged women. *J Rheum*. 1999;26:1586-1592.

Roehrs T, Hyde M, Blaisdell B, Greenwald M, Roth T. Sleep loss and REM sleep loss are hyperalgesic. *Sleep*. 2006;29:145-151.

Sommer C, Kress M. Recent findings on how proinflammatory cytokines cause pain: peripheral mechanisms in inflammatory and neuropathic hyperalgesia. *Neurosci Lett*. 2004;361:184-187.

Walsh JK, Muehlbach MJ, Lauter SA, Hilliker NA, Schweitzer PK. Effects of triazolam on sleep, daytime sleepiness, and morning stiffness in patients with rheumatoid arthritis. *J Rheumatol*. 1996;23:245-252.

Watkins LR, Milligan ED, Maier SF. Glial proinflammatory cytokines mediate exaggerated pain states: implications for clinical pain. *Adv Exp Med Biol*. 2003;521:1-21.

CHEST  
World Congress  
2016

世界胸科大会  
CHINA  
Shanghai • April 15-17



SHANGHAI, CHINA • APRIL 15-17

#### CHEST Membership Offer

Not a member? Register for CHEST World Congress 2016 to receive a free 6-month Basic membership trial, beginning May 2016.

Don't miss CHEST World Congress 2016, organized with support of the Chinese Thoracic Society. CHEST World Congress connects clinicians from around the world specializing in pulmonary, critical care, and sleep medicine to offer:

- Relevant, innovative, and diverse education opportunities similar to the CHEST Annual Meeting in North America
- Original research and guideline recommendations from the journal *CHEST*
- Networking and social opportunities to connect you with influential international professionals from your field

> Register Now [chestworldcongress2016.org](http://chestworldcongress2016.org)



#### PQRSwizard:

#1 Cloud-based registry  
for PQRS reporting



- Avoid penalties
- Quick, easy, and cost-effective
- Individual EP and group practice reporting option (GPRO) reporting
- Data entry and file upload tools
- Real-time data validation

PQRSwizard provides a step-by-step approach to help assure that eligible professionals (EPs) meet all of the data, scoring, and attestation requirements before they submit their Physician Quality Reporting System (PQRS) reports to Center for Medicare and Medicaid Services (CMS). PQRSwizard is powered by the CECity Registry, a CMS-certified registry for PQRS.

Similar to online tax preparation software, the PQRSwizard is a Web-based tool to guide EPs through a few easy steps to help rapidly collect, validate, report, and submit the results to CMS.

> Learn More and Purchase  
[www.acquire.pqrswizard.com](http://www.acquire.pqrswizard.com)

CHEST  
AMERICAN COLLEGE  
of CHEST PHYSICIANS

PQRSwizard®

# What's the hottest recent advance in cardiology?

BY **BRUCE JANCIN**  
*Frontline Medical News*

LONDON – What was the top development in all of cardiology during the past year, the advance that holds the most far-reaching implications for clinical practice?

At the annual congress of the European Society of Cardiology, six experts each made a case for the biggest game changer in their discipline – risk prevention, electrophysiology, imaging, heart failure, percutaneous coronary intervention, and acute cardiac care. And when the audience of perhaps 400-strong had cast their votes, the winner was ... the novel angiotensin receptor neprilysin inhibitor (ARNI) known as LCZ696 or sacubitril/valsartan. In the landmark PARADIGM-HF trial, the drug reduced the risk of cardiovascular death by 20% and heart failure hospitalization by 21% over and above what's achieved with enalapril plus the other current guideline-recommended heart failure medications. "I'm a device person, but I've decided a device is not the most important recent innovation in heart failure," Dr. Cecilia Linde said in her winning argument.

"This ARNI is the first new drug in years with a very clear impact on morbidity and mortality. This is why I believe PARADIGM-HF is the most



**Sacubitril/valsartan 'is the first new drug in years with a very clear impact on morbidity and mortality.'**

DR. LINDE

important study result of the last year in heart failure. It will directly impact treatment and will change the ESC guidelines for heart failure therapy. The PARADIGM-HF results suggest that the ARNI should be given as first-line therapy instead of an ACE inhibitor or angiotensin receptor blocker," said Dr. Linde, professor and head of cardiology at the Karolinska Institute, Stockholm.

In the double-blind, randomized 8,399-patient PARADIGM-HF trial (N Engl J Med. 2014 Sep 11;371[11]:993-1004), the number needed to treat with LCZ696 instead of enalapril for 27 months in order to avoid one cardiovascular death or heart failure hospitalization was 21. The number needed to treat to avoid one cardiovascular death was 32.

## Electrophysiology

The big news here is the concept of the autonomic nervous system as the master controller of atrial fibrillation (AF), governing both the firing of arrhythmic triggers and the change in the arrhythmogenic substrate over time, according to Dr. Sabine Ernst of the National Heart and Lung Institute at Imperial College, London.

"There is a new recognition of how the sympathetic and parasympathetic nervous systems interact to initiate and maintain arrhythmias. This



**The future of antiarrhythmic therapy lies in neuromodulation of the autonomic nervous system.**

DR. ERNST

will change the electrophysiology world forever," she predicted.

Indeed, the future of antiarrhythmic therapy lies in neuromodulation of the autonomic nervous system, and it's a lot closer than most cardiologists realize, she said.

She pointed to a study in which investigators at the University of Oklahoma Heart Rhythm Institute randomized 40 patients with paroxysmal AF to noninvasive low-level electrical stimulation of the vagus nerve or to sham treatment. The stimulation at 20 Hz suppressed AF and reduced levels of inflammatory cytokines (J Am Coll Cardiol. 2015 Mar 10;65[9]:867-75).

Vagus nerve stimulation was accomplished using a pair of clips attached to the external ear in order to access the tragus nerve. At just 20 Hz, participants felt no discomfort.

"This is just the very first step. It's probably not the right frequency or intensity yet. But maybe – and I just want you to start to dream about this – just maybe this could be easily implanted in something we put in our ears. How nice it would be if we could add it to a hearing aid for a patient with atrial fibrillation; we would not need to bother with rate control anymore," Dr. Ernst said.

## Cardiovascular prevention

Dr. Joep Perk nominated as the most important development of the past year in this field a new set of refined ECG screening criteria for asymptomatic hypertrophic cardiomyopathy (HCM) in athletes. Previous criteria have unacceptably high false-positive

rates, which lead to further testing, particularly in black athletes," said Dr. Perk, head of internal medicine at Oskarshamn (Sweden) Hospital.

The so-called refined criteria (Circulation. 2014 Apr 22;129[16]:1637-49) were designed to improve upon the specificity of the ESC and Seattle criteria by excluding several isolated ECG patterns that have been shown not relevant in black athletes.

When the developers of the refined criteria applied all three sets of criteria to a large population of black and white athletes, including 103 young athletes with HCM, all three showed 98% sensitivity for the detection of HCM. However, the false-positive ECG rate in black athletes improved from 40.4% using the ESC criteria, to 18.4% with the Seattle criteria, to 11.5% using the refined criteria. Among white athletes, the false-positive rates using the three sets of criteria were 16.2%, 7.1%, and 5.3%.

"These new refined criteria should be incorporated into guidelines for the screening of athletes. They provide a 71% reduction in positive ECGs in black athletes, compared with ESC recommendations," Dr. Perk said.

## Cardiac imaging

"I really think 3-D printing is going to revolutionize every aspect of medicine," asserted Dr. Luigi Badano of the University of Padua (Italy).

His research group presented a study in which they used custom software to create an exact model of a real patient's tricuspid valve out of liquid resin based on transthoracic echo images. It took 90 minutes.

"This technology allows us to hold the physical structure of the heart in our hands," he noted. "We can use it to teach anatomy to medical students without a corpse, plan surgical interventions, and communicate with patients, showing them exact structures and revolutionizing the concept of informed consent."

And that's just scratching the surface. He noted that investigators at Wake Forest Baptist Medical Center Institute for Regenerative Medicine in North Carolina recently utilized 3-D printing with bio-ink and bio-paper to print 3-D beating cardiac cells clustered into "organoids." It's the first step toward creating a prototype beating heart.

"Can you dream about that? The donor heart shortage could in the future be solved by printing a beating heart for insertion into the patient. The investigators predict they'll have a functional beating heart within 20 years," Dr. Badano said.

## Acute cardiac care

Dr. Maddalena Lettino said that the breakthrough of the year in their field was validation of a novel 1-hour rule-in/rule-out algorithm using high-sensitivity cardiac troponin T to accelerate management of patients who present to the emergency department with chest pain. According to studies totaling more than 3,000



**Using this assay and algorithm, roughly 75% of patients can have acute MI ruled out or ruled in within 1 hour.**

DR. LETTINO

patients with more than 600 MIs in which the assay and algorithm were tested, roughly 75% of patients can safely and accurately have acute MI ruled out or ruled in within 1 hour.

Given that close to 10% of all ED visits are for chest pain, adoption of this algorithm will reduce ED overcrowding, speed physician workflow, save health care systems money, and spare patients and families the anxiety that comes with a delayed diagnosis, said Dr. Lettino of Humanitas Research Hospital in Milan.

## Coronary intervention

The 15%-20% of coronary stent recipients who are at high bleeding risk constitute "the forgotten patient population," said Dr. Philippe Garot of the Paris South Cardiovascular Institute.

He noted that the key question of whether such patients can be managed safely with a mere 1-month course of dual antiplatelet therapy



**'This [3-D printing] technology allows us to hold the physical structure of the heart in our hands.'**

DR. BADANO

will finally be answered this fall with the release of the LEADERS FREE trial results. This large, randomized double-blind trial compares safety and efficacy outcomes in patients assigned to a bare metal stent or the novel drug-eluting BioFreedom stent.

The six presenters indicated they had no relevant financial conflicts.



When considering maintenance bronchodilator therapy for the treatment of COPD

## WHAT IF YOU COULD DIRECT YOUR PATIENTS TOWARD BETTER BREATHING?



### Indication

- ANORO ELLIPTA is a combination anticholinergic/long-acting beta<sub>2</sub>-adrenergic agonist indicated for the long-term, once-daily, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.
- ANORO ELLIPTA is NOT indicated for the relief of acute bronchospasm or for the treatment of asthma.

**Once-daily ANORO ELLIPTA significantly improved lung function by 167 mL ( $P < 0.001$ ) vs placebo at Day 169<sup>1\*</sup>**

\*As measured by the primary endpoint, trough (predose) FEV<sub>1</sub> at Day 169 (mean of the FEV<sub>1</sub> values at 23 and 24 hours after dosing on Day 168), in a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Least squares mean change from baseline of 171 mL for ANORO ELLIPTA (n=413) and 4 mL for placebo (n=280).



### Important Safety Information for ANORO ELLIPTA

#### WARNING: ASTHMA-RELATED DEATH

- Long-acting beta<sub>2</sub>-adrenergic agonists (LABA), such as vilanterol, one of the active ingredients in ANORO ELLIPTA, increase the risk of asthma-related death. A placebo-controlled trial with another LABA (salmeterol) showed an increase in asthma-related deaths in subjects receiving salmeterol. This finding with salmeterol is considered a class effect of all LABA, including vilanterol.
- The safety and efficacy of ANORO ELLIPTA in patients with asthma have not been established. ANORO ELLIPTA is not indicated for the treatment of asthma.

### CONTRAINDICATIONS

- The use of ANORO ELLIPTA is contraindicated in patients with severe hypersensitivity to milk proteins or who have demonstrated hypersensitivity to umeclidinium, vilanterol, or any of the excipients.

### WARNINGS AND PRECAUTIONS

- ANORO ELLIPTA should not be initiated in patients during rapidly deteriorating or potentially life-threatening episodes of COPD.
- ANORO ELLIPTA should not be used for the relief of acute symptoms, ie, as rescue therapy for the treatment of acute episodes of bronchospasm. Acute symptoms should be treated with an inhaled, short-acting beta<sub>2</sub>-agonist.

Please see additional Important Safety Information for ANORO ELLIPTA on the following pages.

Please see Brief Summary of Prescribing Information, including Boxed Warning, for ANORO ELLIPTA following this advertisement.



**ANORO<sup>®</sup> ELLIPTA<sup>®</sup>**  
(umeclidinium 62.5 mcg and vilanterol 25 mcg inhalation powder)



## Lung function comparison studies with tiotropium

### Indications

- ANORO ELLIPTA is a combination anticholinergic/LABA indicated for the long-term, once-daily, maintenance treatment of airflow obstruction in patients with COPD.
- SPIRIVA® HandiHaler® (tiotropium bromide inhalation powder) is an anticholinergic indicated for the long-term, once-daily, maintenance treatment of bronchospasm associated with COPD, and for reducing COPD exacerbations.<sup>2</sup>

### Description of Studies<sup>3-5</sup>

**Design:** Three 24-week, multicenter, randomized, blinded, active-controlled, double-dummy, parallel-group studies that evaluated the efficacy and safety of ANORO ELLIPTA (administered once daily by the ELLIPTA inhaler) and other treatment arms, including tiotropium 18 mcg (administered once daily by the HandiHaler).

**Treatment arms:** In the 1st study, patients were randomized to treatment with ANORO ELLIPTA, tiotropium 18 mcg, UMEC/VI 125 mcg/25 mcg,\* or VI 25 mcg.† In the 2nd study, patients were randomized to treatment with ANORO ELLIPTA, tiotropium 18 mcg, UMEC/VI 125 mcg/25 mcg,\* or UMEC 125 mcg.\* In the 3rd study, patients were randomized to treatment with ANORO ELLIPTA or tiotropium 18 mcg.

**Patients:** Studied in patients (mean age range: 62 to 65 years) with COPD. At screening, patients had a mean postbronchodilator FEV<sub>1</sub> range of 46.4% to 47.7% predicted, a mean reversibility range of 11.7% to 15.6%, and a mean postbronchodilator FEV<sub>1</sub>/FVC ratio range of 0.46 to 0.48.

**Primary endpoint:** Trough (predose) FEV<sub>1</sub> at Day 169 (defined as the mean of the FEV<sub>1</sub> values obtained 23 and 24 hours after dosing on Day 168).

FEV<sub>1</sub>=forced expiratory volume in 1 second; FVC=forced vital capacity; UMEC=umeclidinium; VI=vilanterol.

\*UMEC/VI 125 mcg/25 mcg and UMEC 125 mcg are not approved strengths.

†Vilanterol is not approved as monotherapy.

SPIRIVA and HandiHaler are registered trademarks owned by Boehringer Ingelheim.

### Important Safety Information for ANORO ELLIPTA (cont'd)

#### WARNINGS AND PRECAUTIONS (cont'd)

- ANORO ELLIPTA should not be used more often than recommended, at higher doses than recommended, or in conjunction with other medicines containing LABA, as an overdose may result. Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. Patients using ANORO ELLIPTA should not use another medicine containing a LABA (eg, salmeterol, formoterol fumarate, arformoterol tartrate, indacaterol) for any reason.
- Caution should be exercised when considering the coadministration of ANORO ELLIPTA with long-term ketoconazole and other known strong CYP3A4 inhibitors (eg, ritonavir, clarithromycin, conivaptan, indinavir, itraconazole, lopinavir, nefazodone, nelfinavir, saquinavir, telithromycin, troleandomycin, voriconazole) because increased cardiovascular adverse effects may occur.
- If paradoxical bronchospasm occurs, discontinue ANORO ELLIPTA and institute alternative therapy.
- Vilanterol can produce clinically significant cardiovascular effects in some patients as measured by increases in pulse rate, systolic or diastolic blood pressure, or symptoms. If such effects occur, ANORO ELLIPTA may need to be discontinued. ANORO ELLIPTA should be used with caution in patients with cardiovascular disorders, especially coronary insufficiency, cardiac arrhythmias, and hypertension.
- Use with caution in patients with convulsive disorders, thyrotoxicosis, diabetes mellitus, and ketoacidosis, and in patients who are unusually responsive to sympathomimetic amines.
- Use with caution in patients with narrow-angle glaucoma. Instruct patients to contact a physician immediately if signs or symptoms of acute narrow-angle glaucoma develop.
- Use with caution in patients with urinary retention, especially in patients with prostatic hyperplasia or bladder-neck obstruction. Instruct patients to contact a physician immediately if signs or symptoms of urinary retention develop.
- Be alert to hypokalemia and hyperglycemia.


#### ADVERSE REACTIONS

- The most common adverse reactions ( $\geq 1\%$  and more common than placebo) reported in four 6-month clinical trials with ANORO ELLIPTA (and placebo) were: pharyngitis, 2% ( $<1\%$ ); sinusitis, 1% ( $<1\%$ ); lower respiratory tract infection, 1% ( $<1\%$ ); constipation, 1% ( $<1\%$ ); diarrhea, 2% (1%); pain in extremity, 2% (1%); muscle spasms, 1% ( $<1\%$ ); neck pain, 1% ( $<1\%$ ); and chest pain, 1% ( $<1\%$ ).
- In addition to the 6-month efficacy trials with ANORO ELLIPTA, a 12-month trial evaluated the safety of umeclidinium/vilanterol 125 mcg/25 mcg in subjects with COPD. Adverse reactions (incidence  $\geq 1\%$  and more common than placebo) in subjects receiving umeclidinium/vilanterol 125 mcg/25 mcg were: headache, back pain, sinusitis, cough, urinary tract infection, arthralgia, nausea, vertigo, abdominal pain, pleuritic pain, viral respiratory tract infection, toothache, and diabetes mellitus.



## Once-daily ANORO ELLIPTA demonstrated superior lung function improvement compared with tiotropium in 2 studies

PRIMARY ENDPOINT: TROUGH (PREDOSE) FEV<sub>1</sub> AT DAY 169<sup>3,4</sup>



<sup>†</sup>The comparison of UMEC/VI 125 mcg/25 mcg with UMEC 125 mcg preceded that of ANORO ELLIPTA with tiotropium as part of a predefined hierarchy of treatment comparisons and did not achieve statistical significance. Therefore, results of the comparison of ANORO ELLIPTA with tiotropium were descriptive only and statistical significance could not be inferred.<sup>3</sup>

<sup>§</sup>Reflects rounding.

LS=least squares.

### Adverse events (AEs) occurring in ≥3% of subjects in any of the 3 studies<sup>3-5</sup>

Safety data were descriptive only. The studies were not powered to compare the safety profile of ANORO ELLIPTA with that of tiotropium. The range of AEs across the 3 studies for ANORO ELLIPTA (n=883) and tiotropium 18 mcg (n=874), respectively, were: headache (9-10%, 4-7%), nasopharyngitis (6-10%, 7-8%), back pain (2-5%, 2-5%), lower respiratory tract infection (0-4%, <1-1%), upper respiratory tract infection (<1-4%, <1-7%), COPD (<1-3%, <1-2%), cough (2-3%, 2-3%), gastritis (0-3%, <1%), pain in extremity (<1-3%, <1-2%), hypertension (<1-2%, <1-3%), and urinary tract infection (0-<1%, <1-3%).

### Important Safety Information for ANORO ELLIPTA (cont'd)

#### DRUG INTERACTIONS

- Caution should be exercised when considering the coadministration of ANORO ELLIPTA with ketoconazole and other known strong CYP3A4 inhibitors (eg, ritonavir, clarithromycin, conivaptan, indinavir, itraconazole, lopinavir, nefazodone, nelfinavir, saquinavir, telithromycin, troleanomycin, voriconazole) because increased systemic exposure to vilanterol and cardiovascular adverse effects may occur.
- ANORO ELLIPTA should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors, tricyclic antidepressants, or drugs known to prolong the QTc interval, or within 2 weeks of discontinuation of such agents, because the effect of adrenergic agonists, such as vilanterol, on the cardiovascular system may be potentiated by these agents.
- Use beta-blockers with caution as they not only block the pulmonary effect of beta-agonists, such as vilanterol, but may produce severe bronchospasm in patients with COPD.
- Use with caution in patients taking non-potassium-sparing diuretics, as electrocardiographic changes and/or hypokalemia associated with non-potassium-sparing diuretics may worsen with concomitant beta-agonists.
- Avoid coadministration of ANORO ELLIPTA with other anticholinergic-containing drugs as this may lead to an increase in anticholinergic adverse effects.

**References:** 1. Donohue JF, Maleki-Yazdi MR, Kilbride S, et al. Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD. *Respir Med*. 2013;107(10):1538-1546, Appendix A. 2. SPIRIVA HandiHaler [package insert]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc; 2014. 3. Decramer M, Anzueto A, Kerwin E, et al. Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trials. *Lancet Respir Med*. 2014;2(6):472-486. 4. Maleki-Yazdi MR, Kaelin T, Richard N, et al. Efficacy and safety of umeclidinium/vilanterol 62.5/25 mcg and tiotropium 18 mcg in chronic obstructive pulmonary disease: results of a 24-week, randomized, controlled trial. *Respir Med*. 2014;108(12):1752-1760. 5. Data on file, GSK.

Please see additional Important Safety Information for ANORO ELLIPTA on preceding pages.

Please see Brief Summary of Prescribing Information, including Boxed Warning, for ANORO ELLIPTA on the following pages.

[www.GSKSource.com](http://www.GSKSource.com)

©2015 GSK group of companies.  
All rights reserved. Printed in USA. 183411R0 April 2015

ANORO ELLIPTA was developed in collaboration with Theravance



**ANORO**<sup>®</sup> ELLIPTA<sup>®</sup>  
(umeclidinium 62.5 mcg and  
vilanterol 25 mcg inhalation powder)

## BRIEF SUMMARY

### ANORO® ELLIPTA® (umeclidinium and vilanterol inhalation powder) FOR ORAL INHALATION USE

The following is a brief summary only; see full prescribing information for complete product information.

#### WARNING: ASTHMA-RELATED DEATH

Long-acting beta<sub>2</sub>-adrenergic agonists (LABA) increase the risk of asthma-related death. Data from a large placebo-controlled US trial that compared the safety of another LABA (salmeterol) with placebo added to usual asthma therapy showed an increase in asthma-related deaths in subjects receiving salmeterol. This finding with salmeterol is considered a class effect of all LABA, including vilanterol, one of the active ingredients in ANORO ELLIPTA [see Warnings and Precautions (5.1)].

The safety and efficacy of ANORO ELLIPTA in patients with asthma have not been established. ANORO ELLIPTA is not indicated for the treatment of asthma.

#### 1 INDICATIONS AND USAGE

ANORO ELLIPTA is a combination anticholinergic/long-acting beta<sub>2</sub>-adrenergic agonist (anticholinergic/LABA) indicated for the long-term, once-daily, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.

**Important Limitations of Use:** ANORO ELLIPTA is NOT indicated for the relief of acute bronchospasm or for the treatment of asthma.

#### 4 CONTRAINDICATIONS

The use of ANORO ELLIPTA is contraindicated in patients with severe hypersensitivity to milk proteins or who have demonstrated hypersensitivity to umeclidinium, vilanterol, or any of the excipients [see Warnings and Precautions (5.6), Description (11) of full Prescribing Information].

#### 5 WARNINGS AND PRECAUTIONS

##### 5.1 Asthma-Related Death

- Data from a large placebo-controlled trial in subjects with asthma showed that LABA may increase the risk of asthma-related death. Data are not available to determine whether the rate of death in patients with COPD is increased by LABA.
- A 28-week, placebo-controlled, US trial comparing the safety of another LABA (salmeterol) with placebo, each added to usual asthma therapy, showed an increase in asthma-related deaths in subjects receiving salmeterol (13/13,176 in subjects treated with salmeterol vs. 3/13,179 in subjects treated with placebo; relative risk: 4.37 [95% CI: 1.25, 15.34]). The increased risk of asthma-related death is considered a class effect of LABA, including vilanterol, one of the active ingredients in ANORO ELLIPTA.
- No trial adequate to determine whether the rate of asthma-related death is increased in subjects treated with ANORO ELLIPTA has been conducted. The safety and efficacy of ANORO ELLIPTA in patients with asthma have not been established. ANORO ELLIPTA is not indicated for the treatment of asthma.

##### 5.2 Deterioration of Disease and Acute Episodes

ANORO ELLIPTA should not be initiated in patients during rapidly deteriorating or potentially life-threatening episodes of COPD. ANORO ELLIPTA has not been studied in subjects with acutely deteriorating COPD. The initiation of ANORO ELLIPTA in this setting is not appropriate.

ANORO ELLIPTA should not be used for the relief of acute symptoms, i.e., as rescue therapy for the treatment of acute episodes of bronchospasm. ANORO ELLIPTA has not been studied in the relief of acute symptoms and extra doses should not be used for that purpose. Acute symptoms should be treated with an inhaled, short-acting beta<sub>2</sub>-agonist. When beginning treatment with ANORO ELLIPTA, patients who have been taking oral or inhaled, short-acting beta<sub>2</sub>-agonists on a regular basis (e.g., 4 times a day) should be instructed to discontinue the regular use of these drugs and to use them only for symptomatic relief of acute respiratory symptoms. When prescribing ANORO ELLIPTA, the healthcare provider should also prescribe an inhaled, short-acting beta<sub>2</sub>-agonist and instruct the patient on how it should be used. Increasing inhaled, short-acting beta<sub>2</sub>-agonist use is a signal of deteriorating disease for which prompt medical attention is indicated.

COPD may deteriorate acutely over a period of hours or chronically over several days or longer. If ANORO ELLIPTA no longer controls symptoms of bronchoconstriction; the patient's inhaled, short-acting beta<sub>2</sub>-agonist becomes less effective; or the patient needs more short-acting beta<sub>2</sub>-agonist than usual, these may be markers of deterioration of disease. In this setting a re-evaluation of the patient and the COPD treatment regimen should be undertaken at once. Increasing the daily dose of ANORO ELLIPTA beyond the recommended dose is not appropriate in this situation.

##### 5.3 Excessive Use of ANORO ELLIPTA and Use With Other Long-Acting Beta<sub>2</sub>-Agonists

ANORO ELLIPTA should not be used more often than recommended, at higher doses than recommended, or in conjunction with other medicines containing LABA, as an overdose may result. Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. Patients using ANORO ELLIPTA should not use another medicine containing a LABA (e.g., salmeterol, formoterol fumarate, arformoterol tartrate, indacaterol) for any reason.

##### 5.4 Drug Interactions With Strong Cytochrome P450 3A4 Inhibitors

Caution should be exercised when considering the coadministration of ANORO ELLIPTA with long-term ketoconazole and other known strong cytochrome P450 3A4 (CYP3A4) inhibitors (e.g., ritonavir, clarithromycin, conivaptan, indinavir, itraconazole, lopinavir, nefazodone, nelfinavir, saquinavir, telithromycin, troleanandomycin, voriconazole) because increased cardiovascular adverse effects may occur [see Drug Interactions (7.1), Clinical Pharmacology (12.3) of full Prescribing Information].

##### 5.5 Paradoxical Bronchospasm

As with other inhaled medicines, ANORO ELLIPTA can produce paradoxical bronchospasm, which may be life threatening. If paradoxical bronchospasm occurs following dosing with ANORO ELLIPTA, it should be treated immediately with an inhaled, short-acting bronchodilator; ANORO ELLIPTA should be discontinued immediately; and alternative therapy should be instituted.

##### 5.6 Hypersensitivity Reactions

Hypersensitivity reactions may occur after administration of ANORO ELLIPTA. There have been reports of anaphylactic reactions in patients with severe milk protein allergy after inhalation of other powder products containing lactose; therefore, patients with severe milk protein allergy should not use ANORO ELLIPTA [see Contraindications (4)].

##### 5.7 Cardiovascular Effects

Vilanterol, like other beta<sub>2</sub>-agonists, can produce a clinically significant cardiovascular effect in some patients as measured by increases in pulse rate, systolic or diastolic blood pressure, or symptoms [see Clinical Pharmacology (12.2) of full Prescribing Information]. If such effects occur, ANORO ELLIPTA may need to be discontinued. In addition, beta-agonists have been reported to produce electrocardiographic changes, such as flattening of the T wave, prolongation of the QTc interval, and ST segment depression, although the clinical significance of these findings is unknown.

Therefore, ANORO ELLIPTA should be used with caution in patients with cardiovascular disorders, especially coronary insufficiency, cardiac arrhythmias, and hypertension.

#### 5.8 Coexisting Conditions

ANORO ELLIPTA, like all medicines containing sympathomimetic amines, should be used with caution in patients with convulsive disorders or thyrotoxicosis and in those who are unusually responsive to sympathomimetic amines. Doses of the related beta<sub>2</sub>-adrenoceptor agonist albuterol, when administered intravenously, have been reported to aggravate preexisting diabetes mellitus and ketoacidosis.

#### 5.9 Worsening of Narrow-Angle Glaucoma

ANORO ELLIPTA should be used with caution in patients with narrow-angle glaucoma. Prescribers and patients should be alert for signs and symptoms of acute narrow-angle glaucoma (e.g., eye pain or discomfort, blurred vision, visual halos or colored images in association with red eyes from conjunctival congestion and corneal edema). Instruct patients to consult a physician immediately if any of these signs or symptoms develops.

#### 5.10 Worsening of Urinary Retention

ANORO ELLIPTA should be used with caution in patients with urinary retention. Prescribers and patients should be alert for signs and symptoms of urinary retention (e.g., difficulty passing urine, painful urination), especially in patients with prostatic hyperplasia or bladder-neck obstruction. Instruct patients to consult a physician immediately if any of these signs or symptoms develops.

#### 5.11 Hypokalemia and Hyperglycemia

Beta-adrenergic agonist medicines may produce significant hypokalemia in some patients, possibly through intracellular shunting, which has the potential to produce adverse cardiovascular effects. The decrease in serum potassium is usually transient, not requiring supplementation. Beta-agonist medicines may produce transient hyperglycemia in some patients. In 4 clinical trials of 6-month duration evaluating ANORO ELLIPTA in subjects with COPD, there was no evidence of a treatment effect on serum glucose or potassium.

#### 6 ADVERSE REACTIONS

LABA, such as vilanterol, one of the active ingredients in ANORO ELLIPTA, increase the risk of asthma-related death. ANORO ELLIPTA is not indicated for the treatment of asthma. [See Boxed Warning and Warnings and Precautions (5.1).]

The following adverse reactions are described in greater detail in other sections:

- Paradoxical bronchospasm [see Warnings and Precautions (5.5)]
- Cardiovascular effects [see Warnings and Precautions (5.7)]
- Worsening of narrow-angle glaucoma [see Warnings and Precautions (5.9)]
- Worsening of urinary retention [see Warnings and Precautions (5.10)]

#### 6.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The clinical program for ANORO ELLIPTA included 8,138 subjects with COPD in four 6-month lung function trials, one 12-month long-term safety study, and 9 other trials of shorter duration. A total of 1,124 subjects have received at least 1 dose of ANORO ELLIPTA (umeclidinium/vilanterol 62.5 mcg/25 mcg), and 1,330 subjects have received a higher dose of umeclidinium/vilanterol (125 mcg/25 mcg). The safety data described below are based on the four 6-month and the one 12-month trials. Adverse reactions observed in the other trials were similar to those observed in the confirmatory trials.

**6-Month Trials:** The incidence of adverse reactions associated with ANORO ELLIPTA in Table 1 is based on four 6-month trials: 2 placebo-controlled trials (Trials 1 and 2; n = 1,532 and n = 1,489, respectively) and 2 active-controlled trials (Trials 3 and 4; n = 843 and n = 869, respectively). Of the 4,733 subjects, 68% were male and 84% were Caucasian. They had a mean age of 63 years and an average smoking history of 45 pack-years, with 50% identified as current smokers. At screening, the mean post-bronchodilator percent predicted forced expiratory volume in 1 second (FEV<sub>1</sub>) was 48% (range: 13% to 76%), the mean post-bronchodilator FEV<sub>1</sub>/forced vital capacity (FVC) ratio was 0.47 (range: 0.13 to 0.78), and the mean percent reversibility was 14% (range: -45% to 109%). Subjects received 1 dose once daily of the following: ANORO ELLIPTA, umeclidinium/vilanterol 125 mcg/25 mcg, umeclidinium 62.5 mcg, umeclidinium 125 mcg, vilanterol 25 mcg, active control, or placebo.

**Table 1. Adverse Reactions With ANORO ELLIPTA With ≥1% Incidence and More Common Than With Placebo in Subjects With Chronic Obstructive Pulmonary Disease**

Adverse Reaction	Placebo (n = 555) %	ANORO ELLIPTA (n = 842) %	Umeclidinium 62.5 mcg (n = 418) %	Vilanterol 25 mcg (n = 1,034) %
Infections and infestations				
Pharyngitis	<1	2	1	2
Sinusitis	<1	1	<1	1
Lower respiratory tract infection	<1	1	<1	<1
Gastrointestinal disorders				
Constipation	<1	1	<1	<1
Diarrhea	1	2	<1	2
Musculoskeletal and connective tissue disorders				
Pain in extremity	1	2	<1	2
Muscle spasms	<1	1	<1	<1
Neck pain	<1	1	<1	<1
General disorders and administration site conditions				
Chest pain	<1	1	<1	<1

Other adverse reactions with ANORO ELLIPTA observed with an incidence less than 1% but more common than with placebo included the following: productive cough, dry mouth, dyspepsia, abdominal pain, gastroesophageal reflux disease, vomiting, musculoskeletal chest pain, chest discomfort, asthenia, atrial fibrillation, ventricular extrasystoles, supraventricular extrasystoles, myocardial infarction, pruritus, rash, and conjunctivitis.

**12-Month Trial:** In a long-term safety trial, 335 subjects were treated for up to 12 months with umeclidinium/vilanterol 125 mcg/25 mcg or placebo. The demographic and baseline characteristics of the long-term safety trial were similar to those of the placebo-controlled efficacy trials described above. Adverse reactions that occurred with a frequency of greater than or equal to 1% in the group receiving umeclidinium/vilanterol 125 mcg/25 mcg that exceeded that in placebo in this trial were: headache, back pain, sinusitis, cough, urinary tract infection, arthralgia, nausea, vertigo, abdominal pain, pleuritic pain, viral respiratory tract infection, toothache, and diabetes mellitus.

#### 7 DRUG INTERACTIONS

##### 7.1 Inhibitors of Cytochrome P450 3A4

Vilanterol, a component of ANORO ELLIPTA, is a substrate of CYP3A4. Concomitant administration of the strong CYP3A4 inhibitor ketoconazole increases the systemic exposure to vilanterol. Caution should be exercised when

considering the coadministration of ANORO ELLIPTA with ketoconazole and other known strong CYP3A4 inhibitors (e.g., ritonavir, clarithromycin, voriconazole, indinavir, itraconazole, lopinavir, nefazodone, nelfinavir, saquinavir, telithromycin, troleandomycin, voriconazole) [see *Warnings and Precautions (5.4), Clinical Pharmacology (12.3) of full Prescribing Information*].

### 7.2 Monoamine Oxidase Inhibitors and Tricyclic Antidepressants

Vilanterol, like other beta<sub>2</sub>-agonists, should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors, tricyclic antidepressants, or drugs known to prolong the QTc interval or within 2 weeks of discontinuation of such agents, because the effect of adrenergic agonists on the cardiovascular system may be potentiated by these agents. Drugs that are known to prolong the QTc interval have an increased risk of ventricular arrhythmias.

### 7.3 Beta-Adrenergic Receptor Blocking Agents

Beta-blockers not only block the pulmonary effect of beta-agonists, such as vilanterol, a component of ANORO ELLIPTA, but may produce severe bronchospasm in patients with COPD. Therefore, patients with COPD should not normally be treated with beta-blockers. However, under certain circumstances, there may be no acceptable alternatives to the use of beta-adrenergic blocking agents for these patients; cardioselective beta-blockers could be considered, although they should be administered with caution.

### 7.4 Non-Potassium-Sparing Diuretics

The electrocardiographic changes and/or hypokalemia that may result from the administration of non-potassium-sparing diuretics (such as loop or thiazide diuretics) can be acutely worsened by beta-agonists, such as vilanterol, a component of ANORO ELLIPTA, especially when the recommended dose of the beta-agonist is exceeded. Although the clinical significance of these effects is not known, caution is advised in the coadministration of ANORO ELLIPTA with non-potassium-sparing diuretics.

### 7.5 Anticholinergics

There is potential for an additive interaction with concomitantly used anticholinergic medicines. Therefore, avoid coadministration of ANORO ELLIPTA with other anticholinergic-containing drugs as this may lead to an increase in anticholinergic adverse effects [see *Warnings and Precautions (5.9, 5.10), Adverse Reactions (6)*].

## 8 USE IN SPECIFIC POPULATIONS

### 8.1 Pregnancy

**Teratogenic Effects:** Pregnancy Category C. There are no adequate and well-controlled trials of ANORO ELLIPTA or its individual components, umeclidinium and vilanterol, in pregnant women. Because animal reproduction studies are not always predictive of human response, ANORO ELLIPTA should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Women should be advised to contact their physicians if they become pregnant while taking ANORO ELLIPTA.

**Umeclidinium:** There was no evidence of teratogenic effects in rats and rabbits at approximately 50 and 200 times, respectively, the MRHDID (maximum recommended human daily inhaled dose) in adults (on an AUC basis at maternal inhaled doses up to 278 mcg/kg/day in rats and at maternal subcutaneous doses up to 180 mcg/kg/day in rabbits).

**Vilanterol:** There were no teratogenic effects in rats and rabbits at approximately 13,000 and 70 times, respectively, the MRHDID in adults (on a mcg/m<sup>2</sup> basis at maternal inhaled doses up to 33,700 mcg/kg/day in rats and on an AUC basis at maternal inhaled doses up to 591 mcg/kg/day in rabbits). However, fetal skeletal variations were observed in rabbits at approximately 450 times the MRHDID in adults (on an AUC basis at maternal inhaled or subcutaneous doses of 5,740 or 300 mcg/kg/day, respectively). The skeletal variations included decreased or absent ossification in cervical vertebral centrum and metacarpals.

**Nonteratogenic Effects:** **Umeclidinium:** There were no effects on perinatal and postnatal developments in rats at approximately 80 times the MRHDID in adults (on an AUC basis at maternal subcutaneous doses up to 180 mcg/kg/day).

**Vilanterol:** There were no effects on perinatal and postnatal developments in rats at approximately 3,900 times the MRHDID in adults (on a mcg/m<sup>2</sup> basis at maternal oral doses up to 10,000 mcg/kg/day).

### 8.2 Labor and Delivery

There are no adequate and well-controlled human trials that have investigated the effects of ANORO ELLIPTA during labor and delivery.

Because beta-agonists may potentially interfere with uterine contractility, ANORO ELLIPTA should be used during labor only if the potential benefit justifies the potential risk.

### 8.3 Nursing Mothers

**ANORO ELLIPTA:** It is not known whether ANORO ELLIPTA is excreted in human breast milk. Because many drugs are excreted in human milk, caution should be exercised when ANORO ELLIPTA is administered to a nursing woman. Since there are no data from well-controlled human studies on the use of ANORO ELLIPTA by nursing mothers, based on the data for the individual components, a decision should be made whether to discontinue nursing or to discontinue ANORO ELLIPTA, taking into account the importance of ANORO ELLIPTA to the mother.

**Umeclidinium:** It is not known whether umeclidinium is excreted in human breast milk. However, administration to lactating rats at approximately 25 times the MRHDID in adults resulted in a quantifiable level of umeclidinium in 2 pups, which may indicate transfer of umeclidinium in milk.

**Vilanterol:** It is not known whether vilanterol is excreted in human breast milk. However, other beta<sub>2</sub>-agonists have been detected in human milk.

### 8.4 Pediatric Use

ANORO ELLIPTA is not indicated for use in children. The safety and efficacy in pediatric patients have not been established.

### 8.5 Geriatric Use

Based on available data, no adjustment of the dosage of ANORO ELLIPTA in geriatric patients is necessary, but greater sensitivity in some older individuals cannot be ruled out.

Clinical trials of ANORO ELLIPTA for COPD included 2,143 subjects aged 65 and older and, of those, 478 subjects were aged 75 and older. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger subjects.

### 8.6 Hepatic Impairment

Patients with moderate hepatic impairment (Child-Pugh score of 7-9) showed no relevant increases in C<sub>max</sub> or AUC, nor did protein binding differ between subjects with moderate hepatic impairment and their healthy controls. Studies in subjects with severe hepatic impairment have not been performed [see *Clinical Pharmacology (12.3) of full Prescribing Information*].

### 8.7 Renal Impairment

There were no significant increases in either umeclidinium or vilanterol exposure in subjects with severe renal impairment (CrCl<30 mL/min) compared with healthy subjects. No dosage adjustment is required in patients with renal impairment [see *Clinical Pharmacology (12.3) of full Prescribing Information*].

## 10 OVERDOSAGE

No case of overdose has been reported with ANORO ELLIPTA.

ANORO ELLIPTA contains both umeclidinium and vilanterol; therefore, the risks associated with overdose for the individual components described below apply to ANORO ELLIPTA. Treatment of overdose consists of discontinuation of ANORO ELLIPTA together with institution of appropriate symptomatic and/or supportive therapy. The judicious use of a cardioselective beta-receptor blocker may be considered, bearing in mind that such medicine can produce bronchospasm. Cardiac monitoring is recommended in cases of overdose.

### 10.1 Umeclidinium

High doses of umeclidinium may lead to anticholinergic signs and symptoms. However, there were no systemic anticholinergic adverse effects following a once-daily inhaled dose of up to 1,000 mcg umeclidinium (16 times the maximum recommended daily dose) for 14 days in subjects with COPD.

### 10.2 Vilanterol

The expected signs and symptoms with overdose of vilanterol are those of excessive beta-adrenergic stimulation and/or occurrence or exaggeration of any of the signs and symptoms of beta-adrenergic stimulation (e.g., angina, hypertension or hypotension, tachycardia with rates up to 200 beats/min, arrhythmias, nervousness, headache, tremor, seizures, muscle cramps, dry mouth, palpitation, nausea, dizziness, fatigue, malaise, insomnia, hyperglycemia, hypokalemia, metabolic acidosis). As with all inhaled sympathomimetic medicines, cardiac arrest and even death may be associated with an overdose of vilanterol.

## 13 NONCLINICAL TOXICOLOGY

### 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

**ANORO ELLIPTA:** No studies of carcinogenicity, mutagenicity, or impairment of fertility were conducted with ANORO ELLIPTA; however, studies are available for individual components, umeclidinium and vilanterol, as described below.

**Umeclidinium:** Umeclidinium produced no treatment-related increases in the incidence of tumors in 2-year inhalation studies in rats and mice at inhaled doses up to 137 mcg/kg/day and 295/200 mcg/kg/day (male/female), respectively (approximately 20 and 25/20 times the MRHDID in adults on an AUC basis, respectively).

Umeclidinium tested negative in the following genotoxicity assays: the *in vitro* Ames assay, *in vitro* mouse lymphoma assay, and *in vivo* rat bone marrow micronucleus assay.

No evidence of impairment of fertility was observed in male and female rats at subcutaneous doses up to 180 mcg/kg/day and inhaled doses up to 294 mcg/kg/day, respectively (approximately 100 and 50 times, respectively, the MRHDID in adults on an AUC basis).

**Vilanterol:** In a 2-year carcinogenicity study in mice, vilanterol caused a statistically significant increase in ovarian tubulostromal adenomas in females at an inhalation dose of 29,500 mcg/kg/day (approximately 7,800 times the MRHDID in adults on an AUC basis). No increase in tumors was seen at an inhalation dose of 615 mcg/kg/day (approximately 210 times the MRHDID in adults on an AUC basis).

In a 2-year carcinogenicity study in rats, vilanterol caused statistically significant increases in mesovarian leiomyomas in females and shortening of the latency of pituitary tumors at inhalation doses greater than or equal to 84.4 mcg/kg/day (greater than or equal to approximately 20 times the MRHDID in adults on an AUC basis). No tumors were seen at an inhalation dose of 10.5 mcg/kg/day (approximately 1 time the MRHDID in adults on an AUC basis).

These tumor findings in rodents are similar to those reported previously for other beta-adrenergic agonist drugs. The relevance of these findings to human use is unknown.

Vilanterol tested negative in the following genotoxicity assays: the *in vitro* Ames assay, *in vivo* rat bone marrow micronucleus assay, *in vivo* rat unscheduled DNA synthesis (UDS) assay, and *in vitro* Syrian hamster embryo (SHE) cell assay. Vilanterol tested equivocal in the *in vitro* mouse lymphoma assay.

No evidence of impairment of fertility was observed in reproductive studies conducted in male and female rats at inhaled vilanterol doses up to 31,500 and 37,100 mcg/kg/day, respectively (approximately 12,000 and 14,500 times, respectively, the MRHDID in adults on a mcg/m<sup>2</sup> basis).

## 17 PATIENT COUNSELING INFORMATION

Advise the patient to read the FDA-approved patient labeling (Medication Guide and Instructions for Use).

**Asthma-Related Death:** Inform patients that LABA, such as vilanterol, one of the active ingredients in ANORO ELLIPTA, increase the risk of asthma-related death. ANORO ELLIPTA is not indicated for the treatment of asthma.

**Not for Acute Symptoms:** Inform patients that ANORO ELLIPTA is not meant to relieve acute symptoms of COPD and extra doses should not be used for that purpose. Advise them to treat acute symptoms with a rescue inhaler such as albuterol. Provide patients with such medicine and instruct them in how it should be used.

Instruct patients to seek medical attention immediately if they experience any of the following:

- Symptoms get worse
- Need for more inhalations than usual of their rescue inhaler

Patients should not stop therapy with ANORO ELLIPTA without physician/provider guidance since symptoms may recur after discontinuation.

**Do Not Use Additional Long-Acting Beta<sub>2</sub>-Agonists:** Instruct patients to not use other medicines containing a LABA. Patients should not use more than the recommended once-daily dose of ANORO ELLIPTA.

Instruct patients who have been taking inhaled, short-acting beta<sub>2</sub>-agonists on a regular basis to discontinue the regular use of these products and use them only for the symptomatic relief of acute symptoms.

**Paradoxical Bronchospasm:** As with other inhaled medicines, ANORO ELLIPTA can cause paradoxical bronchospasm. If paradoxical bronchospasm occurs, instruct patients to discontinue ANORO ELLIPTA.

**Risks Associated With Beta-Agonist Therapy:** Inform patients of adverse effects associated with beta<sub>2</sub>-agonists, such as palpitations, chest pain, rapid heart rate, tremor, or nervousness. Instruct patients to consult a physician immediately should any of these signs or symptoms develops.

**Worsening of Narrow-Angle Glaucoma:** Instruct patients to be alert for signs and symptoms of acute narrow-angle glaucoma (e.g., eye pain or discomfort, blurred vision, visual halos or colored images in association with red eyes from conjunctival congestion and corneal edema). Instruct patients to consult a physician immediately if any of these signs or symptoms develops.

**Worsening of Urinary Retention:** Instruct patients to be alert for signs and symptoms of urinary retention (e.g., difficulty passing urine, painful urination). Instruct patients to consult a physician immediately if any of these signs or symptoms develops.

ANORO and ELLIPTA are registered trademarks of GSK group of companies.



ANORO ELLIPTA was developed in collaboration with Theravance .



GlaxoSmithKline  
Research Triangle Park, NC 27709

©2014, the GSK group of companies. All rights reserved.  
Revised 05/2014

ANR:2BRS

©2015 GSK group of companies.

All rights reserved. Printed in USA. 183411R0 April 2015

# Stilled leaflets on bioprosthetic valves trigger concern

BY MITCHEL L. ZOLER  
*Frontline Medical News*

SAN FRANCISCO – The newly discovered issue of reduced leaflet motion and possible thrombus on bioprosthetic aortic heart valves, called by one expert “an imaging observation of uncertain clinical significance,” nonetheless drew lots of attention at the Transcatheter Cardiovascular Therapeutics annual meeting. Reduced leaflet motion was the focus of the meeting’s opening session as well as a specially scheduled press conference.

Much of the attention dealt with clarifying the situation and calling for calm after patient concerns were aroused by a report that examination of detailed CT scans from small series of patients who had recently undergone aortic valve replacement showed reduced-motion or immobilized valve leaflets on some of the bioprosthetic valves. The pattern of the finding, made using four-dimensional CT imaging, indicated that reduced-motion leaflets did not occur, and possibly even resolved, when patients were on anticoagulant therapy, suggesting that leaflet immobilization involved thrombus. Also, reduced-motion leaflets appeared following both transcatheter aortic valve replacement (TAVR) and surgical aortic valve replacement (SAVR), said Dr. Raj R. Makkar.

Dr. Makkar summarized his CT findings in several talks during the meeting and also in a report published a few days before the meeting (*N Engl J Med.* 2015 Oct 5. doi:



**What we thought was an imaging artifact is in fact real, and it is almost certainly related to thrombus.**

DR. MAKKAR

10.1056/NEJMoa1509233).

“We started with what we thought was an imaging artifact and established that it is real. We also established with reasonable certainty that it is related to thrombus,” said Dr. Makkar, professor at the University of California, Los Angeles, and director of the Cardiovascular Interventional Center at Cedars-Sinai Medical Center in Los Angeles. The evidence also indicates that this is a class effect that occurs with all types of TAVR systems as well as surgically placed valves.

What the evidence so far does

not indicate is that patients with reduced-motion leaflets face any clinical consequence nor need for routine CT imaging of a newly-placed TAVR or SAVR valve. Also no need for routine anticoagulant therapy instead of standard treatment with dual antiplatelet therapy for several months following placement of a bioprosthetic aortic valve. “We should not make the leap that following TAVR, everyone should be on an anticoagulant” because anticoagulant treatment carries its own risks, said Dr. Makkar, who noted that roughly a quarter of TAVR patients receive anticoagulant treatment because of another indication, such as atrial fibrillation.

“The study did not show a temporal or causal relationship between the imaging findings and stroke. That needs emphasis,” commented Dr. Susheel Kodali, codirector of the Heart Valve Center at the Center for Interventional Vascular Therapy at



**‘The study did not show a temporal or causal relationship between the imaging findings and stroke.’**

DR. KODALI

Columbia University in New York. The possible link between leaflet immobility and strokes or other neurologic events “warrants further study,” as the data that Dr. Makkar reported involved a total of only six strokes or transient ischemic attacks. Data from all the TAVR trials and registries reported so far showed “no late signal of stroke,” said Dr. Kodali, who added that SAVR had a 30-year record of net benefit for appropriate patients.

“Is valve-leaflet thickening an important controversy or much ado about nothing?” wondered Dr. Martin B. Leon, director of the Center for Interventional Vascular Therapy of Columbia University.



**‘Is valve-leaflet thickening an important controversy or much ado about nothing?’**

DR. LEON

“Patients should not feel at risk, and there is no need to do anything differently” for the time being in

routine practice, commented Dr. Jeffrey J. Popma, professor at Harvard Medical School and director of interventional cardiology at Beth Israel



**‘Patients should not feel at risk, and there is no need to do anything differently’ in routine practice.**

DR. POPMA

Deaconess Medical Center, both in Boston.

Dr. Makkar said that in the days following the publication of his report, he had “a lot of phone calls and time spent allaying anxiety in patients and reassuring them.”

One reason why these leaflet-motion abnormalities may have shown up on CT examinations recently is that “the cameras have gotten better,” said Dr. Jonathon A. Leipsic, codirector of advanced cardiac imaging at the Providence Health Care Heart Center at St. Paul’s Hospital in Vancouver. Dr. Leipsic also highlighted that with state-of-the-art CT images, immobilized leaflets are easy to identify.

Despite that, Dr. Popma stressed that standardized imaging protocols are needed going forward to produce reliable incidence data.

The data that Dr. Makkar reported came from a review of four-dimensional CT imaging done on 187 replacement aortic valves, usually within 3 months of placement. Images for 55 aortic valves came from the device-approval trial for a new TAVR system, taken 30 days after patients underwent TAVR with any of three types of systems. The images showed reduced leaflet motion in 22 valves (40%).

CT images for another 132 valves came from a Cedar’s-Sinai registry and a second, independent registry maintained in Denmark. CT images showed that 17 (13%) of the replaced aortic valves showed a leaflet-motion abnormality, including two valves placed using SAVR. Half the registry patients had undergone CT imaging within 88 days of valve replacement. The only signal of a clinical outcome linked with reduced-motion leaflets was a small increase in the incidence of transient ischemic attacks, but Dr. Makkar cautioned that transient ischemic attacks “are hard to adjudicate.”

Dr. Makkar’s report was “a small but important study, one of the first

## VITALS

**Key clinical point:** CT imaging of recently placed bioprosthetic aortic valves showed several cases of leaflets with reduced motion, suggesting possible clinical consequences.

**Major finding:** CT imaging showed reduced leaflet motion in 22 of 55 (40%) trial patients and 17 of 132 (13%) registry patients.

**Data source:** An observational study of CT images collected on 187 patients who had undergone aortic valve replacement from the PORTICO IDE study (55 patients), and the RESOLVE and SAVORY registries (132 total patients).

**Disclosures:** The PORTICO IDE study and RESOLVE registry were funded by St. Jude. Dr. Makkar has received honoraria and research support from St. Jude, lecture fees from Edwards Lifesciences, research grants from Edwards and Medtronic, and has an equity interest in Entourage.

reports of this phenomenon. You don’t want to lose sight of all the evidence of patient benefit” from aortic valve replacement, stressed Dr. Kodali at the meeting, sponsored by



**One reason these leaflet-motion abnormalities may have shown up on CT scans is that ‘the cameras have gotten better.’**

DR. LEIPSIC

the Cardiovascular Research Foundation. “This needs to be investigated further, probably by a Food and Drug Administration–mandated trial with CT imaging.”

“Aortic valves are lifesaving devices. The last thing that should happen is patients not getting their aortic valves replaced” when their condition demands it, Dr. Makkar said.

Dr. Kodali has been a consultant to Edwards Lifesciences and Claret Medical and has an equity interest in Thubrikar Aortic Valve. Dr. Leon has been a consultant to Edwards. Dr. Popma has been a consultant to Abbott Laboratories, Boston Scientific, and St. Jude, and he has been a speaker for and received grants from Medtronic. Dr. Leipsic has been a consultant to Edwards and Heartflow and received grants from Edwards, Neovasc, and Tendyne.

mzoler@frontlinemedcom.com  
On Twitter @mitchelzoler

# What if your PAH patient may not have PAH?



A ventilation-perfusion (V/Q) scan can rule out chronic thromboembolic pulmonary hypertension (CTEPH) in patients diagnosed with PAH, which is the only form of pulmonary hypertension that can be potentially cured by surgery.<sup>1</sup>

If you know what to look for, a V/Q scan makes it relatively easy to spot.<sup>1</sup>



As many as **1 out of every 25** of your previously treated PE patients (>3 months of anticoagulation<sup>2</sup>) may develop CTEPH.<sup>3,4\*</sup>

#### References:

1. Kim NH, Delacroix M, Jenkins DP, et al. Chronic thromboembolic pulmonary hypertension. *J Am Coll Cardiol*. 2013;62(suppl D):D92-D99.

2. Wilkens H, Lang I, Behr J, et al. Chronic thromboembolic pulmonary hypertension (CTEPH): updated recommendations of the Cologne Consensus Conference 2011. *Int J Cardiol*. 2011;154S:S54-S60.

3. Pengo V, Lensing AWA, Prins MH, et al. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. *N Engl J Med*. 2004;350(22):2257-2264.

4. Tapson VF, Humbert M. Incidence and prevalence of chronic thromboembolic pulmonary hypertension: from acute to chronic pulmonary embolism. *Proc Am Thorac Soc*. 2006;3(7):564-567.

\*Based on a study with 223 patients in which 3.8% were diagnosed with CTEPH within 2 years of their first episode of pulmonary embolism with or without prior deep-vein thrombosis (95% CI, 1.1 to 6.5). CTEPH did not develop after two years in any of the 132 remaining patients with more than 2 years of follow up.

VISIT **scan4CTEPH.COM**  
FOR MORE INFORMATION



Bayer HealthCare LLC  
100 Bayer Boulevard, Whippany, NJ 07981 USA  
©2015 Bayer HealthCare Inc.  
PP-400-US-1616 March 2015

# Screening for CTEPH in Patients With Suspected Pulmonary Hypertension



presented by

## RICHARD CHANNICK, MD

Richard N. Channick, MD, is Associate Professor of Medicine at Harvard Medical School, Boston, Massachusetts, and has been Director of the Pulmonary Hypertension and Thromboendarterectomy Program at Massachusetts General Hospital in Boston since 2009.

### CTEPH IS A FORM OF PULMONARY HYPERTENSION

**Chronic thromboembolic pulmonary hypertension** is a form of pulmonary hypertension (PH), designated by the World Health Organization as Group 4 PH. There are 5 WHO Groups of PH<sup>1</sup>:

- 1: Pulmonary arterial hypertension
- 2: PH due to left heart disease
- 3: PH due to lung diseases and/or hypoxia
- 4: **CTEPH**
- 5: PH with unclear multifactorial mechanisms

Recently, Klok et al have coined the term “post-pulmonary embolism syndrome” to describe chronic complications of pulmonary embolism (PE), involving permanent changes in pulmonary artery flow, pulmonary gas exchange and/or cardiac function which are associated with symptoms of dyspnea and decreased exercise capacity.<sup>2</sup> The most serious manifestation of this syndrome—and the most serious complication of acute PE—is chronic thromboembolic pulmonary hypertension, or CTEPH.<sup>2,3</sup> As many as 1 in 25 survivors of acute PE may go on to develop CTEPH within 2 years.<sup>4</sup>

Hemodynamically, CTEPH is most often defined as a mean pulmonary arterial pressure (mPAP)  $\geq 25$  mmHg, with pulmonary capillary wedge pressure (PCWP)  $\leq 15$  mmHg. These levels must be obtained via right heart catheterization, and they must be observed in the presence of multiple chronic/organized, occlusive thrombi/emboli in the pulmonary arteries after at least 3 months of effective anticoagulation.<sup>5</sup>

Symptoms of CTEPH are nonspecific<sup>6</sup> and include dyspnea on exertion, fatigue, weakness, chest pain, syncope, hemoptysis, and lower-extremity edema.<sup>7</sup> Among the risk factors for CTEPH are unprovoked or recurrent PE, young age at the time of first PE, and splenectomy.<sup>7</sup>

CTEPH is unique among the five groups of PH insofar as it is the only form that is potentially curable—via pulmonary thromboendarterectomy (PTE, also known as pulmonary endarterectomy [PEA]), the treatment of choice for surgical candidates with CTEPH.<sup>8-10</sup> It is this potential to effect a curative

treatment that makes it imperative to suspect and screen for CTEPH—and to differentiate CTEPH from other forms of PH—when patients present with symptoms consistent with PH.

### HOW DOES CTEPH DEVELOP?


CTEPH results after a single PE or recurrent PEs that create endothelialized residua that obstruct or substantially narrow pulmonary arteries.<sup>11</sup> The absence or depletion of endogenous nitric oxide may contribute to endothelial dysfunction in CTEPH.<sup>12</sup> Obstruction and narrowing of the pulmonary arteries drives pulmonary arterial pressures to abnormal levels and increases pulmonary vascular resistance (PVR).<sup>11</sup> Over time, developing small vessel vasculopathy can lead to right ventricular afterload, progression of PH, and CTEPH.<sup>13</sup> If CTEPH is unrecognized or left untreated, right ventricular dysfunction can progress, ultimately resulting in right heart failure.<sup>13</sup>

### HOW COMMON IS CTEPH?

Based on data from small observational studies that followed survivors of acute PE, incidence of CTEPH has been estimated to be 0.57% (N=866 survivors of acute PE observed) to 3.8% (N=314 survivors of acute PE observed)—or almost 1 in 25—within 2 years of the first acute event.<sup>3,13</sup> A more recent, but smaller (N=146 acute PE survivors followed for 26 months) study found that 8 survivors of acute PE were suspected to have CTEPH, and 7 of these—or 4.8% of the study population—were confirmed to have CTEPH.<sup>14</sup> Yet another study of survivors of acute PE (N=104) saw 5.8% of patients develop CTEPH within 2 years. Further follow-up saw an additional 4 cases develop beyond 2 years (time period not specified) for a total of 9.1% of the original study population.<sup>15</sup>

**The absence of prior acute PE does not exclude a diagnosis of CTEPH<sup>9,16,17</sup>**

Applying even the lower end of this range of estimates to the annual population of survivors of acute PE suggests there could be thousands of incident cases of CTEPH each year in the US. Further, though CTEPH is a complication of acute PE, as many as 25% to 30% of patients who have CTEPH may never have had an overt PE or a history suggestive of PE.<sup>9,16,17</sup> The true incidence of CTEPH may, therefore, be underestimated, because postembolism



observational studies do not include patients who have no history of venous thromboembolism.<sup>13</sup>

### HOW DO WE SCREEN FOR CTEPH?

As noted, symptoms of CTEPH are nonspecific, and as a result, CTEPH is often misdiagnosed and is under recognized in practice.<sup>6</sup> If after at least 3 months of anticoagulation following an episode of acute PE a patient still has or develops symptoms of dyspnea, fatigue, decreased exercise capacity, or another of the symptoms of PH, one should suspect and either screen for CTEPH or refer the patient to a PH specialist who can perform CTEPH screening.<sup>18,19</sup>

As noted above, as many as 30% of patients who are ultimately diagnosed with CTEPH may have no history of overt acute PE, so any patient who has unexplained dyspnea should also be screened for CTEPH.<sup>9, 16,17</sup>

**If after 3 months of anticoagulation following an episode of acute PE a patient still has or develops such symptoms, CTEPH should be suspected and the patient referred to a PH specialist who can perform CTEPH screening<sup>17</sup>**

Computed tomographic pulmonary angiography (CTPA) has become the standard diagnostic test for acute PE, and a good-quality CTPA that is negative for acute PE effectively rules the diagnosis out.<sup>19</sup> Unlike for acute PE, though, CTPA is not a preferred diagnostic test for CTEPH.<sup>8</sup> Instead, the ventilation/perfusion, or V/Q, scan is the preferred and recommended screening test for CTEPH.<sup>8</sup> Tunariu et al demonstrated that as a screening test for CTEPH, the V/Q scan had >96% sensitivity, meaning that a negative (ie, normal) V/Q scan essentially rules out the presence of CTEPH.<sup>20</sup> Conversely, Tunariu et al also showed that CTPA had a sensitivity of only 51% as a screening test for CTEPH, with a falsely negative finding in 38 of 78 cases studied.<sup>20</sup> Multiple national and international guidelines recommend the use of the V/Q scan as the CTEPH screening tool of choice.<sup>5,8,21-23</sup> Though it can detect chronic thromboembolic disease in segmental, lobar, or main pulmonary arteries, CTPA may miss disease that is

confined to very distal segmental or subsegmental pulmonary arteries.<sup>8,24</sup>

The V/Q scan has many attributes that contribute to its utility as a screening tool for CTEPH.<sup>8</sup> It is easy to read—suspected perfusion defects, regardless of origin, are readily recognizable. V/Q scanning also requires less radiation exposure than CTPA, and it avoids complications from administration of IV contrast. Finally, it offers a lower likelihood of incidental findings.

PTE surgery is the first-line treatment of choice for surgical candidates who have CTEPH<sup>15</sup>

Many patients who have been diagnosed with pulmonary arterial hypertension (PAH) have never had a V/Q scan to rule out potentially curable CTEPH. Findings from the Pulmonary Arterial Hypertension-Quality Enhancement Research Initiative (PAH-QuERI, N=786) demonstrated that 43% of patients who had been diagnosed with PAH had been so diagnosed despite never having received a V/Q scan to screen for, and potentially rule out, CTEPH.<sup>25</sup> This finding suggests that patients who have been previously diagnosed with PAH without having had a V/Q scan and who are not meeting their PAH treatment goals should receive a V/Q scan to screen for CTEPH.

To stress the importance of the V/Q scan as a screening tool for CTEPH, the World Symposium on Pulmonary Hypertension observed that “underutilization of V/Q scans in screening PH invites potential misdiagnosis of PAH.”<sup>28</sup> Such misdiagnosis can result in delay of assessment for potentially curative surgery for CTEPH.<sup>6,26</sup> If V/Q scanning is not readily available, the patient should be referred to a center that can perform a V/Q scan.

### CONFIRMATION OF CTEPH DIAGNOSIS

An abnormal V/Q scan showing perfusion defects is not enough on its own to diagnose CTEPH. To confirm CTEPH, right heart catheterization (RHC) must be performed to confirm mean PAP  $\geq 25$  mmHg, with pulmonary capillary wedge pressure (PCWP)  $\leq 15$  mmHg. Selective pulmonary angiography is typically used to confirm presence of CTEPH lesions.<sup>8</sup> CTPA and magnetic resonance angiography can contribute complementary information on the lesions, their surroundings, and their accessibility.<sup>5,8</sup>

Once the diagnosis of CTEPH is confirmed, all CTEPH patients must be assessed for operability by an experienced CTEPH team that would plan, perform, and follow-up the patient’s surgery. Operability assessment must consider the patient’s risk, including quality of and accessibility of lesions, hemodynamic assessment, and consideration of comorbidities and patient characteristics.<sup>8</sup> If one experienced CTEPH team determines that a patient has inoperable disease, a corroborating opinion from a second experienced CTEPH team should be secured, if possible.<sup>8</sup> This is because operability assessment is subjective, and what may be deemed by one CTEPH team as inoperable disease may well

be deemed operable by another experienced CTEPH team.

### CTEPH TREATMENT IN SURGICAL CANDIDATES: PULMONARY THROMBOECTOMY

Referral of CTEPH patients to PH centers for confirmation of diagnosis, operability assessment, and comprehensive care is essential.<sup>5</sup> Because it is potentially curative, PTE surgery is considered the first-line treatment of choice for patients diagnosed with CTEPH who are appropriate surgical candidates.<sup>8-10</sup> Rather than reserving PTE surgery as a “last-ditch” treatment option, patients who have operable CTEPH should be referred for surgery without delay.<sup>8</sup> Though all CTEPH patients require lifelong anticoagulation to prevent in situ pulmonary artery thrombosis and recurrent venous thromboembolism,<sup>8</sup> anticoagulation is not sufficient to treat the progressive right ventricular dysfunction that results from CTEPH. PTE surgery allows for the removal of central obstructing lesions, resulting in improvement and often normalization of pulmonary hemodynamics.<sup>7</sup> About two-thirds of patients have normal hemodynamics following PTE.<sup>27</sup>

### REFERENCES

1. Simonneau G, Gatzoulis MA, Adatia I, et al. Updated clinical classification of pulmonary hypertension. *J Am Coll Cardiol*. 2013;62(25 suppl):D34-D41.
2. Kloke FA, van der Hulle T, den Exter PL, et al. The post-PE syndrome: a new concept for chronic complications of pulmonary embolism. *Blood Rev*. 2014;28(6):221-226.
3. Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics—2014 update: A report from the American Heart Association. *Circulation*. 2014;129(3):e28-e292.
4. Pengo V, Lensing AWA, Prins MH, et al. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. *N Engl J Med*. 2004;350(22):2257-2264.
5. Wilkens H, Lang I, Behr J, et al. Chronic thromboembolic pulmonary hypertension (CTEPH): updated recommendations of the Cologne Consensus Conference 2011. *Int J Cardiol*. 2011;154S:S54-S60.
6. Tapson VF, Humbert M. Incidence and prevalence of chronic thromboembolic pulmonary hypertension: from acute to chronic pulmonary embolism. *Proc Am Thorac Soc*. 2006;3(7):564-567.
7. Piazza G, Goldhaber SZ. Chronic thromboembolic pulmonary hypertension. *N Engl J Med*. 2011;364(4):351-360.
8. Kim NH, Delcroix M, Jenkins DP, et al. Chronic thromboembolic pulmonary hypertension. *J Am Coll Cardiol*. 2013;62(suppl D):D92-D99.
9. Jamieson SW, Kapelanski DP, Sakakibara N, et al. Pulmonary endarterectomy: experience and lessons learned in 1500 cases. *Ann Thorac Surg*. 2003;76(5):1457-1464.
10. Keogh AM, Mayer E, Benza RL, et al. Interventional and surgical modalities of treatment in pulmonary hypertension. *J Am Coll Cardiol*. 2009;54(suppl 1):S67-S77.
11. Humbert M. Pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: pathophysiology. *Eur Respir Rev*. 2010;19(115):59-63.
12. Skoro-Sajer N, Mittermayer F, Panzenboeck A, et al. Asymmetric dimethylarginine is increased in chronic thromboembolic pulmonary hypertension. *Am J Respir Crit Care Med*. 2007;176(11):1154-1160.
13. Fedullo P, Kerr KM, Kim NH, Auger WR. Chronic thromboembolic pulmonary hypertension. *Am J Respir Crit Care Med*. 2011;183(12):1605-1613.
14. Guérin L, Couturaud F, Parent F, et al. Prevalence of chronic thromboembolic pulmonary hypertension after acute pulmonary embolism. Prevalence of CTEPH after pulmonary embolism. *Thromb Haemost*. 2014;112(3):598-605.

15. Martí D, Gómez V, Escobar C et al. Incidence of symptomatic and asymptomatic chronic thromboembolic pulmonary hypertension. *Arch Bronconeumol*. 2010;46(12):628-633.
16. Pepke-Zaba J, Delcroix M, Lang I, et al. Chronic thromboembolic pulmonary hypertension (CTEPH): results from an international prospective registry. *Circulation*. 2011;124(18):1973-1981.
17. Bonderman D, Wilkens H, Wakounig H-J, et al. Risk factors for chronic thromboembolic pulmonary hypertension. *Eur Respir J*. 2009;33(2):325-331.
18. McLaughlin VV, Archer SL, Badesch BD, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension. A report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association. Developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association. *Circulation*. 2009;119(16):2250-2294.
19. Tapson VF. Advances in the diagnosis and treatment of acute pulmonary embolism. *F1000 Reports Med*. 2012;4:9.
20. Tunariu N, Gibbs SJR, Win Z, et al. Ventilation-perfusion scintigraphy is more sensitive than multidetector CTPA in detecting chronic thromboembolic pulmonary disease as a treatable cause of pulmonary hypertension. *J Nucl Med* 2007;48(5):680-684.
21. Galiè N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). *Eur Heart J*. 2009;30(20):2493-2537.
22. Jaff MR, McMurtry S, Archer SI, et al. Management of massive and submassive pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboembolic pulmonary hypertension: A scientific statement from the American Heart Association. *Circulation*. 2011;123(16):1788-1830.
23. Mehta S, Helmersen D, Provencher S, et al. Diagnostic evaluation and management of chronic thromboembolic pulmonary hypertension: a clinical practice guideline. *Can Respir J*. 2010;17(6):301-334.
24. Sugiura T, Tanabe N, Matsuura Y, et al. Role of 320-slice CT imaging in the diagnostic workup of patients with chronic thromboembolic pulmonary hypertension. *Chest*. 2013;143(4):1070-1077.
25. McLaughlin VV, Langer A, Tan M, et al. Contemporary trends in the diagnosis and management of pulmonary arterial hypertension: An initiative to close the care gap. *Chest*. 2013;143(2):324-332.
26. Kim NH, Lang IM. Risk factors for chronic thromboembolic pulmonary hypertension. *Eur Respir Rev*. 2012;21(123):27-31.
27. Freed DH, Thomson BM, Berman M, et al. Survival after pulmonary thromboendarterectomy: effect of residual pulmonary hypertension. *J Thorac Cardiovasc Surg*. 2011;141(2):383-387.

\*Based on a study with 223 patients in which 3.8% were diagnosed with CTEPH within 2 years of their first episode of pulmonary embolism with or without prior deep-vein thrombosis (95% CI, 1.1 to 6.5).<sup>4</sup>

VISIT  
scan4CTEPH.com  
FOR MORE INFORMATION

BAYER, and the Bayer Cross are registered trademarks of Bayer.



Bayer HealthCare LLC  
100 Bayer Boulevard, Whippany, NJ 07981 USA  
©2015 Bayer HealthCare Inc.  
PP-400-US-1575 March 2015

# Risk score predicts need for early postop nutrition

BY M. ALEXANDER OTTO  
*Frontline Medical News*

CHICAGO – A few simple baseline variables predict if heart surgery patients will need early nutritional support after their operations, based on a review of more than 1,000 cardiac surgery patients from Johns Hopkins Hospital in Baltimore.

Nonelective surgery and a cardiopulmonary bypass time of 100 minutes or more, plus five preop variables – previous cardiac interventions; total albumin below 4 g/dL; total bilirubin at or above 1.2 mg/dL; white blood cell counts at or above 11,000/mcL; and hematocrit below 27% – predict the need for nutrition in the first few days after cardiac surgery, they found (*J Am Coll Surg*. 2015 Oct; 221[4];e70).

The Hopkins team has combined those factors into a risk score, with 4 points assigned for low albumin, 6 points for nonelective surgery, 6 points for low hematocrit, and 5 points for the other four variables, yielding a maximum score of 36 points.

The researchers developed the system after discovering that it sometimes took more than a week for cardiac patients who needed postop nutrition to get it. About 40% of patients with scores of 20 or higher will need early nutritional support, and those heart patients are now the ones at Hopkins who get a nutrition consult as soon as they return

from the operating room, said Dr. Rika Ohkuma, a general surgery research fellow at Johns Hopkins. “The score can be used for risk stratification and has potential quality improvement implications related to early initiation of nutritional support in high-risk patients.”

Just 2% of patients who score 10 points or below need early nutrition, so consults are less pressing. About 9% of patients who score from 10-20 points will require nutrition, so consults are at the discretion of the physician, the investigators concluded.

Those insights came from a review of 1,056 adult heart cases in 2012. Just 87 patients (8%) had a postop consult for nutritional support. Most wound up with enteral feedings, but they started an average of 5 days after surgery. The handful that needed both parenteral and enteric feedings started them an average of 7 days after surgery.

Meanwhile, those 87 patients had significantly higher hospital mortality (29% vs. 3%), ventilator time (278 vs. 20 hours), and gastrointestinal complications (32% vs. 5%), and fewer discharges to home (49% vs. 84%) than did other patients.



**If patients are likely to need support, ‘we immediately call the nutritional support service for a consult.’**

DR. OHKUMA

Thinking that the delay in feeding might be related to poor outcomes, “we tried to improve our behavior. We know that nutrition is beneficial for critically ill patients and that we need to start early, but there was no gold standard for when to start,” Dr. Ohkuma said.

The investigators came up with the risk score after figuring out how patients who needed nutrition differed from those who did not. They found, for example, that patients who have emergent surgery were more than three times as likely to have a nutrition consult than were those who had elective procedures.

Now when patients are admitted to the ICU after cardiac surgery, “we all know their [nutrition] score; if they are likely to need support, we immediately call the nutritional support service for a consult,” Dr. Ohkuma said.

The researchers launched a prospective study in January 2015. Nutritional needs were addressed sooner, at about postop day 4, for the 70 patients who have needed, and mortality seems to be dropping.

The investigators had no relevant disclosures.

aotto@frontlinemedcom.com

## Drug-coated balloons offer option for in-stent restenosis

BY MITCHEL L. ZOLER  
*Frontline Medical News*

SAN FRANCISCO – Drug-coated balloons have become a widely used option in Europe for treating coronary in-stent restenosis, and the scoring-balloon pretreatment tested in ISAR-DESIRE 4 boosted the efficacy of a drug-coated balloon in a clinically meaningful way, Dr. Marco Valgimigli said in an interview at the Transcatheter Cardiovascular Therapeutics annual meeting.

When patients develop restenosis within a stent, many times it’s because the stent was not properly expanded during initial placement. An advantage to a drug-coated balloon is that it pairs well with therapeutic reexpansion of the existing stent to its proper, fully open position.

In addition, this approach spares the patient from receiving a second stent inside the first stent, said Dr. Valgimigli, an interventional cardiologist at Inselspital in Bern, Switzerland.

Often when patients develop in-stent restenosis, it tends to keep recurring. And when that happens, eventually the

only remaining option for effective revascularization of the patient’s coronary arteries is coronary bypass surgery.

Pretreating in-stent restenosis with a scoring balloon prior to treatment with a drug-coated balloon improved



efficacy in the ISAR-DESIRE 4 trial by a modest amount. But if this treatment strategy can successfully defer or obviate just a few cases that might otherwise require coronary bypass surgery, then using the scoring balloon is a reasonable approach, Dr. Valgimigli said at the meeting, sponsored by the Cardiovascular Research Foundation.

Watch the video interview at chestphysician.org.

mzoler@frontlinemedcom.com  
On Twitter @mitchelzoler

## Novel device aids severe tricuspid regurgitation

BY MICHELE G. SULLIVAN  
*Frontline Medical News*

The investigational FORMA system seems safe and may be effective in patients with NYHA Class III/IV heart failure and severe tricuspid valve regurgitation, based on 13 first-in-human cases.

A Canadian surgical team employed the FORMA system (Edwards Lifesciences) as compassionate use therapy for a set of patients with inoperable tricuspid regurgitation. The device was successfully deployed in 12 of the 13 patients, according to data presented at the Transcatheter Cardiovascular Therapeutics annual meeting. There were no deaths or major clinical complications in any of the patients.

A report on seven of these patients was simultaneously published in the *Journal of the American College of Cardiology*. All of the patients had severe tricuspid regurgitation and heart failure; before surgery, six had a New York Heart Association (NYHA) Functional Classification of III/IV. By 30 days after the proce-

cedure, all had improved to NYHA II, wrote Dr. Francisco Camello-Parada of the Quebec Heart and Lung Institute, the paper’s primary author. Peripheral edema declined and all patients experienced functional improvement, as well.

According to Edwards Lifesciences, the FORMA device uses a foam-filled polymer balloon spacer to reduce tricuspid regurgitation by occupying the regurgitant orifice area and providing a surface for the coaptation of the valve’s native leaflets. Implantation is performed via the left axillary vein.

Patients in the series were a mean of 76 years old. All had severe tricuspid regurgitation. The mean maximal vena contracta was 15.5 mm.

Six had coronary artery disease and five had previously undergone open heart surgery. Additionally, two had previously undergone mitral valve surgery and two had undergone aortic valve surgery. Pulmonary hypertension was present in five.

*Continued on following page*

Continued from previous page

patients also had persistent atrial fibrillation. Six had renal insufficiency, with one patient on dialysis. The baseline furosemide dose was 80 mg/day.

All procedures were performed under general sedation and fluoroscopic guidance, with postprocedural positioning checked by cardiac-CT and/or a chest x-ray. The mean postop stay was 4 days.

Tricuspid regurgitation was reduced by at least 1 degree in all patients during the operation; four patients had an immediate 2-degree reduction, reclassifying their regur-

residual degree of postprocedural tricuspid regurgitation," they said. "Also, the very advanced stage of the disease in most patients may have played a role in the mild reduction at 30 days."

Despite the rather mild, 1-degree improvement, patients did make considerable improvements in heart

failure and functional status. Therefore, the team recommended further study for FORMA, with an eye toward optimizing patient selection.

"Specific criteria for quantifying right ventricular dysfunction and pulmonary hypertension, along with novel quantitative echocardiographic imaging criteria may be

required," the investigators said. "It is conceivable that larger than the currently available spacer sizes may be required to improve echocardiographic results in patients with large noncoaptation defects and vena contracta."

msullivan@frontlinemedcom.com

## VITALS

**Key clinical point:** The investigational FORMA system seems safe and may be effective in patients with NYHA Class III/IV heart failure and severe tricuspid valve regurgitation.

**Major finding:** The improved heart failure from NYHA Class III/IV to Class II in six of seven patients with severe tricuspid valve regurgitation.

**Data source:** The device has been used in 13 patients thus far, under compassionate use allowance.

**Disclosures:** Edwards Lifesciences manufactures and is investigating the device. Dr. Campelo-Parada had no disclosures.

gitation as mild. Two experienced new-onset atrial fibrillation, and one had several episodes of nonsustained ventricular tachycardia that was managed with beta-blockers.


At the first clinical follow-up 30 days after surgery, all but one patient had an improvement to Class II NYHA status.

Two patients were able to reduce their diuretic dosage; there were no other medication changes. Peripheral edema declined in the entire cohort. Tricuspid regurgitation was graded as moderate in all patients.

There were also associated improvements in quality of life, based on scores on the Kansas City Cardiomyopathy Questionnaire, which increased from 59 before surgery to 86 after surgery. Exercise capacity as measured by the 6-Minute Walk Test improved from 297 meters to 326 meters.

The authors suggested that the 15-mm spacer used in the FORMA device was not well-matched with the mean 15.5-mm vena contracta size in the cohort. Better outcomes might be possible if a larger spacer were available.

"Despite good device positioning, complete coaptation was not achieved, resulting in significant



SYMBICORT 160/4.5 for the maintenance treatment of COPD

# REV THE FEV<sub>1</sub>

SYMBICORT offers something extra—  
sustained\* control with better breathing  
starting within 5 minutes each time<sup>1-3</sup>

- SYMBICORT is NOT a rescue medication and does NOT replace fast-acting inhalers to treat acute symptoms
- Mean percent change from baseline in FEV<sub>1</sub> was measured at day of randomization, months 6 and 12<sup>3</sup>

## FAST CONTROL

Majority of FEV<sub>1</sub> improvement at 5 minutes each time<sup>†</sup> in a subset of SUN Study patients taking SYMBICORT 160/4.5 (n=121)<sup>4</sup>

## SUSTAINED EFFECT

Significant lung function improvement with continuous control, as demonstrated over 12 months in the SUN Study (n=494)<sup>1,4</sup>

## REASSURING SENSE OF CONTROL

- The most common adverse reactions ≥3% reported in COPD clinical trials included nasopharyngitis, oral candidiasis, bronchitis, sinusitis, and upper respiratory tract infection

\*Sustained improvement in lung function was demonstrated in a 12-month efficacy and safety study.

<sup>†</sup>In a serial spirometry subset of patients taking SYMBICORT 160/4.5 (n=121) in the SUN Study, 67% of 1-hour postdose FEV<sub>1</sub> improvement occurred at 5 minutes on day of randomization, 83% at month 6, and 84% at end of treatment. See SUN Study design on next page.

## IMPORTANT SAFETY INFORMATION, INCLUDING BOXED WARNING

- ▶ **WARNING:** Long-acting beta<sub>2</sub>-adrenergic agonists (LABA), such as formoterol, one of the active ingredients in SYMBICORT, increase the risk of asthma-related death. A placebo-controlled study with another LABA (salmeterol) showed an increase in asthma-related deaths in patients receiving salmeterol. This finding with salmeterol is considered a class effect of LABA, including formoterol. Currently available data are inadequate to determine whether concurrent use of inhaled corticosteroids or other long-term asthma control drugs mitigates the increased risk of asthma-related death from LABA. Available data from controlled clinical trials suggest that LABA increase the risk of asthma-related hospitalization in pediatric and adolescent patients
- ▶ When treating patients with asthma, prescribe SYMBICORT only for patients not adequately controlled on a long-term asthma control medication, such as an inhaled corticosteroid or whose disease severity clearly warrants initiation of treatment with both an inhaled corticosteroid and LABA. Once asthma control is achieved and maintained, assess the patient at regular intervals and step down therapy (eg, discontinue SYMBICORT) if possible without loss of asthma control, and maintain the patient on a long-term asthma control medication, such as an inhaled corticosteroid. Do not use SYMBICORT for patients whose asthma is adequately controlled on low or medium dose inhaled corticosteroids
- ▶ SYMBICORT is NOT a rescue medication and does NOT replace fast-acting inhalers to treat acute symptoms
- ▶ SYMBICORT should not be initiated in patients during rapidly deteriorating episodes of asthma or COPD
- ▶ Patients who are receiving SYMBICORT should not use additional formoterol or other LABA for any reason
- ▶ Localized infections of the mouth and pharynx with *Candida albicans* has occurred in patients treated with SYMBICORT. Patients should rinse the mouth after inhalation of SYMBICORT
- ▶ Lower respiratory tract infections, including pneumonia, have been reported following the inhaled administration of corticosteroids

Please see additional Important Safety Information and Brief Summary of full Prescribing Information, including Boxed WARNING, on following pages.

**Symbicort**  
(budesonide/formoterol fumarate dihydrate)  
Inhalation Aerosol

# Early intervention cut mortality in severe AS

BY MICHELE G. SULLIVAN  
*Frontline Medical News*

**E**arly valve replacement may be in the best interest of asymptomatic patients with severe aortic

stenosis, possibly halving their 5-year risk of death, based on data from the CURRENT AS registry study.

Compared to watchful waiting, early surgical intervention also reduced by 81% the risk of hospitaliza-

tion for heart failure, Dr. Tomohiko Taniguchi said at the Transcatheter Cardiovascular Therapeutics annual meeting. The study was simultaneously published (*J Am Coll Cardiol*. 2015. doi: 10.1016/j.jacc.2015.10.001).

Observation has been the byword for asymptomatic patients with severe aortic stenosis (AS). The American College of Cardiology recommends a conservative approach


*Continued on page 48*

SYMBICORT 160/4.5 for the maintenance treatment of COPD

## Fast control at 5 minutes each time<sup>1,4</sup>

SYMBICORT IS ON  
EXPRESS SCRIPTS®  
NATIONAL PREFERRED  
FORMULARY  
INDICATED  
FOR BOTH COPD AND ASTHMA  
IN APPROPRIATE PATIENTS

Percent of 1-hour improvement in FEV<sub>1</sub> occurring at 5 minutes over the 12-month study (serial spirometry subset)<sup>4</sup>



**SUN: A 12-month efficacy and safety study.** A 12-month, randomized, double-blind, double-dummy, placebo-controlled, parallel-group, multicenter study of 1964 patients with COPD compared SYMBICORT pMDI 160/4.5 mcg (n=494), SYMBICORT pMDI 80/4.5 mcg (n=494), formoterol 4.5 mcg (n=495), and placebo (n=481), each administered as 2 inhalations twice daily. Subjects were current or ex-smokers with a smoking history of  $\geq 10$  pack-years, aged  $\geq 40$  years with a clinical diagnosis of COPD and symptoms for  $> 2$  years. The study included a 2-week run-in period followed by a 12-month treatment period. This study was designed to assess change from baseline to the average over the randomized treatment period in predose FEV<sub>1</sub> and in 1-hour postdose FEV<sub>1</sub>. The prespecified primary comparisons for predose FEV<sub>1</sub> were vs placebo and formoterol and the primary comparison for 1-hour postdose was vs placebo.

- SYMBICORT is NOT a rescue medication and does NOT replace fast-acting inhalers to treat acute symptoms

COMPARATOR ARMS: Mean improvement in 1-hour postdose FEV<sub>1</sub> (mL%) over 12 months (serial spirometry subset)

Day of randomization: SYMBICORT 160/4.5 mcg (240 mL/26%), formoterol 4.5 mcg (180 mL/20%), placebo (40 mL/5%).

6 months: SYMBICORT 160/4.5 mcg (270 mL/28%), formoterol 4.5 mcg (200 mL/23%), placebo (60 mL/7%).

End of month 12 (LOCF): SYMBICORT 160/4.5 mcg (240 mL/26%), formoterol 4.5 mcg (170 mL/19%), placebo (30 mL/5%).

SYMBICORT 160/4.5 mcg<sup>‡</sup> (n=121), formoterol 4.5 mcg<sup>‡</sup> (n=124), placebo<sup>‡</sup> (n=125).

\*Baseline is defined as the predose FEV<sub>1</sub> value on the day of randomization.

<sup>†</sup>Month 12, last observation carried forward (LOCF).

<sup>‡</sup>Administered as 2 inhalations twice daily.

### IMPORTANT SAFETY INFORMATION, INCLUDING BOXED WARNING (cont'd)

- ▶ Due to possible immunosuppression, potential worsening of infections could occur. A more serious or even fatal course of chickenpox or measles can occur in susceptible patients
- ▶ It is possible that systemic corticosteroid effects such as hypercorticism and adrenal suppression may occur, particularly at higher doses. Particular care is needed for patients who are transferred from systemically active corticosteroids to inhaled corticosteroids. Deaths due to adrenal insufficiency have occurred in asthmatic patients during and after transfer from systemic corticosteroids to less systemically available inhaled corticosteroids
- ▶ Caution should be exercised when considering administration of SYMBICORT in patients on long-term ketoconazole and other known potent CYP3A4 inhibitors
- ▶ As with other inhaled medications, paradoxical bronchospasm may occur with SYMBICORT
- ▶ Immediate hypersensitivity reactions may occur as demonstrated by cases of urticaria, angioedema, rash, and bronchospasm
- ▶ Excessive beta-adrenergic stimulation has been associated with central nervous system and cardiovascular effects. SYMBICORT should be used with caution in patients with cardiovascular disorders, especially coronary insufficiency, cardiac arrhythmias, and hypertension
- ▶ Long-term use of orally inhaled corticosteroids may result in a decrease in bone mineral density (BMD). Since patients with COPD often have multiple risk factors for reduced BMD, assessment of BMD is recommended prior to initiating SYMBICORT and periodically thereafter
- ▶ Orally inhaled corticosteroids may result in a reduction in growth velocity when administered to pediatric patients
- ▶ Glaucoma, increased intraocular pressure, and cataracts have been reported following the inhaled administration of corticosteroids, including budesonide, a component of SYMBICORT. Close monitoring is warranted in patients with a change in vision or history of increased intraocular pressure, glaucoma, or cataracts
- ▶ In rare cases, patients on inhaled corticosteroids may present with systemic eosinophilic conditions
- ▶ SYMBICORT should be used with caution in patients with convulsive disorders, thyrotoxicosis, diabetes mellitus, ketoacidosis, and in patients who are unusually responsive to sympathomimetic amines
- ▶ Beta-adrenergic agonist medications may produce hypokalemia and hyperglycemia in some patients

## VIEW ON THE NEWS

## Should we intervene earlier?

The findings make a good case for carefully considering which patients might benefit more from early intervention than from close obser-

vation. They also suggest a place for less invasive valve replacement rather than watchful waiting in some asymptomatic patients.


I think this finding is fabulous, and raises the question of whether the ventricle cares even if the patient doesn't care. Should we be intervening earlier with transcatheter aortic valve replacement? A less-invasive

therapy early on may have benefits.

*Dr. Jeffrey J. Popma is professor of medicine at Harvard Medical School and director of interventional cardiology at the Beth Israel Deaconess Medical Center, Boston.*

## Sustained effect. Control over 12 months.<sup>1,4</sup>

Improvement in 1-hour postdose FEV<sub>1</sub> over the 12-month study<sup>4</sup>



- SYMBICORT 160/4.5 significantly improved predose FEV<sub>1</sub> averaged over the course of the study compared to placebo and formoterol, a coprimary endpoint<sup>1</sup>

**COMPARATOR ARMS: Mean improvement in 1-hour postdose FEV<sub>1</sub> (mL%) over 12 months**

**1 month:** SYMBICORT 160/4.5 mcg (220 mL/21%), formoterol 4.5 mcg (170 mL/17%), placebo (10 mL/1%).

**6 months:** SYMBICORT 160/4.5 mcg (220 mL/21%), formoterol 4.5 mcg (190 mL/18%), placebo (30 mL/3%).

**End of treatment:** SYMBICORT 160/4.5 mcg (200 mL/20%), formoterol 4.5 mcg (170 mL/17%), placebo (10 mL/1%).

**SYMBICORT 160/4.5 mcg<sup>1</sup> (n=494), formoterol 4.5 mcg<sup>1</sup> (n=495), placebo<sup>1</sup> (n=479).**

<sup>1</sup>Baseline is defined as the predose FEV<sub>1</sub> value on the day of randomization.

<sup>2</sup>Month 12, last observation carried forward (LOCF).

<sup>4</sup>Administered as 2 inhalations twice daily.

- ▶ The most common adverse reactions ≥3% reported in asthma clinical trials included nasopharyngitis, headache, upper respiratory tract infection, pharyngolaryngeal pain, sinusitis, influenza, back pain, nasal congestion, stomach discomfort, vomiting, and oral candidiasis
- ▶ The most common adverse reactions ≥3% reported in COPD clinical trials included nasopharyngitis, oral candidiasis, bronchitis, sinusitis, and upper respiratory tract infection
- ▶ SYMBICORT should be administered with caution to patients being treated with MAO inhibitors or tricyclic antidepressants, or within 2 weeks of discontinuation of such agents
- ▶ Beta-blockers may not only block the pulmonary effect of beta-agonists, such as formoterol, but may produce severe bronchospasm in patients with asthma
- ▶ ECG changes and/or hypokalemia associated with nonpotassium-sparing diuretics may worsen with concomitant beta-agonists. Use caution with the coadministration of SYMBICORT

### INDICATIONS

- ▶ SYMBICORT is indicated for the treatment of asthma in patients 12 years and older (also see Boxed WARNING on front cover)
- ▶ SYMBICORT 160/4.5 is indicated for the maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema
- ▶ SYMBICORT is NOT indicated for the relief of acute bronchospasm

**References:** 1. Rennard SI, Tashkin DP, McElhatten J, et al. Efficacy and tolerability of budesonide/formoterol in one hydrofluoroalkane pressurized metered-dose inhaler in patients with chronic obstructive pulmonary disease: results from a 1-year randomized controlled clinical trial. *Drugs*. 2009;69(5):549-565. 2. SYMBICORT [package insert]. Wilmington, DE: AstraZeneca; 2012. 3. Data on File, 3088224, AZPLP. 4. Data on File, 1084400, AZPLP. 5. 2015 Express Scripts Preferred Drug List.

**Symbicort**<sup>®</sup>  
(budesonide/formoterol fumarate dihydrate)  
Inhalation Aerosol

AstraZeneca

Please see Brief Summary of full Prescribing Information, including Boxed WARNING, on following pages.

SYMBICORT is a registered trademark of the AstraZeneca group of companies. Express Scripts is a registered trademark of the Express Scripts Holding Company. ©2015 AstraZeneca. All rights reserved. 3171924 9/15

Continued from page 46

to the asymptomatic AS patient, but acknowledges the disorder inevitably progresses in nearly all patients.

But the CURRENT AS registry results suggest that “the long-term outcome of asymptomatic patients with severe aortic stenosis was dismal

when they were managed conservatively in real clinical practice,” Dr. Taniguchi said at the meeting, sponsored by the Cardiovascular Research Foundation.

“If you’re watching and waiting, and you wait for sudden death, then that is a problem,” commented Dr. Ajay J. Kirtane. Early intervention

“potentially changes the game because we do have a less-invasive procedure we can offer – transcatheter aortic valve replacement (TAVR),” said Dr. Kirtane of New York-Presbyterian Hospital.

In the CURRENT AS study, severe AS was considered a peak aortic jet velocity over 4.0 m/s, or a mean aor-

tic pressure gradient greater than 40 mm Hg, or an aortic valve area less than 1.0 cm<sup>2</sup>. The registry includes 3,815 patients; Dr. Taniguchi of Kyoto University reported outcomes for a propensity-score matched cohort of 582 patients, 291 in the initial TAVR group and 291 in the conservatively managed group. There was no treat-

## SYMBICORT® 80/4.5

(budesonide 80 mcg and formoterol fumarate dihydrate 4.5 mcg)

Inhalation Aerosol

## SYMBICORT® 160/4.5

(budesonide 160 mcg and formoterol fumarate dihydrate 4.5 mcg)

Inhalation Aerosol

For Oral Inhalation Only  
Rx only

### WARNING: ASTHMA RELATED DEATH

Long-acting beta<sub>2</sub>-adrenergic agonists (LABA), such as formoterol one of the active ingredients in SYMBICORT, increase the risk of asthma-related death. Data from a large placebo-controlled U.S. study that compared the safety of another long-acting beta<sub>2</sub>-adrenergic agonist (salmeterol) or placebo added to usual asthma therapy showed an increase in asthma-related deaths in patients receiving salmeterol. This finding with salmeterol is considered a class effect of the LABA, including formoterol. Currently available data are inadequate to determine whether concurrent use of inhaled corticosteroids or other long-term asthma control drugs mitigates the increased risk of asthma-related death from LABA. Available data from controlled clinical trials suggest that LABA increase the risk of asthma-related hospitalization in pediatric and adolescent patients. Therefore, when treating patients with asthma, SYMBICORT should only be used for patients not adequately controlled on a long-term asthma control medication, such as an inhaled corticosteroid or whose disease severity clearly warrants initiation of treatment with both an inhaled corticosteroid and LABA. Once asthma control is achieved and maintained, assess the patient at regular intervals and step down therapy (e.g., discontinue SYMBICORT) if possible without loss of asthma control and maintain the patient on a long-term asthma control medication, such as an inhaled corticosteroid. Do not use SYMBICORT for patients whose asthma is adequately controlled on low or medium dose inhaled corticosteroids (see WARNINGS AND PRECAUTIONS).

### BRIEF SUMMARY

Before prescribing, please see full Prescribing Information for SYMBICORT® (budesonide/formoterol fumarate dihydrate).

### INDICATIONS AND USAGE

#### Treatment of Asthma

SYMBICORT is indicated for the treatment of asthma in patients 12 years of age and older.

Long-acting beta<sub>2</sub>-adrenergic agonists, such as formoterol one of the active ingredients in SYMBICORT, increase the risk of asthma-related death. Available data from controlled clinical trials suggest that LABA increase the risk of asthma-related hospitalization in pediatric and adolescent patients (see WARNINGS AND PRECAUTIONS). Therefore, when treating patients with asthma, SYMBICORT should only be used for patients not adequately controlled on a long-term asthma-control medication such as an inhaled corticosteroid or whose disease severity clearly warrants initiation of treatment with both an inhaled corticosteroid and LABA. Once asthma control is achieved and maintained, assess the patient at regular intervals and step down therapy (e.g., discontinue SYMBICORT) if possible without loss of asthma control, and maintain the patient on a long-term asthma control medication, such as inhaled corticosteroid. Do not use SYMBICORT for patients whose asthma is adequately controlled on low or medium dose inhaled corticosteroids.

#### Important Limitations of Use:

- SYMBICORT is NOT indicated for the relief of acute bronchospasm.

#### Maintenance Treatment of Chronic Obstructive Pulmonary Disease (COPD)

SYMBICORT 160/4.5 is indicated for the twice daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD) including chronic bronchitis and emphysema. SYMBICORT 160/4.5 is the only approved dosage for the treatment of airflow obstruction in COPD.

Important Limitations of Use: SYMBICORT is not indicated for the relief of acute bronchospasm.

### DOSAGE AND ADMINISTRATION

SYMBICORT should be administered twice daily every day by the orally inhaled route only. After inhalation, the patient should rinse the mouth with water without swallowing (see PATIENT COUNSELING INFORMATION in full Prescribing Information (17.4)).

Prime SYMBICORT before using for the first time by releasing two test sprays into the air away from the face, shaking well for 5 seconds before each spray. In cases where the inhaler has not been used for more than 7 days or when it has been dropped, prime the inhaler again by shaking well before each spray and releasing two test sprays into the air away from the face.

More frequent administration or a higher number of inhalations (more than 2 inhalations twice daily) of the prescribed strength of SYMBICORT is not recommended as some patients are more likely to experience adverse effects with higher doses of formoterol. Patients using SYMBICORT should not use additional long-acting beta<sub>2</sub>-agonists for any reason (see WARNINGS AND PRECAUTIONS).

#### Asthma

If asthma symptoms arise in the period between doses, an inhaled, short-acting beta<sub>2</sub>-agonist should be taken for immediate relief.

Adult and Adolescent Patients 12 Years of Age and Older: For patients 12 years of age and older, the dosage is 2 inhalations twice daily (morning and evening, approximately 12 hours apart).

The recommended starting dosages for SYMBICORT for patients 12 years of age and older are based upon patients' asthma severity.

The maximum recommended dosage is SYMBICORT 160/4.5 mcg twice daily.

Improvement in asthma control following inhaled administration of SYMBICORT can occur within 15 minutes of beginning treatment, although maximum benefit may not be achieved for 2 weeks or longer after beginning treatment. Individual patients will experience a variable time to onset and degree of symptom relief.

For patients who do not respond adequately to the starting dose after 1-2 weeks of therapy with SYMBICORT 80/4.5, replacement with SYMBICORT 160/4.5 may provide additional asthma control.

If a previously effective dosage regimen of SYMBICORT fails to provide adequate control of asthma, the therapeutic regimen should be re-evaluated and additional therapeutic options, (e.g., replacing the lower strength of SYMBICORT with the higher strength, adding additional inhaled corticosteroid, or initiating oral corticosteroids) should be considered.

#### Chronic Obstructive Pulmonary Disease (COPD)

For patients with COPD the recommended dose is SYMBICORT 160/4.5, two inhalations twice daily.

If shortness of breath occurs in the period between doses, an inhaled, short-acting beta<sub>2</sub>-agonist should be taken for immediate relief.

### CONTRAINDICATIONS

The use of SYMBICORT is contraindicated in the following conditions:

- Primary treatment of status asthmaticus or other acute episodes of asthma or COPD where intensive measures are required.
- Hypersensitivity to any of the ingredients in SYMBICORT.

### WARNINGS AND PRECAUTIONS

#### Asthma-Related Death

Long-acting beta<sub>2</sub>-adrenergic agonists, such as formoterol, one of the active ingredients in SYMBICORT, increase the risk of asthma-related death. Currently available data are inadequate to determine whether concurrent use of inhaled corticosteroids or other long-term asthma control drugs mitigates the increased risk of asthma-related death from LABA. Available data from controlled clinical trials suggest that LABA increase the risk of asthma-related hospitalization in pediatric and adolescent patients. Therefore, when treating patients with asthma, SYMBICORT should only be used for patients not adequately controlled on a long-term asthma-control medication, such as an inhaled corticosteroid or whose disease severity clearly warrants initiation of treatment with both an inhaled corticosteroid and LABA. Once asthma control is achieved and maintained, assess the patient at regular intervals and step down therapy (e.g., discontinue SYMBICORT) if possible without loss of asthma control, and maintain the patient on a long-term asthma control medication, such as an inhaled corticosteroid. Do not use SYMBICORT for patients whose asthma is adequately controlled on low or medium dose inhaled corticosteroids.

A 28-week, placebo controlled US study comparing the safety of salmeterol with placebo, each added to usual asthma therapy, showed an increase in asthma-related deaths in patients receiving salmeterol (13/13,176 in patients treated with salmeterol vs 3/13,179 in patients treated with placebo; RR 4.37, 95% CI 1.25, 15.34). This finding with salmeterol is considered a class effect of the LABA, including formoterol, one of the active ingredients in SYMBICORT. No study adequate to determine whether the rate of asthma-related death is increased with SYMBICORT has been conducted.

Clinical studies with formoterol suggested a higher incidence of serious asthma exacerbations in patients who received formoterol than in those who received placebo. The sizes of these studies were not adequate to precisely quantify the differences in serious asthma exacerbation rates between treatment groups.

#### Deterioration of Disease and Acute Episodes

SYMBICORT should not be initiated in patients during rapidly deteriorating or potentially life-threatening episodes of asthma or COPD. SYMBICORT has not been studied in patients with acutely deteriorating asthma or COPD. The initiation of SYMBICORT in this setting is not appropriate.

Increasing use of inhaled, short-acting beta<sub>2</sub>-agonists is a marker of deteriorating asthma. In this situation, the patient requires immediate re-evaluation with reassessment of the treatment regimen, giving special consideration to the possible need for replacing the current strength of SYMBICORT with a higher strength, adding additional inhaled corticosteroid, or initiating systemic corticosteroids. Patients should not use more than 2 inhalations twice daily (morning and evening) of SYMBICORT.

SYMBICORT should not be used for the relief of acute symptoms, i.e., as rescue therapy for the treatment of acute episodes of bronchospasm. An inhaled, short-acting beta<sub>2</sub>-agonist, not SYMBICORT, should be used to relieve acute symptoms such as shortness of breath. When prescribing SYMBICORT, the physician must also provide the patient with an inhaled, short-acting beta<sub>2</sub>-agonist (e.g., albuterol) for treatment of acute symptoms, despite regular twice-daily (morning and evening) use of SYMBICORT.

When beginning treatment with SYMBICORT, patients who have been taking oral or inhaled, short-acting beta<sub>2</sub>-agonists on a regular basis (e.g., 4 times a day) should be instructed to discontinue the regular use of these drugs.

#### Excessive Use of SYMBICORT and Use with Other Long-Acting Beta<sub>2</sub>-Agonists

As with other inhaled drugs containing beta<sub>2</sub>-adrenergic agents, SYMBICORT should not be used more often than recommended, at higher doses than recommended, or in conjunction with other medications containing long-acting beta<sub>2</sub>-agonists, as an overdose may result. Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. Patients using SYMBICORT should not use an additional long-acting beta<sub>2</sub>-agonist (e.g., salmeterol, formoterol fumarate, arformoterol tartrate) for any reason, including prevention of exercise-induced bronchospasm (EIB) or the treatment of asthma or COPD.

#### Local Effects

In clinical studies, the development of localized infections of the mouth and pharynx with *Candida albicans* has occurred in patients treated with SYMBICORT. When such an infection develops, it should be treated with appropriate local or systemic (i.e., oral antifungal) therapy while treatment with SYMBICORT continues, but at times therapy with SYMBICORT may need to be interrupted. Patients should rinse the mouth after inhalation of SYMBICORT.

#### Pneumonia and Other Lower Respiratory Tract Infections

Physicians should remain vigilant for the possible development of pneumonia in patients with COPD as the clinical features of pneumonia and exacerbations frequently overlap. Lower respiratory tract infections, including pneumonia, have been reported following the inhaled administration of corticosteroids.

In a 6 month study of 1,704 patients with COPD, there was a higher incidence of lung infections other than pneumonia (e.g., bronchitis, viral lower respiratory tract infections, etc.) in patients receiving SYMBICORT 160/4.5 (7.6%) than in those receiving SYMBICORT 80/4.5 (3.2%), formoterol 4.5 mcg (4.6%) or placebo (3.3%). Pneumonia did not occur with greater incidence in the SYMBICORT 160/4.5 group (1.1%) compared with placebo (1.3%). In a 12-month study of 1,964 patients with COPD, there was also a higher incidence of lung infections other than pneumonia in patients receiving SYMBICORT 160/4.5 (8.1%) than in those receiving SYMBICORT 80/4.5 (6.9%), formoterol 4.5 mcg (7.1%) or placebo (6.2%). Similar to the 6 month study, pneumonia did not occur with greater incidence in the SYMBICORT 160/4.5 group (4.0%) compared with placebo (5.0%).

#### Immunosuppression

Patients who are on drugs that suppress the immune system are more susceptible to infection than healthy individuals. Chicken pox and measles, for example, can have a more serious or even fatal course in susceptible children or adults using corticosteroids. In such children or adults who have not had these diseases or been properly immunized, particular care should be taken to avoid exposure. How the dose, route, and duration of corticosteroid administration affects the risk of developing a disseminated infection is not known. The contribution of the underlying disease and/or prior corticosteroid treatment to the risk is also not known. If exposed, therapy with varicella zoster immune globulin (VZIG) or pooled intravenous immunoglobulin (IVIG), as appropriate, may be indicated. If exposed to measles, prophylaxis with pooled intramuscular immunoglobulin (IG) may be indicated. (See the respective package inserts for complete VZIG and IG prescribing information.) If chicken pox develops, treatment with antiviral agents may be considered. The immune responsiveness to varicella vaccine was evaluated in pediatric patients with asthma ages 12 months to 8 years with budesonide inhalation suspension.

An open-label, nonrandomized clinical study examined the immune responsiveness to varicella vaccine in 243 asthma patients 12 months to 8 years of age who were treated with budesonide inhalation suspension 0.25 mg to 1 mg daily (n=151) or noncorticosteroid asthma therapy (n=92) (i.e., beta<sub>2</sub>-agonists, leukotriene receptor antagonists, cromones). The percentage of patients developing a seroprotective antibody titer of ≥5.0 (gpELISA value) in response to the vaccination was similar in patients treated with budesonide inhalation suspension (85%), compared to patients treated with noncorticosteroid asthma therapy (90%). No patient treated with budesonide inhalation suspension developed chicken pox as a result of vaccination.

Inhaled corticosteroids should be used with caution, if at all, in patients with active or quiescent tuberculosis infections of the respiratory tract, untreated systemic fungal, bacterial, viral, or parasitic infections; or ocular herpes simplex.

#### Transferring Patients From Systemic Corticosteroid Therapy

Particular care is needed for patients who have been transferred from systemically active corticosteroids to inhaled corticosteroids because deaths due to adrenal insufficiency have occurred in patients with asthma during and after transfer from systemic corticosteroids to less systemically available inhaled corticosteroids. After withdrawal from systemic corticosteroids, a number of months are required for recovery of hypothalamic-pituitary-adrenal (HPA) function.

Patients who have been previously maintained on 20 mg or more per day of prednisone (or its equivalent) may be most susceptible, particularly when their systemic corticosteroids have been almost completely withdrawn. During this period of HPA suppression, patients may exhibit signs and symptoms of adrenal insufficiency when exposed to trauma, surgery, or infection (particularly gastroenteritis) or other conditions associated with severe electrolyte loss. Although SYMBICORT may provide control of asthma symptoms during these episodes, recommended doses of it supplies less than normal physiological amounts of glucocorticoid systemically and does NOT provide the mineralocorticoid activity that is necessary for coping with these emergencies.

During periods of stress or a severe asthma attack, patients who have been withdrawn from systemic corticosteroids should be instructed to resume oral corticosteroids (in large doses) immediately and to contact their physicians for further instruction. These patients should also be instructed to carry a warning card indicating that they may need supplementary systemic corticosteroids during periods of stress or a severe asthma attack.

Patients requiring oral corticosteroids should be weaned slowly from systemic corticosteroid use after transferring to SYMBICORT. Prednisone reduction can be accomplished by reducing the daily prednisone dose by 2.5 mg on a weekly basis during therapy with SYMBICORT. Lung function (mean forced expiratory volume in 1 second [FEV<sub>1</sub>] or morning peak expiratory flow [PEF]), beta-agonist use, and asthma symptoms should be carefully monitored during withdrawal of oral corticosteroids. In addition to monitoring asthma signs and symptoms, patients should be observed for signs and symptoms of adrenal insufficiency, such as fatigue, lassitude, weakness, nausea and vomiting, and hypotension.

Transfer of patients from systemic corticosteroid therapy to inhaled corticosteroids or SYMBICORT may unmask conditions previously suppressed by the systemic corticosteroid therapy (e.g., rhinitis, conjunctivitis, eczema, arthritis, eosinophilic conditions). Some patients may experience symptoms of systemically active corticosteroid withdrawal (e.g., joint and/or muscular pain, lassitude, depression) despite maintenance or even improvement of respiratory function.

#### Hypercorticism and Adrenal Suppression

Budesonide, a component of SYMBICORT, will often help control asthma symptoms with less suppression of HPA function than therapeutically equivalent oral doses of prednisone. Since budesonide is absorbed into the circulation and can be systemically active at higher doses, the beneficial effects of SYMBICORT in minimizing HPA dysfunction may be expected only when recommended dosages are not exceeded and individual patients are titrated to the lowest effective dose.

Because of the possibility of systemic absorption of inhaled corticosteroids, patients treated with SYMBICORT should be

ment randomization; treatment decisions were made at the clinical level.

Patients in the matched cohort were in their early 70s; in 80%, the AS etiology was degenerative. The mean aortic pressure gradient was 54 mm Hg in the early intervention group and 45 mm Hg in the watchful waiting group. In 79% of the early

intervention group and in 54% of the watchful waiting group, the mean aortic pressure gradient was below 40 mm Hg.

Among the patients who underwent TAVR despite being asymptomatic, most (63%) had at least one surgical indication, including severe AS (41%), left ventricular dysfunction

(7%), rapid hemodynamic progression (11%), or active infective endocarditis (0.3%). Other cardiac surgery indications we, Dr. Taniguchi noted.

By the end of the 5-year follow-up period, 26% of the conservative therapy group and 15% of the early AVR group had died – a significant difference (hazard ratio, 0.64;  $P = .02$ ).

The coprimary endpoint of heart failure hospitalization was also significantly more common among the conservatively treated group (19.9% vs. 3.8%; HR, 0.19;  $P$  less than .001).

The study was sponsored by Kyoto University,

msullivan@frontlinemedcom.com

#### SYMBICORT® (budesonide/formoterol fumarate dihydrate) Inhalation Aerosol

2

observed carefully for any evidence of systemic corticosteroid effects. Particular care should be taken in observing patients postoperatively or during periods of stress for evidence of inadequate adrenal response.

It is possible that systemic corticosteroid effects such as hypercorticism and adrenal suppression (including adrenal crisis) may appear in a small number of patients, particularly when budesonide is administered at higher than recommended doses over prolonged periods of time. If such effects occur, the dosage of SYMBICORT should be reduced slowly, consistent with accepted procedures for reducing systemic corticosteroids and for management of asthma symptoms.

#### Drug Interactions With Strong Cytochrome P450 3A4 Inhibitors

Caution should be exercised when considering the coadministration of SYMBICORT with ketoconazole, and other known strong CYP3A4 inhibitors (e.g., ritonavir, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, saquinavir, telithromycin) because adverse effects related to increased systemic exposure to budesonide may occur [see **DRUG INTERACTIONS** and **CLINICAL PHARMACOLOGY** in full Prescribing Information (12.3)].

#### Paradoxical Bronchospasm and Upper Airway Symptoms

As with other inhaled medications, SYMBICORT can produce paradoxical bronchospasm, which may be life threatening. If paradoxical bronchospasm occurs following dosing with SYMBICORT, it should be treated immediately with an inhaled, short-acting bronchodilator. SYMBICORT should be discontinued immediately, and alternative therapy should be instituted.

#### Immediate Hypersensitivity Reactions

Immediate hypersensitivity reactions may occur after administration of SYMBICORT, as demonstrated by cases of urticaria, angioedema, rash, and bronchospasm.

#### Cardiovascular and Central Nervous System Effects

Excessive beta-adrenergic stimulation has been associated with seizures, angina, hypertension or hypotension, tachycardia with rates up to 200 beats/min, arrhythmias, nervousness, headache, tremor, palpitation, nausea, dizziness, fatigue, malaise, and insomnia [see **OVERDOSAGE**]. Therefore, SYMBICORT, like all products containing sympathomimetic amines, should be used with caution in patients with cardiovascular disorders, especially coronary insufficiency, cardiac arrhythmias, and hypertension.

Formoterol, a component of SYMBICORT, can produce a clinically significant cardiovascular effect in some patients as measured by pulse rate, blood pressure, and/or symptoms. Although such effects are uncommon after administration of formoterol at recommended doses, if they occur, the drug may need to be discontinued. In addition, beta-agonists have been reported to produce ECG changes, such as flattening of the T wave, prolongation of the QTc interval, and ST segment depression. The clinical significance of these findings is unknown. Fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs.

#### Reduction in Bone Mineral Density

Decreases in bone mineral density (BMD) have been observed with long-term administration of products containing inhaled corticosteroids. The clinical significance of small changes in BMD with regard to long-term consequences such as fracture is unknown. Patients with major risk factors for decreased bone mineral content, such as prolonged immobilization, family history of osteoporosis, postmenopausal status, tobacco use, advanced age, poor nutrition, or chronic use of drugs that can reduce bone mass (e.g., anticonvulsants, oral corticosteroids) should be monitored and treated with established standards of care. Since patients with COPD often have multiple risk factors for reduced BMD, assessment of BMD is recommended prior to initiating SYMBICORT and periodically thereafter. If significant reductions in BMD are seen and SYMBICORT is still considered medically important for that patient's COPD therapy, use of medication to treat or prevent osteoporosis should be strongly considered.

Effects of treatment with SYMBICORT 160/4.5, SYMBICORT 80/4.5, formoterol 4.5, or placebo on BMD was evaluated in a subset of 326 patients (females and males 41 to 88 years of age) with COPD in the 12-month study. BMD evaluations of the hip and lumbar spine regions were conducted at baseline and 52 weeks using dual energy x-ray absorptiometry (DEXA) scans. Mean changes in BMD from baseline to end of treatment were small (mean changes ranged from -0.01 - 0.01 g/cm<sup>2</sup>). ANCOVA results for total spine and total hip BMD based on the end of treatment time point showed that all geometric LS Mean ratios for the pairwise treatment group comparisons were close to 1, indicating that overall, bone mineral density for total hip and total spine regions for the 12 month time point were stable over the entire treatment period.

#### Effect on Growth

Orally inhaled corticosteroids may cause a reduction in growth velocity when administered to pediatric patients. Monitor the growth of pediatric patients receiving SYMBICORT routinely (e.g., via stadiometry). To minimize the systemic effects of orally inhaled corticosteroids, including SYMBICORT, titrate each patient's dose to the lowest dosage that effectively controls his/her symptoms [see **DOSE AND ADMINISTRATION** and **USE IN SPECIFIC POPULATIONS**].

#### Glaucoma and Cataracts

Glaucoma, increased intraocular pressure, and cataracts have been reported in patients with asthma and COPD following the long-term administration of inhaled corticosteroids, including budesonide, a component of SYMBICORT. Therefore, close monitoring is warranted in patients with a change in vision or with history of increased intraocular pressure, glaucoma, and/or cataracts.

Effects of treatment with SYMBICORT 160/4.5, SYMBICORT 80/4.5, formoterol 4.5, or placebo on development of cataracts or glaucoma were evaluated in a subset of 461 patients with COPD in the 12-month study. Ophthalmic examinations were conducted at baseline, 24 weeks, and 52 weeks. There were 26 subjects (6%) with an increase in posterior subcapsular score from baseline to maximum value (>0.7) during the randomized treatment period. Changes in posterior subcapsular scores of >0.7 from baseline to treatment maximum occurred in 11 patients (9.0%) in the SYMBICORT 160/4.5 group, 4 patients (3.8%) in the SYMBICORT 80/4.5 group, 5 patients (4.2%) in the formoterol group, and 6 patients (5.2%) in the placebo group.

#### Eosinophilic Conditions and Churg-Strauss Syndrome

In rare cases, patients on inhaled corticosteroids may present with systemic eosinophilic conditions. Some of these patients have clinical features of vasculitis consistent with Churg-Strauss syndrome, a condition that is often treated with systemic corticosteroid therapy. These events usually, but not always, have been associated with the reduction and/or withdrawal of oral corticosteroid therapy following the introduction of inhaled corticosteroids. Physicians should be alert to eosinophilia, vasculitic rash, worsening pulmonary symptoms, cardiac complications, and/or neuropathy presenting in their patients. A causal relationship between budesonide and these underlying conditions has not been established.

#### Coexisting Conditions

SYMBICORT, like all medications containing sympathomimetic amines, should be used with caution in patients with convulsive disorders or thyrotoxicosis and in those who are unusually responsive to sympathomimetic amines. Doses of the related beta<sub>2</sub>-adrenoceptor agonist albuterol, when administered intravenously, have been reported to aggravate preexisting diabetes mellitus and ketoacidosis.

#### Hypokalemia and Hyperglycemia

Beta-adrenergic agonist medications may produce significant hypokalemia in some patients, possibly through intracellular shunting, which has the potential to produce adverse cardiovascular effects [see **CLINICAL PHARMACOLOGY** in full Prescribing Information (12.2)]. The decrease in serum potassium is usually transient, not requiring supplementation. Clinically significant changes in blood glucose and/or serum potassium were seen infrequently during clinical studies with SYMBICORT at recommended doses.

#### ADVERSE REACTIONS

**Long-acting beta<sub>2</sub>-adrenergic agonists, such as formoterol one of the active ingredients in SYMBICORT, increase the risk of asthma-related death. Currently available data are inadequate to determine whether concurrent use of inhaled corticosteroids or other long-term asthma control drugs mitigates the increased risk of asthma-related death from LABA. Available data from controlled clinical trials suggest that LABA increase the risk of asthma-related hospitalization in pediatric and adolescent patients.** Data from a large placebo-controlled US study that compared the safety of another long-acting beta<sub>2</sub>-adrenergic agonist (salmeterol) or placebo added to usual asthma therapy showed an increase in asthma-related deaths in patients receiving salmeterol [see **WARNINGS AND PRECAUTIONS**].

Systemic and inhaled corticosteroid use may result in the following:

- *Candida albicans* infection [see **WARNINGS AND PRECAUTIONS**]
- Pneumonia or lower respiratory tract infections in patients with COPD [see **WARNINGS AND PRECAUTIONS**]
- Immunosuppression [see **WARNINGS AND PRECAUTIONS**]
- Hypercorticism and adrenal suppression [see **WARNINGS AND PRECAUTIONS**]
- Growth effects in pediatric patients [see **WARNINGS AND PRECAUTIONS**]
- Glaucoma and cataracts [see **WARNINGS AND PRECAUTIONS**]

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

#### Clinical Trials Experience in Asthma

##### Patients 12 years and older

The overall safety data in adults and adolescents are based upon 10 active- and placebo-controlled clinical trials in which 3393 patients ages 12 years and older (2052 females and 1341 males) with asthma of varying severity were treated with SYMBICORT 80/4.5 or 160/4.5 mcg taken two inhalations once or twice daily for 12 to 52 weeks. In these trials, the patients on SYMBICORT had a mean age of 38 years and were predominantly Caucasian (82%).

The incidence of common adverse events in Table 1 below is based upon pooled data from three 12-week, double-blind, placebo-controlled clinical studies in which 401 adult and adolescent patients (148 males and 253 females) age 12 years and older were treated with two inhalations of SYMBICORT 80/4.5 or SYMBICORT 160/4.5 twice daily. The SYMBICORT group was composed of mostly Caucasian (84%) patients with a mean age of 38 years, and a mean percent predicted FEV<sub>1</sub> at baseline of 76 and 68 for the 80/4.5 mcg and 160/4.5 mcg treatment groups, respectively. Control arms for comparison included two inhalations of budesonide HFA metered dose inhaler (MDI) 80 or 160 mcg, formoterol dry powder inhaler (DPI) 4.5 mcg, or placebo (MDI and DPI) twice daily. Table 1 includes all adverse events that occurred at an incidence of ≥3% in any one SYMBICORT group and more commonly than in the placebo group with twice-daily dosing. In considering these data, the increased average duration of patient exposure for SYMBICORT patients should be taken into account, as incidences are not adjusted for an imbalance of treatment duration.

**Table 1 Adverse reactions occurring at an incidence of ≥3% and more commonly than placebo in the SYMBICORT groups: pooled data from three 12-week, double-blind, placebo-controlled clinical asthma trials in patients 12 years and older**

Treatment*	SYMBICORT		Budesonide		Formoterol	Placebo
	80/4.5 mcg N = 277	160/4.5 mcg N = 124	80 mcg N = 121	160 mcg N = 109		
Adverse Event	%	%	%	%	%	%
Nasopharyngitis	10.5	9.7	14.0	11.0	10.1	9.0
Headache	6.5	11.3	11.6	12.8	8.9	6.5
Upper respiratory tract infection	7.6	10.5	8.3	9.2	7.6	7.8
Pharyngolaryngeal pain	6.1	8.9	5.0	7.3	3.0	4.8
Sinusitis	5.8	4.8	5.8	2.8	6.3	4.8
Influenza	3.2	2.4	6.6	0.9	3.0	1.3
Back pain	3.2	1.6	2.5	5.5	2.1	0.8
Nasal congestion	2.5	3.2	2.5	3.7	1.3	1.0
Stomach discomfort	1.1	6.5	2.5	4.6	1.3	1.8
Vomiting	1.4	3.2	0.8	2.8	1.7	1.0
Oral Candidiasis	1.4	3.2	0	0	0	0.8
<b>Average Duration of Exposure (days)</b>	<b>77.7</b>	<b>73.8</b>	<b>77.0</b>	<b>71.4</b>	<b>62.4</b>	<b>55.9</b>

\* All treatments were administered as two inhalations twice daily.

#### Long-term safety - asthma clinical trials in patients 12 years and older

Long-term safety studies in adolescent and adult patients 12 years of age and older, treated for up to 1 year at doses up to 1280/36 mcg/day (640/18 mcg twice daily), revealed neither clinically important changes in the incidence nor new types of adverse events emerging after longer periods of treatment. Similarly, no significant or unexpected patterns of abnormalities were observed for up to 1 year in safety measures including chemistry, hematology, ECG, Holter monitor, and HPA-axis assessments.

#### Clinical Trials Experience in Chronic Obstructive Pulmonary Disease

The incidence of common adverse events in Table 2 below is based upon pooled data from two double-blind, placebo-controlled clinical studies (6 and 12 months in duration) in which 771 adult COPD patients (496 males and 275 females) 40 years of age and older were treated with SYMBICORT 160/4.5, two inhalations twice daily. Of these patients 651 were treated for 6 months and 366 were treated for 12 months. The SYMBICORT group was composed of mostly Caucasian (93%) patients with a mean age of 63 years, and a mean percent predicted FEV<sub>1</sub> at baseline of 33%. Control arms for comparison included two inhalations of budesonide HFA (MDI) 160 mcg, formoterol (DPI) 4.5 mcg or placebo (MDI and DPI) twice daily. Table 2 includes all adverse events that occurred at an incidence of ≥3% in the SYMBICORT group and more commonly than in the placebo group. In considering these data, the increased average duration of patient exposure to SYMBICORT should be taken into account, as incidences are not adjusted for an imbalance of treatment duration.

**Table 2 Adverse reactions occurring at an incidence of ≥3% and more commonly than placebo in the SYMBICORT group: pooled data from two double-blind, placebo-controlled clinical COPD trials**

Treatment*	SYMBICORT		Budesonide	Formoterol	Placebo
	160/4.5 mcg N = 771	160 mcg N = 275			
Adverse Event	%	%	%	%	%
Nasopharyngitis	7.3	3.3	5.8	4.9	
Oral candidiasis	6.0	4.4	1.2	1.8	
Bronchitis	5.4	4.7	4.5	3.5	
Sinusitis	3.5	1.5	3.1	1.8	
Upper respiratory tract infection viral	3.5	1.8	3.6	2.7	
<b>Average Duration of Exposure (days)</b>	<b>255.2</b>	<b>157.1</b>	<b>240.3</b>	<b>223.7</b>	

\* All treatments were administered as two inhalations twice daily.

Lung infections other than pneumonia (mostly bronchitis) occurred in a greater percentage of subjects treated with SYMBICORT 160/4.5 compared with placebo (7.9% vs. 5.1%, respectively). There were no clinically important or unexpected patterns of abnormalities observed for up to 1 year in chemistry, haematology, ECG, ECG (Holter) monitoring, HPA-axis, bone mineral density and ophthalmology assessments.

#### Postmarketing Experience

The following adverse reactions have been reported during post-approval use of SYMBICORT. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Some of these adverse reactions may also have been observed in clinical studies with SYMBICORT.

**Cardiac disorders:** angina pectoris, tachycardia, atrial and ventricular tachyarrhythmias, atrial fibrillation, extrasystoles, palpitations

**Endocrine disorders:** hypercorticism, growth velocity reduction in pediatric patients

**Eye disorders:** cataract, glaucoma, increased intraocular pressure

**Gastrointestinal disorders:** oropharyngeal candidiasis, nausea

**Immune system disorders:** immediate and delayed hypersensitivity reactions, such as anaphylactic reaction, angioedema, bronchospasm, urticaria, exanthema, dermatitis, pruritus

**Metabolic and nutrition disorders:** hyperglycemia, hypokalemia

**Musculoskeletal, connective tissue, and bone disorders:** muscle cramps

**Nervous system disorders:** tremor, dizziness

**Psychiatric disorders:** behavior disturbances, sleep disturbances, nervousness, agitation, depression, restlessness

**Respiratory, thoracic, and mediastinal disorders:** dysphonia, cough, throat irritation

**Skin and subcutaneous tissue disorders:** skin bruising

**Vascular disorders:** hypotension, hypertension

#### DRUG INTERACTIONS

In clinical studies, concurrent administration of SYMBICORT and other drugs, such as short-acting beta<sub>2</sub>-agonists, intranasal corticosteroids, and antihistamines/decongestants has not resulted in an increased frequency of adverse reactions. No formal drug interaction studies have been performed with SYMBICORT.

# FDA expands nivolumab use to nonsquamous NSCLC

BY LAURA NIKOLAIDES  
Frontline Medical News

The Food and Drug Administration approved nivolumab for the treatment of patients with

metastatic nonsquamous non-small cell lung cancer (NSCLC) that has progressed during or after platinum-based chemotherapy, along with a companion diagnostic to detect PD-L1 protein expression levels.

The FDA approved nivolumab for patients with metastatic squamous NSCLC with progression on or after platinum-based chemotherapy in March of this year. The October approval expands the use of nivolumab

to include patients with nonsquamous NSCLC.

The approval was based on improvement in overall survival (OS) in an international, multicenter, open-label, randomized trial comparing nivolumab to docetaxel in 582 patients with metastatic nonsquamous NSCLC with progression on or after platinum-based chemotherapy, according to an Oct. 9 statement issued by the FDA.

Median OS was 12.2 months in patients treated with 3 mg/kg nivolumab every 2 weeks (n = 292) compared with 9.4 months in patients treated with 75 mg/m<sup>2</sup> docetaxel every 3 weeks (n = 290). There was also a significant improvement in overall response rate in the nivolumab arm (19% vs 12%); the median response duration was 17 months in the nivolumab arm and 6 months in the docetaxel arm. There was no significant difference in progression-free survival. Patients with PD-L1 positive NSCLC had a greater survival benefit than did those with PD-L1 negative NSCLC, and therefore, the FDA also approved the PD-L1 IHC 28-8 pharmDx test to detect PD-L1 protein expression levels.

Serious adverse events were reported in 47 of the 292 patients in the nivolumab arm. The most common serious adverse events were pneumonia, pulmonary embolism, dyspnea, and pleural effusion. Immune-mediated adverse events included hypothyroidism/thyroiditis, rash, pneumonitis, diarrhea/colitis, hyperthyroidism, hepatitis, nephritis, limbic encephalitis, and polymyalgia rheumatica.

The most common grade 3-4 adverse reactions in the nivolumab arm were dyspnea, fatigue, pneumonia, pulmonary embolism, pleural effusion, hyperglycemia, respiratory failure, and pain. The most common grade 3-4 laboratory abnormalities included lymphopenia, hyponatremia, anemia, increased AST, and increased ALT, the FDA said.

This approval follows closely behind the accelerated approval of pembrolizumab to treat patients with metastatic NSCLC who have disease that has progressed after other treatments and tumors that express PD-L1. This anti-PD-L1 drug was also approved with a companion diagnostic, the PD-L1 IHC 22C3 pharmDx test.

Nivolumab is marketed as Opdivo by Bristol-Myers Squibb and the PD-L1 IHC 28-8 pharmDx test is marketed by Dako North America Inc.

SYMBICORT® (budesonide/formoterol fumarate dihydrate) Inhalation Aerosol

3

## Inhibitors of Cytochrome P450 3A4

The main route of metabolism of corticosteroids, including budesonide, a component of SYMBICORT, is via cytochrome P450 (CYP) isoenzyme 3A4 (CYP3A4). After oral administration of ketoconazole, a strong inhibitor of CYP3A4, the mean plasma concentration of orally administered budesonide increased. Concomitant administration of CYP3A4 may inhibit the metabolism of, and increase the systemic exposure to, budesonide. Caution should be exercised when considering the concomitant administration of SYMBICORT with long-term ketoconazole and other known strong CYP3A4 inhibitors (e.g., ritonavir, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, saquinavir, telithromycin) [see **WARNINGS AND PRECAUTIONS**].

## Monamine Oxidase Inhibitors and Tricyclic Antidepressants

SYMBICORT should be administered with caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants, or within 2 weeks of discontinuation of such agents, because the action of formoterol, a component of SYMBICORT, on the vascular system may be potentiated by these agents. In clinical trials with SYMBICORT, a limited number of COPD and asthma patients received tricyclic antidepressants, and, therefore, no clinically meaningful conclusions on adverse events can be made.

## Beta-Adrenergic Receptor Blocking Agents

Beta-blockers (including eye drops) may not only block the pulmonary effect of beta-agonists, such as formoterol, a component of SYMBICORT, but may produce severe bronchospasm in patients with asthma. Therefore, patients with asthma should not normally be treated with beta-blockers. However, under certain circumstances, there may be no acceptable alternatives to the use of beta-adrenergic blocking agents in patients with asthma. In this setting, cardioselective beta-blockers could be considered, although they should be administered with caution.

## Diuretics

The ECG changes and/or hypokalemia that may result from the administration of non-potassium-sparing diuretics (such as loop or thiazide diuretics) can be acutely worsened by beta-agonists, especially when the recommended dose of the beta-agonist is exceeded. Although the clinical significance of these effects is not known, caution is advised in the concomitant administration of SYMBICORT with non-potassium-sparing diuretics.

## USE IN SPECIFIC POPULATIONS

### Pregnancy

#### Teratogenic Effects: Pregnancy Category C.

There are no adequate and well-controlled studies of SYMBICORT in pregnant women. SYMBICORT was teratogenic and embryocidal in rats. Budesonide alone was teratogenic and embryocidal in rats and rabbits, but not in humans at therapeutic doses. Formoterol fumarate alone was teratogenic in rats and rabbits. Formoterol fumarate was also embryocidal, increased pup loss at birth and during lactation, and decreased pup weight in rats. SYMBICORT should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

### SYMBICORT

In a reproduction study in rats, budesonide combined with formoterol fumarate by the inhalation route at doses approximately 1/7 and 1/3, respectively, the maximum recommended human daily inhalation dose on a mg/m<sup>2</sup> basis produced umbilical hernia. No teratogenic or embryocidal effects were detected with budesonide combined with formoterol fumarate by the inhalation route at doses approximately 1/32 and 1/16, respectively, the maximum recommended human daily inhalation dose on a mg/m<sup>2</sup> basis.

### Budesonide

Studies of pregnant women have not shown that inhaled budesonide increases the risk of abnormalities when administered during pregnancy. The results from a large population-based prospective cohort epidemiological study reviewing data from three Swedish registries covering approximately 99% of the pregnancies from 1995-1997 (ie, Swedish Medical Birth Registry; Registry of Congenital Malformations; Child Cardiology Registry) indicate no increased risk for congenital malformations from the use of inhaled budesonide during early pregnancy. Congenital malformations were studied in 2014 infants born to mothers reporting the use of inhaled budesonide for asthma in early pregnancy (usually 10-12 weeks after the last menstrual period), the period when most major organ malformations occur. The rate of recorded congenital malformations was similar compared to the general population rate (3.8% vs 3.5%, respectively). In addition, after exposure to inhaled budesonide, the number of infants born with orofacial clefts was similar to the expected number in the normal population (4 children vs 3.3, respectively).

These same data were utilized in a second study bringing the total to 2534 infants whose mothers were exposed to inhaled budesonide. In this study, the rate of congenital malformations among infants whose mothers were exposed to inhaled budesonide during early pregnancy was not different from the rate for all newborn babies during the same period (3.6%).

Budesonide produced fetal loss, decreased pup weight, and skeletal abnormalities at subcutaneous doses in rabbits less than the maximum recommended human daily inhalation dose on a mcg/m<sup>2</sup> basis and in rats at doses approximately 6 times the maximum recommended human daily inhalation dose on a mcg/m<sup>2</sup> basis. In another study in rats, no teratogenic or embryocidal effects were seen at inhalation doses up to 3 times the maximum recommended human daily inhalation dose on a mcg/m<sup>2</sup> basis.

Experience with oral corticosteroids since their introduction in pharmacologic as opposed to physiologic doses suggests that rodents are more prone to teratogenic effects from corticosteroids than humans.

### Formoterol

Formoterol fumarate has been shown to be teratogenic, embryocidal, to increase pup loss at birth and during lactation, and to decrease pup weights in rats when given at oral doses 1400 times and greater the maximum recommended human daily inhalation dose on a mcg/m<sup>2</sup> basis. Umbilical hernia was observed in rat fetuses at oral doses 1400 times and greater the maximum recommended human daily inhalation dose on a mcg/m<sup>2</sup> basis. Brachygnathia was observed in rat fetuses at an oral dose 7000 times the maximum recommended human daily inhalation dose on a mcg/m<sup>2</sup> basis. Pregnancy was prolonged at an oral dose 7000 times the maximum recommended human daily inhalation dose on a mcg/m<sup>2</sup> basis. In another study in rats, no teratogenic effects were seen at inhalation doses up to 500 times the maximum recommended human daily inhalation dose on a mcg/m<sup>2</sup> basis.

Subcapsular cysts on the liver were observed in rabbit fetuses at an oral dose 54,000 times the maximum recommended human daily inhalation dose on a mcg/m<sup>2</sup> basis. No teratogenic effects were observed at oral doses up to 3200 times the maximum recommended human daily inhalation dose on a mcg/m<sup>2</sup> basis.

### Nonteratogenic Effects

Hypoadrenalism may occur in infants born of mothers receiving corticosteroids during pregnancy. Such infants should be carefully observed.

### Labor and Delivery

There are no well-controlled human studies that have investigated the effects of SYMBICORT on preterm labor or labor at term. Because of the potential for beta-agonist interference with uterine contractility, use of SYMBICORT for management of asthma during labor should be restricted to those patients in whom the benefits clearly outweigh the risks.

### Nursing Mothers

Since there are no data from controlled trials on the use of SYMBICORT by nursing mothers, a decision should be made whether to discontinue nursing or to discontinue SYMBICORT, taking into account the importance of SYMBICORT to the mother.

Budesonide, like other corticosteroids, is secreted in human milk. Data with budesonide delivered via dry powder inhaler indicates that the total daily oral dose of budesonide available in breast milk to the infant is approximately 0.3% to 1% of the dose inhaled by the mother [see **CLINICAL PHARMACOLOGY, Pharmacokinetics** in full Prescribing Information (12.3)]. For SYMBICORT, the dose of budesonide available to the infant in breast milk, as a percentage of the maternal dose, would be expected to be similar.

In reproductive studies in rats, formoterol was excreted in the milk. It is not known whether formoterol is excreted in human milk.

### Pediatric Use

Safety and effectiveness of SYMBICORT in asthma patients 12 years of age and older have been established in studies up to 12 months. In the two 12-week, double-blind, placebo-controlled US pivotal studies 25 patients 12 to 17 years of age were treated with SYMBICORT twice daily [see **CLINICAL STUDIES** in full Prescribing Information (14.1)]. Efficacy results in this age group were similar to those observed in patients 18 years and older. There were no obvious differences in the type or frequency of adverse events reported in this age group compared with patients 18 years of age and older.

The safety and effectiveness of SYMBICORT in asthma patients 6 to <12 years of age has not been established. Overall 1447 asthma patients 6 to <12 years of age participated in placebo- and active-controlled SYMBICORT studies. Of these 1447 patients, 539 received SYMBICORT twice daily. The overall safety profile of these patients was similar to that observed in patients ≥12 years of age who also received SYMBICORT twice daily in studies of similar design.

Controlled clinical studies have shown that orally inhaled corticosteroids including budesonide, a component of SYMBICORT, may cause a reduction in growth velocity in pediatric patients. This effect has been observed in the absence of laboratory evidence of HPA-axis suppression, suggesting that growth velocity is a more sensitive indicator of systemic corticosteroid exposure in pediatric patients than some commonly used tests of HPA-axis function. The long-term effect of this reduction in growth velocity associated with orally inhaled corticosteroids, including the impact on final height are unknown. The potential for "catch-up" growth following discontinuation of treatment with orally inhaled corticosteroids has not been adequately studied.

In a study of asthmatic children 5-12 years of age, those treated with budesonide DPI 200 mcg twice daily (n=311) had a 1.1 centimeter reduction in growth compared with those receiving placebo (n=418) at the end of one year; the difference between these two treatment groups did not increase further over three years of additional treatment. By the end of 4 years, children treated with budesonide DPI and children treated with placebo had similar growth velocities. Conclusions drawn from this study may be confounded by the unequal use of corticosteroids in the treatment groups and inclusion of data from patients attaining puberty during the course of the study.

The growth of pediatric patients receiving orally inhaled corticosteroids, including SYMBICORT, should be monitored. If a child or adolescent on any corticosteroid appears to have growth suppression, the possibility that he/she is particularly sensitive to this effect should be considered. The potential growth effects of prolonged treatment should be weighed against the clinical benefits obtained. To minimize the systemic effects of orally inhaled corticosteroids, including SYMBICORT, each patient should be titrated to the lowest strength that effectively controls his/her asthma [see **DOSE AND ADMINISTRATION**].

### Geriatric Use

Of the total number of patients in asthma clinical studies treated with SYMBICORT twice daily, 149 were 65 years of age or older, of whom 25 were 75 years of age or older.

In the COPD studies of 6 to 12 months duration, 349 patients treated with SYMBICORT 160/4.5 twice daily were 65 years old and above and of those, 73 patients were 75 years of age and older. No overall differences in safety or effectiveness were observed between these patients and younger patients, and other reported clinical experience has not identified differences in responses between the elderly and younger patients.

As with other products containing beta<sub>2</sub>-agonists, special caution should be observed when using SYMBICORT in geriatric patients who have concomitant cardiovascular disease that could be adversely affected by beta<sub>2</sub>-agonists.

Based on available data for SYMBICORT or its active components, no adjustment of dosage of SYMBICORT in geriatric patients is warranted.

### Hepatic Impairment

Formal pharmacokinetic studies using SYMBICORT have not been conducted in patients with hepatic impairment. However, since both budesonide and formoterol fumarate are predominantly cleared by hepatic metabolism, impairment of liver function may lead to accumulation of budesonide and formoterol fumarate in plasma. Therefore, patients with hepatic disease should be closely monitored.

### Renal Impairment

Formal pharmacokinetic studies using SYMBICORT have not been conducted in patients with renal impairment.

### OVERDOSAGE

#### SYMBICORT

SYMBICORT contains both budesonide and formoterol; therefore, the risks associated with overdosage for the individual components described below apply to SYMBICORT. In pharmacokinetic studies, single doses of 960/54 mcg (12 actuations of SYMBICORT 80/4.5) and 1280/36 mcg (8 actuations of 160/4.5), were administered to patients with COPD. A total of 1920/54 mcg (12 actuations of SYMBICORT 160/4.5) was administered as a single dose to both healthy subjects and patients with asthma. In a long-term active-controlled safety study in asthma patients, SYMBICORT 160/4.5 was administered for up to 12 months at doses up to twice the highest recommended daily dose. There were no clinically significant adverse reactions observed in any of these studies.

Clinical signs in dogs that received a single inhalation dose of SYMBICORT (a combination of budesonide and formoterol) in a dry powder included tremor, mucosal redness, nasal catarrh, redness of intact skin, abdominal respiration, vomiting, and salivation; in the rat, the only clinical sign observed was increased respiratory rate in the first hour after dosing. No deaths occurred in rats given a combination of budesonide and formoterol at acute inhalation doses of 97 and 3 mg/kg, respectively (approximately 1200 and 1350 times the maximum recommended human daily inhalation dose on a mcg/m<sup>2</sup> basis). No deaths occurred in dogs given a combination of budesonide and formoterol at the acute inhalation doses of 732 and 22 mcg/kg, respectively (approximately 30 times the maximum recommended human daily inhalation dose of budesonide and formoterol on a mcg/m<sup>2</sup> basis).

#### Budesonide

The potential for acute toxic effects following overdose of budesonide is low. If used at excessive doses for prolonged periods, systemic corticosteroid effects such as hypercorticism may occur [see **WARNINGS AND PRECAUTIONS**]. Budesonide at five times the highest recommended dose (3200 mcg daily) administered to humans for 6 weeks caused a significant reduction (27%) in the plasma cortisol response to a 6-hour infusion of ACTH compared with placebo (+1%). The corresponding effect of 10 mg prednisone daily was a 35% reduction in the plasma cortisol response to ACTH.

In mice, the minimal inhalation lethal dose was 100 mg/kg (approximately 600 times the maximum recommended human daily inhalation dose on a mcg/m<sup>2</sup> basis). In rats, there were no deaths following the administration of an inhalation dose of 68 mg/kg (approximately 900 times the maximum recommended human daily inhalation dose on a mcg/m<sup>2</sup> basis). The minimal oral lethal dose in mice was 200 mg/kg (approximately 1300 times the maximum recommended human daily inhalation dose on a mcg/m<sup>2</sup> basis) and less than 100 mg/kg in rats (approximately 1300 times the maximum recommended human daily inhalation dose on a mcg/m<sup>2</sup> basis).

#### Formoterol

An overdose of formoterol would likely lead to an exaggeration of effects that are typical for beta<sub>2</sub>-agonists: seizures, angina, hypertension, hypotension, tachycardia, atrial and ventricular tachyarrhythmias, nervousness, headache, tremor, palpitations, muscle cramps, nausea, dizziness, sleep disturbances, metabolic acidosis, hyperglycemia, hypokalemia. As with all sympathomimetic medications, cardiac arrest and even death may be associated with abuse of formoterol. No clinically significant adverse reactions were seen when formoterol was delivered to adult patients with acute bronchoconstriction at a dose of 90 mcg/day over 3 hours or to stable asthmatics 3 times a day at a total dose of 54 mcg/day for 3 days.

Treatment of formoterol overdosage consists of discontinuation of the medication together with institution of appropriate symptomatic and/or supportive therapy. The judicious use of a cardioselective beta-receptor blocker may be considered, bearing in mind that such medication can produce bronchospasm. There is insufficient evidence to determine if dialysis is beneficial for overdosage of formoterol. Cardiac monitoring is recommended in cases of overdosage.

No deaths were seen in mice given formoterol at an inhalation dose of 276 mg/kg (more than 62,200 times the maximum recommended human daily inhalation dose on a mcg/m<sup>2</sup> basis). In rats, the minimum lethal inhalation dose was 40 mg/kg (approximately 18,000 times the maximum recommended human daily inhalation dose on a mcg/m<sup>2</sup> basis). No deaths were seen in mice that received an oral dose of 2000 mg/kg (more than 450,000 times the maximum recommended human daily inhalation dose on a mcg/m<sup>2</sup> basis). Maximum nonlethal oral doses were 252 mg/kg in young rats and 1500 mg/kg in adult rats (approximately 114,000 times and 675,000 times the maximum recommended human inhalation dose on a mcg/m<sup>2</sup> basis).

SYMBICORT is a trademark of the AstraZeneca group of companies.

© AstraZeneca 2008, 2009, 2010, 2012

Manufactured for: AstraZeneca LP, Wilmington, DE 19850

By: AstraZeneca Dunquerque Production, Dunquerque, France

Product of France

Rev. 5/12 2839500 8/13

AstraZeneca

# Workshop focuses on CT screening for lung cancer

BY SUSAN LONDON  
Frontline Medical News

DENVER – In its third CT Screening Workshop, the Strategic Screening Advisory Committee of the International Association for the Study of Lung Cancer discussed the finer points of using this imaging technology to screen for lung cancer, including issues such as metrics, quality control, and cost-effectiveness.

“Lung cancer is the major problem of all cancers,” committee chair Dr. John K. Field maintained in press conference at the annual World Conference on Lung Cancer, which was held in conjunction with the workshop. This cancer still causes more deaths than all of those from breast, colon, and prostate cancer combined.

“However, the good news is that the future does lie in early detection,” he said. The National Lung Screening Trial established that low-dose CT screening reduces the risk of lung cancer death by 20% compared with plain chest radiographic screening (*N Engl J Med.* 2011;365:395-409).

“That was the first time anybody had actually demonstrated such a

mortality advantage with anything in lung cancer, so it led to an enormous stage shift in our thinking,” noted Dr. Field, who is also Personal Clinical Chair in Molecular Oncology at the University of Liverpool, England.

In the workshop, committee members reviewed new guidelines



**Cost-effectiveness [of CT screening] is going to be a major issue, especially in Europe.**

DR. FIELD

on managing screen-detected nodules from the ongoing NELSON (Dutch Belgian Randomised Lung Cancer Screening Trial) (*Lancet Oncol.* 2014;15:1332-41) and from the British Thoracic Society (*Thorax.* 2015;70:794-8). Main results from NELSON, as well as from the similar U.K. Lung Cancer Screening Trial, are expected shortly.

“We also looked at quality control for future screening programs. It’s extremely important that if we do have screening in place, that we have the necessary quality control behind

it,” Dr. Field asserted.

Another topic discussed was whether CT screening is cost-effective. “Cost-effectiveness is going to be a major issue, especially in Europe,” where policy makers are awaiting results from the two trials before implementing screening, he said. “At this moment in time, it looks as though we will be cost-effective.”

The committee also assessed the potential of lung cancer biomarkers. “If we can actually improve the CT screening by using a particular biomarker, that would help us identify individuals easier. But also, once we undertake the CT, we are sometimes left with a gray situation of nodules that may become malignant but are not large enough to actually undertake any surgical intervention. And if we had a biomarker that would tell us if it was an aggressive tumor, that would be an enormous advantage,” Dr. Field elaborated.

Finally, the committee reviewed the status of national plans for implementing lung cancer CT screening around the world. Implementation is a multistep process requiring clinical experts and policy makers to hammer out a variety of issues, he noted (*Lancet.*

2013;382:732-41).

These issues include how best to identify individuals at high risk, typically accomplished with the LLP (Liverpool Lung Project) risk model in the United Kingdom and the PLCO (Prostate, Lung, Colorectal, and Ovarian) risk model in the United States. Screening age must also be considered. “In the U.K., our recommendation would probably be 60-75, but in the U.S. it would be 55-80, which came from the U.S. Preventive Services Task Force,” Dr. Field noted.

Another issue is whether nodules identified on CT are better measured by their maximal diameter (used in the National Lung Screening Trial) or their volume (used in the ongoing NELSON and U.K. trials).

“There are advantages and disadvantages of both. We feel that volume is the way forward,” he said.

The nature of any subsequent work-up, including whether a biopsy is performed and additional tests, is also a consideration, as is the management of small nodules, including whether patients should undergo video-assisted thoracoscopic surgery.

Dr. Field disclosed no relevant conflicts of interest.

## Carboplatin-vinorelbine supported in early NSCLC

BY SUSAN LONDON  
Frontline Medical News

DENVER – An adjuvant regimen of carboplatin plus vinorelbine is well tolerated and efficacious in patients who have undergone complete resection of early non-small cell lung cancer (NSCLC), results from a multicenter phase II trial suggested.

The 74 patients in SWITCH 1 received carboplatin plus intravenous vinorelbine on day 1, with a switch to oral vinorelbine on day 8. A total of four cycles of a 21-day regimen were planned.

Main results reported at a world lung cancer conference sponsored by the International Association for the Study of Lung Cancer showed that the regimen was well tolerated, with higher-grade neutropenia seen in only about a quarter of patients and no deaths because of toxicity. More than four-fifths of patients completed all of the planned treatment, and median survival was nearly 6 years.

“Adjuvant chemotherapy with carboplatin and vinorelbine given [intravenously] and switched to oral formula is feasible, tolerable, and effective in early-stage NSCLC,” commented first author Dr. Vitezslav Kolek, a pulmonary oncologist at University Hospital in Olomouc, Czech Republic.

Although comparison with large phase III adjuvant trials is problematic, he acknowledged, “this regimen gives better comfort to the patients, and

provides high dose intensity and more completed treatments, compared with cisplatin-based trials. And the present regimen achieved comparable survival to cisplatin-based therapy.”

“The take-home message could be that we don’t have reliable, routinely used predictors in the adjuvant setting. Under these conditions, probably the most intensive [therapy] doesn’t mean the best,” he concluded.

Dr. Giorgio V. Scagliotti of the University of Torino (Italy) took issue with the lack of presentation of a statistical hypothesis and with the cross-trial comparison.

“The most proven regimen is cisplatin-vinorelbine. ... Cisplatin doublets with proven efficacy in advanced disease remain the standard of care for adjuvant chemotherapy,” he said. “For elderly or unfit patients, carboplatin may be considered in individual cases.”

Dr. Kolek noted that carboplatin and cisplatin have not been directly compared in the adjuvant setting. The combination of cisplatin and vinorelbine, however, is known to result in some deaths due to toxicity, and a large share of patients are unable to complete the therapy. In addition, oral

vinorelbine seems to perform as well as the intravenous formulation, and patients generally prefer oral therapy, he said.

The patients enrolled in SWITCH 1 had undergone complete resection of stage IB, II, or IIIA NSCLC. The median age was 64 years, and 72% were male; 62% had squamous histology.

The mean relative dose intensity was 83% for oral vinorelbine, 93% for intravenous vinorelbine, and 89% for carboplatin, Dr. Kolek reported. The mean number of cycles of chemotherapy received was 3.8 per patient and, overall, 82% of patients completed the planned therapy.

With a median follow-up of 4.7 years, median disease-free and overall survival were 4.4 years and 5.9 years, respectively. Corresponding 5-year rates were 48% and 56%.

The most common grade 3 or 4 toxicities per cycle were neutropenia (seen in 26% of patients), leukopenia (16%), alopecia (12%), and anemia (8%). None of the patients died from treatment toxicity.

Dr. Kolek reported that he receives honoraria from AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, GlaxoSmithKline, Novartis, Pfizer, Pierre Fabre, and Roche.



**The regimen ‘gives better comfort to the patients, and provides high dose intensity and more completed treatments.’**

DR. KOLEK

Reduce lung function decline

# Delay IPF progression with Esbriet



## Indication

Esbriet® (pirfenidone) is indicated for the treatment of idiopathic pulmonary fibrosis (IPF).

## Select Important Safety Information

**Elevated liver enzymes:** Increases in ALT and AST  $>3\times$  ULN have been reported in patients treated with Esbriet. Rarely these have been associated with concomitant elevations in bilirubin. Patients treated with Esbriet had a higher incidence of elevations in ALT or AST than placebo patients (3.7% vs 0.8%, respectively). No cases of liver transplant or death due to liver failure that were related to Esbriet have been reported. However, the combination of transaminase elevations and elevated bilirubin without evidence of obstruction is generally recognized as an important predictor of severe liver injury that could lead to death or the need for liver transplants in some patients. Conduct liver function tests (ALT, AST, and bilirubin) prior to initiating Esbriet, then monthly for the first 6 months and every 3 months thereafter. Dosage modifications or interruption may be necessary.

**Photosensitivity reaction or rash:** Patients treated with Esbriet had a higher incidence of photosensitivity reactions (9%) compared with patients treated with placebo (1%). Patients should avoid or minimize exposure to sunlight (including sunlamps), use a sunblock (SPF 50 or higher), and wear clothing that protects against sun exposure. Patients should avoid concomitant medications that cause photosensitivity. Dosage reduction or discontinuation may be necessary.

**Gastrointestinal disorders:** Gastrointestinal events of nausea, diarrhea, dyspepsia, vomiting, gastroesophageal reflux disease, and abdominal pain were more frequently reported in patients treated with Esbriet. Dosage reduction or interruption for gastrointestinal events was required in 18.5% of patients in the Esbriet 2403 mg/day group, as compared to 5.8% of patients in the placebo group; 2.2% of patients in the Esbriet 2403 mg/day group discontinued treatment due to a gastrointestinal event, as compared to 1.0% in the placebo group. The most common ( $>2\%$ ) gastrointestinal events that led to dosage reduction or interruption were nausea, diarrhea, vomiting, and dyspepsia. Dosage modifications may be necessary in some cases.

**Adverse reactions:** The most common adverse reactions ( $\geq 10\%$ ) were nausea, rash, abdominal pain, upper respiratory tract infection, diarrhea, fatigue, headache, dyspepsia, dizziness, vomiting, anorexia, gastroesophageal reflux disease, sinusitis, insomnia, weight decreased, and arthralgia.

**Drug interactions:** Concomitant administration with strong inhibitors of CYP1A2 (eg, fluvoxamine) significantly increases systemic exposure of Esbriet and is not recommended. Discontinue prior to administration of Esbriet. If strong CYP1A2 inhibitors cannot be avoided, dosage reductions of Esbriet are recommended. Monitor for adverse reactions and consider discontinuation of Esbriet as needed.

## Proven to delay progression in IPF<sup>1</sup>

- Fewer patients had a meaningful decline in lung function with Esbriet at 52 weeks vs placebo (17% vs 32% of patients had  $\geq 10\%$  decline in %FVC,  $P < 0.001$ ). Treatment effect was evident at 13 weeks ( $P < 0.001$ ) and increased through trial duration<sup>1,2,\*†</sup>
- More patients had stable lung function with Esbriet than with placebo at 52 weeks (23% vs 10%)<sup>2,\*†</sup>
- In clinical trials, elevated liver enzymes, photosensitivity reactions, and gastrointestinal disorders have been reported with Esbriet<sup>2</sup>
- Esbriet has been approved outside the US since 2011, with approximately 15,000 patients treated with pirfenidone worldwide<sup>3</sup>

**Learn more about Esbriet and how to access medication at [Esbriet.com](http://Esbriet.com).**

\*The efficacy of Esbriet was evaluated in three phase 3, randomized, double-blind, placebo-controlled trials. In ASCEND, 555 patients with IPF were randomized to receive Esbriet 2403 mg/day or placebo for 52 weeks. Eligible patients had %FVC between 50%-90% and %DL<sub>CO</sub> between 30%-90%. The primary endpoint was change in %FVC from baseline to week 52.

Concomitant administration of Esbriet and ciprofloxacin (a moderate inhibitor of CYP1A2) moderately increases exposure to Esbriet. If ciprofloxacin at the dosage of 750 mg twice daily cannot be avoided, dosage reductions are recommended. Monitor patients closely when ciprofloxacin is used.

Agents that are moderate or strong inhibitors of both CYP1A2 and CYP isoenzymes involved in the metabolism of Esbriet should be avoided during treatment.

The concomitant use of a CYP1A2 inducer may decrease the exposure of Esbriet, and may lead to loss of efficacy. Concomitant use of strong CYP1A2 inducers should be avoided.

**Specific populations:** Esbriet should be used with caution in patients with mild to moderate (Child-Pugh Class A and B) hepatic impairment. Monitor for adverse reactions and consider dosage modification or discontinuation of Esbriet as needed. The safety, efficacy, and pharmacokinetics of Esbriet have not been studied in patients with severe hepatic impairment. Esbriet is not recommended for use in patients with severe (Child-Pugh Class C) hepatic impairment.

Esbriet should be used with caution in patients with mild ( $CL_{cr}$  50-80 mL/min), moderate ( $CL_{cr}$  30-50 mL/min), or severe ( $CL_{cr}$  less than 30 mL/min) renal impairment. Monitor for adverse reactions and consider dosage modification or discontinuation of Esbriet as needed. The safety, efficacy, and pharmacokinetics of Esbriet have not been studied in patients with end-stage renal disease requiring dialysis. Use of Esbriet in patients with end-stage renal disease requiring dialysis is not recommended.

Smoking causes decreased exposure to Esbriet, which may alter the efficacy profile of Esbriet. Instruct patients to stop smoking prior to treatment with Esbriet and to avoid smoking when using Esbriet.

**You may report side effects to the FDA at 1-800-FDA-1088 or [www.fda.gov/medwatch](http://www.fda.gov/medwatch). You may also report side effects to Genentech at 1-888-835-2555.**

**Please see Brief Summary of Prescribing Information on adjacent pages for additional important safety information.**

†Rank ANCOVA with lowest rank imputation for missing data due to death. Patients who died were counted in the  $\geq 10\%$  decline category.

‡Stable was defined as no decline in lung function.

**References:** 1. King TE Jr, Bradford WZ, Castro-Bernardini S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. *N Engl J Med*. 2014;370:2083-2092. Erratum in: *N Engl J Med*. 2014;371:1172. 2. Esbriet full Prescribing Information. InterMune, Inc. October 2014. 3. InterMune, Inc. Data on file.

**Genentech**

A Member of the Roche Group

© 2015 Genentech USA, Inc. All rights reserved. ESB/021215/0039

Rx only

## BRIEF SUMMARY

The following is a brief summary of the full Prescribing Information for ESBRIET<sup>®</sup> (pirfenidone). Please review the full Prescribing Information prior to prescribing ESBRIET.

## INDICATIONS AND USAGE

ESBRIET is indicated for the treatment of idiopathic pulmonary fibrosis (IPF).

## CONTRAINDICATIONS

None.

## WARNINGS AND PRECAUTIONS

### Elevated Liver Enzymes

Increases in ALT and AST  $>3 \times$  ULN have been reported in patients treated with ESBRIET. Rarely these have been associated with concomitant elevations in bilirubin. Patients treated with ESBRIET 2403 mg/day in the three Phase 3 trials had a higher incidence of elevations in ALT or AST  $\geq 3 \times$  ULN than placebo patients (3.7% vs. 0.8%, respectively). Elevations  $\geq 10 \times$  ULN in ALT or AST occurred in 0.3% of patients in the ESBRIET 2403 mg/day group and in 0.2% of patients in the placebo group. Increases in ALT and AST  $\geq 3 \times$  ULN were reversible with dose modification or treatment discontinuation. No cases of liver transplant or death due to liver failure that were related to ESBRIET have been reported. However, the combination of transaminase elevations and elevated bilirubin without evidence of obstruction is generally recognized as an important predictor of severe liver injury, that could lead to death or the need for liver transplants in some patients. Conduct liver function tests (ALT, AST, and bilirubin) prior to the initiation of therapy with ESBRIET in all patients, then monthly for the first 6 months and every 3 months thereafter. Dosage modifications or interruption may be necessary for liver enzyme elevations [see *Dosage and Administration sections 2.1 and 2.3 in full Prescribing Information*].

### Photosensitivity Reaction or Rash

Patients treated with ESBRIET 2403 mg/day in the three Phase 3 studies had a higher incidence of photosensitivity reactions (9%) compared with patients treated with placebo (1%). The majority of the photosensitivity reactions occurred during the initial 6 months. Instruct patients to avoid or minimize exposure to sunlight (including sunlamps), to use a sunblock (SPF 50 or higher), and to wear clothing that protects against sun exposure. Additionally, instruct patients to avoid concomitant medications known to cause photosensitivity. Dosage reduction or discontinuation may be necessary in some cases of photosensitivity reaction or rash [see *Dosage and Administration section 2.3 in full Prescribing Information*].

### Gastrointestinal Disorders

In the clinical studies, gastrointestinal events of nausea, diarrhea, dyspepsia, vomiting, gastro-esophageal reflux disease, and abdominal pain were more frequently reported by patients in the ESBRIET treatment groups than in those taking placebo. Dosage reduction or interruption for gastrointestinal events was required in 18.5% of patients in the 2403 mg/day group, as compared to 5.8% of patients in the placebo group; 2.2% of patients in the ESBRIET 2403 mg/day group discontinued treatment due to a gastrointestinal event, as compared to 1.0% in the placebo group. The most common ( $>2\%$ ) gastrointestinal events that led to dosage reduction or interruption were nausea, diarrhea, vomiting, and dyspepsia. The incidence of gastrointestinal events was highest early in the course of treatment (with highest incidence occurring during the initial 3 months) and decreased over time. Dosage modifications may be necessary in some cases of gastrointestinal adverse reactions [see *Dosage and Administration section 2.3 in full Prescribing Information*].

## ADVERSE REACTIONS

The following adverse reactions are discussed in greater detail in other sections of the labeling:

- Liver Enzyme Elevations [see *Warnings and Precautions*]
- Photosensitivity Reaction or Rash [see *Warnings and Precautions*]
- Gastrointestinal Disorders [see *Warnings and Precautions*]

## Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The safety of pirfenidone has been evaluated in more than 1400 subjects with over 170 subjects exposed to pirfenidone for more than 5 years in clinical trials.

ESBRIET was studied in 3 randomized, double-blind, placebo-controlled trials (Studies 1, 2, and 3) in which a total of 623 patients received 2403 mg/day of ESBRIET and 624 patients received placebo. Subjects ages ranged from 40 to 80 years (mean age of 67 years). Most patients were male (74%) and Caucasian (95%). The mean duration of exposure to ESBRIET was 62 weeks (range: 2 to 118 weeks) in these 3 trials.

At the recommended dosage of 2403 mg/day, 14.6% of patients on ESBRIET compared to 9.6% on placebo permanently discontinued treatment because of an adverse event. The most common ( $>1\%$ ) adverse reactions leading to discontinuation were rash and nausea. The most common ( $>3\%$ ) adverse reactions leading to dosage reduction or interruption were rash, nausea, diarrhea, and photosensitivity reaction.

The most common adverse reactions with an incidence of  $\geq 10\%$  and more frequent in the ESBRIET than placebo treatment group are listed in Table 1.

**Table 1. Adverse Reactions Occurring in  $\geq 10\%$  of ESBRIET-Treated Patients and More Commonly Than Placebo in Studies 1, 2, and 3**

Adverse Reaction	% of Patients (0 to 118 Weeks)	
	ESBRIET 2403 mg/day (N = 623)	Placebo (N = 624)
Nausea	36%	16%
Rash	30%	10%
Abdominal Pain <sup>1</sup>	24%	15%
Upper Respiratory Tract Infection	27%	25%
Diarrhea	26%	20%
Fatigue	26%	19%
Headache	22%	19%
Dyspepsia	19%	7%
Dizziness	18%	11%
Vomiting	13%	6%
Anorexia	13%	5%
Gastro-esophageal Reflux Disease	11%	7%
Sinusitis	11%	10%
Insomnia	10%	7%
Weight Decreased	10%	5%
Arthralgia	10%	7%

<sup>1</sup> Includes abdominal pain, upper abdominal pain, abdominal distension, and stomach discomfort.

Adverse reactions occurring in  $\geq 5$  to  $<10\%$  of ESBRIET-treated patients and more commonly than placebo are photosensitivity reaction (9% vs. 1%), decreased appetite (8% vs. 3%), pruritus (8% vs. 5%), asthenia (6% vs. 4%), dysgeusia (6% vs. 2%), and non-cardiac chest pain (5% vs. 4%).

## Postmarketing Experience

In addition to adverse reactions identified from clinical trials the following adverse reactions have been identified during postapproval use of pirfenidone. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency.

### Blood and Lymphatic System Disorders

Agranulocytosis

### Immune System Disorders

Angioedema

### Hepatobiliary Disorders

Bilirubin increased in combination with increases of ALT and AST

**DRUG INTERACTIONS****CYP1A2 Inhibitors**

Pirfenidone is metabolized primarily (70 to 80%) via CYP1A2 with minor contributions from other CYP isoenzymes including CYP2C9, 2C19, 2D6 and 2E1.

**Strong CYP1A Inhibitors**

The concomitant administration of ESBRIET and fluvoxamine or other strong CYP1A2 inhibitors (e.g., enoxacin) is not recommended because it significantly increases exposure to ESBRIET [see *Clinical Pharmacology section 12.3 in full Prescribing Information*]. Use of fluvoxamine or other strong CYP1A2 inhibitors should be discontinued prior to administration of ESBRIET and avoided during ESBRIET treatment. In the event that fluvoxamine or other strong CYP1A2 inhibitors are the only drug of choice, dosage reductions are recommended. Monitor for adverse reactions and consider discontinuation of ESBRIET as needed [see *Dosage and Administration section 2.4 in full Prescribing Information*].

**Moderate CYP1A Inhibitors**

Concomitant administration of ESBRIET and ciprofloxacin (a moderate inhibitor of CYP1A2) moderately increases exposure to ESBRIET [see *Clinical Pharmacology section 12.3 in full Prescribing Information*]. If ciprofloxacin at the dosage of 750 mg twice daily cannot be avoided, dosage reductions are recommended [see *Dosage and Administration section 2.4 in full Prescribing Information*]. Monitor patients closely when ciprofloxacin is used at a dosage of 250 mg or 500 mg once daily.

**Concomitant CYP1A2 and other CYP Inhibitors**

Agents or combinations of agents that are moderate or strong inhibitors of both CYP1A2 and one or more other CYP isoenzymes involved in the metabolism of ESBRIET (i.e., CYP2C9, 2C19, 2D6, and 2E1) should be discontinued prior to and avoided during ESBRIET treatment.

**CYP1A2 Inducers**

The concomitant use of ESBRIET and a CYP1A2 inducer may decrease the exposure of ESBRIET and this may lead to loss of efficacy. Therefore, discontinue use of strong CYP1A2 inducers prior to ESBRIET treatment and avoid the concomitant use of ESBRIET and a strong CYP1A2 inducer [see *Clinical Pharmacology section 12.3 in full Prescribing Information*].

**USE IN SPECIFIC POPULATIONS****Pregnancy**

Teratogenic Effects: **Pregnancy Category C.**

There are no adequate and well-controlled studies of ESBRIET in pregnant women. Pirfenidone was not teratogenic in rats and rabbits. Because animal reproduction studies are not always predictive of human response, ESBRIET should be used during pregnancy only if the benefit outweighs the risk to the patient.

A fertility and embryo-fetal development study with rats and an embryo-fetal development study with rabbits that received oral doses up to 3 and 2 times, respectively, the maximum recommended daily dose (MRDD) in adults (on mg/m<sup>2</sup> basis at maternal doses up to 1000 and 300 mg/kg/day, respectively) revealed no evidence of impaired fertility or harm to the fetus due to pirfenidone. In the presence of maternal toxicity, acyclic/irregular cycles (e.g., prolonged estrous cycle) were seen in rats at doses approximately equal to and higher than the MRDD in adults (on a mg/m<sup>2</sup> basis at maternal doses of 450 mg/kg/day and higher). In a pre- and post-natal development study, prolongation of the gestation period, decreased numbers of live newborn, and reduced pup viability and body weights were seen in rats at an oral dosage approximately 3 times the MRDD in adults (on a mg/m<sup>2</sup> basis at a maternal dose of 1000 mg/kg/day).

**Nursing Mothers**

A study with radio-labeled pirfenidone in rats has shown that pirfenidone or its metabolites are excreted in milk. It is not known whether ESBRIET is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or to discontinue ESBRIET, taking into account the importance of the drug to the mother.

**Pediatric Use**

Safety and effectiveness of ESBRIET in pediatric patients have not been established.

**Geriatric Use**

Of the total number of subjects in the clinical studies receiving ESBRIET, 714 (67%) were 65 years old and over, while 231 (22%) were 75 years old and over. No overall differences in safety or effectiveness were observed between older and younger patients. No dosage adjustment is required based upon age.

**Hepatic Impairment**

ESBRIET should be used with caution in patients with mild (Child Pugh Class A) to moderate (Child Pugh Class B) hepatic impairment. Monitor for adverse reactions and consider dosage modification or discontinuation of ESBRIET as needed [see *Dosage and Administration section 2.2 in full Prescribing Information*].

The safety, efficacy, and pharmacokinetics of ESBRIET have not been studied in patients with severe hepatic impairment. ESBRIET is not recommended for use in patients with severe (Child Pugh Class C) hepatic impairment [see *Clinical Pharmacology section 12.3 in full Prescribing Information*].

**Renal Impairment**

ESBRIET should be used with caution in patients with mild (CL<sub>cr</sub> 50–80 mL/min), moderate (CL<sub>cr</sub> 30–50 mL/min), or severe (CL<sub>cr</sub> less than 30 mL/min) renal impairment [see *Clinical Pharmacology section 12.3 in full Prescribing Information*]. Monitor for adverse reactions and consider dosage modification or discontinuation of ESBRIET as needed [see *Dosage and Administration section 2.3 in full Prescribing Information*]. The safety, efficacy, and pharmacokinetics of ESBRIET have not been studied in patients with end-stage renal disease requiring dialysis. Use of ESBRIET in patients with end-stage renal diseases requiring dialysis is not recommended.

**Smokers**

Smoking causes decreased exposure to ESBRIET [see *Clinical Pharmacology section 12.3 in full Prescribing Information*], which may alter the efficacy profile of ESBRIET. Instruct patients to stop smoking prior to treatment with ESBRIET and to avoid smoking when using ESBRIET.

**OVERDOSAGE**

There is limited clinical experience with overdosage. Multiple dosages of ESBRIET up to a maximum tolerated dose of 4005 mg per day were administered as five 267 mg capsules three times daily to healthy adult volunteers over a 12-day dose escalation.

In the event of a suspected overdosage, appropriate supportive medical care should be provided, including monitoring of vital signs and observation of the clinical status of the patient.

**PATIENT COUNSELING INFORMATION**

Advise the patient to read the FDA-approved patient labeling (Patient Information).

**Liver Enzyme Elevations**

Advise patients that they may be required to undergo liver function testing periodically. Instruct patients to immediately report any symptoms of a liver problem (e.g., skin or the white of eyes turn yellow, urine turns dark or brown [tea colored], pain on the right side of stomach, bleed or bruise more easily than normal, lethargy) [see *Warnings and Precautions*].

**Photosensitivity Reaction or Rash**

Advise patients to avoid or minimize exposure to sunlight (including sunlamps) during use of ESBRIET because of concern for photosensitivity reactions or rash. Instruct patients to use a sunblock and to wear clothing that protects against sun exposure. Instruct patients to report symptoms of photosensitivity reaction or rash to their physician. Temporary dosage reductions or discontinuations may be required [see *Warnings and Precautions*].

**Gastrointestinal Events**

Instruct patients to report symptoms of persistent gastrointestinal effects including nausea, diarrhea, dyspepsia, vomiting, gastro-esophageal reflux disease, and abdominal pain. Temporary dosage reductions or discontinuations may be required [see *Warnings and Precautions*].

**Smokers**

Encourage patients to stop smoking prior to treatment with ESBRIET and to avoid smoking when using ESBRIET [see *Clinical Pharmacology section 12.3 in full Prescribing Information*].

**Take with Food**

Instruct patients to take ESBRIET with food to help decrease nausea and dizziness.

Manufactured for:  
InterMune, Inc.  
Brisbane, CA 94005 USA

**INTERMUNE®**

# ABIM 2020 Goals Align With CHEST Educational Principles

BY ROBB RABITO, CHCP  
Director, CHEST Education Operations

The American Board of Internal Medicine (ABIM) recently released *Assessment 2020, A Vision for Certification in Internal Medicine in 2020*, developed by a commissioned task force to “develop a vision for the future of assessment for certification (initial and maintenance) in internal medicine and associated subspecialties.”

Assessment 2020 highlights three

key recommendations that aim to reduce the burden of recertification, deliver more relevant assessments focused on practice-based skills, and recognize the value of specialization.

The Assessment 2020 recommendations include the following:

- 1. Replace the 10-Year Maintenance of Certification examination with more frequent, less burdensome assessments**
- 2. Focus assessments on cognitive and technical skills**

### 3. Recognize specialization

CHEST supports this effort to better align certification and recertification with the relevant practice of physicians and has long promoted the principles behind these recommendations. CHEST is the first medical society to receive accreditation from the Society for Simulation in Healthcare, and The CHEST Certificate of Completion (COC) program provides ongoing opportunity for learning and formative evaluation of

knowledge and performance alongside rigorous assessment.

We are interested in your feedback on this report and each of these recommendations. Please provide us with your comments at <https://www.surveymonkey.com/r/FWHCCS5>.

CHEST will incorporate your feedback into our future work with ABIM and will continue to inform you of any important changes to certification and recertification.

## This Month in CHEST: Editor's Picks

BY DR. RICHARD S. IRWIN,  
MASTER FCCP

Modification Program in OSA. By  
Dr. S. S. Ng et al.

The Association Between Heroin Inhalation and Early Onset Emphysema. By Dr. P. P. Walker et al.



Prognosis for Spontaneous Resolution of OSA in Children. By Dr. R. D. Chervin et al.

A Randomized Controlled Study to Examine the Effect of a Lifestyle

Giants in Chest Medicine: Dr. John F. Murray. By Dr. Philip C. Hopewell. (Video included)

## ERS International Congress 2015

Enjoying the ERS International Congress 2015 in Amsterdam (L-R): Canadian Thoracic Society President, Dr. Diane Loughheed; European Respiratory Society Immediate Past President, Dr. Elisabeth Bel; and new CHEST President, Dr. Barbara A. Phillips, FCCP.



“Getting involved with CHEST and the CHEST Foundation has been one of the most rewarding aspects of my career. It’s about giving back to your profession and making a contribution to an organization that serves your patients.”

- Jack D Buckley, MD, MPH, FCCP  
CHEST Foundation Donor  
and Regent-at-Large, Board of Regents



### Why I Donate.

**CHEST**  
FOUNDATION

The CHEST Foundation is the philanthropic arm of the American College of Chest Physicians. With a mission to champion lung health through community service and clinical research grants, patient-focused public education, and programs in tobacco education and cessation, every contribution is essential to ensuring the CHEST Foundation’s role in building healthier communities and saving lives.

For more information or to donate visit:  
[chestnet.org/Foundation](http://chestnet.org/Foundation)



## COPD HUB

The Latest News in Pulmonary Medicine for Clinicians



Now includes  
**ClinicalEdge**

Stay on top of the trends and research about COPD by visiting COPD-HUB. This CHEST partner website features:

- Exclusive news stories
- Conference coverage
- Clinical studies
- A video library

All content on COPD-HUB is drawn from research and clinical advances presented at medical conferences and meetings, recent US Food and Drug Administration regulatory findings, and specialty medical journals.

> Learn More [cprd-hub.com](http://cprd-hub.com)

**COPD HUB** | **CHEST** Physician

# CHEST World Congress 2016 in Shanghai, China

## Get Your Fill of the Latest Clinical Science, Authentic Cuisine

**A**s you plan your trip to Shanghai for CHEST World Congress 2016, you are probably eagerly anticipating authentic Chinese cuisine. You may be imagining Chinese food as you know it in North America – buffets; fortune cookies; and small, white takeout boxes. Buffets actually are commonplace in Shanghai, but you likely won't find a fortune cookie anywhere. We're here to give you a rundown of what to expect from Chinese cuisine, but read this at your own risk. Your stomach may growl, and we can't promise that your local Chinese restaurant will serve many of the authentic dishes featured below.

Let's get started with the basics. Shanghai cooking is known for a heavy, highly flavorful sauce. Dishes favor sugar, soy sauce, and oil, and seafood is featured prominently. You may find it to be rather oily and sweet. Generally expect to find meals served as family-style, and soup is oftentimes served as the last course. Finally, tips aren't needed, though there may be a service charge added to your bill at hotel restaurants.

Shanghai is most famous for its Shengjian Bao, fried soup dumplings. These dumplings are a thin dough wrapped around ground pork and a gelatinous soup. Yang's Dumpling franchise is the most popular place to get this tasty snack or breakfast treat, but you can also find them at many other restaurants in Shanghai. Follow Chinese tradition, and save yourself from getting burned, by eating dumplings in this order:



EURNGRANT/THINKSTOCK

- Place your dumpling on a spoon with help from your chopsticks.
- Bite off a small piece on top to make a hole.
- Blow and wait for the soup to cool.
- Slurp the soup inside.
- Dip into vinegar, if you wish.
- Eat the remainder of the dumpling.

Shanghai is also known for these popular street foods:

- Jianbing - These egg pancakes are served for breakfast by street vendors. The batter is made from mung bean flour, and crepes are topped with an egg or two, chopped pickled greens, scallions, and cilantro. Then spice is added with red bean, hoisin, and chili sauces.
- Hot Pot - Basic stock or spicy stock is offered with sides of thinly sliced raw meats, vegetables, and noodles.

• Chuanr - These skewers are made with lamb, chicken, beef, seafood like shellfish, and vegetarian options like eggplant and tofu. They are topped with cumin seeds, salt, sesame seeds or sesame oil, dried pepper flakes, and a spicy sauce.

If you're looking for a more upscale dining experience, the travel site, Frommers, has recommendations. Here are a few recommended restaurants located at the luxurious development, Three on the Bund:

- Jean Georges - contemporary and light French fare.
- Whampoa Club - Classic Shanghai foods with a contemporary spin.
- Laris - A seafood restaurant with an Australian chef.
- New Heights - casual, more affordable bistro fare.

Whether you decide to fill up with eats from the street, or you sit down at a cafe or restaurant, we know you'll find the cuisine you're craving with one of Shanghai's many dining options.

Similarly, you'll get your fill of science at CHEST World Congress with assorted clinical education opportunities. When CHEST travels to Shanghai, April 15 - 17, 2016, you'll have your choice of simulation-based education, case and problem-based sessions, and evidence-based medicine for clinical respirologists, intensive care physicians, and specialists in sleep medicine. Learn more at [chestworldcongress2016.org](http://chestworldcongress2016.org).

## CHEST Foundation Grants Seed Future Research

**A**s CHEST 2015 wraps up, and the CHEST Foundation begins to award new grants to fund research in chest medicine, it's important to check in with previous grant winners to see how their innovative projects have progressed.

One notable and inspiring CHEST Foundation grant recipient, Dr. Ghada Bourjely, FCCP, turned her two \$10,000 CHEST Foundation grants into a \$2.8 million federally funded, interdisciplinary, team-based research program for women's health.

"These grants were instrumental in helping my team," Dr. Bourjely stated when asked about the effects winning the grants had on her research. "Without the results from the CHEST Foundation grant-funded research, my team and I would have been unable to apply for federal funding. We were recently awarded about \$2.8 million in federal funding." Her projects, Differences in Respiratory Sleep Parameters of Pregnant and Nonpregnant Women, and Sleep-Disordered Breathing in Pregnant Women With Gestational Diabetes Mellitus: Prevalence and



**Dr. Bourjely's research coordinators, nurses, and administrators. People collaborating on the projects but not pictured: Dr. Jennifer Fung; Dr. Mary Kao, (MD'16); and Palak Walia.**

Mechanisms, both aimed at gaining a better understanding of sleep-disordered breathing during pregnancy. "I am extremely grateful to the CHEST Foundation for its generous support

in helping launch our project and to the CHEST NetWorks and steering committees, which are helpful for guiding young physicians toward opportunities like CHEST Foundation

grants, which help them succeed in their careers."

The CHEST Foundation believes that a team-based approach to chest medicine research is a cornerstone for advancing lung health. Our grants support such team-based, interdisciplinary efforts, and we are excited to continue partnering with CHEST members on new clinical research and community-based projects in the upcoming grant cycle for 2016.

It is critical to acknowledge that the success of these projects is made possible by the support of members and friends in the chest medicine community who donate each year to the foundation's Annual Fund. Become part of our Annual Fund Giving Club today by visiting [chestnet.org/donate](http://chestnet.org/donate), and learn more about grant opportunities for 2016 by stopping by [chestnet.org/grants](http://chestnet.org/grants). Thank you for your contributions and for your support of the CHEST Foundation's mission to champion lung health.

*Dr. Bourjely is with the Women's Medicine Collaborative through Miriam Hospital/Lifespan.*

# EV-D68 less dangerous than flu in children

BY AMY KARON  
Frontline Medical News

SAN DIEGO – Enterovirus D68 appeared more virulent – but not more lethal – than rhinovirus and other strains of enterovirus among children, said the authors of a single-center study.

EV-D68 was linked to higher rates of respiratory distress, hospital admission, and magnesium sulfate therapy, but patients were no more likely to die or require critical care unit admission than were those infected with other EV genotypes or rhinovirus, said Dr. Dominik Mertz of the division of infectious diseases at McMaster University, in Hamilton, Ont.

The study also uncovered no evidence of EV-68 transmission at the hospital, Dr. Mertz and his associates said at an annual scientific meeting on infectious diseases.

In 2014, an outbreak of EV-D68 in the United States included more than 1,000 confirmed cases, almost all among children, and many of whom had comorbid asthma or a history of wheezing. Fourteen patients died, and the Centers for Disease Control and Prevention noted that millions



Although EV-D68 appears more virulent than other enteroviruses and rhinoviruses, it is no deadlier, said Dr. Jeffrey Pernica (left) and Dr. Dominik Mertz.

more individuals probably had milder EV-D68 infections for which they were never tested.

Dr. Mertz and his associates studied children who presented consecutively to the hospital during the 3 months between Aug. 1 and Oct. 31, 2014. During that time, nasopharyngeal swabs that were positive for EV or rhinovirus were automatically tested for EV-D68. The researchers matched EV-D68-positive patients with children who were positive for rhinovirus or other EVs on the basis of sex, age, and

date of presentation to the hospital.

Almost a third (93 of 297; 31%) of rhinovirus or EV samples were positive for EV-D68. Among 87 matched pairs, EV-D68 infection was associated with a threefold greater odds of respiratory distress (95% confidence interval, 1.47-6.14), and a more than twofold rise in the odds of needing magnesium sulfate therapy (odds ratio, 2.62; 95% CI, 1.06-6.47). There was a trend toward greater risk of hospital admission with EV-D68, although it was not statistically significant (OR,

2.29; 95% CI, 0.96-5.46;  $P = .06$ ).

Notably, EV-68 did not increase the likelihood of death or CCU admission, while, influenza causes dozens of deaths among children in the United States every year, Dr. Mertz and his coinvestigator Dr. Jeffrey Pernica noted in an interview (MMWR. 2014 Jun 6:63[22];483-90). “There was a lot of fuss made about EV-D68,” said Dr. Mertz. “But we have flu every year, and many more kids get the flu and die of flu than EV-D68.”

Patients with EV-D68 infection were more likely than others to have a family history of atopy (OR, 2.25) and a personal history of asthma or wheezing (OR, 1.77), hay fever (1.22), and eosinophilia (4.5), although none of these associations reached statistical significance, the investigators reported. “It seems reasonable to hypothesize that EV-D68 is a more virulent pulmonary pathogen to those with preexisting atopic disease than other rhinoviruses and enteroviruses,” Dr. Mertz and his associates wrote in an associated article (CMAJ. 2015 Oct. 13. doi: 10.1503/cmaj.150619). The investigators received no funding for the study and reported no conflicts of interest.



## Live Learning Courses

Mechanical Ventilation:  
Advanced Critical Care  
Management

February 26-28

Comprehensive Bronchoscopy With Endobronchial  
Ultrasound

March 4-6

Ultrasonography:  
Essentials in Critical Care

March 11-13

Advanced Clinical Training in  
Pulmonary Function Testing

April 9-10

Critical Care Ultrasonography:  
Integration Into Clinical  
Practice

May 5-7

Advanced Critical Care  
Echocardiography

June 2-4

Transesophageal  
Echocardiography (TEE)

June 5

Comprehensive  
Pleural Procedures

June 17-18

Difficult Airway Management

July 15-17

Mechanical Ventilation:  
Advanced Critical Care  
Management

July 29-31

Bronchoscopy Procedures  
for the Intensivist

August 6-7

Ultrasonography:

Essentials in Critical Care

September 9-11

Cardiopulmonary  
Exercise Testing (CPET)

September 16-18

Comprehensive Bronchoscopy With Endobronchial  
Ultrasound

September 23-25

Critical Care Ultrasonography:  
Integration Into Clinical  
Practice

November 11-13

Ultrasonography:  
Essentials in Critical Care

December 2-4

> Learn More [chestnet.org/live-learning](http://chestnet.org/live-learning)

Ultrasonography:  
Essentials in Critical Care

December 3-5, 2015

Seats still available.

CHEST Board Review  
Phoenix, Arizona

August 19-28

CHEST Annual Meeting

CHEST 2016

October 22-26


Los Angeles, California

Calendar subject to change.

For most current course list and more information, visit [chestnet.org/live-learning](http://chestnet.org/live-learning).

CHEST  
Annual Meeting  
2016

Connecting a Global Community in Clinical Chest Medicine



LOS ANGELES  
OCTOBER 22 - 26

With mild temperatures and sunshine nearly 300 days a year, Los Angeles is often described as “perfect.” And, it’s a perfect setting for CHEST 2016, where we’ll connect a global community in clinical chest medicine. As always, our program will deliver current pulmonary, critical care, and sleep medicine topics presented by world-renowned faculty in a variety of innovative instruction formats.


DON'T MISS CHEST 2016  
[chestmeeting.chestnet.org](http://chestmeeting.chestnet.org)

# Palivizumab reduced RSV hospitalization risk

BY AMY KARON  
Frontline Medical News

SAN DIEGO – Prophylactic palivizumab cut the odds of hospitalization for severe respiratory syncytial virus (RSV) infection by about 75% in preterm infants born at more than 29 weeks' gestational age – even those without congenital heart disease or chronic lung disease.

The finding belies the American Academy of Pediatrics' recommendation to limit use of the humanized monoclonal antibody to infants born



FRONTLINE MEDICAL NEWS

**'Our results validate the older studies, except this was done in real life,' said Dr. Eric Simões.**

before 29 weeks' gestation and to children who have other risk factors for severe RSV infection, Dr. Ram Yogev of Ann and Robert H. Lurie Children's Hospital, Chicago, said in an interview.

"Our results validate the older studies, except this was done in real life," added lead investigator Dr. Eric Simões of Children's Hospital Colorado, Aurora, who presented the findings at an annual scientific meeting on infectious diseases.

RSV usually causes mild upper respiratory tract infections, but premature infants and children who have comorbid cardiac or pulmonary disease can develop severe infections of the lower respiratory tract. Weekly palivizumab dosing was 45%-80% effective in preventing RSV-related hospitalizations in clinical trials of these high-risk patients, noted Dr. Simões and his associates.

But in 2014, the American Academy of Pediatrics reviewed the literature and revised its guidance to limit palivizumab to preterm infants born before 29 weeks' gestation and to infants with comorbid risk conditions. The biologic "has been shown to have a limited effect on reducing RSV hospitalization," the academy concluded.

The update drew criticism from some pediatric infectious disease ex-

perts, who contended that AAP cited observational studies that actually contradicted its conclusions.

To further examine the issue, Dr. Simões and associates analyzed data from a multicenter study of high-

risk infants and children under the age of 2 years who had been hospitalized with lower respiratory tract infections. During 2002-2006, 849 of these patients had a nasopharyngeal wash or endotracheal aspirate tested

for RSV, and 403 were positive. The investigators determined that the odds of a positive RSV test were 58% lower for patients who had received prophylactic palivizumab, compared

*Continued on following page*

Of all the things you recommend to protect your patients aged 65+



GET VACCINATED  
AGAINST PNEUMOCOCCAL  
PNEUMONIA

HERE'S ONE YOU  
CAN GET DONE TODAY

Make vaccination a priority.

Help protect your appropriate patients with Prevnar 13®.

- Pneumococcal pneumonia can have serious consequences and may lead to hospitalization<sup>1</sup>
- The CDC's ACIP recommends Prevnar 13® for adults aged 65+<sup>2</sup>
- Prevnar 13® was shown to prevent pneumococcal pneumonia and IPD in a landmark efficacy trial of 84,496 adults aged 65+<sup>3</sup>
- Prevnar 13® is covered by the Medicare Part B FFS benefit for adults aged 65+ with \$0 in out-of-pocket costs

Learn more about Prevnar 13® and the information above at [www.Prevnar13info.com](http://www.Prevnar13info.com)

ACIP=Advisory Committee on Immunization Practices; CDC=Centers for Disease Control and Prevention; FFS=fee-for-service; IPD=invasive pneumococcal disease.

## INDICATION

- In adults 50 years of age and older, Prevnar 13® is indicated for active immunization for the prevention of pneumonia and invasive disease caused by *Streptococcus pneumoniae* serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F

## Limitations of Use and Effectiveness

- Prevnar 13® will only help protect against *S pneumoniae* serotypes in the vaccine

## IMPORTANT SAFETY INFORMATION

- Severe allergic reaction (eg, anaphylaxis) to any component of Prevnar 13® or any diphtheria toxoid-containing vaccine is a contraindication
- Immunocompromised individuals or individuals with impaired immune responsiveness due to the use of immunosuppressive therapy may have reduced antibody response
- In adults, antibody responses to Prevnar 13® were diminished when given with inactivated trivalent influenza vaccine
- In adults, the commonly reported solicited adverse reactions were pain, redness, and swelling at the injection site, limitation of arm movement, fatigue, headache, muscle or joint pain, decreased appetite, chills, or rash

Please see Brief Summary of Prescribing Information on adjacent page(s).

**References:** 1. Griffin MR, Zhu Y, Moore MR, Whitney CG, Grijalva CG. U.S. hospitalizations for pneumonia after a decade of pneumococcal vaccination. *N Engl J Med.* 2013;369(2):155-163. 2. Tomczyk S, Bennett NM, Stoecker C, et al. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged ≥65 years: recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR Morb Mortal Wkly Rep.* 2014;63(37):822-825. 3. Bonten MJM, Huijts SM, Bolkenbaas M, et al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. *N Engl J Med.* 2015;372(12):1114-1125.

PREVNAR 13 is a registered trademark of Wyeth LLC.

Manufactured by Wyeth Pharmaceuticals Inc.

PSA741205-01

© 2015 Pfizer Inc.

All rights reserved.

Marketed by Pfizer Inc.



Printed in USA/June 2015

**Prevnar 13®**  
Pneumococcal 13-valent Conjugate Vaccine  
(Diphtheria CRM<sub>197</sub> Protein)

Continued from previous page

with patients who had not (95% confidence interval for efficacy, 43%-69%; *P* less than .0001).

Furthermore, palivizumab was 75% effective against severe RSV disease in preterm patients born at 29-35 weeks' gestation who were chronologically

younger than 6 months and had no congenital heart disease or chronic lung disease, said the investigators. Based on that finding, AAP should reconsider its recommendations on palivizumab, said Dr. Yogev.

"This study should answer some of the issues raised in the AAP recommendations," added Dr. Simões.

Palivizumab did not prevent hospitalizations for human metapneumovirus (hMPV) infection, which further validated the results on RSV, said Dr. Simões.

IDWeek marked the combined annual meetings of the Infectious Diseases Society of America, the Society for Healthcare Epidemiology

of America, the HIV Medicine Association, and the Pediatric Infectious Diseases Society.

MedImmune sponsored the original study of hMPV tract infections, from which these data were obtained. Dr. Simões reported having received funding support and consulting fees from MedImmune.

#### BRIEF SUMMARY OF FULL PRESCRIBING INFORMATION



This brief summary does not include all of the information needed to use Pneumovax 13<sup>®</sup> safely and effectively. Before prescribing, please consult the full Prescribing Information for Pneumovax 13<sup>®</sup>.

#### DOSAGE FORMS AND STRENGTHS

Pneumovax 13<sup>®</sup> is a suspension for intramuscular injection available in 0.5 mL single-dose prefilled syringes.

#### CONTRAINDICATIONS

Severe allergic reaction (eg, anaphylaxis) to any component of Pneumovax 13<sup>®</sup> or any diphtheria toxoid-containing vaccine.

#### WARNINGS AND PRECAUTIONS

##### Management of Allergic Reactions

Epinephrine and other appropriate agents used to manage immediate allergic reactions must be immediately available should an acute anaphylactic reaction occur following administration of Pneumovax 13<sup>®</sup>.

##### Altered Immunocompetence

Data on the safety and effectiveness of Pneumovax 13<sup>®</sup> when administered to immunocompromised individuals including those at higher risk for invasive pneumococcal disease (eg, individuals with congenital or acquired splenic dysfunction, HIV infection, malignancy, hematopoietic stem cell transplant, nephrotic syndrome) are not available. Individuals in these groups may have reduced antibody response to active immunization due to impaired immune responsiveness.

##### Apnea in Premature Infants

Apnea following intramuscular vaccination has been observed in some infants born prematurely. Decisions about when to administer an intramuscular vaccine, including Pneumovax 13<sup>®</sup>, to infants born prematurely should be based on consideration of the individual infant's medical status and the potential benefits and possible risks of vaccination.

#### ADVERSE REACTIONS

Because clinical trials are conducted under widely varying conditions, adverse-reaction rates observed in the clinical trials of a vaccine cannot be directly compared to rates in the clinical trials of another vaccine and may not reflect the rates observed in practice. As with any vaccine, there is the possibility that broad use of Pneumovax 13<sup>®</sup> could reveal adverse reactions not observed in clinical trials.

##### Clinical Trials Experience With Pneumovax 13<sup>®</sup> in Infants and Toddlers

The safety of Pneumovax 13<sup>®</sup> was evaluated in 13 clinical trials in which 4729 infants and toddlers received at least 1 dose of Pneumovax 13<sup>®</sup> and 2760 infants and toddlers received at least 1 dose of Pneumovax<sup>®</sup> active control. Overall, the safety data show a similar proportion of Pneumovax 13<sup>®</sup> and Pneumovax<sup>®</sup> subjects reporting serious adverse events. Among US study subjects, a similar proportion of Pneumovax 13<sup>®</sup> and Pneumovax<sup>®</sup> recipients reported solicited local and systemic adverse reactions as well as unsolicited adverse events.

##### Serious Adverse Events in All Infant and Toddler Clinical Studies

Serious adverse events were collected throughout the study period for all 13 clinical trials. This reporting period is longer than the 30-day post-vaccination period used in some vaccine trials. The longer reporting may have resulted in serious adverse events being reported in a higher percentage of subjects than for other vaccines. Serious adverse events reported following vaccination in infants and toddlers occurred in 8.2% among Pneumovax 13<sup>®</sup> recipients and 7.2% among Pneumovax<sup>®</sup> recipients. Serious adverse events observed during different study periods for Pneumovax 13<sup>®</sup> and Pneumovax<sup>®</sup>, respectively, were: 1) 3.7% and 3.5% from dose 1 to the bleed approximately 1 month after the infant series; 2) 3.6% and 2.7% from the bleed after the infant series to the toddler dose; 3) 0.9% and 0.8% from the toddler dose to the bleed approximately 1 month after the toddler dose; and 4) 2.5% and 2.8% during the 6-month follow-up period after the last dose.

The most commonly reported serious adverse events were in the "infections and infestations" system organ class, including bronchiolitis (0.9%, 1.1%), gastroenteritis (0.9%, 0.9%), and pneumonia (0.9%, 0.5%) for Pneumovax 13<sup>®</sup> and Pneumovax<sup>®</sup>, respectively.

There were 3 (0.063%) deaths among Pneumovax 13<sup>®</sup> recipients and 1 (0.036%) death among Pneumovax<sup>®</sup> recipients, all as a result of sudden infant death syndrome (SIDS). These SIDS rates are consistent with published age-specific background rates of SIDS from the year 2000.

Among 6839 subjects who received at least 1 dose of Pneumovax 13<sup>®</sup> in clinical trials conducted globally, there was 1 hypotonic-hyporesponsive episode adverse reaction reported (0.015%). Among 4204 subjects who received at least 1 dose of Pneumovax<sup>®</sup> in clinical trials conducted globally, there were 3 hypotonic-hyporesponsive episode adverse reactions reported (0.071%). All 4 events occurred in a single clinical trial in Brazil in which subjects received whole cell pertussis vaccine at the same time as Pneumovax 13<sup>®</sup> or Pneumovax<sup>®</sup>.

##### Solicited Adverse Reactions in the 3 US Infant and Toddler Studies

A total of 1907 subjects received at least 1 dose of Pneumovax 13<sup>®</sup> and 701 subjects received at least 1 dose of Pneumovax<sup>®</sup> in the 3 US studies.

Solicited adverse reactions that occurred within 7 days following each dose of Pneumovax 13<sup>®</sup> or Pneumovax<sup>®</sup> administered to US infants and toddlers were: in infants and toddlers vaccinated at 2, 4, 6, and 12-15 months of age in US clinical trials, the most commonly reported solicited adverse reactions were irritability (>70%), injection site tenderness (>50%), decreased appetite (>40%), decreased sleep (>40%), increased sleep (>40%), fever (>20%), injection site redness (>20%), and injection site swelling (>20%).

##### Unsolicited Adverse Reactions in the 3 US Infant and Toddler Safety Studies

The following were determined to be adverse drug reactions based on experience with Pneumovax 13<sup>®</sup> in clinical trials: reactions occurring in greater than 1% of infants and toddlers: diarrhea, vomiting, and rash; and reactions occurring in less than 1% of infants and toddlers: crying, hypersensitivity reaction (including face edema, dyspnea, and bronchospasm), seizures (including febrile seizures), and urticaria or urticaria-like rash.

##### Clinical Trials Experience With Pneumovax 13<sup>®</sup> in Adults Aged ≥50 Years

The safety of Pneumovax 13<sup>®</sup> was assessed in 7 clinical studies (Studies 6-12) conducted in the US and Europe, which included 90,694 adults (47,907 received Pneumovax 13<sup>®</sup>) ranging in age from 50 through 101 years.

The 47,907 Pneumovax 13<sup>®</sup> recipients included 2616 adults who were aged 50 through 64 years and 45,291 adults aged 65 years and older. Of the 47,907 Pneumovax 13<sup>®</sup> recipients, 45,991 adults had not previously received PPSV23 ("PPSV23 unvaccinated") and 1916 adults were previously

vaccinated ("PPSV23 previously vaccinated") with PPSV23 at least 3 years prior to enrollment.

##### Serious Adverse Events in Adult Clinical Studies

Across the 6 safety and immunogenicity studies, serious adverse events within 1 month of vaccination were reported after an initial study dose in 0.2%-1.4% of 5055 subjects vaccinated with Pneumovax 13<sup>®</sup> and in 0.4%-1.7% of 1124 subjects vaccinated after an initial study dose of the 23-valent pneumococcal polysaccharide vaccine (PPSV23). From 1 month to 6 months after an initial study dose, serious adverse events were reported in 1.2%-5.8% of subjects vaccinated during the studies with Pneumovax 13<sup>®</sup> and in 2.4%-5.5% of subjects vaccinated with PPSV23. One case of erythema multiforme occurred 34 days after receipt of a second dose of Pneumovax 13<sup>®</sup>.

Twelve of 5667 (0.21%) Pneumovax 13<sup>®</sup> recipients and 4 of 1391 (0.29%) PPSV23 recipients died. Deaths occurred between day 3 and day 309 after study vaccination with Pneumovax 13<sup>®</sup> or PPSV23. Two of 12 deaths occurred within 30 days of vaccination with Pneumovax 13<sup>®</sup> and both deaths were in subjects >65 years of age. One death due to cardiac failure occurred 3 days after receiving Pneumovax 13<sup>®</sup> administered with trivalent inactivated influenza vaccine (TIV) and the other death was due to peritonitis 20 days after receiving Pneumovax 13<sup>®</sup>. The reported causes of the 10 remaining deaths occurring greater than 30 days after receiving Pneumovax 13<sup>®</sup> were cardiac disorders (4), neoplasms (4), *Mycobacterium avium* complex pulmonary infection (1), and septic shock (1).

In an efficacy study of subjects 65 years of age and older, serious adverse events within 1 month of vaccination were reported in 327 of 42,237 (0.8%) Pneumovax 13<sup>®</sup> recipients (352 events) and in 314 of 42,225 (0.7%) placebo recipients (337 events). In the subset of subjects where serious adverse events were monitored for 6 months, 70 of 1006 (7%) Pneumovax 13<sup>®</sup> vaccinated subjects (90 events) and 60 of 1005 (6%) placebo vaccinated subjects (69 events) reported serious adverse events.

During the follow-up period (average of 4 years) for case accumulation there were 3006 deaths (7.1%) in the Pneumovax 13<sup>®</sup> group and 3005 deaths (7.1%) in the placebo group. There were 10 deaths (<0.1%) in the Pneumovax 13<sup>®</sup> group and 10 deaths (<0.1%) in the placebo group within 28 days of vaccination. There were 161 deaths (0.4%) in the Pneumovax 13<sup>®</sup> group and 144 deaths (0.3%) in the placebo group within 29 days – 6 months following vaccination. These data do not provide evidence for a causal relationship between deaths and vaccination with Pneumovax 13<sup>®</sup>.

##### Solicited Adverse Reactions in Adult Clinical Studies

In adults aged 50 years and older, the commonly reported solicited adverse reactions were pain at the injection site (>50%), fatigue (>30%), headache (>20%), muscle pain (>20%), joint pain (>10%), decreased appetite (>10%), injection site redness (>10%), injection site swelling (>10%), limitation of arm movement (>10%), chills (>5%), or rash (>5%).

##### Solicited Adverse Reactions in Adult Clinical Studies of Concomitant Administration of Pneumovax 13<sup>®</sup> and TIV (Fluarix)

The safety of concomitant administration of Pneumovax 13<sup>®</sup> with TIV was assessed in 2 studies in PPSV23 unvaccinated adults aged 50 through 59 years and aged ≥65 years.

Frequencies of local reactions within 14 days post-vaccination in adults aged 50 through 59 years and in adults aged ≥65 years were similar after Pneumovax 13<sup>®</sup> was administered with TIV compared to Pneumovax 13<sup>®</sup> administered alone, with the exception of mild redness at the injection site, which was increased when Pneumovax 13<sup>®</sup> was administered concomitantly with TIV.

An increase in some solicited systemic reactions within 14 days post-vaccination was noted when Pneumovax 13<sup>®</sup> was administered concomitantly with TIV compared with TIV given alone (headache, chills, rash, decreased appetite, muscle and joint pain) or with Pneumovax 13<sup>®</sup> given alone (fatigue, headache, chills, decreased appetite, and joint pain).

##### Clinical Trials Experience With Pneumovax<sup>®</sup> in Infants and Toddlers

The safety experience with Pneumovax<sup>®</sup> is relevant to Pneumovax 13<sup>®</sup> because the 2 vaccines share common components.

Generally, the adverse reactions reported in clinical trials with Pneumovax 13<sup>®</sup> were also reported in clinical trials with Pneumovax<sup>®</sup>.

Overall, the safety of Pneumovax<sup>®</sup> was evaluated in a total of 5 clinical studies in the United States in which 18,168 infants and children received a total of 58,699 doses of vaccine at 2, 4, 6, and 12-15 months of age.

Adverse events reported in clinical trials with Pneumovax<sup>®</sup> that occurred within 3 days of vaccination in infants and toddlers and resulted in emergency room visits or hospitalizations, but were not presented in Section 6.1 as adverse reactions for Pneumovax 13<sup>®</sup>, are listed below:

Bronchiolitis, UTI, acute gastroenteritis, asthma, aspiration, breath holding, influenza, inguinal hernia repair, viral syndrome, URI, croup, thrush, wheezing, choking, conjunctivitis, pharyngitis, colic, colitis, congestive heart failure, roseola, and sepsis.

##### Post-marketing Experience With Pneumovax<sup>®</sup> in Infants and Toddlers

The following adverse events have been reported through passive surveillance since market introduction of Pneumovax<sup>®</sup> and, therefore, are considered adverse events for Pneumovax 13<sup>®</sup> as well. Because these events are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to the vaccine.

**Administration site conditions:** Injection site dermatitis, injection site pruritus, injection site urticaria

**Blood and lymphatic system disorders:** Lymphadenopathy localized to the region of the injection site

**Immune system disorders:** Anaphylactic/anaphylactoid reaction including shock

**Skin and subcutaneous tissue disorders:** Angioneurotic edema, erythema multiforme

**Respiratory:** Apnea

#### DRUG INTERACTIONS

##### Concomitant Immunizations

In clinical trials with infants and toddlers, Pneumovax 13<sup>®</sup> was administered concomitantly with the following US licensed vaccines: Pediarix [Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Hepatitis B (Recombinant) and Inactivated Poliovirus Vaccine Combined] (DTaP-HBV-IPV) and ActHIB [Haemophilus b Conjugate Vaccine (Tetanus Toxoid Conjugate)] (PRP-T) for the first 3 doses and with PedvaxHIB [Haemophilus b Conjugate Vaccine (Meningococcal Protein Conjugate)] (PRP-OMP), M-M-R II [Measles, Mumps, Rubella Virus Vaccine Live] (MMR) and Varivax [Varicella Virus Vaccine Live], or ProQuad [Measles, Mumps, Rubella, and Varicella Virus Vaccine Live] (MMRV) and VAQTA [Hepatitis A Vaccine, Inactivated] (HepA) for dose 4.

In adults, Pneumovax 13<sup>®</sup> was administered concomitantly with US licensed Fluarix (TIV) for the 2007/2008 influenza season. There are no data on the concomitant administration of Pneumovax 13<sup>®</sup> with diphtheria toxoid-containing vaccines and other vaccines licensed for use in adults 50 years of age and older.

When Pneumovax 13<sup>®</sup> is administered at the same time as another injectable vaccine(s), the vaccines should always be administered with different syringes and given at different injection sites.

Do not mix Pneumovax 13<sup>®</sup> with other vaccines/products in the same syringe.

##### Immunosuppressive Therapies

Individuals with impaired immune responsiveness due to the use of immunosuppressive therapy (including irradiation, corticosteroids, antimetabolites, alkylating agents, and cytotoxic agents) may not respond optimally to active immunization.

##### Antipyretics

A post-marketing clinical study conducted in Poland using a non-US vaccination schedule (2, 3, 4, and 12 months of age) evaluated the impact of prophylactic oral acetaminophen on antibody responses to Pneumovax 13<sup>®</sup>. The data show that 3 doses of acetaminophen (the first dose administered at the time of each vaccination and the subsequent doses at 6 to 8 hour intervals) reduced the antibody response to some serotypes following the third dose of Pneumovax 13<sup>®</sup>, compared with responses among infants who received antipyretics only as needed for treatment. Reduced antibody responses were not observed after the fourth dose of Pneumovax 13<sup>®</sup> when acetaminophen was administered prophylactically.

##### Prior Vaccination With PPSV23

Prior receipt of Pneumovax<sup>®</sup> 23 (23 valent pneumococcal vaccine polyvalent, PPSV23) within 1 year results in diminished immune responses to Pneumovax 13<sup>®</sup> compared to PPSV23 naive individuals.

#### USE IN SPECIFIC POPULATIONS

##### Pregnancy

##### Pregnancy Category B

A developmental and reproductive toxicity study has been performed in female rabbits at a dose approximately 20 times the human dose (on mg/kg basis) and revealed no evidence of impaired female fertility or harm to the fetus due to Pneumovax 13<sup>®</sup>. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this vaccine should be used during pregnancy only if clearly needed.

##### Nursing Mothers

It is not known whether this vaccine is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Pneumovax 13<sup>®</sup> is administered to a nursing woman.

##### Pediatric Use

Safety and effectiveness of Pneumovax 13<sup>®</sup> in children below the age of 6 weeks or on or after the 6th birthday have not been established.

Immune responses elicited by Pneumovax 13<sup>®</sup> among infants born prematurely have not been specifically studied.

##### Geriatric Use

Of the total number of Pneumovax 13<sup>®</sup> recipients aged 50 years and older in clinical studies (N=47,907), 94.5% (45,291 of 47,907) were 65 years and older and 30.3% (14,498 of 47,907) were 75 years and older.

##### High Risk Populations

Individuals with the diseases or conditions listed below are at increased risk of pneumococcal disease. Immunogenicity and safety data in these populations are limited.

##### Infants Born Prematurely

Immune responses elicited by Pneumovax 13<sup>®</sup> administered on a US schedule to preterm infants have not been studied. When preterm infants (<37 weeks gestational age, N=100) were administered 4 doses of Pneumovax 13<sup>®</sup> on a non-US schedule, the serotype-specific IgG antibody responses after the third and fourth dose were lower compared to responses among term infants (≥37 weeks gestational age, N=100) for some serotypes; the effectiveness of Pneumovax 13<sup>®</sup> in preterm infants cannot be established from this study.

##### Children With Sickle Cell Disease

In an open-label, single-arm, descriptive study, 2 doses of Pneumovax 13<sup>®</sup> were administered 6 months apart to children ≥6 to <18 years of age with sickle cell disease who previously received PPSV23 at least 6 months prior to enrollment. Children with a prior history of pneumococcal conjugate vaccination were excluded. For all vaccine serotypes, anti-pneumococcal opsonophagocytic activity (OPA) geometric mean antibody titers (GMTs) were higher after the first dose compared to pre-vaccination (N=95-131); OPA GMTs following the first and second dose were comparable. The effectiveness of Pneumovax 13<sup>®</sup> in this specific population has not been established.

##### Adults With HIV Infection

In an open-label, single-arm, descriptive study, 3 doses of Pneumovax 13<sup>®</sup> were administered 6 months apart to HIV-infected adults ≥50 years of age (median age 55 years), with CD4 counts ≥200 cells/μL and serum HIV RNA titer <50,000 copies/mL. All subjects had been vaccinated previously with PPSV23 at least 6 months prior to enrollment. For all vaccine serotypes anti-pneumococcal OPA GMTs were higher after the first dose compared to pre-vaccination (N=94-108); OPA GMTs following the first, second and third dose were generally comparable. The effectiveness of Pneumovax 13<sup>®</sup> in this specific population has not been established.

#### PATIENT COUNSELING INFORMATION

##### Potential Benefits and Risks

Prior to administration of this vaccine, the health care professional should inform the individual, parent, guardian, or other responsible adult of the following potential benefits and risks of immunization with Pneumovax 13<sup>®</sup> [see Warnings and Precautions (5) and Adverse Reactions (6)], the importance of completing the immunization series for their child(ren) unless contraindicated, and that any suspected adverse reactions should be reported to their healthcare professional.

Provide the Vaccine Information Statements, which are available free of charge at the Centers for Disease Control and Prevention (CDC) website ([www.cdc.gov/vaccines](http://www.cdc.gov/vaccines)).

This product's label may have been updated. For current Prescribing Information and further product information, please visit [www.pfizerpro.com/products](http://www.pfizerpro.com/products) or call Pfizer Medical Information toll-free at 1-800-438-1985.



US Govt. License No. 3

Based on LAB-0469 12.0 (May 2015)

CPT Code 90670

United States Patent Number: 5,614,382.

# Antibiotic prescribing varies widely for pediatric CAP

BY DOUG BRUNK  
Frontline Medical News

SAN DIEGO – Antibiotic prescribing patterns for pediatric community-acquired pneumonia vary substantially across both children's hospitals and facilities that are not children's hospitals, a large analysis found.

Specifically, children's hospitals are far more likely to prescribe in accordance with national guidelines than are other hospitals.

"Moving forward, there's a need for further study to understand these differences, so we can begin to narrow this gap between children's and non-children's hospitals," lead study author Dr. Alison Tribble said at an annual scientific meeting on infectious diseases. "Across the board, we need to continue efforts to improve guideline adherence for all children hospitalized with community-acquired pneumonia."

In 2012, community-acquired pneumonia (CAP) accounted for 120,000 known pneumonia admissions among children in the United States and about 7% of all pediatric hospitalizations, said Dr. Tribble, a pediatric infectious disease specialist at C.S. Mott Children's Hospital and the University of Michigan Medical Center, both in Ann Arbor. "We also know that pneumonia accounts for more days of antibiotic therapy than any other indication for admission to U.S. children's hospitals," she said.

In 2011, the Infectious Diseases Society of America and Pediatric Infectious Diseases Society released guidelines for pediatric CAP, which recommend a first-line therapy with penicillin, ampicillin, or amoxicillin

for most children who are immunized and healthy. "Only in situations where there's a significant concern for an atypical organism should we be adding coverage for that – even in older children," Dr. Tribble said. Following the release of the guidelines, she continued, multiple studies have shown that the use of first-line therapy is increasing in children's hospitals. "However, a substantial proportion of children with pneumo-



**Children's hospitals are far more likely to prescribe in accordance with national guidelines.**

DR. TRIBBLE

nia are admitted to non-children's hospitals," she said. "Prior to release of the guidelines, one study showed that use of first-line therapy for pediatric CAP was low in non-children's hospitals (J Pediatr. 2014 165[3]:585-91), but postguideline CAP therapy in non-children's hospitals has not yet been evaluated."

For the current study, Dr. Tribble and her associates set out to evaluate antibiotic prescribing patterns for pediatric CAP in non-children's hospitals and to compare prescribing patterns between children's and non-children's hospitals. They conducted a retrospective cross-sectional study of children aged 1-17 years admitted for CAP in 2013 to 323 hospitals, captured via the Pediatric Health Information System (PHIS) and Premier Perspective

databases. PHIS is an administrative database that includes billing data, diagnosis codes, and procedure codes for about 44 freestanding children's hospitals nationwide, while Premier Perspective encompasses data from 522 hospitals nationwide. The researchers used a validated ICD-9 code-based algorithm to identify patients with CAP and excluded those with complicated pneumonia or complex chronic conditions, those who received intensive care, and those with methicillin-resistant *Staphylococcus aureus* infection or colonization.

Children's hospitals were defined as those with pediatric admissions accounting for more than 75% of all admissions. "This was after excluding newborns and admission for childbirth, because many community hospitals will have a birthing center or a NICU, but otherwise would not be considered a children's hospital," Dr. Tribble explained. Any other hospital was considered a non-children's hospital.

Three different outcomes for antibiotic use were examined: those who ever received penicillin, amoxicillin, or ampicillin (guideline therapy); those who ever received a macrolide, fluoroquinolone, or tetracycline (atypical therapy); and those who received anything other than penicillin, amoxicillin, or ampicillin (nonguideline therapy). The standardized probability of exposure to select antibiotics was compared between children's and non-children's hospitals, adjusted for age, sex, and insurance provider.

In all, 323 hospitals contributed 15,495 CAP cases. Of the 323 hospitals, 49 were identified as children's hospitals (44 from the PHIS database

and 5 from the Premier database). Dr. Tribble reported results from 9,224 subjects admitted to children's hospitals and 6,271 subjects admitted to non-children's hospitals. The demographics between the two groups were similar: The patients' mean age was 3 years, and 66% were younger than age 5 years.

After adjustment of data, patients admitted to children's hospitals were found to be more likely to receive guideline therapy, compared with those admitted to non-children's hospitals (46% vs. 15%, respectively), were less likely to receive atypical therapy (36% vs. 51%), and were less likely to receive nonguideline therapy (78% vs. 94%; *P* less than .001 for all comparisons).

Dr. Tribble acknowledged certain limitations of the study, including the potential for misclassification of children's hospitals in the Premier database. Another limitation is that the study design did not account for the potential of combination therapy, "and you can't account for change in therapy during hospitalization. Lastly, we compared data across different databases and across different hospital types."

IDWeek marks the combined annual meetings of the Infectious Diseases Society of America, the Society for Healthcare Epidemiology of America, the HIV Medicine Association, and the Pediatric Infectious Diseases Society. The study was supported by a training grant from the National Institute of Child Health and Human Development. The researchers reported having no relevant financial disclosures.

dbrunk@frontlinemedcom.com

## Carbapenem resistance on the rise in children

BY BIANCA NOGRADY  
Frontline Medical News


The prevalence of carbapenem-resistant *Enterobacteriaceae* (CRE) in children is low but has increased significantly since 1999, particularly among isolates from intensive care units and from blood and lower respiratory tract cultures, new data suggest.

Analysis of 316,253 *Enterobacteriaceae* isolates reported to 300 U.S. laboratories participating in the Surveillance Network-USA database between 1999 and 2012 showed 0.08% of isolates were carbapenem resistant, with the most common resistant isolates being *Enterobacter* species isolated from urinary sources and from the inpatient non-ICU setting.

"Unlike for adults, where increases were greater than for children, we did not find that the

increase in CRE in children appeared to be related to residence in long-term care facilities, because only 0.1% of CRE isolates came from this setting," wrote Dr. Latania K. Logan, director of pediatric infectious diseases at Rush University Medical Center, Chicago, and her coauthors.

The study, published Oct. 14 in *Emerging Infectious Diseases*, showed a significant overall increase from 0% to 0.47% in carbapenem-resistant *Enterobacteriaceae* over the 12-year study period; among ICU isolates, the prevalence increased from 0% to 4.5% over the same period.



Many of the carbapenem-resistant isolates also were resistant to other antimicrobial drugs, such as trimethoprim/sulfamethoxazole and ciprofloxacin, and nearly half (48.3%) were resistant to more than three antimicrobial drug classes (Emerg Infect Dis. 2015 Oct 14. doi: 10.3201/eid2111.150548).

The study was supported by the National Institutes of Health, the Children's Foundation, the Global Antibiotic Resistance Partnership, the Bill and Melinda Gates Foundation, and the Health Grand Challenges Program at Princeton University. No conflicts of interest were declared.



For the long-term, once-daily, maintenance bronchodilator treatment in patients with chronic obstructive pulmonary disease (COPD)

**Prescribe INCRUSE ELLIPTA  
one inhalation, once daily**

**help patients add more  
breath to their day**

### Indication

- INCRUSE ELLIPTA is an anticholinergic indicated for the long-term, once-daily, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.

### Important Safety Information for INCRUSE ELLIPTA

#### CONTRAINDICATIONS

- The use of INCRUSE ELLIPTA is contraindicated in patients with severe hypersensitivity to milk proteins or who have hypersensitivity to umeclidinium or any of the excipients.

#### WARNINGS AND PRECAUTIONS


- INCRUSE ELLIPTA should not be initiated in patients during rapidly deteriorating or potentially life-threatening episodes of COPD.
- INCRUSE ELLIPTA should not be used for the relief of acute symptoms, i.e., as rescue therapy for the treatment of acute episodes of bronchospasm. Acute symptoms should be treated with an inhaled, short-acting beta<sub>2</sub>-agonist.
- If paradoxical bronchospasm occurs, discontinue INCRUSE ELLIPTA and institute alternative therapy.
- Use with caution in patients with narrow-angle glaucoma. Instruct patients to contact a physician immediately if signs or symptoms of acute narrow-angle glaucoma develop.
- Use with caution in patients with urinary retention, especially in patients with prostatic hyperplasia or bladder-neck obstruction. Instruct patients to contact a physician immediately if signs or symptoms of urinary retention develop.

#### ADVERSE REACTIONS

- The most common adverse reactions ( $\geq 1\%$  and more common than placebo) reported in one 12-week and one 24-week clinical trial with INCRUSE ELLIPTA (and placebo) were: nasopharyngitis, 8% (7%); upper respiratory tract infection, 5% (4%); pharyngitis, 1% ( $<1\%$ ); viral upper respiratory tract infection, 1% ( $<1\%$ ); cough, 3% (2%); arthralgia, 2% (1%); myalgia, 1% ( $<1\%$ ); upper abdominal pain, 1% ( $<1\%$ ); toothache, 1% ( $<1\%$ ); contusion, 1% ( $<1\%$ ); tachycardia, 1% ( $<1\%$ ). Other adverse reactions with INCRUSE ELLIPTA observed with an incidence  $<1\%$  but more common than placebo included atrial fibrillation.

## Once-daily INCRUSE ELLIPTA Helps Improve Breathing in Patients With COPD

### Primary Endpoint: Trough (Predose) FEV<sub>1</sub> at Day 169<sup>1,2</sup>



- Results from a 6-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study that compared the efficacy and safety of INCRUSE ELLIPTA and placebo, each administered once daily by the ELLIPTA Inhaler. The primary endpoint was defined as the mean of the FEV<sub>1</sub> values obtained 23 and 24 hours after dosing on Day 168<sup>1</sup>



### Provided improvement in health-related quality of life as measured by the St. George's Respiratory Questionnaire (SGRQ)

- In the same 6-month study, INCRUSE ELLIPTA demonstrated an improvement in health-related quality of life, as measured by a decrease in mean SGRQ total score of 4.69 units, compared with placebo at Day 168
- The proportion of patients with a clinically meaningful decrease (defined as a decrease of at least 4 units from baseline) at Week 24 was greater for INCRUSE ELLIPTA (42%; 172/410) compared with placebo (31%; 86/274)
- These endpoints were not adjusted for multiple comparisons
- The SGRQ is a respiratory disease-specific, patient-reported instrument that measures symptoms, activities, and impact on daily life<sup>3</sup>

### Important Safety Information for INCRUSE ELLIPTA (cont'd)

#### ADVERSE REACTIONS (cont'd)

- In addition to the two placebo-controlled clinical trials with INCRUSE ELLIPTA, a 12-month trial evaluated the safety of umeclidinium 125 mcg in subjects with COPD. Adverse reactions (incidence  $\geq 1\%$  and exceeded that in placebo) in subjects receiving umeclidinium 125 mcg were: nasopharyngitis, upper respiratory tract infection, urinary tract infection, pharyngitis, pneumonia, lower respiratory tract infection, rhinitis, supraventricular tachycardia, supraventricular extrasystoles, sinus tachycardia, idioventricular rhythm, headache, dizziness, sinus headache, cough, back pain, arthralgia, pain in extremity, neck pain, myalgia, nausea, dyspepsia, diarrhea, rash, depression, and vertigo.

#### DRUG INTERACTIONS

- Avoid coadministration of INCRUSE ELLIPTA with other anticholinergic-containing drugs as this may lead to an increase in anticholinergic adverse effects.

**References:** 1. Donohue JF, Maleki-Yazdi MR, Kilbride S, et al. Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD. *Respir Med.* 2013;107(10):1538-1546. 2. Data on file, GSK. 3. Jones PW, Quirk FH, Baveystock CM. The St George's Respiratory Questionnaire. *Respir Med.* 1991;85 (suppl B):25-31.

Please see Brief Summary of Prescribing Information for INCRUSE ELLIPTA on the following pages.

[www.GSKSource.com](http://www.GSKSource.com)

**INCRUSE<sup>®</sup> ELLIPTA<sup>®</sup>**  
(umeclidinium 62.5 mcg  
inhalation powder)

## BRIEF SUMMARY

### INCRUSE® ELLIPTA® (umeclidinium inhalation powder) FOR ORAL INHALATION USE

The following is a brief summary only; see full prescribing information for complete product information.

#### 1 INDICATIONS AND USAGE

INCRUSE ELLIPTA is an anticholinergic indicated for the long-term, once-daily, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.

#### 4 CONTRAINDICATIONS

The use of INCRUSE ELLIPTA is contraindicated in the following conditions: severe hypersensitivity to milk proteins or hypersensitivity to umeclidinium or any of the excipients [see Warnings and Precautions (5.3), Description (11) of full prescribing information].

#### 5 WARNINGS AND PRECAUTIONS

##### 5.1 Deterioration of Disease and Acute Episodes

INCRUSE ELLIPTA should not be initiated in patients during rapidly deteriorating or potentially life-threatening episodes of COPD. INCRUSE ELLIPTA has not been studied in subjects with acutely deteriorating COPD. The initiation of INCRUSE ELLIPTA in this setting is not appropriate.

INCRUSE ELLIPTA should not be used for the relief of acute symptoms, i.e., as rescue therapy for the treatment of acute episodes of bronchospasm. INCRUSE ELLIPTA has not been studied in the relief of acute symptoms and extra doses should not be used for that purpose. Acute symptoms should be treated with an inhaled, short-acting beta<sub>2</sub>-agonist.

COPD may deteriorate acutely over a period of hours or chronically over several days or longer. If INCRUSE ELLIPTA no longer controls symptoms of bronchoconstriction; the patient's inhaled, short-acting beta<sub>2</sub>-agonist becomes less effective; or the patient needs more short-acting beta<sub>2</sub>-agonist than usual, these may be markers of deterioration of disease. In this setting a re-evaluation of the patient and the COPD treatment regimen should be undertaken at once. Increasing the daily dose of INCRUSE ELLIPTA beyond the recommended dose is not appropriate in this situation.

##### 5.2 Paradoxical Bronchospasm

As with other inhaled medicines, INCRUSE ELLIPTA can produce paradoxical bronchospasm, which may be life threatening. If paradoxical bronchospasm occurs following dosing with INCRUSE ELLIPTA, it should be treated immediately with an inhaled, short-acting bronchodilator; INCRUSE ELLIPTA should be discontinued immediately; and alternative therapy should be instituted.

##### 5.3 Hypersensitivity Reactions

Hypersensitivity reactions may occur after administration of INCRUSE ELLIPTA. There have been reports of anaphylactic reactions in patients with severe milk protein allergy after inhalation of other powder products containing lactose; therefore, patients with severe milk protein allergy should not use INCRUSE ELLIPTA [see Contraindications (4)].

##### 5.4 Worsening of Narrow-Angle Glaucoma

INCRUSE ELLIPTA should be used with caution in patients with narrow-angle glaucoma. Prescribers and patients should be alert for signs and symptoms of acute narrow-angle glaucoma (e.g., eye pain or discomfort, blurred vision, visual halos or colored images in association with red eyes from conjunctival congestion and corneal edema). Instruct patients to consult a physician immediately if any of these signs or symptoms develops.

##### 5.5 Worsening of Urinary Retention

INCRUSE ELLIPTA should be used with caution in patients with urinary retention. Prescribers and patients should be alert for signs and symptoms of urinary retention (e.g., difficulty passing urine, painful urination), especially in patients with prostatic hyperplasia or bladder-neck obstruction. Instruct patients to consult a physician immediately if any of these signs or symptoms develops.

## 6 ADVERSE REACTIONS

The following adverse reactions are described in greater detail in other sections:

- Paradoxical bronchospasm [see Warnings and Precautions (5.2)]
- Worsening of narrow-angle glaucoma [see Warnings and Precautions (5.4)]
- Worsening of urinary retention [see Warnings and Precautions (5.5)]

### 6.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in practice.

A total of 1,663 subjects with COPD across 8 clinical trials (mean age: 62.7 years; 89% white; 65% male across all treatments, including placebo) received at least 1 inhalation dose of umeclidinium at doses of 62.5 or 125 mcg. In the 4 randomized, double-blind, placebo- or active-controlled, efficacy clinical trials, 1,185 subjects received umeclidinium for up to 24 weeks, of which 487 subjects received the recommended dose of umeclidinium 62.5 mcg. In a 12-month, randomized, double-blind, placebo-controlled, long-term safety trial, 227 subjects received umeclidinium 125 mcg for up to 52 weeks [see Clinical Studies (14) of full prescribing information].

The incidence of adverse reactions associated with INCRUSE ELLIPTA in Table 1 is based upon 2 placebo-controlled efficacy trials: one 12-week trial and one 24-week trial.

**Table 1. Adverse Reactions With INCRUSE ELLIPTA With ≥1% Incidence and More Common Than With Placebo in Subjects With Chronic Obstructive Pulmonary Disease**

Adverse Reaction	INCRUSE ELLIPTA (n = 487) %	Placebo (n = 348) %
Infections and infestations		
Nasopharyngitis	8%	7%
Upper respiratory tract infection	5%	4%
Pharyngitis	1%	<1%
Viral upper respiratory tract infection	1%	<1%
Respiratory, thoracic, and mediastinal disorders		
Cough	3%	2%
Musculoskeletal and connective tissue disorders		
Arthralgia	2%	1%
Myalgia	1%	<1%
Gastrointestinal disorders		
Abdominal pain upper	1%	<1%
Toothache	1%	<1%
Injury, poisoning, and procedural complications		
Contusion	1%	<1%
Cardiac disorders		
Tachycardia	1%	<1%

Other adverse reactions with INCRUSE ELLIPTA observed with an incidence less than 1% but more common than placebo included atrial fibrillation. In a long-term safety trial, 336 subjects (n = 227 umeclidinium 125 mcg, n = 109 placebo) were treated for up to 52 weeks with umeclidinium 125 mcg or placebo. The demographic and baseline characteristics of the long-term safety trial were similar to those of the efficacy trials described above. Adverse reactions that occurred with a frequency greater than or equal to 1% in subjects

receiving umeclidinium 125 mcg that exceeded that in placebo in this trial were: nasopharyngitis, upper respiratory tract infection, urinary tract infection, pharyngitis, pneumonia, lower respiratory tract infection, rhinitis, supraventricular tachycardia, supraventricular extrasystoles, sinus tachycardia, idioventricular rhythm, headache, dizziness, sinus headache, cough, back pain, arthralgia, pain in extremity, neck pain, myalgia, nausea, dyspepsia, diarrhea, rash, depression, and vertigo.

## 7 DRUG INTERACTIONS

### 7.1 Anticholinergics

There is potential for an additive interaction with concomitantly used anticholinergic medicines. Therefore, avoid coadministration of INCRUSE ELLIPTA with other anticholinergic-containing drugs as this may lead to an increase in anticholinergic adverse effects [see *Warnings and Precautions (5.4, 5.5), Adverse Reactions (6)*].

## 8 USE IN SPECIFIC POPULATIONS

### 8.1 Pregnancy

**Teratogenic Effects:** Pregnancy Category C. There are no adequate and well-controlled trials with INCRUSE ELLIPTA in pregnant women. Because animal reproduction studies are not always predictive of human response, INCRUSE ELLIPTA should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Women should be advised to contact their physicians if they become pregnant while taking INCRUSE ELLIPTA.

### 8.2 Labor and Delivery

There are no adequate and well-controlled human trials that have investigated the effects of INCRUSE ELLIPTA during labor and delivery. INCRUSE ELLIPTA should be used during labor only if the potential benefit justifies the potential risk.

### 8.3 Nursing Mothers

It is not known whether INCRUSE ELLIPTA is excreted in human breast milk. Because many drugs are excreted in human milk, caution should be exercised when INCRUSE ELLIPTA is administered to a nursing woman. Since there are no data from well-controlled human studies on the use of INCRUSE ELLIPTA by nursing mothers, a decision should be made whether to discontinue nursing or to discontinue INCRUSE ELLIPTA, taking into account the importance of INCRUSE ELLIPTA to the mother.

Subcutaneous administration of umeclidinium to lactating rats at approximately 25 times the MRHDID in adults resulted in a quantifiable level of umeclidinium in 2 pups, which may indicate transfer of umeclidinium in milk.

### 8.4 Pediatric Use

INCRUSE ELLIPTA is not indicated for use in children. The safety and efficacy in pediatric patients have not been established.

### 8.5 Geriatric Use

Based on available data, no adjustment of the dosage of INCRUSE ELLIPTA in geriatric patients is necessary, but greater sensitivity in some older individuals cannot be ruled out.

Clinical trials of INCRUSE ELLIPTA included 810 subjects aged 65 years and older, and, of those, 183 subjects were aged 75 years and older. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger subjects.

### 8.6 Hepatic Impairment

Patients with moderate hepatic impairment (Child-Pugh score of 7-9) showed no relevant increases in  $C_{max}$  or AUC, nor did protein binding differ between subjects with moderate hepatic impairment and their healthy controls. Studies in subjects with severe hepatic impairment have not been performed [see *Clinical Pharmacology (12.3) of full prescribing information*].

### 8.7 Renal Impairment

Patients with severe renal impairment (creatinine clearance less than 30 mL/min) showed no relevant increases in  $C_{max}$  or AUC, nor did protein binding differ between subjects with severe renal impairment and their healthy

controls. No dosage adjustment is required in patients with renal impairment [see *Clinical Pharmacology (12.3) of full prescribing information*].

## 10 OVERDOSAGE

No case of overdose has been reported with INCRUSE ELLIPTA. High doses of umeclidinium may lead to anticholinergic signs and symptoms. However, there were no systemic anticholinergic adverse effects following a once-daily inhaled dose of up to 1,000 mcg umeclidinium (16 times the maximum recommended daily dose) for 14 days in subjects with COPD. Treatment of overdose consists of discontinuation of INCRUSE ELLIPTA together with institution of appropriate symptomatic and/or supportive therapy.

## 13 NONCLINICAL TOXICOLOGY

### 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

Umeclidinium produced no treatment-related increases in the incidence of tumors in 2-year inhalation studies in rats and mice at inhaled doses up to 137 and 295/200 mcg/kg/day (male/female), respectively (approximately 20 and 25/20 times the MRHDID in adults on an AUC basis, respectively). Umeclidinium tested negative in the following genotoxicity assays: the *in vitro* Ames assay, *in vitro* mouse lymphoma assay, and *in vivo* rat bone marrow micronucleus assay.

No evidence of impairment of fertility was observed in male and female rats at subcutaneous doses up to 180 mcg/kg/day and inhaled doses up to 294 mcg/kg/day, respectively (approximately 100 and 50 times, respectively, the MRHDID in adults on an AUC basis).

## 17 PATIENT COUNSELING INFORMATION

Advise the patient to read the FDA-approved patient labeling (Patient Information and Instructions for Use).

**Not for Acute Symptoms:** Inform patients that INCRUSE ELLIPTA is not meant to relieve acute symptoms of COPD and extra doses should not be used for that purpose. Advise them to treat acute symptoms with a rescue inhaler such as albuterol. Provide patients with such medicine and instruct them in how it should be used.

Instruct patients to seek medical attention immediately if they experience any of the following:

- Symptoms get worse
- Need for more inhalations than usual of their rescue inhaler

Patients should not stop therapy with INCRUSE ELLIPTA without physician/provider guidance since symptoms may recur after discontinuation.

**Paradoxical Bronchospasm:** As with other inhaled medicines, INCRUSE ELLIPTA can cause paradoxical bronchospasm. If paradoxical bronchospasm occurs, instruct patients to discontinue INCRUSE ELLIPTA.

**Worsening of Narrow-Angle Glaucoma:** Instruct patients to be alert for signs and symptoms of acute narrow-angle glaucoma (e.g., eye pain or discomfort, blurred vision, visual halos or colored images in association with red eyes from conjunctival congestion and corneal edema). Instruct patients to consult a physician immediately if any of these signs or symptoms develops.

**Worsening of Urinary Retention:** Instruct patients to be alert for signs and symptoms of urinary retention (e.g., difficulty passing urine, painful urination). Instruct patients to consult a physician immediately if any of these signs or symptoms develops.

INCRUSE and ELLIPTA are registered trademarks of the GSK group of companies.



GSK  
Research Triangle Park, NC 27709

©2014, GSK group of companies. All rights reserved.  
Revised: 6/2014

INC:3BRS

©2015 GSK group of companies.  
All rights reserved. Printed in USA. 86808R0 August 2015

# Experts debate ‘bare beneath the elbows’

BY AMY KARON  
Frontline Medical News

SAN DIEGO – Going tieless and “bare beneath the elbows” has been touted for infection control. But while some clinicians endorse the practice, others call it inconvenient, unprofessional, and distracting. At an annual conference on infectious diseases, two specialists in the field debated going “BBE” and its evidence base.

Widespread practice of BBE dates to at least 2008, when the National Health Service in the United Kingdom mandated it as part of a set of measures to decrease nosocomial transmission of methicillin-resistant *Staphylococcus aureus* (MRSA) and *Clostridium difficile*. Clinicians at NHS were directed to leave jewelry, neckties, and wrist watches at



©CHIFI/STOCKPHOTO

home, hang up their lab coats, and wear short sleeves. The policy aims not only to reduce points of physical contact between providers and patients, but also to improve hand and wrist washing, said Dr. Michael Edmond, who is at the University of Iowa Hospitals and Clinics in Iowa City.

Some evidence supports going BBE, said Dr. Edmond. Pathogenic gram-negative rods have been cultured from neckties, scrubs, uniforms, and white coats in multiple studies, he added. Inadequate laundering is part of the problem – clinical faculty in one study reported washing their coats about once every 2 weeks, even less often than medical students did.

“So when is biological plausibility enough to support a change in practice?” Dr. Edmond asked. “There is a potential for benefit in going BBE. There is no risk for harm. And there is minimal cost. On the basis of the same evidence and assumptions, we are willing to wrap ourselves in plastic and confine patients to their hospital rooms – that is, to use con-

tact precautions. And yet, we are not willing to eliminate white coats and ties.”

Patient perception is not at issue, Dr. Edmond argued. Only about half of patients at one British hospital said they wanted physicians to wear traditional white coats, and that proportion dropped to 22% after patients received educational materials on clothing contamination, he noted. In another study, patients ranked their physician’s appearance behind knowledge, compassion, and politeness when asked which characteristics they valued most.

“Without strong evidence for benefit, we should recommend – not mandate – this new practice,” Dr. Edmond concluded.

But Dr. Neil O. Fishman disagreed, calling BBE “an evidence-free zone.” Dr. Fishman, who is at the University of Pennsylvania in Philadelphia, noted a total lack of randomized, controlled trials or well-performed observational studies supporting BBE. “No clinical studies have demonstrated cross-transmission of health care-associated pathogens from a health care provider to a patient,” he said.

Moreover, BBE does not prevent contamination, Dr. Fishman said. Bacterial cultures of the hands of BBE clinicians and controls revealed no differences in total bacteria counts or numbers of clinically significant pathogens, he said. Cultures of white coats and the undersides of wrists also were similar in terms of total bacteria and MRSA counts, he added.

Despite the lack of evidence, BBE has been implemented at NHS “mainly as a political gesture and has had unintended consequences,” Dr. Fishman said. Informal attire has promoted a less-robust view of infection control, junior doctors have adopted scruffy attire and “slovenly” personal hygiene, and all the focus on clothing has distracted from hand washing, he added.

Furthermore, less than 12% of clinicians have complied with BBE, according to Dr. Fishman. Abstainers report feeling cold and not knowing what time it is. Women, in particular, say they have no pockets to carry work essentials. Dr. Edmond and Dr. Fishman reported no disclosures.

# Malpractice premiums flat in 2015, but that could change

BY ALICIA GALLEGOS  
Frontline Medical News

Physicians paid about the same in liability insurance premiums in 2015 as in 2014, and analysts don’t see costs changing anytime soon. A nationwide survey of insurers by the Medical Liability Monitor shows that 71% of insurance premiums did not change this year, while 17% of rates rose and 12% fell.



**‘The claims counts are just not rising. Its great for the industry, it’s great for physicians, but it is puzzling.’**

MR. GREVE

Internists experienced an average premium increase of 0.6% in 2015, while general surgeons saw a 0.2% average rate decrease, and ob.gyns experienced an average 0.5% rate increase.

The static premium market is being largely driven by the low number of lawsuits filed by patients and family members in recent years, said survey coauthor Paul Greve Jr., executive vice president/senior consultant for the Willis Health Care Practice, a global risk management consultant firm.

“It’s amazing to see the continuing stability in claim frequency,” Mr. Greve said in an interview. “The claims counts are just not rising. Its great for the industry, and it’s great for physicians, but it is puzzling because you wonder what has caused what amounts to a sea change in the attitudes of the general public toward malpractice litigation such that the claim counts were drop off.”

Premiums continue to vary geographically. Southern Florida internists for example, will pay \$47,707 for malpractice insurance this year, while their counterparts in Minnesota will pay \$3,375. For ob.gyns., premiums range from \$214,999 in southern New York to \$16,240 in central California. General surgeons in Southern Florida will pay \$190,829 this year, while Wisconsin surgeons will pay \$10,868.

Various factors influence premium amounts, including the overall legal climate and the rate of insurer competition in each state, said Susan J. Forray, principal and consulting actuary with the Milwaukee office of Milliman, a global provider of actuarial services.

“The dollar amounts themselves are a function of the litigation environment and the cost of medicine or living within the state,” Ms. Forray said in an interview. “In terms of rate changes, we are seeing certain environments where there is more competition.”

On a regional basis, Southern physicians experienced the largest rate increases, while doctors in the Northeast, West, and Midwest continued to see decreases. The Midwest’s 0.8% rate decrease was the largest decline, while Western states experienced a 0.2% average rate decrease. On average, the South showed a rate increase of 0.9% and the Northeast experienced a 0.1% average decrease. Doctors in Georgia, North Carolina, and Texas saw rate increases in excess of 5%, while Iowa physicians experienced an 11% rate decrease. Only three western states experienced rate increases: New Mexico at 2.5%, Oregon at 2%, and Idaho at 1%. Premium changes for Northeastern doctors fluctuated from Rhode Island’s 7% increase to Pennsylvania’s 8% decrease. Additionally, for the first time in 8 years, the premium market experienced an average overall increase of 0.3% in 2015, compared with an average overall decrease of 1.5% last year.

The jury is still out on how the Affordable Care Act and other health reforms will impact the malpractice premium market, Mr. Greve said. He said that he believes the majority of upcoming health reforms will improve patient safety, thus reducing liability for doctors. However, as more physicians become part of larger networks to deliver new models of care, their contractual liability spreads, he said.

“We’re just beginning to see the tip of the iceberg here,” Mr. Greve said. “In the past, it was overutilization, [the claim] that you did something in order to put money in your pocket. With putting providers at financial risk with capitated or bundled payments or global payments, then the argument is going to be, ‘You didn’t deliver enough care,’ or ‘You [used that device] because it was less expensive.’”

The MLM survey, published yearly in October, gathered July 1 premium data from the major malpractice insurers and examines rates for mature, claims-made policies with \$1 million/\$3 million limits for internists, general surgeons, and ob.gyns.

agallegos@frontlinemedcom.com  
On Twitter @legal\_med

# CLASSIFIEDS

Also available at [MedJobNetwork.com](http://MedJobNetwork.com)

## PROFESSIONAL OPPORTUNITIES

### ALABAMA

#### LUNG CENTER

Comprehensive Pulmonary/Critical Care Medicine

#### SEEKS A PULM/CC PHYSICIAN IMMEDIATELY!

- EBUS ultrasound
- Super Dimension Bronchoscopies
- Teaching opportunities through UAB
- Established, hospital-owned practice
- Employment w/excellent compensation package
- Medical, Surgical/Trauma, Neurological and Cardiovascular ICUs
- 941 bed Level I Trauma/Regional Referral Center
- 20-25 patients/half day
- Huntsville named in Forbes list of Top Ten Smartest Cities in the World

Interested physicians should contact:

Kimberly Salvail  
Huntsville Hospital  
[kimberly.salvail@hhsys.org](mailto:kimberly.salvail@hhsys.org)  
256-265-7073



Memorial Sloan Kettering  
Cancer Center.

#### Chief, Pulmonary Service

#### Memorial Sloan Kettering Cancer Center

Memorial Sloan Kettering Cancer Center (MSK) is seeking a Chief for the Pulmonary Service in the Division of General Medicine of the Department of Medicine. The Pulmonary Service at MSK consults on and manages all clinical problems within the full spectrum of benign and malignant pulmonary diseases. The Pulmonary Service encompasses the Interventional Pulmonology Program, inpatient consultative services, a busy outpatient program and Pulmonary Function Laboratories.

The full range of Pulmonary diagnostic and therapeutic procedures is available, including standard bronchoscopy, endobronchial ultrasound, electromagnetic navigational bronchoscopy, airway stenting, whole lung lavage, placement of tunneled catheters, and pleuroscopy. The Interventional Pulmonology Program and Bronchoscopy Unit also support many clinical investigative projects. The MSK Pulmonary Service offers an ACGME-approved two-year Pulmonary Fellowship Training Program and a one-year advanced Interventional Pulmonary Fellowship, providing outstanding training in patient care and research.

Applicants must be ABIM-Certified in Pulmonary Medicine and preferably in Critical Care Medicine. This leader will be responsible for all aspects of the Pulmonary Service, including clinical programs, education, research (clinical, translational and basic) and strategic development. A record of productivity in research and educational activities is essential. Academic appointment at MSK will be at the rank of Associate Member or Member, commensurate with experience, training, and achievements. A parallel appointment as Associate Professor or Professor of Medicine at the Weill Cornell Medical College will be available.

Interested individuals should submit a **curriculum vitae and a cover letter outlining relevant prior experience and interests to:**

Hans Gerdesh, MD, Chair, Pulmonary Service Search Committee, Division of General Medicine, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065; email: [gerdesh@mskcc.org](mailto:gerdesh@mskcc.org)

*Memorial Sloan Kettering Cancer Center is an equal opportunity employer with a strong commitment to enhancing the diversity of its faculty and staff.*



**CHEST MEDICINE ASSOCIATES**  
The Pulmonary • Critical Care • Sleep Medicine Specialists

#### PULMONARY / CRITICAL CARE / SLEEP MEDICINE – PORTLAND, MAINE

Chest Medicine Associates is a well-respected, established, 16 physician single specialty, private practice group in Portland, Maine. We seek pulmonary/critical care/sleep medicine physicians to expand our services. We have a strong partnership with Maine Medical Center, the state's largest tertiary care and teaching hospital, to provide 24/7 medical and neurological critical care and consultative pulmonary medicine services.

We offer a collegial and intellectually stimulating environment with opportunity for individual professional development. Our physicians are involved in active clinical research and extensively engaged in teaching in the Pulm-CCM fellowship, Medicine and Emergency Medicine residency programs. We have a robust outpatient practice with pulmonary function and sleep labs and in-office ultrasound. We provide regional expertise in pulmonary hypertension, cystic fibrosis, and lung cancer, and we offer endobronchial ultrasound and navigational bronchoscopy.

Enjoy life situated on Maine's southern coastline. The region is known for its excellent school systems, lifestyle, arts, exceptional culinary experiences, and abundant four season recreational opportunities in the nearby ocean, lakes, trails, and mountains.

Candidates must be BC/BE in pulmonary/critical care. Training, interest, and board certification in sleep medicine are highly desirable. Interest in programmatic development and clinical research in outpatient medicine (i.e. interstitial lung disease, airways diseases, sleep, etc) is welcome. A career focus in critical care or pulmonary/sleep medicine will be considered.

Not a J-1 opportunity. If interested, please e-mail cover letter and CV to Stephen R. Gorman, DO at [sgorman@cmamaine.com](mailto:sgorman@cmamaine.com)  
Web: <http://www.cmamaine.com>

EOE

### CHEST Physician

— CLASSIFIEDS —

For Deadlines and  
More Information, Contact:

Lauren Morgan  
Tel: (267) 980-6087  
[lmorgan@americanmedicalcomm.com](mailto:lmorgan@americanmedicalcomm.com)

**FRONTLINE**  
MEDICAL COMMUNICATIONS

### Disclaimer

Chest Physician assumes the statements made in classified advertisements are accurate, but cannot investigate the statements and assumes no responsibility or liability concerning their content. The Publisher reserves the right to decline, withdraw, or edit advertisements. Every effort will be made to avoid mistakes, but responsibility cannot be accepted for clerical or printer errors.

### FIND YOUR NEXT JOB AT



**MEDJOBNETWORK.com**

Physician • NP/PA Career Center

#### The first mobile job board for Physicians, NPs, and PAs

**Mobile Job Searches**—access  
MedJobNetwork.com on the go  
from your smartphone or tablet

**Advanced Search Capabilities**—  
search for jobs by specialty,  
job title, geographic location,  
employers, and more



Scan this QR code  
to access the  
mobile version of  
MedJobNetwork.com



### MINISTRY HEALTH CARE

PULMONOLOGY/CRITICAL CARE OPPORTUNITY - MIDWEST

Ministry Health Care is actively seeking a BC/BE Pulmonology/Critical Care physician for a growing program at our 110-bed tertiary referral center in Weston, WI. This is an excellent opportunity to join a financially sound, physician-led organization and play a significant role in the growth and success of our Pulm/Critical Care program.

#### The Position:

- Call is 1:4
- 12+ ICU bed coverage with significant support from Hospitalist team, Anesthesia and E-ICU
- EBUS and EUS on site; would support any procedures you were interested in
- Strong referral network from both central and northern WI
- Digitally advanced facility consistently named one of the nation's "Most Wired" hospitals
- You'll enjoy an excellent quality of life in the Wausau/Weston area. The community is vibrant, safe and affordable and offers a full complement of metropolitan amenities complete with a downhill ski resort and a regional airport

**CONTACT: BRENDA CHAMBERS (715) 342-6579**  
[mrmrecruitment@ministryhealth.org](mailto:mrmrecruitment@ministryhealth.org)

#### WHY JOIN MINISTRY?

Our physicians say it best.  
[www.ministryhealth.org/recruitment](http://www.ministryhealth.org/recruitment)



# CLASSIFIEDS

Also available at [MedJobNetwork.com](http://MedJobNetwork.com)

## PROFESSIONAL OPPORTUNITIES



### Mount Nittany Health Pulmonologist Opportunity

Position Highlights include:

**Mount Nittany Physician Group** currently provides a range of pulmonary medicine services including interventional procedures, allergy/immunology, and sleep medicine.

- \* Established practice with 6 physicians and growing patient demand within an expanding health system
- \* Mix of outpatient pulmonary medicine/procedures and inpatient pulmonary consults.
- \* Fully integrated EMR, electronic documentation and order entry
- \* Limited intensivist work available if desired, not required

**Mount Nittany Medical Center**, located in State College, PA, is a not-for-profit, 260 bed, acute care facility housing both inpatient and outpatient medical/surgical services. It is a growing and thriving facility offering unparalleled patient-focused care made all the more distinctive by excellent physicians, ease of access and facilities and systems engineered for the best in patient care.

**State College**, home to **Penn State University**, is a vibrant college town. It offers a diverse culture, a beautiful environment, excellent public and private schools, countless options for dining, theatre, sports and recreation, nightlife and more. This is all located within a safe, friendly community that makes the area perfect for raising a family. University Park Airport is located only five miles from town and State College offers easy access to Interstates 80 and 99.

Shelly Palumbo  
Physician Recruiter  
State College, PA  
(814)231-6892 or (814)558-6223  
michele.palumbo@mountnittany.org  
[www.mountnittany.org](http://www.mountnittany.org)



### Cardiac Intensivist Employment Opportunity

#### Join a Leading Healthcare System in South Florida

Memorial Healthcare System is seeking a critical care physician, dedicated to night shifts, to join the critical care team. Successful candidate will demonstrate excellent clinical skills, a broad knowledge base in critical care and dedication to providing high quality, evidence-based care. Applicants must be BE/BC in critical care medicine. Previous experience in managing cardiac surgery patients is a plus but not a requirement. Physician would have exposure to all aspects of the care of cardiac surgery patients, including mechanical devices, advanced heart failure patients, ECMO and transplant.

- 12-hour in-house shifts (7 pm – 7 am); no responsibilities outside of in-house shifts
- Approximately 15 shifts per month (more if desired)
- Highly competitive salary differential for the nocturnist position

This is a full-time employed position within the multi-specialty Memorial Physician Group. The position offers competitive benefits and a compensation package that is commensurate with training and experience. Professional malpractice and medical liability are covered under sovereign immunity.

#### About Memorial Healthcare System

Memorial Healthcare System is the third-largest public healthcare system in the United States. A national leader in quality care and patient satisfaction, Memorial has ranked 11 times since 2008 on nationally recognized lists of great places to work – including Modern Healthcare magazine, Florida Trend magazine and Becker's Hospital Review, to name just a few.

Memorial's facilities include its flagship, Memorial Regional Hospital, one of the largest in Florida; Memorial Regional Hospital South; Joe DiMaggio Children's Hospital, the only freestanding children's hospital in Broward and Palm Beach counties; Memorial Hospital West; Memorial Hospital Miramar; Memorial Hospital Pembroke; and Memorial Manor, a US News five-star rated nursing home.

Memorial's work environment has been rated by employees and physicians alike as an open-door, inclusive culture that is committed to safety, transparency and, above all, outstanding service to patients and families.

[memorialphysician.com](http://memorialphysician.com)



### PULMONARY / CRITICAL CARE PHYSICIAN

Presbyterian Healthcare Services (PHS) is seeking a Pulmonary/Critical Care trained physician to join our established group.

The physician will consist of 75% Critical Care and 25% Pulmonary.

PHS is a non-profit integrated health-care system that employs over 600 providers and includes a healthplan.

Benefits include medical, dental, vision, 403(b) plus match, CME, malpractice coverage (tail insurance included), competitive salary, sign on bonus and relocation assistance.

For more information, please contact:

Kelly Herrera  
505-923-5662  
[kherrera@phs.org](mailto:kherrera@phs.org)



### Inpatient Pulmonary/Critical Care Position in Maine:

Join a vibrant Inpatient Pulmonary and Critical Care group of five in beautiful Maine! Central Maine Medical Center (CMMC) is seeking a BC/BE Pulmonary/Critical Care Physician to help provide pulmonary and critical care services to medical, surgical, trauma, and cardiac patients.

CMMC is a 250 bed, full service regional referral center with busy trauma, cardiothoracic, interventional radiology, vascular, and neurosurgical programs. We have a state-of-the-art 19 bed ICU and a separate 16 bed cardiothoracic unit.

Competitive salary and benefits including CME, paid vacation, student loan repayment, 403b match, and relocation fees. Work schedule revolves around a 6 day on and 6 day off philosophy, with no longer than 12 hour shifts per day. There is no outpatient clinic work.

Residents and visitors enjoy an extraordinary lifestyle that revolves around top school systems, ski resorts, lake and ocean water sports, theatre, and world-class dining.

Interested applicants may submit CV to Julia Lauer, Medical Staff Recruiter, Central Maine Medical Center, 300 Main Street, Lewiston, ME 04240. Email: [JLauer@cmhc.org](mailto:JLauer@cmhc.org). Fax: 207/795-5696. Call: 800/445-7431. Visit our website, [www.cmmc.org](http://www.cmmc.org).

### Pulmonology/Intensivist

Join eight university trained, Board Certified Pulmonary, Critical Care and Sleep Medicine physicians. Our integrated multi-specialty physician clinic and hospital includes a Level II Trauma Center and an accredited sleep center. Practice with strong colleagues in the region's tertiary referral center.



Contact: Rochelle Woods  
1-888-554-5922  
physicianrecruiter@billingsclinic.org

[billingsclinic.com](http://billingsclinic.com)



### Physician-Led Medicine in Montana

Billings Clinic is nationally recognized for clinical excellence and is a proud member of the Mayo Clinic Care Network. Located in the magnificent Rocky Mountains in Billings, Montana, this friendly college community has great schools, safe neighborhoods and family activities. Exciting outdoor recreation minutes from home. 300 days of sunshine!



Large private practice group looking for a Critical Care Intensivist needed for 40 bed CVICU in Memphis, Tennessee. 6pm-7am. 7 Days on /7 days off. Highly competitive salary plus benefits including 401(k)/pension/health insurance. Large multi-cultural city located along the beautiful Mississippi River with lots of outdoor activities. Interested parties please send CV to [kwavery@mspulmonary.com](mailto:kwavery@mspulmonary.com)

**Moving?** Look to Classified Notices for practices available in your area.

### WANTED

Pulmonary/Critical Care Physician. Pulmonary Consultants P.C. located in Phoenix Arizona is a Six-Doctor Pulmonary/Critical group seeking additional Physician due to practice growth. Diverse Hospital/office practice encompassing pulmonary, critical care medicine. Competitive salary/excellent benefits. Please send your CV via fax to 480 218-5706 or email to [aliciaga@PCofMesa.com](mailto:aliciaga@PCofMesa.com) cell 480-466-2612

### Disclaimer

Chest Physician assumes the statements made in classified advertisements are accurate, but cannot investigate the statements and assumes no responsibility or liability concerning their content. The Publisher reserves the right to decline, withdraw, or edit advertisements. Every effort will be made to avoid mistakes, but responsibility cannot be accepted for clerical or printer errors.

## COMMENT: Responding to online physician review sites

BY JEFFREY BENABIO, M.D.  
*Frontline Medical News*

Recently, Niam Yaraghi of the Brookings Institution caused quite a kerfuffle regarding the validity of online doctor reviews in a U.S. News and World Report op-ed piece titled, “Don’t Yelp Your Doctor.”

In it, he argues that customers are “generally qualified and capable” of reviewing a restaurant – anyone can tell if a steak is chewy or a server is rude, he says. (Of course, chefs may disagree.) Yet, when it comes to online physician reviews, Mr. Yaraghi argues that “patients are neither qualified nor capable of evaluating the quality of the medical services that they receive.” I can see many of you nodding in vigorous agreement with that last sentence.

Who among us hasn’t felt indignant after reading a negative online review? Particularly one that criticizes our office decor or billing, yet makes no mention of our expert clinical abilities? But here’s my advice. Have your moment of indignation, then start working on improving your online reputation, which may improve your actual practice as well.

Here are a few tips for optimizing online physician review sites:

- Google yourself and your practice to see which sites your patients are

commonly using.

- Set up a Google Alert at <https://www.google.com/alerts>. Google Alerts are email updates that you receive based on your queries. Include your name and the name of your practice. This way, you’ll receive notice when you’re mentioned online.

- According to SoftwareAdvice.com, the most trusted review sites in descending order are: Yelp and Healthgrades (tied), RateMDs, Vitals, ZocDoc, and others. So familiarize yourself with these sites.

- Claim your page on review sites. Be sure all of the information listed is updated and correct.

- Upload a professional photo of yourself. It’s much more effective to see a picture of you than an empty avatar.

- Be sure someone in your office is responsible for responding to comments online, particularly negative ones. It’s best to respond promptly rather than have it linger without a response for weeks. If you don’t write it, then at least approve it before it is posted.

- Respond to both positive and negative comments. Yelp, for instance, rewards business owners who maintain their site and actively respond to comments.

- For specific tips on how to respond to negative online reviews, see my column from July 2013 titled “How



DR. BENABIO

## Enhance your reading experience.



FREE APP DOWNLOAD

Optimized for mobile and tablets

chestphysician.org

iOS, Android and Amazon Kindle



THE NEWSPAPER OF THE AMERICAN COLLEGE OF CHEST PHYSICIANS

to handle negative reviews.”

When it comes to online physician reviews, I want you to remember a few things:

- Physician reviews are usually favorable.
- Negative reviews are sometimes opportunities to improve your service.
- In the long run, we should want more, not fewer, reviews. Which would you rather have, two negative reviews, or two negative reviews and eight positive ones?
- The more reviews you have, the more credible you appear to prospective patients. This is particularly true for cosmetic practices.
- Patients are more likely to leave a positive review when they see other positive reviews posted about you. Let’s delve more deeply into the second point, “Negative reviews are opportunities for you and your staff to improve your service.”

According to the 2014 “IndustryView report” from Software Advice, when it came to administrative issues such as wait times, billing, and staff friendliness, 25% of respondents cited wait times as the most important factor in their experience. Moreover, their 2013 report found that 41% of patients said they would consider switching doctors if it reduced their wait times!

We live in a consumer-centric society and service matters. For most patients, service equals quality. If you’ve got multiple negative reviews regarding your front desk staff, for instance, then address it directly with them. If you’ve got complaints about long wait times, then consider ways

to improve it or improve the patient’s experience of waiting. You might hire a consultant to help with reducing wait times or you might provide Wi-Fi or light refreshments in your waiting room to make the wait more pleasant.

Let’s return to Mr. Yaraghi’s contention that patients are unqualified to accurately assess our abilities. It is a moot discussion. Patients have, and will continue, evaluating us regardless of how qualified they are to do so. A restaurant patron may not be an expert of sous-vide cooking but can judge his or her experience of the meal and restaurant staff. Similarly, a patient may not be an expert in psoriasis, but he or she can accurately assess an experience in our office and with our staff.

The good news is that there are sites that are trying to incorporate more objective data in the reviews. For instance, Healthgrades lists doctors’ board certifications, hospital affiliations, conditions treated, and procedures performed. The hope is that more objective criteria will improve the quality of the reviews and make the occasional angry and unwarranted rant less important.

One thing is for sure, there is much more discussion to come.

*Dr. Benabio is a partner physician in the department of dermatology of the Southern California Permanente Group in San Diego, and a volunteer clinical assistant professor at the University of California, San Diego. Dr. Benabio is @dermdoc on Twitter.*

## Physician survey: 45% order tests to avoid lawsuits


BY RICHARD FRANKI  
*Frontline Medical News*

Almost 45% of physicians say that they have practiced defensive medicine, according to a survey of 1,001 physicians conducted by Physicians Practice, a practice management newspaper and website.

In addition, almost 44% of the physician respondents said that they had been threatened with a malpractice lawsuit, and nearly 32% reported that they had been the defendant in such a lawsuit. Physicians Practice reported in its 2015 Great American Physician Survey.

### Defensive medicine

Have you ordered procedures or tests that you “thought were probably not medically necessary just to avoid a potential lawsuit”?



**Note:** Based on a 2015 survey involving 1,001 physician respondents.

**Source:** Physicians Practice

rfranki@frontlinemedcom.com

# California to allow physician-assisted suicide

BY ALICIA GALLEGOS  
*Frontline Medical News*

California Gov. Jerry Brown (D) has signed into law a controversial measure that allows physicians to help terminally ill patients legally end their lives, making California the fourth state to permit doctor-assisted suicide through its legislature.

Gov. Brown, a former seminary student, approved the End of Life Option Act Oct. 5, after state lawmakers passed the bill Sept. 11.

In a signing message, Gov. Brown said that he had considered all sides of the issue and carefully weighed religious and theological perspectives that shortening a patient's life is sinful.

"In the end, I was left to reflect on what I would want in the face of my own death," Gov. Brown said in the message. "I do not know what I would do if I were dying in prolonged and excruciating pain. I am

certain, however, that it would be a comfort to be able to consider the options afforded by this bill. And I wouldn't deny that right to others."

Modeled after Oregon's statute, California's law requires two doctors to determine that a patient has 6 months or less to live before doctors could prescribe life-ending medication. Patients must have the mental capacity to make medical decisions and would physically have to be able to swallow the drugs.

In addition, patients seeking physician aid in dying must submit two oral requests, a minimum of 15 days apart, and a written request to their physician. The attending physician must receive all three requests directly from the patient and not through a designee. Before prescribing end-of-life drugs, the attending physician must refer the patient to a consulting physician for confirmation of the diagnosis and prognosis and of the pa-

tient's capacity to make the decision.

Oregon, Vermont, and Washington each have laws permitting physician-assisted death. Court rulings in New Mexico and Montana have



**'I am certain ... that it would be a comfort to be able to consider the options afforded by this bill.'**

GOV. BROWN

allowed for the practice, but litigation in those states is ongoing and the decisions have yet to be enforced.

The signing ends nearly a year of passionate debate in California that divided physicians, religious groups, lawmakers, and community members. In May, the California Medical Association (CMA) became the first

state medical society to change its stance against physician-assisted suicide to that of being neutral.

"The decision to participate in the End of Life Option Act is a very personal one between a doctor and their patient, which is why CMA has removed policy that outright objects to physicians aiding terminally ill patients in end of life options," Dr. Luther F. Cobb, CMA president, said in a statement. "We believe it is up to the individual physician and their patient to decide voluntarily whether the End of Life Option Act is something in which they want to engage. Protecting that physician-patient relationship is essential."

The California law will take effect 90 days after the state legislature adjourns its special session on health care. The earliest likely enactment would be spring 2016.

agallegos@frontlinemedcom.com  
On Twitter @legal\_med

## 80% support Medicare coverage of end-of-life talks

BY JORDAN RAU, KAISER HEALTH NEWS

The public overwhelmingly supports Medicare's plan to pay for end-of-life discussions between doctors and patients, despite GOP objections that such chats would lead to rationed care for the elderly and ill, a poll finds.

About 8 of every 10 people surveyed by the Kaiser Family Foundation – in a nationally representative sample of 1,202 adults – supported coverage by the government or insurers for planning discussions about the type of care patients preferred in the waning days or weeks of their lives. (KHN is an editorially independent program of the foundation.) These discussions can include whether people would want to be kept alive by artificial means even if they had no chance of regaining consciousness or autonomy and whether they would want their organs to be donated. These preferences can be incorporated into advance directives, or living wills, which are used if someone can no longer communicate.

The Centers for Medicare & Medicaid Services earlier this year proposed paying doctors to have these talks with patients. A final decision is due out soon. The idea had been included in early drafts of the 2010 federal health care law, but former Alaska Gov. Sarah Palin and other opponents of the law labeled the counseling sessions and other provisions "death panels" motivated by desires to save money, and the provision was

deleted from the bill.

The notion of helping patients prepare for death has support among many doctors, who sometimes see terminal patients suffer from futile efforts to keep them alive. Last year, the Institute of Medicine issued a report that encouraged end-of-life discussions beginning as early as age 16.

The Kaiser poll found that these talks remain in-



©INGRAM PUBLISHING/THINKSTOCK

frequent. Overall, only 17% of those surveyed said they had had such discussions with their doctors or other health care professionals, even though 89% believe doctors should engage in such counseling. A third of respondents said they had talked to doctors about another family member's wishes for how they would want to be cared for at the end of life.

While none of these proposals calls for the cost of care to weigh on these discussions, the final

years of life are indeed expensive for America's health care system. The Dartmouth Atlas of Health Care has calculated that a third of Medicare spending goes to the care of people with chronic illnesses in their last 2 years of life. That is likely to increase as the population of those older than 65 increases. An analysis by the Kaiser foundation found that Medicare spending per person more than doubled from age 70 to 96, where it peaked at \$16,145 per beneficiary in 2011.

The Kaiser poll found less public support for a cost-containment provision that did make it into the health law. The "Cadillac tax" begins in 2018 and will impose a tax on expensive insurance that employers provide to their workers. Sixty percent oppose the plan, which economists have long favored as a way to discourage lavish coverage and make people aware that extensive use of Medicare services is linked to premiums.

The poll also found that 57% of people favor repealing the medical device tax, another piece of the health law that Republicans in Congress are trying to repeal. The tax applies to artificial hips, pacemakers and other devices that doctors implant.

The poll was conducted from Sept. 17 through Sept. 23. The margin of error was +/- 3 percentage points.

*Kaiser Health News is a nonprofit national health policy news service that is part of the nonpartisan Henry J. Kaiser Family Foundation.*



## ZYFLO CONNECT® PROGRAM – TERMS & CONDITIONS

### HOW IT WORKS

If you are uninsured or have commercial insurance, including insurance purchased through the Affordable Care Act Exchange plans, Chiesi USA may help pay the out-of-pocket expenses (co-pay, co-insurance, deductibles) of your prescription. For patients taking ZYFLO CR® (zileuton) extended-release tablets, up to \$2,500 per month will be provided, if you meet the eligibility requirements below. If the total costs of your out-of-pocket expenses are over \$2,500 per month, you will be responsible for the outstanding balance.

### ELIGIBILITY REQUIREMENTS

- You are either:
  - Uninsured, or
  - You are insured by commercial or private insurance and your insurance does not cover the full cost of ZYFLO CR
- Your prescriptions are not covered in full or in part by any state or federally funded insurance program, including but not limited to Medicare, Medicaid, Medigap, Veterans Affairs (VA) or Department of Defense (DOD) programs, or the Government Health Insurance Plan available in Puerto Rico (formerly known as “La Reforma de Salud”); patients who move from commercial to state or federally funded prescription insurance will no longer be eligible
- You are at least 18 years of age
- Void where prohibited by law

### TERMS OF USE

- By accepting this offer and participating in the ZYFLO Connect program, you are representing and warranting to Chiesi that you currently meet the eligibility requirements described above and will comply with these Terms of Use.
- Out-of-pocket benefit equals an amount up to \$2,500 per month (maximum benefit of \$30,000 per year) for ZYFLO CR. Patient is responsible for applicable taxes, if any.  
EXAMPLE: If your monthly ZYFLO CR prescription co-pay or out-of-pocket cost is \$3,000, eligible patients will only pay \$500 per month for ZYFLO CR, a savings of \$2,500 off of their co-pay or total out-of-pocket costs. If your co-pay or out-of-pocket costs are no more than \$2,500, you pay \$0. For a mail-order 3-month prescription, your total maximum savings will be \$7,500 (\$2,500 x 3).
- If a patient exceeds the maximum monthly benefit of \$2,500, the patient will be responsible for the outstanding balance.
- Patients, pharmacists, and prescribers cannot seek reimbursement from health insurance or any third party, for any part of the benefit received by the patient through this offer.
- Your acceptance of this offer confirms that this offer is consistent with your insurance and that you will report the value received as may be required by your insurance provider.
- Only valid in the United States or Puerto Rico; this offer is void where restricted or prohibited by law.
- No membership fees.
- The ZYFLO Connect program is not insurance.
- The ZYFLO Connect program cannot be combined with any other rebate/coupon, free trial, or similar offer for the specified prescription.
- The ZYFLO Connect program expires on December 31, 2016.
- The ZYFLO Connect program is limited to one per person.
- Chiesi USA reserves the right to rescind, revoke, or amend this offer at any time without notice.
- **The ZYFLO Connect program is only offered through distribution from Foundation Care, a full-service pharmacy serving patients in all 50 states and Puerto Rico.**

Foundation Care, 4010 Wedgeway Court, Earth City, MO 63045 Phone: (844) 699-9356



ZYFLO CR® is a registered trademark of Chiesi USA, Inc.  
ZYFLO Connect® is a registered trademark of Chiesi USA, Inc.  
©2015 Chiesi USA, Inc. All rights reserved. Printed in the USA. 07/15. ZC-Q315-08

**ZYFLO CR®**  
(zileuton) extended-release tablets

# ZYFLO connect<sup>®</sup>

Savings. Shipping. Support.

**\$0**

**\$0 monthly co-pay\***  
up to \$2,500 per month in savings  
on every prescription



**FREE next-day delivery**  
direct to your patient's door



**Reimbursement support**  
by phone to help with the PA process  
if required



**Pharmacist on call 24/7**  
to answer questions



**Refill reminder phone calls**  
from a ZYFLO Connect pharmacist



**Simple and streamlined**  
enrollment process via phone,  
fax, or EMR



**CONNECT**

patients with  
**VALUABLE  
BENEFITS**

Contact your patients about these benefits today

Visit [myZYFLO.com](http://myZYFLO.com)

or

Call 1-844-ZYFLO-RX

\*Terms and conditions apply. Please see full Terms and Conditions on adjacent page.

